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Ductal Carcinoma in Situ (DCIS) is a non obligate precursor of invasive breast cancer. 
Due mainly to improved screening methods the detection of DCIS has risen over the 
last twenty years. The inability to reliably predict progression to invasive breast cancer 
results in the possible overtreatment of what can be regarded as a non-life threatening 
condition. Current treatment options remain controversial with no consensus upon the 
choice of mastectomy or breast conserving surgery with or without radiotherapy or 
adjuvant hormone therapies. The natural progression and molecular pathology of 
DCIS also still remains poorly understood.  
Examination of DCIS cases with known clinical outcome has been carried out using 
traditional pathological criteria, immunohistochemistry and genomic analysis. Tissue 
microarrays have been constructed and stained with a panel of antibody markers 
demonstrating the presence of molecular subtypes of DCIS similar to those found in 
invasive breast disease, although at different frequencies.  
Molecular inversion probe arrays have revealed a complex heterogeneity exists in 
early stages of breast cancer that may be drivers of invasion. Comparison with 
invasive breast disease and with DCIS associated with invasive breast disease 
reveals a highly complex system, where progression may rely on genomic changes 
already established within pure DCIS or those that occur during the DCIS phase of 
tumourigenesis.  
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Chapter 1. Introduction 
5.6 The Normal Breast and Ductal Carcinoma in Situ 
The normal human female breast consists of six to ten major duct systems which, 
along with the lobules, comprise the parenchymal tissue of the breast. Ducts 
converge via multiple central ducts to the nipple; however each system exhibits little 
symmetry in shape and size. The ductal system is embedded in stromal connective 
tissue composed of varying amounts of fat and collagen-rich fibrous tissue. The large 
ducts and the interspersed smaller terminal ducts terminate in lobular acini. The acini 
consist of a lumen surrounded by columnar or cuboidal epithelial cells above a single 
myoepithelial cell layer, which sits upon a basement membrane. The stromal 
connective tissue around the ducts also contains lymphoid and plasma cells in small 
quantities. Epithelial cells of the lobular and ductal system are not quiescent, having 
a high degree of proliferative activity particularly during the secretory phase of the 
menstrual cycle. Proliferation also increases during pregnancy and lactation and 
slows down with age and the onset of the menopause. 
Ductal carcinoma in situ (DCIS) is defined as a pre-invasive proliferation of cells 
confined to the breast parenchyma showing no invasion into surrounding tissues, or 
metastasis (1). The ducts become populated with a clonal expansion of epithelial cells 
that line, or fill, the breast duct. Cells exhibit the cytological features of malignancy 
but do not invade across the basement membrane. DCIS is believed to originate in 
the terminal duct lobular units and not specifically in the larger ducts (1). 
  
1.2 Epidemiology of Ductal Carcinoma in Situ 
1.2.1 Incidence of ductal carcinoma in situ (DCIS) 
The incidence of DCIS has risen from 1- 5% of lesions detected prior to 
mammographic screening to approximately 20 - 25 % of all screen detected lesions 
in the UK (1-3). DCIS may be described as intraductal carcinoma or non-invasive 
tumour but regardless of terminology it now has the highest increase in frequency of 
all breast cancers (4). The reason for this seeming rise in incidence is almost entirely 
down to breast screening mammography, where, in some series, almost 50% of 
detected lesions are DCIS (5). In some screening populations DCIS is associated 
with age, where a younger screening population has a higher incidence of the disease 
than older women (3). 
Breast cancer worldwide accounted for 22.9% of all female cancers (1,384,155 
cases) and 13.7% (458,503 cases) of all cancer deaths according to the World Health 
Organisation’s figures for 2008. Currently there are no worldwide statistics available 
on the incidence on DCIS. Countries in the developed world utilising breast screening 
programs would, by default, register a higher incidence than developing and third 
world countries, thus making direct comparison difficult. Statistics released by the 
National Health Screening Breast Screening Program (NHSBSP) for 2010/11 
provides data for the incidence of breast cancer and DCIS in the screening population 
(women aged 47-97 years) for the United Kingdom (6); 2,188,608 women were 
screened with 17,258 cancers detected. Of these, 3522 were non-invasive or 
microinvasive carcinoma, accounting for approximately 20.4% of screen detected 
lesions. In the UK, for all ages, 2,221,975 women underwent breast screening with 
14,177 (0.8%) breast cancers detected, with 3613 (25%) of these being classed as 
non-invasive cancers. There is currently no data available for the type of non-invasive 
disease, i.e. either DCIS or lobular carcinoma in situ (LCIS), but it is likely that the 
majority of these will be DCIS, due to its tendency to present with microcalcification 
(see below) whereas LCIS is often identified co-incidentally within a biopsy. Cancer 
Research UK gives figures of 5,765 women and 26 men diagnosed with in situ breast 
carcinoma in 2010 (7). 
In the USA, the incidence of DCIS increased sevenfold from the 1970’s to the 1990’s. 
The National Institutes of Health (NIH) Consensus and State of the Science 
Statement on the Diagnosis and Management of DCIS gave an estimation of 
approximately half a million women living with DCIS in 2005 (8). The prevalence is 
higher in Caucasians compared to other ethnicities.  A Surveillance, Incidence and 
End Results (SEER) publication for the USA gives an incidence for in situ cancer of 
the female breast from 1973 to 2007 for all ages of 21.19 cases per 100,000 (9). This 
figure rises to 53.42 per 100,000 in the over fifty age group. The incidence of in situ 
disease in black women and white women is essentially similar in those aged over 
50, at 53.41 and 53.35 per 100,000 respectively, but is reportedly higher for white 
females below 50 years, at 9.03 compared to 7.29 per 100,000. Of note, the NIH 
advises caution interpreting these data as trends in pathological reporting and 
definitions have changed over time; as an example, one relevant element may be the 
absence of data on atypical ductal hyperplasia, which may have been previously 
reported as benign. However, another review of the SEER data from 1973 to 2000 by 
Joslyn (10) also identified that women between the ages of 35-44 have a higher 
incidence of DCIS than older groups. Differences between ethnics groups were also 
apparent with Asian women more likely to be diagnosed with DCIS followed by black 
women, white women and finally native Alaskan or American Indians. Thus the NIH 
data and SEER data are contradictory when comparing the incidence between black 
and white women but the relative times frames, changes in mammographic breast 
screening and diagnosis patterns are also possible causes of this discrepancy and 
highlight the difficulty in analysis of DCIS incidence. 
1.2.2 Ductal Carcinoma in Situ and Gender. 
Breast cancers are significantly more common in women than men with only 1% of 
breast cancers being found in males (11). Of this 1% of male lesions it is estimated 
that approximately 5% are DCIS. The lower incidence can be almost entirely 
attributed to the increased detection of DCIS in asymptomatic women due to breast 
screening programs and the absence of screening in the male population.  
1.2.3 Risk Factors of Ductal Carcinoma in Situ 
Risk factors for DCIS are difficult to quantify due to the absence of data prior to breast 
screening programmes and the difficulty in defining the asymptomatic incidence in 
the general population. Risk factors for DCIS are understandably believed to be 
similar to those known for invasive breast cancer. BRCA mutations are a known risk 
factor for invasive breast cancer with the cumulative risk by age 70 being 65% for 
BRCA1 and 45% for BRCA2 mutation carriers (12). Smith et al (12) found that 
patients carrying the BRCA1 mutation had a lower incidence of DCIS than found in 
sporadic cases. This may indicate that DCIS has a shorter or ‘not observed’ phase in 
BRCA1 mutation carriers. Conversely, Hwang et al (13) found that DCIS was equally 
prevalent in BRCA mutation carriers as in non-carriers although the onset of DCIS 
was at an earlier age in the former. 
Comparison studies of risk factors for DCIS and invasive breast carcinoma have 
shown similarities in overall risk (OR). A family history of breast cancer and early 
menarche showed an increase OR (14). Late childbirth and nullparity however only 
showed an increased OR in older patients (>50 years) for both DCIS and invasive 
breast cancer (14). Invasive breast cancer risk is strongly associated with increased 
age, whereas DCIS is associated comparatively with younger age (14). This would fit 
with the hypothesis that DCIS is a precursor lesion of invasive disease.  
Kerlikowske et al (14) found that increased body mass index (>25kg/m2) resulted in 
reduced OR in younger females (<45 years) for DCIS with a “trend bordering on 
significance”. They hypothesise that this is due to composition of breast tissue; 
women with lower body mass indices tend to have mammographically dense breasts 
and a two-threefold increased risk of invasive breast cancer compared to those with 
less dense, fatty tissue found in breasts (as seen in women with a higher body mass 
index). No increase in risk was found for DCIS in association with alcohol intake, 
smoking or previous smoking, hormone replacement therapy or oral contraception in 
individual studies (15-19). 
1.2.4 Risk of Ductal Carcinoma in Situ Progressing to Invasive Disease. 
The natural history of DCIS remains unclear. When DCIS has been detected 
subsequent treatment is generally aimed at complete excision of the lesion. Studies 
focussed upon misdiagnosed DCIS as a benign lesion that could be used to look at 
the natural history are rare, as are series where the patient has declined surgical 
excision after definitive diagnosis of DCIS.  
The Nurses’ Health Study is the largest epidemiological study of women in the USA. 
It consists of two cohorts funded by the USA’s National Institutes of Health, the first 
started in 1976 by Dr F Speizer (20) and the second in 1989 by Dr W Willett (20), with 
data on over 120,000 registered nurses. The study provides data on risk indicators 
for cancer, as well as other diseases. Collins et al (21) reviewed this cohort looking 
for the incidence of untreated DCIS finding only thirteen cases, thus highlighting the 
rarity of such incidences. Observations of the natural progression of these untreated 
DCIS found that ten women developed either a subsequent ipsilateral invasive or an 
in-situ lesion (2-5 years post original biopsy). The original DCIS lesions included 
lesions of low, intermediate and high nuclear grade. Although the number of cases 
studied is small the incidence of ‘recurrences’ is highly indicative of DCIS presenting 
a high risk of presenting with a subsequent cancer. In 1978 Betsill et al (22) reviewed 
intraductal carcinomas treated by biopsy alone and reported that an invasive 
recurrence occurred in 39% (range 25%-75%) of cases reported in the literature, 
however, some recurrences were quoted at ten months and could arguably represent 
disease that was present at the time of initial DCIS diagnosis.  
 
 
1.3 Detection of Ductal Carcinoma in Situ 
1.2.1  Mammography 
The primary screening tool for the detection of DCIS is mammography. Other 
techniques such as magnetic resonance imaging (MRI), ultrasound and 
scintimammography are generally regarded as insufficiently sensitive, in the absence 
of invasive disease (23).  Mammograms are radiographic images of the breast that 
utilise low energy x-rays to identify the contrasting difference between normal breast 
parenchymal tissue, adipose tissue and breast tumours (1). Radiographic images are 
usually taken through two aspects, the cranio-caudal and medial-lateral oblique 
views, to determine the exact location of any lesion. Calcification seen by 
mammography can be, but is not exclusively predictive of, an indicator of malignant 
change (see Figure 1). 
   
Figure 1: Cranio-caudal and medio-lateral oblique mammographic views of a case 
with two needle-localisation wires in place to mark an area of abnormality. 
The most common mammographic feature of DCIS is microcalcification, seen in 80-
90% of cases radiographically (24). Mammographic detection of DCIS thus typically 
relies upon the identification of calcification deposits that either result from a 
breakdown product of cells, seen as comedo-type necrosis, or from secretions in the 
luminal spaces. The clinical presentation of symptomatic cases is variable and may 
appear as a palpable mass, nipple discharge or as Paget’s disease of the nipple (23). 
Radiographic abnormalities are also often seen in the presence of symptomatic 
disease with up to 50% of Paget’s disease also showing some form of radiological 
abnormality (23).  
Mammographic calcifications (and histological microcalcifications) are not specific for 
DCIS and occur in many other processes, including normal breast tissue and both 
benign and malignant lesions, such as involutional changes, duct ectasia and 
fibrocystic change. It is not possible to accurately grade DCIS on mammography 
alone and even high grade DCIS lesions can be missed if the area is small.  
1.2.2 Ultrasound 
Ultrasound is a useful imaging tool for women who present with symptomatic breast 
disease and can be used to differentiate between a benign and malignant mass in 
some cases, for example by assessment of the regularity of the margin of the lesion. 
Its use for identification of DCIS is limited due to a low sensitivity for this disease (1). 
Nevertheless, ultrasound may be of use in the detection of DCIS where calcification 
is not present (approximately 16% of cases) which are undetected using 
mammography. A small study, of 22 cases, has shown that high definition ultrasound 
can improve upon mammographic screening where calcification is not present (25). 
Practically, however, it would be difficult to implement ultrasound screening for every 
patient who attends for breast screening who does not exhibit calcification in the 
breast on mammography. 
1.2.3 Magnetic Resonance Imaging (MRI) 
Magnetic resonance imaging (MRI) is a highly sensitive method for detection of 
invasive breast carcinoma. Historically, the sensitivity for benign lesions and for DCIS 
has been shown to be less reliable than other techniques (1, 2, 26) but more recent 
studies have indicated that it is more sensitive than mammography (1, 27). MRI does 
not visualise calcification but uses a contrast agent to detect neovascularisation. 
Identification of soft tissue changes in DCIS has been reported in 27% of cases using 
analogue mammography and 60% using digital mammography (27). The cost and 
time consuming nature of MRI coupled with the claustrophobic nature of the process, 
however, also inhibits its acceptance as a population screening technique for those 
not at high risk of developing cancer.  
1.3 Histology of Ductal Carcinoma in Situ 
1.3.1 Histological Diagnosis of Ductal Carcinoma in Situ 
Once a breast lesion has been identified and sampled it requires histological 
diagnosis and classification. Specimens are placed in a fixative or snap frozen before 
undergoing microtomy followed by haematoxylin and eosin staining (H&E) of cut 
sections. H&E staining provides morphological and nuclear detail of cellular 
structures and is a reliable stain for a diagnosis of a particular disease state.  
The biological events in the transition from a normal to a malignant state in breast 
tissues are difficult to assign into predefined groups. There is a spectrum of breast 
lesions with variable, but low, risk of developing invasive disease. Hyperplastic and 
atypical changes, such as usual epithelial hyperplasia (UEH), columnar cell lesions 
(CCLs) including flat epithelial atypia (FEA), and atypical ductal hyperplasia (ADH), 
represent a disparate group of entities that may exhibit some of the features of, but 
fall short of, DCIS. These entities are included here to highlight possible diagnostic 
pitfalls and to demonstrate the morphological and molecular similarities with DCIS. 
1.3.2  Usual Epithelial Hyperplasia 
Usual epithelial hyperplasia (Figure 2) is defined as a proliferation of cells above the 
basement membrane (BM) that have only mild or no abnormal architectural and/or 
cytological features. In the normal breast there is a two cell layer above the BM, that 
of a single layer of myoepithelial cells and a layer of epithelial cells.  Where the 
intraluminal proliferation is confined to four layers or less then the term mild usual 
epithelial hyperplasia is used.  Where five or more cells are present above the BM 
the term used is moderate epithelial hyperplasia. Where cells have undergone 
significant proliferation and crossed the ductal spaces enlarging the ducts then the 
term florid may be used. Clinically there is no increased risk of developing breast 
cancer where mild epithelial hyperplasia is present and the risk due to moderate or 
florid usual epithelial hyperplasia is low. Features that distinguish usual epithelial 
hyperplasia from more serious lesions such as atypical ductal hyperplasia (ADH) or 
DCIS as set out by the NHSBSP guidelines for 2005 are: 
1. The presence of a mixed cell population 
2. A syncytial growth pattern 
3. Irregular lumen often with a slit-like shape 
4. Peripheral lumina 
5. Streaming epithelial bridges 
6. No abnormal mitoses and few normal ones 
 Figure 2: Usual epithelial hyperplasia 
1.3.3 Columnar Cell Lesions (CCLs) including Flat Epithelial Atypia 
(FEA) 
Columnar cell lesions (CCLs) are formed from enlarged terminal duct lobular units 
typically with dilated acini lined by columnar shaped epithelial cells. These lesions are 
increasingly seen in image guided needle biopsies targeting mammographic 
microcalcification, which is typically present within secretions in the luminal spaces. 
In 2003 Schnitt and Vincent–Salomon (28) proposed a classification system 
consisting of four categories: columnar cell change, columnar cell hyperplasia, 
columnar cell change with atypia and columnar cell hyperplasia with atypia. The latter 
two categories were combined to a single entity of flat epithelial atypia (FEA) in 2003 
by the World Health Organisation (WHO) Working Group on the Pathology and 
Genetics of Breast Tumours. Columnar cell change and columnar cell hyperplasia 
are not considered to increase a risk of breast cancer development. FEA lesions are 
being detected with increased frequency due to breast screening programs where 
they may present with mammographic microcalificatons (29). The natural history of 
these lesions is poorly understood but possible progression to ADH, low grade DCIS 
and invasive carcinoma cannot be ruled out (29). This necessitates the distinction of 
FEA (Fig 3) from non-atypical CCLs for future patient management and surveillance. 
Molecular evidence indicates that FEA may be the earliest morphological 
identification of neoplastic change in the breast (30), as FEA lesions have a loss of 
heterozygosity (LOH) matched by those seen in adjacent concurrent DCIS or invasive 
cancers. In addition, common chromosomal alterations have been identified on 16q, 
11q and 13q, which are not observed in UEH but are frequently seen ADH and DCIS 
(30, 31). 
 
Figure 3: Flat epithelial atypia 
1.3.4 Atypical Ductal Hyperplasia (ADH) 
The morphology and cytological features of ADH are similar to low grade DCIS but 
this is a microfocal lesion that is generally confined to a single lobular unit. 
Specifically, ADH does not involve two complete membrane-bound spaces. The 
nuclei in ADH are uniform, small, regular and evenly-spaced. As well as the uniformity 
of cells, ADH forms rigid cellular bars and secondary spaces, which are not seen in 
FEA (Figure 4). There are presently no immunohistochemical markers available to 
distinguish ADH from low grade DCIS.  
 
 Figure 4: Atypical Ductal Hyperplasia 
1.3.5 Lobular Carcinoma In Situ, Atypical Lobular Hyperplasia, Lobular 
Neoplasia 
Atypical lobular hyperplasia and lobular carcinoma in situ have identical cytological 
features and are distinguished from each other by the extent of involved spaces (1). 
As such, the term lobular neoplasia was coined to describe both lesions. Cells lack 
cellular adherence, exhibit eccentric nuclei and often have intracytoplasmic mucinous 
vacuoles (Figure 5) (1). Lobular carcinoma in situ is considered a separate 
morphological non-obligate precursor to DCIS, conferring less risk of progression 
over a longer latent phase.  
 Figure 5. Lobular carcinoma in-situ 
1.3.6 Microinvasive Carcinoma  
Where a DCIS lesion exists and one or more foci of invasion are present but none 
measure more than 1mm in diameter the classification of microinvasion is given. This 
is most commonly seen in association with high grade DCIS but is uncommon in DCIS 
of any grade. Microinvasion may be misdiagnosed when DCIS spreads into lobules, 
a term known as ‘cancerisation’ of lobules. Correct classification can often be given 
by examination of further tissue sections (‘levels’) and/or immunohistochemistry with 
myoepithelial and basement marker examination. Cancerisation remains within the 
breast parenchymal structures and does not extend through the myoepithelial layer 
and basement membrane (Figure 6). 
 Figure 6: DCIS (top right) with microinvasion (left). 
1.3.7 Histological Variants of Ductal Carcinoma in Situ. 
Histologically DCIS was classified by the architectural pattern of the proliferating 
epithelial cells. Both the cytology and architecture of DCIS are complex and giving 
credence to DCIS as a group of heterogeneous lesions. In the United Kingdom the 
NHS Breast Screening Programme has issued a “Pathology Reporting of Breast 
Disease Guideline” (32) outlining criteria for the classification and reporting of all 
breast disease, including DCIS. A brief description and microphotograph of each 
entity is given below (1, 5, 32).  
Comedo pattern DCIS (Figure 7), also historically known as comedo carcinoma, is 
characterised by sheets of high grade malignant cells with an area of central necrosis 
typically surrounded by apoptotic cells. The necrotic area often contains 
microcalcifications identified mammographically. “Comedo” describes the central 
necrosis, rather than a specific cell type or grade and is therefore not now regarded 
as a true architectural type of DCIS. 
Solid DCIS (Figure 8) is characterised by sheets of malignant cells completely filling 
the duct space. Cells may be small with few mitoses or, more commonly, large and 
pleomorphic. Solid DCIS can be confused with lobular carcinoma in situ (LCIS), 
however the cells of solid DCIS have cell-cell adhesion, seen as distinct cell 
boundaries, and may bear microacini with cells showing polarisation around small 
luminal spaces.  
Papillary DCIS/papillary carcinoma in situ (Figure 9) presents architecturally as finger-
like projections into the ductal lumen. These are composed of fine fibrovascular fronds 
surrounded by columnar carcinoma cells. Duct spaces can be expanded/dilated. 
Myoepithelial cells are not observed between the epithelial cells and the fibrovascular 
cores, but are present around the external aspect of the duct space in true in situ 
disease. Where the projections are composed of epithelial cells alone and lack a 
fibrovascular core the term micropapillary is used. Micropapillary DCIS often also 
forms complex intraductal bridges and maybe admixed with cribriform patterns. 
Cribriform DCIS (Figure 10) has intraepithelial luminal spaces that are classically 
evenly-distributed and regular in shape. The central area of the lumen is usually 
present and may or may not contain areas of microcalcification and necrotic material.  
 
Figure 7: Central comedo necrosis within DCIS 
 
 Figure 8: Solid architecture DCIS 
 
Figure 9: Papillary DCIS/papillary carcinoma in situ 
 
Figure 10: Cribriform DCIS 
1.3.8 Rare Histological Forms of Ductal Carcinoma in Situ. 
Several rarer morphological variants of DCIS exist, some of which exhibit features 
that have potential for causing errors in histological diagnosis. The clinical 
significance of the histological features and genetic mutations present in such lesions 
remains poorly researched and are not understood.  
Clear cell DCIS is formed of cells with distinct margins and clear cytoplasm. Both 
cribriform and solid structures may be present with central necrosis. Poorly fixed 
tissues can take on the appearance of clear cell lesions (1). 
In apocrine DCIS the cells have the features of apocrine cells with abundant, granular 
eosinophilic cytoplasm, large nuclei and prominent nucleoli. Severe cytological atypia 
is often present, as is central necrosis (1). 
Neuroendocrine DCIS has polygonal or spindle shaped cells that usually have 
granular cytoplasm. A pseudo-rosette architecture and papillary areas may be seen. 
Often positive for oestrogen receptor and neuroendocrine markers this lesion should 
not be confused with epithelial hyperplasia which has a similar “streaming” 
architecture (1).  
Flat high grade DCIS is possibly a variant of micropapillary DCIS. The features are 
similar to a variety of columnar cell changes seen in both benign and malignant breast 
disease which makes identification and classification difficult (1).  
Cystic hypersecretory DCIS is also a variant of micropapillary DCIS but produces 
eosinophilic or mucinous secretions, which expand the ducts to give a cystic 
appearance. Microcalcifications are common (1).  
One of the challenges encountered with classification based on architectural features 
lies with the presence of more than one of the morphological subtypes coexisting in 
the same lesion. Descriptive histology terms such as comedo, cribriform, 
micropapillary, solid, papillary or even “clinging” provide some indication of extent and 
likely behaviour of disease but are often present in combination, making 
categorisation difficult for the pathologist. Quinn et al (33) found that heterogeneity or 
a mixed architecture was present in up to 62% of cases. 
1.4 Classification Systems for Ductal Carcinoma in Situ 
1.4.1  Growth Patterns for Ductal Carcinoma in Situ 
DCIS usually presents in a single duct system and rarely exhibits a multifocal 
distribution (34). Several studies have been carried out looking at growth patterns in 
DCIS (35-37). All postulate that where apparently multicentric disease (i.e. more than 
one cancer separated by normal breast tissue) is present it is due to large lesion size 
with extended growth along the ductal system. Micropapillary DCIS, however, has 
been shown to have a greater incidence of multiple foci when compared to other 
histological subtypes (37). 
1.4.2 High Grade, Intermediate Grade and Low Grade Ductal 
Carcinoma in Situ 
There are several grading systems (38-43) classifying DCIS largely utilising 
cytonuclear features, into high grade, intermediate grade or low grade categories. It 
should be noted that whichever grading system is used that there is a degree of 
interobserver variability between pathologists, particularly with regard to intermediate 
grade DCIS. The current UK grading system for is based upon guidelines set by the 
NHSBSP (6). 
 
High Grade DCIS is characterised by large pleomorphic cells with variation in size 
shape and polarity. Coarse chromatin and prominent nucleoli are abundant and 
mitotic cells are frequently seen. Nuclear outlines have irregular contours and may 
appear crenelated with the enlarged nuclei being greater than three times the size of 
erythrocytes. High grade DCIS is usually associated with a central necrosis and 
calcification deposits within this area. This calcified necrotic debris is identified on 
mammographic screening.  
Low grade DCIS comprises more evenly-spaced uniform cells that are generally 
smaller than other forms of the disease. The cells have regular, round nuclei located 
centrally and are normally one to two times the size of erythrocytes. Cells are 
arranged in well-ordered patterns showing polarity. Mitotic figures are sparse. A solid 
sheet architecture is rare but cribriform and micropapillary patterns are common, often 
with both present in the same lesion. When both are seen the cribriform pattern tends 
to dominate.  
Intermediate grade DCIS cells exhibit moderate pleomorphism and lack the uniformity 
of a low grade lesion.  Nuclear size is greater than that seen in low grade DCIS being 
two to three times the size of erythrocytes and occasional nucleoli are present. 
Lesions can have a cribriform, solid or micropapillary pattern with some polarisation 
of cells.  
Although rare, sometimes a DCIS lesion will exhibit a range of nuclear features; when 
this occurs the classification is according to the highest nuclear grade present. 
1.4.3 The Van Nuys Grading System for DCIS and the Van Nuys 
Prognostic Index (VNPI) 
The Van Nuys grading system (38) applies a combination of cytonuclear features (as 
above), combined with the presence of comedo-type necrosis to classify DCIS. High 
grade lesions are classified according to the cytonuclear grade, regardless of the 
presence of necrosis, whilst non-high grade lesions are classified as non-high grade 
with necrosis or non-high grade without necrosis. This classification divides DCIS into 
three groups with differing risk of recurrence.  
The grading system was further enhanced into a prognostic index for DCIS by adding 
tumour size and margin width (distance of tumour cells from excision margin) to the 
pathological classification. This classification was named the Van Nuy’s Prognostic 
Index (VNPI) (39). The VNPI takes into account these three parameters associated 
with local tumour recurrence in patients with DCIS. Tumour size, margin width and 
pathological classification are all assigned a score of 1-3; 1 relating to best prognosis. 
A sum of the scores, of 3-9, was determined and a cut-off point relating to treatment 
failure, i.e. recurrence, was calculated. The original classification study was carried 
out on 333 patients and determined that a VNPI score of 3 or 4 showed no additional 
benefit for disease free survival from radiation treatment compared to scores of 6 or 
7 who did receive benefit. Those patients with scores of 8 and 9 had a high recurrence 
rate regardless of treatment. The VNPI was updated by Silverstein et al as the 
University of California/ VNPI in 2003 with the addition of age as a factor in 
determining treatment (44). 
1.4.4 The Tavassoli Grading/Classification System  
The Tavassoli system (40) splits high grade, intermediate and low grade DCIS into 
ductal intraepithelial neoplasia groups (DIN). The designation removes ‘carcinoma’ 
from the terminology, similar to neoplasia grading in cervical screening. DIN3 
represents high grade DCIS with, or without, marked intraluminal necrosis and 
severely atypical nuclei. DIN2 is characterised by cribriform or micropapillary type 
lesions with mild to moderate nuclear atypia, with or without necrosis. The 
classification of DIN1 requires the absence of necrosis and mild atypia with uniform 
nuclei and includes hyperplasia of usual type (HUT) and atypical hyperplasia (see 
above).  
1.4.5 R Holland and the European Pathologists Working Group 
Classification System  
This grading system, first proposed by Holland et al (41), uses nuclear pleomorphism 
combined with cell polarity to define high grade, intermediate grade and low grade 
DCIS. Polarisation of cells is the orientation in relationship to luminal spaces, where 
loss of polarisation indicates a higher risk of local recurrence. The European Breast 
Screening Working Group adopted a similar system (42), relying on nuclear grade but 
ignoring polarisation on the grounds of difficult reproducibility amongst pathologists. 
This is the system currently recommended in the NHSBSP guidelines (32). 
1.4.6 Summary of Classification of DCIS 
There are at least ten grading systems described for reporting of DCIS. All have their 
merits and disadvantages. Shoker and Sloane (45) reviewed the available 
classifications in 1999 and determined that nuclear grade was the best predictor of 
risk of recurrence. Pinder et al (46) reviewed over 1600 cases of DCIS for the UK 
Coordinating Committee on Cancer Research (UKCCCR) trial. A full pathological 
assessment of all cases was undertaken and compared the Van Nuy’s, Nottingham 
and Holland classifications. There results found that all grading systems of DCIS 
showed a significant association with recurrence of ipsilateral DCIS or invasive 
disease. However, they identified an additional subgroup, which had a particularly 
poor recurrence rate. This group was defined by over 50% of ducts showing central 
comedo type necrosis, a high cytonuclear grade and over 50% of ducts showing a 
solid architecture pattern. Pinder et al proposed a new three group system to define 
DCIS. The categories are: 1) low and intermediate cytonuclear grade DCIS, (2) high 
cytonuclear grade DCIS with non-solid architecture and < 50% of ducts with necrosis 
(3) high cytonuclear grade DCIS with a predominantly solid architecture and >50% of 
ducts bearing central comedo necrosis.  
All of the classification systems rely upon traditional pathological evaluation of H&E 
stained tissue sections. Whilst they all have been shown to have a predictive element 
and be related to risk of disease recurrence, none are currently definitive in the 
assessment of a possible relapse; thus even patient’s with low grade (low risk) DCIS 
may develop recurrent disease as in situ or invasive breast cancer. This may be due 
in some part to the subjective nature of pathology reporting and interpretation of 
morphological definitions.  
1.5 Treatment of Ductal Carcinoma in Situ 
1.5.1 Surgical Procedures and Options for Ductal Carcinoma in Situ 
Treatment options for DCIS are similar to those for invasive carcinoma being 
mastectomy, or breast conserving surgery (BCS) with or without radiotherapy (RT) 
(47). The American College of Radiology (ACR) issued appropriateness criteria in 
2011 which reflect both the heterogeneity of DCIS and the patient-driven choice (47). 
The recommendations state that BCS with whole breast radiotherapy for localised 
DCIS is acceptable, as opposed to mastectomy. Older patients with fully excised low 
grade DCIS may undergo observation alone. In cases where microinvasion is present 
with DCIS (mDCIS) then a sentinel lymph node biopsy is advised.  
1.5.2 Radiotherapy for Ductal Carcinoma in Situ 
Radiotherapeutic treatment for DCIS is primarily recommended after breast 
conserving surgery and seldom performed after a mastectomy for DCIS. There 
remains some controversy as to the clinical need and effectiveness compared to 
breast conserving surgery alone. In 2013 Donker et al (48) reviewed the treatment of 
DCIS with and without radiotherapy (RT) after local excision of lesions. They studied 
survival rates over a period of fifteen years for both groups from a European 
Organisation for Research and Treatment of Cancer (EORTC) randomized phase III 
trial (number EORTC10853). They found that 30% of women who underwent local 
excision for DCIS without radiotherapy had a local recurrence (LR) with 50% of these 
being invasive. In the group in receipt of both local excision and RT, only 17% had a 
recurrence, with 56% of these having an invasive recurrence. In both groups the risk 
of recurrence in the first five years was greater than ten or fifteen years. From these 
data radiotherapy is shown to decrease the risk of local recurrence. However, a 
difference in local recurrence between the two groups was not translated into any 
change in breast cancer specific survival. All subgroups of DCIS had a reduced 
recurrence rate with RT with clinging/micropapillary DCIS showing the least additional 
benefit (no RT = 12.5% recurrence, with RT = 5%).  
Other clinical trials have similarly demonstrated a reduction in local recurrence with 
the use of RT (49-52). In a Swedish study, Holmberg et al (49)  found that RT 
substantially reduced the risk of recurrence but was more beneficial in older women 
compared to younger women. Confounding factors in the treatment of DCIS with RT 
such as DCIS grade, age, RT dose, length of dosage time and the use of boost (a 
higher final dose aimed at the tumour bed) and the effect of adjuvant intervention 
(such as hormone therapy) make definitive conclusions difficult to make over such 
long survival periods.  The Loris trial (53) is an ongoing a phase III trial addressing 
possible overtreatment of low grade DCIS by using active monitoring as opposed 
surgical treatment for screen detected or asymptomatic low grade DCIS.  
Cuzick et al (50) looked at the effect of Tamoxifen and RT in DCIS patients. 1701 
women were randomly assigned to treatment groups: RT and Tamoxifen, RT alone, 
Tamoxifen alone, or to no adjuvant treatment. Their findings also showed a benefit in 
reducing either DCIS or invasive ipsilateral recurrence with RT. They also found that 
RT had no benefit for overall survival (OR). They reported that Tamoxifen had an 
increased benefit in prevention of development of cancer in the contralateral breast. 
1.5.3 Hormone Therapy for Ductal Carcinoma in Situ 
DCIS may be treated with anti-oestrogens such as Tamoxifen or aromatase inhibitors 
(AI) if a lesion is positive for oestrogen receptors. Staley et al (54) reviewed the 
Cochrane Central Register of Controlled Trials (CENTRAL, The Cochrane Library), 
the Cochrane Breast Cancer Group’s Specialised Registry, and the World Health 
Organization’s International Clinical Trials Registry Platform (WHO ICTRP) in 2011 
looking at randomised clinical trials using Tamoxifen with or without radiotherapy. 
They conclude that, in a similar fashion to RT, Tamoxifen reduces the recurrence rate 
but has no effect on OS. The NASBP-24 trial (55) found that Tamoxifen reduced 
recurrence in ER positive DCIS but not in ER negative DCIS. 
1.5.4 Chemotherapy for Ductal Carcinoma in Situ 
Chemotherapy as a treatment is not usually given or recommended for DCIS. As pure 
DCIS is a non-invasive lesion, which has not metastasized, systemic treatment is 
regarded as having little or no benefit for patients.  
1.6 Techniques for the Diagnosis and Investigation of Prognosis in DCIS 
and Invasive Breast Cancer 
1.6.1 Sampling Techniques. 
Once a suspected lesion is identified, either through screening or symptomatic 
presentation, a confirmed histological diagnosis is required. In order to achieve this 
there are several possible sampling techniques the clinician may choose.  These are 
discussed below with relation to suitability for a diagnosis of DCIS. 
Fine needle aspirate (FNA) or fine needle aspiration cytology (FNAC) is a 
percutaneous process of using a small needle attached to a syringe to extract cells. 
Cells are directly drawn from the site of interest and smeared onto glass slides where 
the cells are stained and interpreted. This procedure is suitable for the identification 
of cancerous cells but has severe limitations in its ability to distinguish in-situ lesions 
from invasive carcinoma, due to the lack of relevant architecture/morphology. The 
NHS Breast Screening Programme specifically does not recommend FNAC for the 
diagnosis of microcalcifications. 
A core biopsy is the removal of a solid core of tissue by the use of a hollow needle. 
The needles can be of various sizes or gauges. The choice of biopsy size for palpable 
lesions is often a matter of clinical preference, although there are studies that indicate 
that a 14 gauge is superior to either a 16 or 18 gauge needle (56, 57). The use of 
ultrasound guidance and/or a stereotactic needle biopsy (where 3 dimensional 
coordinates are used to locate the area to be sampled on x-ray) are required for non-
palpable lesions. There is evidence that ultrasound guidance reduces the false 
negative rate in identifying breast carcinoma using core biopsies (58, 59). Core 
needle biopsies are suitable for the identification of DCIS, however some caution is 
advised when giving a definitive diagnosis based on core biopsy alone (60); studies 
of the underestimation of invasive disease where a core needle biopsy shows DCIS 
range from 8% to 41% (58, 61). Chan et al found that lesion size and the number of 
cores taken were predictive factors in cases where a diagnosis of DCIS was made 
but there was adjacent invasive disease present compared to core sampling alone 
(62). 
Vacuum-assisted biopsies utilise a larger gauge needle and have the advantage that 
multiple tissue samples can be obtained from one insertion. Vacuum-assisted 
biopsies are normally performed under image guidance, in the form of x-rays or 
ultrasound, to assist the sampling of breast abnormalities. Studies comparing 
vacuum-assisted biopsies against non-vacuum stereotactic biopsies have shown that 
the need for repeat biopsies is reduced, although not eliminated (63, 64). 
In some instance definitive diagnosis with FNAC or core biopsy pre-surgery may not 
be possible. If there is a high suspicion of malignancy then an open biopsy may be 
performed by surgical excision.  
1.6.2  Fixation and Processing of Biopsies 
Once a tissue sample has been removed, it requires preparation for light microscopy. 
The standard practise in most UK laboratories is to fix tissues in a formaldehyde 
fixative, or one of its derivatives, and process to paraffin wax blocks. Fixation stops 
putrefaction and autolysis whilst processing to paraffin wax has a twofold aim. This is 
the removal of water, which assists fixation, and the hardening of tissue so that it can 
be suspended in a suitable medium (paraffin wax). This enables slicing thin enough 
for light to pass through thus enabling light microscopy. Processing is achieved by 
passing tissues through a variety of graded alcohols and organic solvents followed 
by impregnation with molten wax. Thin sections of wax embedded tissue are cut, 
usually 3-4m thick, and stained with haematoxylin and eosin stain (H&E) to 
demonstrate the nuclear and cytological components of cells. A diagnosis is generally 
made on the H&E stains, although a panel of immunohistochemistry (IHC) antibodies 
may also be used as ancillary tests to aid in a definitive diagnosis. In invasive breast 
cancer additional IHC is then performed to establish the expression of hormonal 
markers such as oestrogen and progesterone receptors and growth factors such as 
HER2 in order to determine subsequent optimum clinical treatment.  
Immunohistochemistry (IHC) is a technique for identifying tissue components 
(antigens) by means of an antibody-antigen reaction. Antibodies specific to a known 
epitope, or epitopes, can be produced by injecting a host species (usually a mouse 
or rabbit) with the antigen. The host then produces an immune response in the form 
of antibodies. These antibodies (known as the primary antibody) can be harvested 
and applied to histological sections where they will bind to their target antigen if it is 
present. In fluorescence microscopy a fluorophore is usually bound to the primary 
antibody to give a fluorescent image.  In chromogenic or light microscopy the primary 
antibody signal is usually amplified by the application of secondary antibodies. These 
secondary antibodies are links binding to the primary antibody and an enzyme, either 
with the use of a polymer chain or an avidin biotin complex. The substrate for the 
enzyme forms an insoluble coloured end product when applied and can be viewed 
using light microscopy. The most common enzyme substrate reaction used in IHC is 
currently horseradish peroxidase (HRP) combined with a diaminobenzidine (DAB) 
substrate, which produces a brown coloured end product. The use of IHC to identify 
proteins or antigens in tissues has significant advantages over other protein assays, 
as the target protein can be identified in its morphological setting. This enables 
identification of proteins in tumours or normal tissues.  
IHC as a technique does however have some inherent problems. In the UK, the 
majority of tissues for examination are fixed in formaldehyde or one of its derivatives. 
Whilst an excellent fixative, formalin produces cross links in the form of hydroxymethyl 
and methylene bridges, which may effectively mask the antigen of interest (65), and 
prevents primary antibody binding. In order to overcome this, antigen retrieval (AR) 
techniques utilising heat and salt solutions have been incorporated in many IHC 
protocols. Unfortunately there is little standardisation of the use of fixatives with 
regard to type and length of fixation, resulting in the need for optimisation of individual 
antibodies with known positive controls in each different laboratory. The lack of 
standardisation in laboratories may affect interpretation of IHC markers and is one of 
the contributory factors that make IHC scoring somewhat subjective in nature. 
However, despite these limitations, IHC has proven to be a valuable tool in both 
diagnosis and in prediction of response to therapy in breast cancer diagnosis.  
1.6.3 Immunohistochemistry in Assessment and Prognosis of Ductal 
Carcinoma in Situ  
Immunohistochemistry is commonly used to assess DCIS. The demonstration of an 
intact basement membrane (BM) or myoepithelial cell layer is integral to a diagnosis 
of DCIS as opposed to an invasive lesion. Antibodies raised against the BM include 
collagen IV and laminin whilst myoepithelial markers such as smooth muscle myosin 
heavy chain (SMMHC), p63 and smooth muscle actin (SMA) are all used in diagnostic 
laboratories to confirm that the lesion is in-situ. Other IHC markers may be used to 
help in the differential diagnosis of a lesion, for example E-cadherin is typically 
positive in DCIS but absent or reduced in LCIS, and ER and basal cytokeratins, such 
as cytokeratin 5 and cytokeratin 14, typically show homogenous staining patterns in 
DCIS and can be used to aid in a differential diagnosis between UEH and DCIS (1). 
There are currently no IHC markers to distinguish ADH from DCIS.   
The demonstration of hormonal markers, HER2 or other IHC markers are not routinely 
used to classify DCIS or predict the possibility of invasion. ER expression in DCIS 
remains difficult to assess mainly due to the lack of clinical data defining positive and 
negative thresholds. The various scoring techniques employed e.g. Histoscore, Allred 
and percentage score also prevent systematic comparison. Expression of ER is lower 
in high grade DCIS than low grade DCIS and the percentage of DCIS ER positive 
cases is approximately 70%, which is similar to that found in invasive series (1). The 
expression of HER2 in DCIS has been shown to be higher in high grade DCIS than 
in grade 3 invasive tumours, with expression in 50-60% cases compared to 
approximately 20%, cases respectively. For example, Park et al (66) found that pure 
DCIS expressed HER2 at a greater frequency than invasive breast disease. Borgquist 
et el used tissue microarrays to determine Her2 expression in primary DCIS. In their 
cohort of 458 patients over 30% had Her2 positive DCIS (n=132). They found the risk 
of developing an invasive breast cancer recurrence was “statistically significantly 
lower subsequent to a HER2 positive DCIS compared to a HER2 negative DCIS(67)”,  
1.6.4 Tissue Microarrays (TMAs) 
Tissue microarrays (TMAs) were first described in their current format by Kononen as 
a tool for gene expression and copy number analyses (68). Subsequently, the 
technique was recognised, and has been widely used, as an efficient method for 
assessing biological markers on large numbers of cases economically. Biomarker 
validation using TMAs with immunohistochemistry (IHC) and in situ hybridisation 
(ISH) is valuable for evaluation of putative diagnostic and prognostic markers and 
also drug targets when applied to large series and especially to randomised clinical 
trial samples. Tissue microarrays (TMAs) have become an established research tool 
over the last ten years enabling rapid assessment of significant numbers of test 
tissues using tinctorial staining, IHC or ISH. The premise of the procedure is to sample 
pre-existing blocks of histologically processed tissue for further evaluation by 
removing individual cores from each test case and amalgamating these into one block 
from which multiple tissue sections can be taken for analysis. The procedure allows 
simultaneous testing of multiple cores, giving reduced costs and improved 
standardisation of experiments. The vast majority of TMAs are constructed from 
formalin fixed paraffin wax embedded tissues using 0.6mm, 1.0mm or 1.5mm cores 
taken from a donor block using a hollow tube (stylet) to biopsy the original tissue 
which are then are placed into a recipient wax block (Figure 11) into which up to a 
hundred or more cores can be placed. Once the blocks have been constructed the 
cores are annealed to the recipient block by a process of gentle heating and cooling. 
Once this has been achieved, sections are cut in the normal manner on a microtome 




Figure 11: TMA manufacture and stylets  
(TMA image courtesy of Yale University, Department of Pathology, Connecticut 
USA.) 
1.6.5 Genetic Aberrations & Molecular Inversion Probe Arrays for 
Genomic Profiling 
Profiling of the human genome is increasing our understanding of the disease process 
and is seen as a potential tool to identify new biomarker targets for interventional 
therapy. However, the human genome contains more than ten million nucleotide 
positions that have >1% or “common” variations between individuals. Identification of 
these differences and subsequent comparison of the genomic changes found in 
progression from normal to a tumour state in breast and other, cancers requires 
reliable and robust sequencing methodologies. The field of genomics has made 
significant advances since the publication of the human genome sequence 
simultaneously by Lander et al (69) and Ventner et al (70).  
An individual has two copies of the genome, one from each parent. Where a single 
base differs in the genome between these two inherited copies a single nucleotide 
polymorphism (SNP) is present giving rise to heterozygosity in the individual’s 
genome. Chromosomal arrangement in humans is paired, allowing for 
heterozygosity. However, loss of a genomic region from one parent can occur giving 
only one region, which by default cannot be heterozygous at a SNP location; this is 
termed as loss of heterozygosity (LOH). LOH of a tumour suppressor gene results in 
only one copy of the suppressing gene. A point mutation (replacement of a single 
base) can lead to inactivation of the tumour suppressing gene given rise to potential 
tumourigenesis. However, LOH is not restricted to a loss of a genomic region; copy 
neutral LOH can occur where no overall net loss of chromosomes or copy number is 
apparent. Also known as unipartietal disomy (UPD) (71), errors during meiosis may 
result in two copies, or partial copies, of a genomic region which are inherited from 
one parent and not the other parent. This can cause inherited homozygosity and, if a 
non-functional tumour suppressor gene is present, may also result in tumorigenesis. 
It is estimated that up to 50-75% of human cancers demonstrate LOH (71, 72).  
In addition to LOH, and copy neutral LOH, deletions of chromosomal regions and 
amplifications can also lead to cancer development. Copy number variations (CNVs) 
are abnormal variants in one or more regions of the genome. They usually correspond 
to large regions ranging from one kilobase to several megabases and can be either 
deletions or amplifications. They differ from SNPs in that the copy number variation 
can be repeated along the length of DNA, e.g. a section that has repeat elements with 
GGATCC may be replaced with GGGATCC (duplication) or GGATC (deletion).  CNVs 
have been estimated to account for approximately 13% of human genomic DNA (73).  
Various platforms have been developed to improve the speed, accuracy and quality 
of genomic profiling (74). The goal of personalised whole genome association studies 
requires the ability to identify aberrant genomically regions from very little tissue or 
DNA with minimal cross reaction; as may seen with PCR amplification where 
carryover of PCR products to subsequent amplification reactions can occur, in a 
cheap and reproducible system (75).  Molecular Inversion Probe (MIP) arrays are a 
technology for analysis of SNPs, copy number alterations, somatic mutations and loss 
of heterozygosity (LOH) (including copy-neutral LOH). The probes consist of primers 
of approximately 20 nucleotides separated by a linker region (usually an 
endoribonuclease) and sequences of single stranded DNA that are complimentary to 
regions adjacent to a SNP in the target DNA sequence of a sample. The technique 
works on the principle of a SNP-genotype reaction being placed directly upon the 
genomic DNA target prior to any amplification and then subsequently using a PCR 
step to only increase the amplification of detected target molecules. This alleviates 
problems of multiplex PCR where undesired reactions such as “primer dimers” are 
caused by unwanted binding of complimentary bases instead of the intended DNA 
amplicons. Each MIP has two sequences that are complementary to the target DNA 
at the 3 primed (3’) and 5 primed (5’) ends of the DNA strand (Figure 12). Each 
sequence hybridizes to the target, becoming “inverted” and forming a circle with the 
3’ and 5’ ends adjacent to each other with the restriction endoribonuclease forming a 
free hanging loop. 
 




Figure 13: MIP array process for genomic profiling 
 (Adapted from http://en.wikipedia.org/wiki/File:MIP_technique_timothy.png#filelinks 
copyright permission licensed under the GFDL see: Appendix 1) 
 
MIP array technology has been further developed by the commercial company, 
Affymetrix (California, USA), to be used in archival formalin fixed paraffin wax 
embedded material (FFPE).  The company cites the advantages of MIP array as the 
ability to identify genomic regions of interest in partially degraded samples such as 
FFPE tissue allowing as little as 40bp per genomic region of interest and being able 
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to identify difference in copy number states in as little as 60bp with a high 
discrimination between “signal” and “noise” ratio in degraded samples. One additional 
advantage of MIP array technology is the multiplexing ability where thousands of loci 
can be simultaneously analysed; the Affymetrix system offers over 300,000 markers.  
1.7 Molecular Portraits of Breast Cancer 
1.7.1 Genetic Subgroups of Invasive Breast Cancer 
The morphological and molecular heterogeneity of breast tumours makes the 
classification of lesions challenging. Perou (76) and Sorlie (77) have shown that 
invasive breast cancers can be classified into distinct genetic subgroups that correlate 
with overall survival (OS) and disease free survival (DFS) and have potentially 
important clinical implications. Their findings have been corroborated in other studies 
(76, 78, 79). The sub-groups of invasive breast carcinoma, designated as luminal A, 
luminal B, ERBB2-positive, basal-like and “normal” demonstrate that the phenotypic 
variety seen histologically is, unsurprisingly, present at the molecular level. The 
molecular phenotypes correlate well with certain immunohistochemical profiles. 
Approaches have confirmed the existence of some subclasses, such as the basal-
like groups of tumours which had been previously described in some IHC series (78, 
80-83) but which, until genomic expression profiling, had not been truly regarded as 
a distinct subgroup of invasive breast cancer.   
Perou’s experiments examined breast cancer profiles using known gene clusters for 
65 tissue tumour samples along with cultured cell lines of known genomic sequences 
to ascertain a molecular signature of the breast cancers studied. In developing a 
system for classifying tumours based upon the gene expression, a second subset of 
genes (known as the intrinsic subset) to further classify tumours was 
examined/proposed. Using the rationale that any samples taken from the same 
tumour should demonstrate a similar profile and that separate tumours should vary in 
their expression, twenty paired samples were analysed and gave rise to identification 
of 496 genes with significant variation between tumours compared to the paired 
samples. As Perou points out there, is a great multidimensional variation in gene 
expression in that the patterns are mainly independent.  However, there are distinct 
molecular portraits that relate to both similarities and differences of tumours. These 
include a proliferation cluster as the largest group, which correlated with the 
histological mitotic index and the immunohistochemical markers of proliferation, Ki67 
and PCNA. As the hierarchical cluster is further broken down, two dendogram 
branches reveal oestrogen receptor (ER) positive and ER negative tumours 
separated by clusters of genes expressed by luminal cells of the breast. The ER 
positive, luminal grouping was also correlated with immunohistochemical expression 
of cytokeratins 8 and 18. Further evaluation by Sorlie et al, elucidated that these 
luminal groups could be further subdivided into groups luminal A, B and “normal” like.  
Six tumour samples from the original Perou experiments clustered in a group 
associated with genes characterised in basal or myoepithelial cells of the breast. This 
group had a protein expression of cytokeratins 5/6 and 17. The basal-like subgroup 
has particular clinical implications as the vast majority of these tumours exhibit 
negative IHC staining profiles for ER, progesterone receptor (PR) and HER2. These 
tumours are unlikely, therefore, to respond to Tamoxifen or aromatase inhibitors as 
they lack expression of hormone receptors. Similarly, the lack of HER2 expression 
means that tailored anti-HER2 therapy, such as with trastuzumab, is also likely to be 
of little value. The lack of expression of these three markers which is frequently seen 
in these basal-like lesions has resulted in the ‘triple negative’ term being erroneously 
used synonymously to such “basal–like” tumours. Rakha (84) reviewed the 
expression profiles of basal-like lesions and addressed some of the confusion 
surrounding the definition of basal-like tumours. Rakha points out that there is a large 
subset of the basal-like group that is triple negative in immunophenotype but that the 
absence of these three markers does not automatically indicate a basal-like 
phenotype. Conversely, tumours within other molecular sub-groups may also exhibit 
a triple negative profile.  It should also be noted that the expression of one single 
“basal” IHC marker does not necessarily detect a basal tumour. Rakha advocates the 
use of a panel (CK5/6, CK14, CK17, EGFR), with positive expression of these, as 
well as ER and HER2 negativity required for the identification of a basal-like tumour. 
The majority of invasive breast cancers arising in BRCA1 carriers also fall into the 
basal group, but this also is not exclusive. The definition of basal-like tumours cannot 
therefore be defined by either a triple negative phenotype or a BRCA1 carrier group, 
once again demonstrating the heterogeneity of invasive breast tumours. The basal-
like immunophenotype has also been identified in forms of DCIS (85-87). 
The next subdivision postulated by Perou et al is the HER2 expressing group. This 
cluster contained not only the Erb-B2 locus, but also several other genes located in 
the same region on chromosome 17. This subset also showed lower levels of ER 
positivity. 
The “normal like” subgroup was identified and named based on similarities in gene 
expression patterns to those of normal epithelial cells, adipose tissue and other non-
epithelial cell type. Norum describes these tumours in 2014 as “clearly carcinomas 
that have gene expression features common to both basal-like and luminal subtypes, 
showing no expression of proliferation-associated genes” There is an 
acknowledgement that these samples may have a low tumour cell percentage within 
the samples(88).   
The molecular profiling of invasive breast tumours, and subsequent subdivision of 
tumours into groups, may have wide-ranging clinical implications. Currently, the 
pathological assessment of tumours and patient’s prognosis and subsequent clinical 
management is based upon descriptive histological factors such as lymph node 
stage, pathological measurement of carcinoma size and histological grade, the latter 
incorporating a proliferative assessment, and morphological (architectural and 
cytological) subtypes. These factors are routine coupled with the IHC expression of 
several markers, notably ER, PR and HER2, which are used as predictive markers 
and on which likelihood of response to hormone therapy and trastuzumab is based. 
Other antibodies can help with the identification of morphological tumour type but 
have a limited prognostic value; for example, it is well recognised that invasive lobular 
carcinoma typically shows a loss of E-cadherin immunohistochemically. In addition, 
many novel markers, although demonstrating some potential as prognostic markers, 
for example c-kit (86, 87), Aurora A (89, 90) and BCL2 (91-93) are not widely accepted 
as independent predictive markers of significance compared to existing pathological 
criteria.  
The molecular expression profiles demonstrate that morphologically similar tumours 
may be subdivided into groups which appear to have different genetic origins, leading 
to questions regarding current histological classification, particularly the “histological 
special types” (94, 95). Such findings also raise questions as to the validity of current 
practice. However, it should be noted that studies of genetic molecular profiling of 
invasive breast tumours have been carried out on relatively small numbers. Validation 
of these classification criteria using microarray based systems on thousands of 
samples is cost prohibitive and any novel genetic taxonomy would require detailed 
correlation with existing clinical practice.  
1.7.2 IHC as a Surrogate to Genomic Profiling. 
The use of tissue microarrays and IHC can facilitate the examination of the 
robustness of the genetic subdivisions. Several studies have focussed upon this 
method, with promising results (82, 86, 96). Abd El-Rehim (96) et al analysed over 
1000 breast tumours with a large immunohistochemical panel of 25 antibodies. These 
included antibodies for the luminal phenotype based upon the expression of 
cytokeratins 7/8, 18 & 19 and the basal phenotype with cytokeratins 5/6 and 14. In 
addition to this hormonal markers ER, PR, androgen receptor (AR), tumour 
suppressor genes (p53, BRCA1, Anti-FHIT), cell adhesion molecules (E-cadherin, P-
cadherin), mucins (Muc-1, Muc-1 core, Muc-2), apocrine differentiation (Anti-GCDFP-
15), and neuroendocrine differentiation (chromogranin A, synaptophysin) were 
evaluated. Using an agglomerative clustering approach, Abd El-Rehim et al classified 
tumours into six groups, with nine of the twenty five antibodies being key 
discriminatory markers (AR, c-erbB-2, CK18, MUC1, CK5/6, p53, nuclear BRCA1, ER 
and E-cadherin). Interestingly, the results broadly correlate with the genomic arrays 
of Perou and Sorlie and defined six classes of breast cancer. Two were hormonal 
positive luminal groups having similar immunohistochemical profiles to luminal A and 
B sub-groups but having differing overall disease free survival, a third group had c-
erbB2 (HER2) positivity with strong Muc1 expression, altered E-cadherin and weak 
hormonal marker expression. The fifth group showed elevated p53 and basal marker 
expression and lower hormone receptor expression, group six consisted of HER2 and 
E-cadherin positive tumours that had weak or no hormone receptor status and MUC1. 
Group four only consisted of four tumours so it is difficult to draw conclusions for this 
division. 
These authors similarly showed, like Perou et al, that the IHC identification of sub-
groups was of prognostic value in invasive breast cancer. The grouping determined 
in this series was defined by a panel of antibodies reflecting the various genetic 
pathways that may be responsible for tumour growth. Other workers, such as Nielsen 
(82) and Rakha (84), have also demonstrated that the basal subgroup can be 
identified using IHC markers.  
In 2011, the St Gallen International Expert Consensus on the Primary Therapy of 
Early Breast Cancer agreed to define subgroups for invasive breast cancer based on 
clinicopathological criteria, including immunohistochemistry for ER, PR, HER2 and 
Ki67, as opposed to a gene expression array criterion. Their reasoning was that 
systemic therapy approximately matches the subtype classification (97). They 
proposed the following subgroups: luminal A (ER and/or PR positive, HER2 negative 
and Ki67 <14%), luminal B/HER2- (ER and/or PR positive, HER2 negative and Ki67 
≥14%), luminal B/HER2+ (ER and/or PR positive, HER2 positive), HER2+/ER- (non 
luminal) (ER and PR negative and HER2 positive) and triple negative (ductal), (ER, 
PR and HER2 negative). To date only one study (98) has used this specific criteria to 
assess DCIS, finding no link between the subgrouping and risk of recurrence, as 
either invasive carcinoma or DCIS, over a ten year period.  
 
1.8 Conclusion 
DCIS still represents a clinical dilemma for patient management. The inability to 
reliably predict possible progression to invasive breast cancer results in the possible 
overtreatment of what can be regarded as a non-life threatening condition. Current 
treatment options remain controversial with no consensus upon the choice of 
mastectomy, or breast conserving surgery with or without radiotherapy, or indeed 
adjuvant hormone treatments.  
The natural progression and molecular pathology of DCIS also still remains poorly 
understood. This thesis aims to address some of these problems by analysing a 
series of DCIS cases with known clinical outcome. This includes DCIS lesions that 
have not progressed (pure DCIS), DCIS lesion that have had a DCIS recurrence and 
DCIS lesions that have an invasive recurrence with or without associated DCIS. A 
further series of cases of pure DCIS and DCIS admixed with invasive disease 
contemporaneously allows comparison of biomarker and genomic changes in the 
different disease states. Analysis of genomic changes using Molecular Inversion 
Probe arrays (MIPs) and immunohistochemical (IHC) profiles in these cases will 
hopefully identify possible biomarkers of interest and genetic abnormalities that 
confer greater or lesser risk of progression from DCIS to invasive disease and allow 
comparison of groups of lesions with regard to genetic changes and biology.  
  
 1.9 Hypothesis 
An immunohistochemical and genomic assessment of “pure” DCIS and of DCIS 
associated with invasive breast cancer will identify differences in biomarkers and 
gene expression between individual cases. Within immunophenotypic sub-groups 
variations in biomarkers and gene patterns may identify cases with increased risk of 
recurrence and/or progression.  
 
Summary of Aims: 
 
1. To determine the expression of a range of immunohistochemical markers 
in DCIS lesions and determine if these markers can identify molecular 
subtypes similar to those found in invasive breast cancer. 
2. To create a database of significant size providing information on  DCIS 
samples with genomic, immunohistochemical and demographic data. This 
database will provide a resource for further research beyond the scope of 
this thesis.  
3. To undertake an analysis of archival DCIS samples to identify genomic 
variation, abnormalities and changes between different pure DCIS lesions 
and DCIS lesions associated with invasion 
4. To identify any protein and/or genomic changes in all DCIS (pure and that 
associated with invasion) compared to invasive breast disease to 
determine potential biomarkers responsible for progression to an invasive 
state. 
  
 Chapter 2. Construction of Tissue Microarrays 
(TMAs) for Immunohistochemical Evaluation of 
Ductal Carcinoma in Situ 
2.1 Introduction 
In this study, the evaluation of multiple immunohistochemical markers is used to 
determine if DCIS can be classified and sub-typed in a similar fashion to invasive 
breast carcinoma on an immunohistochemical level. In order to assess multiple 
markers on significant numbers of DCIS cases, TMAs have been used. The nature of 
DCIS, including size and distribution of lesions and intralesional heterogeneity, 
introduces some challenges in TMA construction. The design and manufacture of 
TMAs had to address several criteria specific to DCIS, as well as some general 
principles not often cited in the literature. These include core size, number of cores, 
core placement, tissue selection criteria, heterogeneity of tissue and subsequent TMA 
analysis. These issues are discussed below.   
2.2 Materials and Methods 
A search was carried out for DCIS specimens within the King’s Health Partners Tissue 
Bank (KHPB), formerly the Guy’s and St Thomas’s Breast Tissue and Data bank 
(BTBD), yielding a list of 579 cases for evaluation. The specimens were defined as 
containing a “pure” DCIS component not associated with invasive carcinoma, or DCIS 
as a recurrence. All tissue had been uniformly fixed in 10% neutral buffered formalin 
within 60 minutes of surgery.  The haematoxylin and eosin (H&E) stained slides for 
cases were retrieved from the archive and screened by a consultant breast 
histopathologist (SEP) to reclassify each lesion using the current classification and 
terminology.  Each case was then assessed for suitability for coring for tissue 
microarray. Cases where core biopsy material alone was available were discounted 
due to lack of tissue.  
Once the slides had been reviewed, the matching formalin fixed paraffin wax 
embedded (FFPE) blocks corresponding to the marked slides were retrieved from the 
archive. The blocks were assessed for amount of remaining tissue and any deemed 
insufficient were excluded from the study. It was noted that for some of the cases the 
tissue in the FFPE blocks did not match the shape of the tissue sections due to taking 
of multiple sections for other, previous, studies. All the blocks were subsequently re-
embedded and a single section cut and H&E stained for marking using an optical 
marker (Nikon-Melville, New York U.S.A.) attached to a microscope (Figure 14). 
 
Figure 14. Optical marking of disease on an H&E section. 
 
Once areas of interest had been marked, TMAs were constructed. As described in 
Chapter 1, the basic principle is to take an empty paraffin wax block (recipient block) 
with which a small hole is drilled using a first stylet. Then a second, slightly larger, 
stylet is used to sample the paraffin wax block containing the tissue of interest (donor 
block). This core of tissue is then inserted into the small hole in the recipient block. 
Once all the desired cores have been transferred from the donor to the recipient block 
then the newly constructed TMA undergoes an annealing process. This process 
involves heating and cooling the newly constructed TMA block to just below the 
melting temperature of the wax to enable the cores to meld to the wax of the recipient 
block. Various temperatures and times are used dependent upon core size and tissue 
type. For this study, trial and error demonstrated that placing the new TMA blocks in 
a pre-warmed oven at 56ºC for ten minutes followed by 30 minutes cooling repeated 
thrice produced TMAs with suitable annealing to prevent core loss. 
Each case of DCIS had three 2mm cores taken, with each of these cores placed into 
a separate block labelled A, B and C respectively. The standard size for TMA cores 
in studies of invasive carcinoma is 0.6-1.0 mm (99). A larger core size (2mm) has 
been used in this study to be certain of obtaining representative morphology from 
ducts bearing in-situ carcinoma. This results in a larger tissue surface area to 
demonstrate IHC expression and to assess the presence of staining heterogeneity. 
Each TMA block consisted of twenty DCIS test cases, and five control tissue cores of 
either kidney or liver tissue, to enable easy orientation of cores when examining the 










Figure 15. Template for TMA composed of 2.0mm cores  
 
Control core, liver 
tissue 
Control core, kidney 
tissue 
Test DCIS  cores 
Once constructed, a peripheral surface section was cut from the TMAs and an H&E 
stained slide produced in order to assess the accuracy of the coring and confirm the 
presence of DCIS. Examples of sample 2.0mm cores with DCIS present are shown 
in Figure 16 with an example of a whole TMA section in Figure 17. 
 
   
Figure 16: DCIS in 2.0mm cores 
 
 
Figure 17: TMA construct 
  
Use of tissues and data (see 3.2.1) was approved under NHS REC agreement 
(07/H0874/131) with Biobank Access Committee approval. 
2.3 Results 
2.3.1 TMA Constructs 
 
The 579 cases of DCIS in the initial database yielded a total of 280 cases of pure 
DCIS suitable for TMA construction.  These were made into 14 tissue microarray 
blocks in triplicate giving a total of 740 cores for IHC staining.  
2.3.2 Scanning  
 
All TMAs had a 4m section cut and stained with H&E to verify the presence of DCIS 
within cores. A total of 42 H&E sections were taken and scanned using a 
“Nanzoomer” digital scanner (Hamamatsu, Welwyn Garden City, UK) to provide 
digital images for analysis. Loss of DCIS due to either missing cores, incorrect coring 
from donor block or lack of viable cells was evident in 15-20% of cases. 
2.4 Discussion 
2.4.1 Tissue Selection Criteria 
 
The selection of good quality tissue for inclusion in any TMA is paramount. However, 
the vast majority of TMAs are drawn from archival diagnostic stores with very few 
having tissue prospectively acquired. A major problem with the use of archival tissue 
is that fixation and processing is typically poorly documented, and often highly 
variable even within a single institution.  The archive based at Guy’s and Thomas’ 
Tissue and Data bank has specimens dating back to the early 1970’s available for 
research. The archive also includes accurate records of time to fixation and duration 
in fixative; the breast tissue used in this study were expertly sliced and placed in 
formalin within 30 minutes of surgery. The maximum duration of fixation was 48 hours. 
The quality of the archive owes much to the foresight of the individuals who 
established the tissue bank, and who recognised the importance of adequate fixation 
and detailed record keeping before the advent of modern immunohistochemistry and 
molecular techniques.  
2.4.2 TMA cores size, number and distribution within a TMA block 
There is variation in the literature as to what is considered “representative” when 
selecting the number, size and distribution of cores within a TMA. Core diameter and 
number ranging from a single 1.0 mm core to six 0.6 mm cores have been suggested 
as suitable. Some authors have reported that a single core, regardless of size (1.0mm 
to 0.6mm), correlated with whole section mounts when assessed for ER, PR, HER2 
and Ki67 (100-102). However, others have advocated the use of multiple cores to 
provide more accurate concordance; Graham et al suggested that a minimum of four 
assessable cores from six sampled areas were required for accurate evaluation of 
HER2 status of invasive breast cancer (103). Bharghava showed that between two to 
four cores had a high (99%) concordance with whole sections for HER2 status by 
fluorescent in-situ hybridisation (FISH), again in invasive disease (104). Sapino et al 
recommended that at least 4 cores are required and that where a negative hormonal 
marker such as ER or PR is found then the IHC should be repeated on a whole section 
(105). Thus there is little agreement, for even standard biomarkers, on the number of 
TMA cores that should be assessed, let alone the number of cells required. 
Table 1 compares the surface areas of the most common cores sizes: 0.6mm, 1.0mm, 
1.5mm and 2.0mm and the total surface area obtained when multiple cores are 
examined. Taking one 1.0mm core is roughly equivalent to three 0.6mm cores. This 
excludes demonstration of regional heterogeneity within a cancer, but for markers 
with uniform expression significant time and cost savings could be made by use of a 
larger core size. Where multiple cores are taken from lesions of known heterogeneity, 
increasing the core size from 0.6mm to 1.0 mm will give a threefold increase in tissue 










0.60 0.30 1.885 0.283 
1.00 0.50 3.142 0.785 
1.50 0.75 4.712 1.767 
2.00 1.00 6.283 3.142 
Table 1: Surface areas of different TMA core sizes. 
 
There is an inevitable loss of cores when cutting TMA sections and performing 
subsequent tests such as IHC. Such loss can be due to tissue type, fixation, poor 
region selection, poor annealing of cores in the donor block, core size, section 
thickness, section drying and overuse of organic solvents. Technical expertise can 
minimise some of these, although the use of archival material that is poorly processed 
will have an influence on core preservation. Heating of sections for processes such 
as antigen retrieval in IHC and denaturation of DNA in ISH are a particular cause of 
core loss and a percentage will be lost in such processes, even when performed by 
expert technicians.  
Histopathological sections of diseased tissue are, by their very nature, a small 
representation of an entire tumour or disease state. Rarely is a tumour sampled in its 
entirety with every section of tissue cut and examined for tumour heterogeneity with 
repeated antibody testing. Large tumours are excised and the pathologist selects 
representative pieces which, in general, have only one H&E section taken and 
examined from the block. TMAs have, since their inception, have been dogged with 
the criticism that they are not representative of the entire tumour and cannot capture 
the heterogeneity seen in whole sections. Camp et al (99) point out that the general 
consensus is that in most cases two 0.6mm cores are representative of a whole 
section but that  some antibodies, such as those involved in hypoxia, that show 
heterogeneous expression may require more cores. In this study, selection was 
based on the diagnosis of DCIS. Larger cores were chosen as they allowed entire 
duct spaces, with their surrounding myoepithelial layer and basement membrane to 
be visualised within the TMA core. This would also address issues of potential 
staining heterogeneity (by manufacturing triplicate blocks) and included a sufficient 
quantity of tissue to be considered representative of a lesion when compared to the 
guidelines quoted in the literature. Indeed the actual sampling in this thesis exceeds 
the vast majority of current studies. It is anticipated that this would give a true 
reflection of IHC staining patterns in the tissues examined.  
  
Chapter 3. Immunohistochemical Studies on 
Ductal Carcinoma in Situ 
3.1 Introduction 
The expression of key proteins, or biomarkers, is of prognostic and/or predictive 
importance in invasive breast cancer. Panels of proteins have been proposed that 
can divide breast cancer into clinically important subtypes with differing survival 
outcomes. However, there is currently a lack of information as to whether these 
tumour subtypes are represented at the in situ stage, and their prognostic significance 
in DCIS.  Immunohistochemical experiments looking at a number of proteins of known 
importance in invasive breast cancer were carried out for this thesis to investigate 
their expression within DCIS. Sections 3.3 to 3.9 refer to specific types of antibody 
with regard to their target antigen and the rationale for inclusion into a prospective 
panel. The procedure for staining for all antibodies was similar and is summarised 
below with details of any variations given. 
3.2 Material and Methods 
3.2.1 Correlation of Immunohistochemical Results to Patient Data and 
Outcome 
See Appendices 2, 3 & 4 
In order to evaluate the effect of any IHC biomarker upon the likelihood of recurrence, 
whether invasive, in situ or not present, it was necessary to determine the patient 
outcome in our cohort. Patient demographics including age, treatment, details of local, 
ipsilateral and contralateral recurrence, if any, were retrieved from the King’s Health 
Partner’s Breast Cancer Biobank records.  
Samples of pure DCIS tissues from this cohort of patients were taken between the 
years 1974 and 2005. Patient details in some instances were incomplete and not 
suitable for further analysis. Reasons for these losses included patient relocation, loss 
of records or conflicting data. This reduced the total number of TMA cases available 
for correlation with patient demographics. For these cases TMA core loss also 
occurred in a small percentage of cases giving a slight variance in numbers available 
for each antibody assessed.  
The data in the bank is prospectively populated with follow up data from clinical visits 
by patients and from cause of death registration.  Patients were diagnosed with DCIS 
between 1974 and 2005.  
Table 2 summarises patient demographics. Records for 180 patients were available. 
Mean patient age at diagnosis was 72 (range 22-90).  
Records list 112 patients with an excision biopsy as first form of surgery, 11 had 
microductectomy, 2 had a needle localisation excision biopsy, 5 had a wide local 
excision and 12 had a simple mastectomy. Data on type of first surgery was 
unavailable for 20 patients. The majority of patients underwent further treatment 
(n=131), of these patients 41 had a simple mastectomy, 50 has a wide local excision, 
7 were listed as both wide local excision and simple mastectomy, 14 had a modified 
radical mastectomy, 2 had an excision biopsy, one biopsy and one microdochectomy. 
There was no data on the type of subsequent surgery for two patients.  
Twenty three patients had a known recurrence more than 3 months (range 108-4363 
days) after original diagnosis and surgery.  
3.2.2 Histological Assessment of Necrosis and Inflammatory Response. 
. 
Histological re-assessment of samples (Chapter 2) provided details of the degree of 
comedo-type necrosis and of inflammatory response as well as cytonuclear grade 
and architecture of the DCIS. The histological data frequencies are shown in Table 2. 
The presence of necrosis was scored as “mild”, “moderate” or “marked” where 10% 
or less of the ducts bearing comedo-type necrosis were defined as a mild degree, 
moderate corresponded to approximately 10-50% and marked to 50% or more of 
ducts exhibiting necrosis (46). Assessment of the presence of inflammation was 
based on 'routine' categorisation of the degree of chronic inflammatory cell infiltrate 
adjacent to and/or surrounding the duct spaces bearing DCIS. Previous work in 
classifying inflammation in DCIS has shown good reproducibility between consultant 
pathologists in (RM and SEP unpublished data). 
 
Table 2: Patient Demographics and Histological Details. 
  Number of 
patients 
% (of 180 in TMA 
series) 
Mean patient age at diagnosis 
(range) 
72 (range 22-90) 
166 92 
Size of DCIS (mm) Average                   14.9 
Median                    14.9 




Solid                    74 (43) 
Cribriform             69 (40) 
Micropapillary     18 (10) 




Left                     92 (58) 




High                 103 (60) 
          Intermediate      57 (33) 




Yes                     18 (13) 







Ipsilateral            9 (50) 
Bilateral             1  (6) 







Invasive Recurrence Grade 
n (%) 
High                    8 (77) 
Intermediate                  3 (23) 
Low                    0 (0) 
11 7 
DCIS Recurrence                               2 (100) 2 1 
DCIS Recurrence Site  Ipsilateral             1  (50) 




DCIS Recurrence Grade High                     2 (100) 2 1 
New Lesion (contralateral)                    3 3 2 
 
3.2.3 Immunohistochemical Experiments 
Tissue sections from the manufactured in-house TMAs (Chapter 2) were cut at 4m 
and dried overnight at 37 ºC before being baked at 57 ºC for two hours prior to IHC 
staining. Immunohistochemical staining, using antibodies raised against oestrogen 
receptor (ER) clone 6F11 (Leica, Newcastle, UK), progesterone receptor (PR) clone 
636 (Dako, Ely, UK), HER2 (Oracle kit, Leica, Newcastle, UK) cytokeratin 5/6 (CK5/6) 
clone D5/16 B4 (Dako, Ely, UK), cytokeratin 5 (CK5) clone XM26 (Leica, Newcastle, 
UK) , cytokeratin 14 (CK14) clone NCL-CK14 (Leica, Newcastle, UK), Ki67 (clone 
MIB1) (Dako, Ely, UK), MCM2 –clone NCL-MCM2 (Leica, Newcastle ,UK) and 
epidermal growth factor receptor (EGFR) clone 384 (Leica, Newcastle, UK), was 
performed. All TMAs were stained in triplicate to reduce the loss of data due to core 
loss and ensure sufficient cells were available for assessment. Sections were stained 
using a two-step compact polymer chain biotin free IHC protocol using a 3-
3’diaminobenzindine chromogen on the BondMax™ Leica automated staining 
system. HER2 tests were carried out on the same system using the HER2 Oracle kit 
(Leica, Newcastle, UK).  All slides underwent blocking for endogenous peroxidase 
and a haematoxylin counterstain prior to coverslipping in an organic medium.  Antigen 
retrieval was undertaken for each antibody according to manufacturer’s 
recommendations. All slides were stained alongside appropriate known positive 
control sections for quality control purposes. ER and PR status was previously 
recorded for some of the cases in this study, however due to changes in IHC 
methodology and improvements in antibody clones it was determined that repeat 
would be undertaken for all. Appendix 4 lists reagents and protocols for 





3.3 Hormone Receptors 
3.3.1 Oestrogen Receptor Structure and Function 
Oestrogens are steroidal sex hormones involved in a large number of physiological 
processes (106). They have a major effect on the female reproductive system, 
including ovulation, pregnancy, childbirth and lactation (106). They are also involved 
in the cardiovascular system, immune response, central nervous system and bone 
growth (106). Many of the physiological actions of oestrogen are mediated via binding 
to the oestrogen receptor (ER) (106-108). 
ER is a ligand-activated intracellular transcription factor responsible for the biological 
effects of oestrogen via gene regulatory pathways (109-111). ER belongs to a groups 
of proteins known as the nuclear hormone receptor (NHR) superfamily which includes 
progesterone (PR), testosterone and vitamins A and D (111). There are two identified 
isoforms, ERα and ERβ, coded for by the genes ESR1 (located 6q24-q27) and ESR2 
(located 14q21-q22). These isoforms have 95% amino acid homology (110). ER 
protein structure (Figure 18) consists of a variable N terminal domain containing an 
activation domain, AF1, followed by a DNA binding domain (DBD). The DBD is linked 
to a variable hinged region connected to a ligand binding domain (LBD). The LBD 
contains a second activation domain AF2. The activation domains regulate the 
transcriptional activity of ER (110, 112). The DBD allows the ER to bind to specific 
DNA loci within the nucleus, known as oestrogen response elements (EREs), due to 
the presence of two highly conserved zinc fingers distinct to the NHR superfamily. 
The variable hinged region of ER is a flexible region of the protein and acts as a 
nuclear localisation signal connecting the DBD and LBD (110). The LBD acts as a 
“molecular switch” which, upon binding the hormone oestrogen, becomes 
transcriptionally active (112, 113). ERα and ERβ binding of 17β estradiol (E2) via the 
EREs and the transcriptional activation has been designated the classic pathway of 
oestrogen action (114). The binding of E2 to the receptor results in conformational 
changes leading to dimerisation with coactivator or corepressor molecules which 
regulate downstream physiological responses (115). 
  AF1      AF2 
NH2                 
COOH 
Figure 18: Structure and Functional Domains of ER 
3.3.2 Oestrogen Receptor and Breast Cancer 
Unlike most of the NHR superfamily, oestrogen receptor (ER) (and androgen receptor 
(AR)) have the ability to stimulate cellular proliferation and are essential for the normal 
development of the female breast during puberty and pregnancy (116). However, it is 
this very ability that, when aberrations occur, can lead to tumourigenesis and 
uncontrolled proliferation. The exact mechanism of how the ER/E2 complex initiates 
cellular proliferation remains elusive. 
IHC expression of ER status is a weak prognostic marker of independent clinical 
outcome but a strong predictive marker of response to therapy in invasive breast 
cancer (117). Approximately 60-70% of breast cancers in women under 50 years and 
80% of breast cancers in women over 50 are ER positive (118). Unlike many IHC 
markers, ER is used clinically to help determine the likelihood of response to 
endocrine therapy for patients with invasive breast cancer, which can be in the form 
of antagonists that directly block the receptor pathway (Tamoxifen) or indirect 
blocking such as the aromatase inhibitors which prevent conversion of androgens to 
oestrogen (119).  










3.3.3 The Oestrogen Receptor and Ductal Carcinoma in Situ 
The expression of oestrogen receptor in DCIS may have important implications for 
the treatment of precursor lesions, with some studies showing ER, PR and HER2 
predict an increased risk of local recurrence (120, 121). Up to 80% of DCIS lesions 
are ER positive. (122). However, treatment of DCIS with anti-oestrogen therapy such 
as Tamoxifen has not shown an overall decrease in mortality (54). Randomised trials 
by the National Surgical Adjuvant Breast and Bowel Project (NSABP) have 
demonstrated a reduction of incidence of both invasive breast cancer and DCIS with 
Tamoxifen treatment for women aged over 35 recognised to be at increased risk of 
developing breast cancer (123).  
3.3.4 Progesterone Receptor 
Progesterone receptor (PR) is another member of the steroid receptor superfamily 
important for growth and development in the breast and female genital tract. PR 
expression is induced by oestrogen, and is thought to be an indicator of an intact ER 
pathway. Thus, PR positivity may be an adjunct to prediction of response to oestrogen 
related therapies (118). PR is also often advocated as an IHC marker where a 
possible false negative ER result is suspected (118). It has been shown that some 
ER+ PR- invasive breast tumours have a reduced response to tamoxifen compared 
to ER+ PR+ tumours, however the exact mechanism as to how both oestrogen and 
progesterone interact is not known (118, 119, 124). Tamoxifen therapy induces a 
greater drop in PR than ER levels, with some lesions losing PR expression 
completely; this may be one mechanism in the development of acquired tamoxifen 
resistance and a poorer overall survival (OS) in patients with invasive breast cancer 
(124). The ATAC trial (125)  studied the response of ER positive breast disease 
treated with tamoxifen or anastrozole (arimidex) alone or in combination. Results from 
this study showed that patients treated with anastrozole had prolonged disease free 
survival, time to recurrence, distant metastases and contralateral breast cancers after 
five years compared to tamoxifen (125) . These findings were also reported in a long 
term follow up of the ATC trial after 10 years (126). 
3.4 Epidermal Growth Factor Receptors 
3.4.1 Epidermal Growth Factor Receptor Structure and Function. 
The epidermal growth factor receptor (EGFR) or ErbB family of tyrosine kinases 
(phosphorylation enzymes) comprises four related transmembrane proteins (HER1 
to HER4) that can form oligomers, usually in the form of a homo-dimers or hetero-
dimers (127). The HER family of proteins acts as conduits for the activation of 
intracellular signalling pathways from extracellular signals (128). All four of the HER 
proteins are characterised by an extracellular ligand binding domain, a 
transmembrane domain and an intracellular tyrosine kinase domain (128). 
Crystollographic studies by Burgess et al (129) defined the structure and ligand 
induced dimerization, however the exact kinetic mechanisms remained elusive. 
Zhang et al (130) elucidated, through further crystallographic & mutational analysis, 
that the allosteric mechanism was similar to CDK2/cyclin A activation, where the C-
terminal lobe of one kinase interacts with the N terminal of the adjacent kinase. The 
Erb family of proteins plays key roles in mediating the cellular proliferation of cells, 
differentiation, metabolism and motility (131). 
The HER2 gene was first identified in human breast cancer by King et al in 1985. Also 
known as ErbB2 (referring to both human and rodent gene), “HER2” refers to the 
human gene and protein and not the rodent (128). Unlike HER1, HER3 and HER4, 
HER2 does not bind specific ligands but relies on hetero-dimerisation, with one of the 
other ligand-bound HER proteins (132) (Figure 19). 
  
Figure 19: EGFR Structure. DOI: http://dx.doi.org/10.7554/eLife.00708.003 
reproduced through Creative Commons Attribution license: original image from 
reference (132)  
 
The overexpression of both HER1 (EGFR) and HER2 (C-erbB2) has been implicated 
in many solid tumours, including bladder, breast, colon and lung cancers (127, 133, 
134).  
EGFR (HER1) has been shown to be expressed in the basal-like invasive breast 
tumours and in some DCIS (127, 134) and is one of the targets currently under 
investigation for monoclonal antibody therapy with drugs such as erlotinib, cetuximab, 
and lapatanib in invasive breast cancer (135, 136). There are a several antibodies 
commercially available for the immunohistochemical assessment of EGFR. Although 
membrane reactivity is regarded as ‘positive’ for EGFR, significant staining variation 
between antibodies exists (unpublished data) and there is yet to be a defined 
pathological scoring system such as the HER2 scoring system for this antibody. 
In breast cancer HER2 overexpression is present in between 15-25% of invasive 
lesions. Although associated with a poorer prognosis overall, targeted therapy, for 
example with the drug trastuzumab (Herceptin), is available (137) and widely 
recommended and effective for patients with HER2 positive invasive breast cancer.  
3.5 Proliferation Markers 
3.5.1 Introduction 
Deregulated proliferation is one of the hallmarks of the cancerous state (138). In order 
for a tumour to grow and infiltrate surrounding tissues, the ability for a neoplastic cell 
to replicate is essential for the progression of a lesion. Several IHC markers have 
been established as indicators of proliferation, and have found use in both the 
research and diagnostic laboratory setting. In this study, Ki67and the 
minichromosome maintenance protein 2 (MCM2) have been selected as suitable 
indicators of proliferation.  
3.5.2 Ki-67  
Ki-67 is an established marker for the assessment of cellular proliferation (139). First 
used to show proliferative activity in frozen or freeze-dried sections of human lung 
tissue (140) it is one of the most utilised biomarkers in cancer research. A Pubmed 
enquiry in 2015 using the search criteria “Ki-67 & cancer” yields over 15,000 articles, 
a search for Ki-67 alone yields over 19,000. The large number of articles belies the 
fact that the exact function of this protein is still not fully understood and there is a 
relative paucity of papers looking at Ki-67 structure and function (139). However, it is 
almost universally accepted that Ki-67 protein expression is essential for the cell cycle 
(139). Removal of phosphorylated Ki67 from cells using antisense nucleotides 
prevents cell cycling (141). Loss or inhibition of Ki67 results in ribosomal RNA 
synthesis inhibition (142). Ki67 is expressed during all stages of the cell cycle, G1, 
G2, S and mitosis, however, it is not expressed in G0 (143).  
3.5.2.1 Ki-67 nomenclature 
The Ki-67 antigen is known to be a large protein and is referred to as Ki67 protein, as 
opposed to the original antibody, raised against the protein which is referred to as the 
Ki67 antibody. This antibody was the prototype for other Ki67 antibodies raised to 
different epitopes on this large molecule and was produced by immunizing mice with 
nuclei from a Hodgkin lymphoma cell line (L428) (139, 141). These include the clone 
MIB1 (Molecular Immunology Borstel), MIB5 and TEC-3. The name Ki-67 originates 
from the city of discovery (Kiel) and the position in a 96 well plate of the original clone 
(139). 
3.5.2.2 The Structure and Function of Ki-67 
Ki-67 has 2 prominent forms detectable at the protein level (Figure 20), a 395kDa and 
a 320kDa protein encoded by nearly 30,00 base pairs (141). Schulter et al (144) 
published the cDNA sequence encoding for the Ki-67 protein in 1993 identifying 2 
spliced isoforms of mRNA (modifications of the RNA transcript by removing introns 
and introducing exons) which differed by the absence in one region encoded by exon 
7. They also describe a series of 366 base pair “Ki67 repeat” elements in a 6,845 
base pair exon located centrally within the antigen. This exon (138) is one of the 
largest mammalian exons known. They concluded that Ki-67 has no known homology 
with other known amino acid sequences and it is a short-lived category of cell cycle 
associated nuclear non-histone protein. Further studies by Hofmann and Butcher 
identified a forkhead associated domain (FHA) in Ki67 as well as other unrelated 
proteins found in yeast, bacteria and mammals but all believed to be involved in DNA 
repair, synthesis or cell cycle regulation (145). The Ki-67 protein contains 143 protein 
kinase C, 89 casein kinase II and 2 tyrosine kinases (protein kinases phosphorylate 
serine, threonine, tyrosine, or histidine residues to modify a protein function) (139). 
Analysis of the amino acid sequence has led to the prediction of ten nuclear targeting 
signals, which may explain why Ki-67 is only found in the nuclei during interphase 
(139, 146-148).  
    
Figure 20: Ki-67: Protein structure 1R-21-1-120 (human) A & 2AFF-1-120 (human) B.  
Images courtesy of RCSB PDB rendering based on 1r21.en.wikipedia.org 
 
Despite the fact that Ki-67 has been described, and used in immunohistochemical 
studies, for over thirty years the exact function remains elusive as do its possible 
interactions with other cell cycle markers. There are several possible explanations 
why Ki67 function is difficult to elucidate. Scholzen et al suggest that its large size 
and susceptibility to proteolytic cleavage make biochemical assays difficult. Secondly, 
they cite the lack of similarity to other proteins makes study of this molecule with 
standard methods difficult. To date there is no definitive explanation of Ki-67 function. 
Although believed to be expressed solely in the active proliferative phases of cell 
cycling (G1, G2, S and mitoses) there is some evidence that Ki67 can be detected in 
quiescent cells (G0) and has a possible role in RNA transcription (149) and RNA 
synthesis (142). 
3.5.2.3 Ki-67 as a Biological Marker in Cancer 
 
There have been many studies showing that Ki67 assessment has prognostic value 
in invasive cancer. Brown and Gatter’s review in 2002 showed a total of 23 papers 
B A 
examining Ki67 in breast cancer alone as having an independent prognostic value 
(141). A Pubmed search on the 26th April 2015 for “Ki-67, breast cancer and 
independent prognostic factor” yielded over 160 journal articles citing Ki67 alone, or 
in combination with other markers, having potential value as a prognostic marker. 
More recently, the focus has been on the use of Ki67 as a predictive factor (i.e. in 
selection of response to therapy) with Darb-Esfahani al reporting that Ki67 can be 
utilised as an independent predictor of response to anthracycline/taxane-based 
neoadjuvant chemotherapy regardless of invasive tumour type (150) although Jones 
et al found no association with Ki67 and clinical response (151). Other studies have 
reported that changes in Ki67 level are a valuable predictor of response to hormone 
therapy. Finally, groups, such as Cheang et al, have used a Ki67 Index in association 
HER2 and ER to define/classify the luminal B subgroup of invasive breast cancer 
using immunohistochemistry (152). 
3.5.2.4 Ki67 and Ductal Carcinoma in Situ 
In DCIS, Ki67 expression in conjunction with COX-2 and p16 expression, has been 
suggested to be an important factor and associated with an increased risk of 
developing subsequent invasive disease (120). Altinas et al examined a range of 
biological markers, including Ki67, as possible predictors of local recurrence and no 
found evidence that Ki67 alone or in conjunction with other markers was significant 
(153).  
However, much of the data on Ki67 and definition of sub-groups for comparison with 
outcome has been undertaken on invasive disease. Zhou et al used Ki67 with a cut-
off of >14% to distinguish positive cases to assign subgroups in invasive disease. 
Those with >14% were defined luminal A and those with <14% were defined as 
luminal B/HER2 negative (as defined by the St Gallen International Expert Consensus 
from Cheang’s publication (145), although they found no significant prognostic value 
in their cohort (97). Ruiz et al (154) compared three molecular classification 
subgroups, finding that only the classification including Ki67 as a marker improved 
prediction of overall survival in invasive disease. 
3.5.3 Mini Chromosome Maintenance Proteins 
3.5.3.1 The Structure and Function of Mini Chromosome Maintenance 
Proteins 
Unlike Ki67, the structure and function of the Mini Chromosome Maintenance (MCM) 
proteins are well understood. A review by Bochman & Schwacha in 2009 (155) 
references 280 articles on MCM structure and function in both archaeal and 
eukaryotic forms. For the purpose of this thesis, information on eukaryotic MCM 
function is given.   
MCM proteins are essential components of DNA replication in the cell cycle (156). 
Several gene variants exist encoding for the proteins MCM2 to MCM7, which are 
required to establish a pre-replication complex prior to cellular division. MCM2, MCM3 
and MCM5 were first discovered in the yeast Schizosaccharomyces cerevisiae (157), 
followed by the discovery of MCM4, MCM7 and cell division mutations (155). MCM6 
was discovered in Schizosaccharomyces pombe in 1994 (158). Further studies on 
Xenopus Laevis (African clawed frog) identified that all six proteins (MCM2 to MCM7) 
were required to couple to DNA for replication to occur (155, 159). In eukaryotic cells, 
all six cell cycle related MCMs have a similar 250 amino acid region encoding for 
ATPases. ATPases, also known as AAA proteins, are a diverse group of proteins with 
a wide range of functions acting as DNA helicases and proteases (155).  
MCM proteins form ring-like structures to incorporate ATP binding and enable 
hydrolysis to alter DNA within the central circle or channel of the ring-like structure 
and perform helicase activity, unwinding the DNA and forming replication forks (160). 
The MCM2 to MCM7 helicase structure is essential for initiation and elongation of 
double stranded DNA (155). 
The activation of MCMs from an inactive form to an enzymatic helicase requires the 
recruitment of several protein cofactors. This includes, but may not be exclusive of, 
proteins Cdt1, Cdc6, MCM10, geminin and the kinase Cdc7-Dbf4 (161). During G1 
inactive MCM proteins are transported by Cdt1 protein to the origin of replication site 
where cells undergo ”licensing” for replication by a group of six polypeptides, known 
as the origin recognition complex1-6 (ORC1-6)(162). ORC1-6 is a heterohexameric 
protein complex which binds proteins Cdt1 and Cdc6 (162, 163) followed by the 
binding of MCMs thus forming a heterohexamer pre-replication complex (Figure 22). 
The binding of MCMs requires the presence of ORC1-6 and Cdc6, which provide ATP 
hydrolysis and thus the energy for this active process (155, 164). Once the MCMs are 
bound to DNA ORC1-6 and Cdc6 are disassociated from the complex. In S phase of 
the cell cycle, cyclin dependent kinases (CDKS) promote the formation of DNA 
replication forks and possibly the initiation of MCM function (155). MCMs demonstrate 
a helicase activity responsible for the unwinding of the DNA helix prior to replication 
(165). Once the pre-replication complex has loaded, DNA polymerases are recruited 
and DNA replication ensues. Sanchez-Berrondo et al (166) demonstrated in Bacillus 
cereus MCMs bind DNA and not only act as a helicase but also function as a primase 
and a polymerase.  
Once replication has occurred, MCMs are inactivated by phosphorylation, leading to 
their dissociation from the pre-replicative complex thus limiting replication to once per 
cell cycle (Figure 22). 
  
  
Figure 21: Examples of a Hexameric Helicase Protein Structure for DNA replication.  
(Image courtesy of http://www.ebi.ac.uk/) 
 
 
Figure 22: MCM Proteins in the Cell Cycle  
(Creative Commons Attribution-Share Alike 3.0 Unported license, author: Azackta1 
2013) 
3.5.3.2 Minichromosome Maintenance Proteins and Cancer 
Previous studies examining MCM2 and MCM5 have shown them as potential 
alternatives to Ki67 for assessment of proliferation in invasive cancer (167-170). 
Some have shown MCMs to be independent prognostic markers in invasive breast 
cancer (171, 172) although MCM expression correlates with Ki67 expression and 
histological grade (173). The deregulation of MCMs 2-7 has been shown to be an 
early event in tumourigenesis, both in actively cycling cells and, unlike Ki67, non-
proliferating cells that have the potential to enter the cell cycle (167, 170, 174-178). 
To date, there are only two studies examining the relationship between precursors of 
invasive breast cancer and MCM2 (179, 180). Reena et al (179) advocate MCM2 as 
a reliable proliferation marker in DCIS, whilst Nasir et el (180) included MCM2 in a 
panel alongside TOP2A and BUB1B as “potential molecular biomarkers of 
malignancy in histologically normal and benign breast tissues”. 
 
3.6 Basal Markers 
3.6.1 Cytokeratins 5, 6 and 14 
Basal epithelial cells were traditionally described as cells adjacent to the basement 
membrane (181). However, since Moll’s work on cytokeratins (182), the term has 
become synonymous with those cells expressing the high molecular weight 
cytokeratins, 5 and 14 and 17 (CK5, CK14, CK17). The term ‘basal cell’ is often 
incorrectly applied to myoepithelial cells although the expression of these cytokeratins 
is not solely confined to myoepithelial cells (183). This has led to a dual meaning for 
the term basal, which can now refer to either myoepithelial cells or cells expressing 
“basal” cytokeratins, and is further complicated by the term basal-like breast cancer, 
which is a molecular phenotype. Basal-like breast tumours are often triple negative 
(i.e. tumours negative for ER, PR and HER2) and a significant proportion of the triple 
negative carcinomas express CK5, 14 or 17. However, the two terms are not synonymous, with some triple negative tumours lacking basal 
marker expression and occasional basal like tumours being positive for hormone receptors or HER2. Triple negative invasive tumours have a 
poorer prognosis that many other types of breast carcinoma, with no targeted therapy currently available (86, 184). Thus accurate identification 
of the premalignant stage could be beneficial in the early identification of these difficult to manage lesions, without the need for adjuvant systemic 
treatments. In the context of this study, the immunohistochemical expression of one or more of CK5, 5/6 and 14 and / or EGFR is used to define 
basal breast carcinoma (BBC) as a pathological entity. 
 
 
3.7 Scoring of Antibody Markers in Immunohistochemical Studies 
5.7 TMA slides with immunohistochemical stains were independently scored by a consultant breast pathologist (SEP) and the author (JPB). 




location ER Average PR HER2 EGFR CK5/6 CK14 KI67 MCM2 
DCIS 15A A1 0 0 0 0 0 1 1 0 
DCIS 15A A2 0 0 0 0 0 0 x 0 
DCIS 15A A4 2 0 0 0 x 10 1 0 
DCIS 15A A5 0 0 1 3 0 5 40 10 
DCIS 15A B1 x x x 0 x x x x 
DCIS 15A B3 0 0 0 3 0 0 10 40 
DCIS 15A B4 0 0 0 0 0 0 30 x 
DCIS 15A B5 2 0 0 1 0 0 15 30 
DCIS 15A C2 5 0 0 0 0 0 5 5 
DCIS 15A C3 1 0 1 2 0 0 5 5 
DCIS 15A C4 5 7 2 0 0 0 1 1 
DCIS 15A C5 8 8 0 0 0 0 0 2 
DCIS 15A D1 x x x x x x x x 
DCIS 15A D2 x x x x x x x x 
DCIS 15A D3 0 x x x x x x x 
DCIS 15A D4 x x x x x x x x 
DCIS 15A E1 2 x x x x x x x 
DCIS 15A E2 0 0 0 0 0 x 0 5 
DCIS 15A E3 5 x x x x x x x 
DCIS 15A E4 8 x 0 0 0 0 1 1 









(HER2) CK5/6 (%) CK14 (%) KI67 (%) MCM 
DCIS 16A A2 8 5 x 0 0 0 1 3 
DCIS 16A A4 7 0 3 0 0 0 1 5 
DCIS 16A A5 2 4 2 0 0 0 0 0 
DCIS 16A B1 3 x x x x x x x 
DCIS 16A B3 5 8 2 0 0 0 2 5 
DCIS 16A B4 1 x x x 0 0 x x 
DCIS 16A B5 4 0 0 x 0 0 20 45 
DCIS 16A C2 5 8 2 x 0 0 10 25 
DCIS 16A C3 4 0 1 3 0 0 25 30 
DCIS 16A C4 2 0 0 1 0 0 10 25 
DCIS 16A C5 4 0 3 1 0 0 5 35 
DCIS 16A D1 0 0 0 0 0 0 15 40 
DCIS 16A D2 3 x x x x x x x 
DCIS 16A D3 5 x x x x x x x 
DCIS 16A D4 5 8 0 0 0 0 x x 
DCIS 16A E1 5 0 x x 0 0 10 10 
DCIS 16A E2 1 x 3 0 0 0 x x 
DCIS 16A E3 4 0 3 0 0 0 10 30 
DCIS 16A E4 2 0 2 1 1 0 2 10 
DCIS 16A E5 x 0 x 2 0 0 3 35 
INV T 15 A1 0 0 0 3 15 0 8 8 
INV T 15 A2 0 0 0 3 0 0 5 2 
INV T 15 A4 0 0 0 3 60 95 4 53 









(HER2) CK5/6 (%) CK14 (%) KI67 (%) MCM 
INV T 15 A6 0 0 2 3 0 20 30 17 
INV T 15 A7 0 0 0 3 0 100 10 37 
INV T 15 B1 0 0 0 0 0 0 50 17 
INV T 15 B3 4 0 x 2 0 25 20 15 
INV T 15 B4 6 0 1 2 0 0 20 7 
INV T 15 B5 8 6 0 0 0 0 3 1 
INV T 15 B6 8 7 2 0 0 0 15 5 
INV T 15 B7 8 8 0 0 0 0 0 0 
INV T 15 C2 8 7 1 0 0 0 15 5 
INV T 15 C3 8 8 1 0 0 0 4 1 
INV T 15 C4 3 0 0 1 0 0 x x 
INV T 15 C5 8 0 3 1 0 0 5 2 
INV T 15 C6 4 0 0 3 0 0 20 7 
INV T 15 C7 6 0 0 3 0 0 5 2 
INV T 15 D1 8 8 3 0 0 0 8 3 
INV T 15 D2 8 7 0 0 0 0 5 2 
INV T 15 D3 7 8 2 1 0 0 4 1 
INV T 15 D4 8 6 0 1 0 0 3 1 
INV T 15 D6 8 6 1 1 0 0 4 1 
INV T 15 D7 8 0 3 0 0 0 4 1 
INV T 15 E1 8 7 0 0 0 0 0 0 
INV T 15 E2 8 8 0 0 0 0 4 1 
INV T 15 E3 7 0 3 0 0 0 5 x 
INV T 15 E4 6 0 0 1 0 80 30 37 








(HER2) CK5/6 (%) CK14 (%) KI67 (%) MCM 
INV T 15 E5 8 8 0 1 0 0 5 2 
INV T 15 E6 4 0 0 2 0 0 35 12 
INV T 15 E7 0 0 0 2 0 0 20 7 
INV T 15 F1 3 0 3 0 0 0 x x 
INV T 15 F2 0 3 0 2 5 4 20 10 
INV T 15 F3 8 8 3 0 0 0 8 3 
INV T 15 F4 8 8 0 0 0 0 5 2 
INV T 15 F5 8 4 0 1 0 0 4 1 
INV T 15 F7 8 0 0 0 0 0 5 2 
INV T 15 G1 4 0 3 1 0 0 15 5 
INV T 15 G2 8 0 3 0 0 0 x x 
INV T 15 G3 3 0 0 2 20 0 25 15 
INV T 15 G4 0 0 0 2 10 0 40 17 
INV T 15 G6 8 0 2 0 0 0 5 2 
INV T 15 G7 4 0 0 3 0 0 12 4 
 2. ER and PR stained sections were scored according to the Allred method based 
upon the proportion and staining intensity of tumour nuclei. A score between 0 and 3 
is given for intensity of staining and a score of 0-5 for % of cells stained. These two 
scores are combined to give a score out of eight. At the current time, an Allred score 
of three or more is regarded as positive in invasive breast carcinoma, with patients 
with ER positive invasive breast cancers eligible for anti-oestrogen therapy (32). 
HER2 and EGFR were scored using the HerceptTest™ (DAKO, Ely, UK) scoring 
method, based upon tumour cell membrane staining. The membranous staining of 
tumour cells is assigned a value of 0-3 with zero being completely negative for 
staining, one having less than 10% of complete tumour cell membrane staining with 
faint or barely perceptible staining intensity. A value of two relates to greater than 
10% of cells staining with moderate, complete, membrane reactivity and a score of 
three is assigned when greater than 10% of cells show complete tumour cell 
membrane staining with strong intensity. Normal breast ducts should be negative and 
thus act as an internal control to ensure no over-staining has occurred. Where a score 
2+ for HER2 is found the result is deemed to be equivocal. For this study chromogenic 
in-situ hybridisation (CISH) was selected to test those cases of DCIS with HER2 
scores of 2+ for genomic amplification of the HER2 gene. Fluorescence in-situ 
hybridisation (FISH) is a regarded by some authors as being more consistent for 
identifying HER2 gene amplifications in FFPE tissues (185). However, concordance 
has been demonstrated between chromogenic in-situ hybridisation (CISH) and FISH 
(186) and the former does not require a fluorescence microscope or specialist filters. 
In this Study the “INFORM HER2 Dual ISH DNA Probe Cocktail Assay” (Ventana, 
Tuscan, USA) was assessed on all cases scoring 2+ using IHC. HER2 gene status is 
determined by enumeration of the ratio of the HER2 gene to Chromosome 17 with a 
ratio of HER2 to chromosome 17 of more than 2.00 or copy number of 6 or more 
indicating gene amplification/HER2 positivity. 
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Cytokeratins were deemed as staining positively where cytoplasmic and/or 
membranous staining was present in tumour cells and a semi-quantitative percentage 
score recorded for the number of tumour cells stained. 
Ki67 (MIB1) staining was scored semi-quantitatively as a percentage of positive 
tumour cell nuclei.  
Fourteen TMAs containing 20 cases of DCIS each were stained in triplicate giving a 
total of 840 cores for assessment for each antibody. The use of large 2.0mm cores 
gives a greater area than generally deemed representative in the literature, as 
described above. For this reason for scoring purposes only one core was required to 
meet the criteria of adequate for inclusion in analysis. Where two or three cores were 
available either an average or the maximum/highest score was recorded dependent 
upon the protein under evaluation (see below).  
3.7.1 Analysis of differing IHC Scores. 
Each antibody had a potential of three TMA cores requiring a score. This could, 
depending upon tissue heterogeneity, result in different scores for each TMA core per 
case. This posed a dilemma for analysis. As previously stated, the consensus in the 
literature indicates that a single core in this study would be regarded as representative 
but three separate scores in a single case would question this assumption. If variation 
between cores existed in a single lesion as scored by an individual observer then how 
should the final score be assigned? Should the highest or an average score of cores 
available be taken for each antibody?  
There are guidelines for ER, PR and HER2 scoring of invasive tumours, with clinical 
cut-off values relating to suitability for targeted therapy. For ER and PR, the Allred 
method of scoring was chosen, as it is the recommended scoring system from the UK 
NHS Breast Screening Program for invasive breast cancer (NHSBSP guidelines 
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2005) for invasive cancer. For these antibodies the same rationale for scoring was 
applied to DCIS (Table 3). 
 
The Allred of scoring was chosen, as it is the recommended scoring system from the 
UK NHS Breast Screening Program for invasive breast cancer (NHSBSP guidelines 
2005) for invasive cancer. For these antibodies the same rationale for scoring was 
applied to DCIS). 
Similarly, as the scoring for EGFR mirrored HER2 in terms of pattern, the same cut-
off principles were applied. Cut-off values for the basal cytokeratins and Ki67 were 
harder to determine, with significant variation in the literature (see discussion). For 
these an average score of all representative cores was taken.  
Currently there are limited data on the value of TMAs for setting quantitative 
relationships or cut-off values to clinical samples and this invariably plays a role in 
comparison of different series. The International Ki67 in Breast Cancer working group 
(187) suggest that TMAs should not be used to predict cut-offs, however, the use of 
2mm cores as opposed to 0.6mm may somewhat ameliorate any discrepancy 
between whole sections and TMAs. In this series the median value was chosen as a 





3.7.2 Inter Observer Variability in Scoring Immunohistochemistry 
 
All cores were independently scored by the two reviewers. Comparison of results 
between the two reviewers was performed to determine reproducibility. The degree 
of variance allowed and the best scoring method needed to be defined prior to 
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screening to eliminate any possible bias; the allowances for inter observer variation 
are given in 4. Scores that differed between individuals greater than the accepted 
variance underwent joint review by both scorers with a consensus being reached. 
 
Score for proportion Score for intensity 
0 = no staining 0 = no staining 
1 = <1% nuclei staining 1 = weak staining 
2 = 1-10% nuclei staining 2 = moderate staining 
3 = 11-33% nuclei staining 3 = strong staining 
4 = 34-66% nuclei staining  
5 = 67-100% nuclei staining  
Table 3: Allred Scoring Method 
3.8 Statistical Analysis of Immunohistochemical Scoring 
Statistical analyses were performed using  the software pakage StatView (SAS 
Institute Inc. San Francisco, CA). Frequency distrubutions and non parametric 
univariate analysis was undertaken to compare the expression the biomarkers with 
each other and with the pathological criteria utilising the Chi-square (2) and Fisher’s 
exact tests as appropriate. Fisher’s exact test is suitable for defining a p value where 
two categorical variables have small values (usually less than 5). Chi- square is used 
to test for associations between larger values. Frequency distributions and univariate 
analyses tables are listed in Appendix 5. 
3.9 Immunohistochemistry Results 




Immunohistochemical results for staining of DCIS are given below (Table 5) with the 
number of positive and negative stained cases according to the scoring criteria above. 
Staining frequencies for each antibody are listed in Table 5. Representative images 
for IHC staining of pure DCIS & CISH for HER2 are seen in Figure 23 to Figure 29 
(section 3.9.2) Sections 3.9.3 to 3.9.9 give representative examples of paired 
univariate analysis for IHC markers and observed frequencies. Appendix 5 lists all 
other sets.  
 
Antibodies Scoring Method, 
recorded score 
Allowed variance between observers 
ER and PR Allred (0-8). The 
average of all 
cores is taken. 
Scores must be within 1 of each other i.e. a 




HER2 score, 0-3. 
Highest value is 
regarded as 
definitive. 
No variance accepted 
CKs (5, 5/6, 
14) 
%, an average of 
scores from the 
cores is regarded 
as final result. 
Variance of 5% is acceptable 
Ki67  %, an average of 
scores from the 
cores is regarded 
as final score. 
Variance of 5% is acceptable  
Table 4: IHC methods of scoring, of handling differing scores from cores and defined 
















ER 224 165 (74) 59 (26) 
PR 236 113 (48) 123 (52) 
HER2 248 57 (23) 191 (77) 
EGFR 227 11 (5) 213 (95) 
CK5 227 32 (14) 195 (86) 
CK5/6 220 69 (31) 151(69) 
CK14 231 38 (16) 193 (84) 
Ki67 237 136 (57) 101 (43) 
MCM2 237 130 (55) 107 (45) 












3.9.2 Immunohistochemical Images 

















Figure 27: CK14 staining of DCIS in 2mm TMA core (X40, X200). 
[Peripheral myoepithelial cell staining was not included in assessment of the DCIS] 
 
 





Figure 29: CISH for HER2 showing amplification of the HER2 Gene in DCIS, 2mm 
Core (x40, X200) 




3.9.3 Non Parametric Tests- Univariate Paired analysis: 
Positive univariate paired analyses tables and p-values for ER, PR, HER2, EGFR, 
Ki67, MCM2, CK5, CK5/6, CK14 and histological parameters are given below (Table 
6).  








CK5/6 CK14 CK5 EGFR 



































































0.0025 0.0008 0.0098      
CK5/6 0.0041 0.0298 0.0542 0.2279 0.1044 0.0025 0.0515 0.3772 
0.006
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3.9.4 Univariate Analysis of Hormone Receptor Immunohistochemistry  
 





















Cty. Cor. Chi Square
Cty. Cor. P-Value
Fis her's Exact P-Value
Summary Table for FINAL ER STATUS, FINAL HER2 STATUS








Observed Frequencies for FINAL ER STATUS, FINAL HER2 STATUS




















Cty. Cor. Chi Square
Cty. Cor. P-Value
Fis her's Exact P-Value
Summary Table for FINAL EGFR STATUS, FINAL ER STATUS








Observed Frequencies for FINAL EGFR STATUS, FINAL ER STATUS




 Table 8: Univariate paired analysis for progesterone receptor immunohistochemistry. 
The majority of DCIS cases were positive for hormone receptors (ER n=165, PR 
n=144- Table 7Table 8). For ER status there was an inverse correlation (p=0.001) 
with both EGFR and HER2 (Table 9); ER positive DCIS was associated with a 




















Cty. Cor. Chi Square
Cty. Cor. P-Value
Fis her's Exact P-Value
Summary Table for FINAL PR STATUS, FINAL HER2 STATUS








Observed Frequencies for FINAL PR STATUS, FINAL HER2 STATUS




















Cty. Cor. Chi Square
Cty. Cor. P-Value
Fis her's Exact P-Value
Summary Table for FINAL EGFR STATUS, FINAL PR STATUS








Observed Frequencies for FINAL EGFR STATUS, FINAL PR STATUS
 Row exclusion: DCIS STATVIEW DATASET
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(n=102 Table 10) There was an inverse correlation for CK5 and CK14 and ER with 
90% (n=147) and 88% (n=142) of ER positive cases being CK5 and CK14 negative 
respectively (Table 12). Few cases were negative for both ER and proliferation 
markers (ER-ve + Ki67-ve n=8 Table 13 and ER-ve MCM –ve n=15  
 
Table 14) All low grade DCIS (n=9) was ER positive (6% of all graded cases) and 
82% (n=46) of intermediate grade DCIS (n=50) was ER positive (34% of all graded 
cases; Table 15). High grade DCIS (n=90) made up 60% of cases and 61% (n=55) 
of these lesions were ER positive (p<0.0001). ER positive cases were more likely to 
have cribriform (n=55) or solid (n=38) architecture (Table 16). ER status did not 
predict the likelihood of recurrence of either DCIS or invasive disease (p=0.784; Table 
20 ). 
 ER -ve ER +ve Total 
HER2 -
ve 
23 145 168 
HER2 
+ve 
36 19 55 
Total 59 164 223 
 
Table 9: Univariate analyses for ER and HER2 IHC: Fishers exact test p value < 
0.0001 
 ER -ve ER +ve Total 
PR -ve 56 55 111 
PR +ve 0 102 102 
Total 56 157 213 
 




 ER -ve ER +ve Total 
CK5 -ve 41 147 188 
CK5 +ve 15 16 31 
Total 56 163 219 
 


















Table 13: Univariate analyses for ER and Ki67 (>5%) IHC; Fishers exact test p value 
<0.0001 
 
 ER -ve ER +ve Total 
CK14 -ve 40 142 182 
CK14 
+ve 
18 19 37 
Total 58 161 219 
 ER -ve ER +ve Total 
Ki67 -ve 8 78 86 
Ki67+ve 51 79 130 




























Table 16: Univariate analyses for ER IHC and Histological Architecture; Chi square p 
Value < 0.0001 
 ER -ve ER +ve Total 
MCM2 -
ve 
15 77 92 
MCM2+ve 44 83 127 
Total 59 160 219 
 ER -ve ER +ve Total 
HG 35 55 90 
IG 4 46 50 
LG 0 9 9 
Total 39 110 149 
 ER -ve ER +ve Total 
Crib 5 55 60 
Micropap 7 6 13 
Pap 1 11 12 
Solid 26 38 64 
Total 39 110 149 
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3.9.5 Univariate Analysis for HER2 Immunohistochemistry 
 




















Cty. Cor. Chi Square
Cty. Cor. P-Value
Fis her's Exact P-Value
Summary Table for FINAL HER2 STATUS, FINAL EGFR STATUS








Observed Frequencies for FINAL HER2 STATUS, FINAL EGFR STATUS




















Cty. Cor. Chi Square
Cty. Cor. P-Value
Fis her's Exact P-Value
Summary Table for FINAL HER2 STATUS, FINAL ER STATUS








Observed Frequencies for FINAL HER2 STATUS, FINAL ER STATUS




A total of 248 cases had HER2 IHC results (Table 17), of these 23% (n=57) were 
HER2 positive. This included 5% (n=13) of the 2+ cases on IHC (n=47)  which were 
subsequently shown to show HER2 gene amplification by CISH. Of the HER2 positive 
cases 9% (n=19) were also ER positive. 24% (n=39) of patients for whom clinical data 
was available (n=161) had HER2 positive DCIS. Of these HER2 positive cases 28% 
(n=11) were also ER positive (p<0.0001) 13% (n=5) was of intermediate grade 
(p=0.0001). Of note, 4 of the 5 cases of intermediate grade DCIS which were HER2 
positive were also ER positive (80%). There were no low grade HER2 positive DCIS 
cases. A significant p value was given between HER2 positivity and architectural 
pattern (p=0.0003), the presence of necrosis (p=0.0001) and chronic inflammation 
(p<0.001).  None of the 11 HER2/ER positive cases had an invasive recurrence, 45% 
(n=5) underwent mastectomy as a result of the DCIS diagnosis and 3 had recurrent 
DCIS in the same year. Three cases of DCIS were both HER2 and EGFR positive 



































Cty. Cor. Chi Square
Cty. Cor. P-Value
Fis her's Exact P-Value
Summary Table for FINAL KI67 (AT MEDIAN, 5%), FINAL HER2 STATUS








Observed Frequencies for FINAL KI67 (AT MEDIAN, 5%), FINAL HER2 STATUS




















Cty. Cor. Chi Square
Cty. Cor. P-Value
Fis her's Exact P-Value
Summary Table for FINAL EGFR STATUS, FINAL KI67 (AT MEDIAN, 5%)








Observed Frequencies for FINAL EGFR STATUS, FINAL KI67 (AT MEDIAN, 5%)

























Cty. Cor. Chi Square
Cty. Cor. P-Value
Fis her's Exact P-Value
Summary Table for FINAL MCM2 (AT MEDIAN, 27.5%), FINAL HER2 STATUS








Observed Frequencies for FINAL MCM2 (AT MEDIAN, 27.5%), FINAL HER2 STATUS




















Cty. Cor. Chi Square
Cty. Cor. P-Value
Fis her's Exact P-Value
Summary Table for FINAL EGFR STATUS, FINAL MCM2 (AT MEDIAN, 27.5%)








Observed Frequencies for FINAL EGFR STATUS, FINAL MCM2 (AT MEDIAN, 27.5%)




The proliferation markers examined (Table 18), Ki67 and MCM2, were both scored 
as positive when >5% of DCIS cells showed nuclear positivity, which corresponded 
to the median value for Ki67. 91% (n=78) of Ki67 negative cases were positive for 
ER. Only 4% (n=8) of cases were negative for both Ki67 and ER (p=<0.0001).  
 
The association between PR and Ki67 was similar to ER and Ki67; 16% (n=36) cases 
were negative for both PR and Ki67 (p<0.0001). If one of these markers was positive 
the other was most likely to be negative. MCM2 and ER showed a similar profile to 
Ki67 and ER, with 7% (n=15) of cases negative for both markers and 75%  (n=44) of 
ER negative cases being MCM2 positive (p=0.0032). Similar to Ki67 and PR, 18% 
(n=42) of DCIS cases were negative for both PR and MCM2, whilst cases tended to 






































Cty. Cor. Chi Square
Cty. Cor. P-Value
Fis her's Exact P-Value
Summary Table for FINAL CK5 (AT 1%), FINAL HER2 STATUS








Observed Frequencies for FINAL CK5 (AT 1%), FINAL HER2 STATUS




















Cty. Cor. Chi Square
Cty. Cor. P-Value
Fis her's Exact P-Value
Summary Table for FINAL EGFR STATUS, FINAL CK5 (AT 1%)








Observed Frequencies for FINAL EGFR STATUS, FINAL CK5 (AT 1%)
























Cty. Cor. Chi Square
Cty. Cor. P-Value
Fis her's Exact P-Value
Summary Table for FINAL CK5/6 (AT 1%), FINAL HER2 STATUS








Observed Frequencies for FINAL CK5/6 (AT 1%), FINAL HER2 STATUS




















Cty. Cor. Chi Square
Cty. Cor. P-Value
Fis her's Exact P-Value
Summary Table for FINAL EGFR STATUS, FINAL CK5/6 (AT 1%)








Observed Frequencies for FINAL EGFR STATUS, FINAL CK5/6 (AT 1%)

























Cty. Cor. Chi Square
Cty. Cor. P-Value
Fis her's Exact P-Value
Summary Table for FINAL CK14 (AT 1%), FINAL HER2 STATUS








Observed Frequencies for FINAL CK14 (AT 1%), FINAL HER2 STATUS




















Cty. Cor. Chi Square
Cty. Cor. P-Value
Fis her's Exact P-Value
Summary Table for FINAL EGFR STATUS, FINAL CK14 (AT 1%)








Observed Frequencies for FINAL EGFR STATUS, FINAL CK14 (AT 1%)
 Row exclusion: DCIS STATVIEW DATASET
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The frequency of expression of CK5 and CK5/6 was distinctly different; 31% of cases 
were positive for CK5/6 (n=69) compared to only 14% for CK5 (n=32)(Table 19). Few 
cases showed EGFR positivity (n=11, 5%); 3 EGFR positive cases were also either 
CK5/6 or CK5 positive and 2 cases exhibited both CK14 and EGFR positivity.  
 
Of the basal cytokeratin markers, CK14 (p=0.0018) and CK5 (p=0.0033) 
demonstrated an inverse relationship with ER but no significant association between 
CK5/6 (p=0.298) and ER was seen. Over 90% of EGFR positive cases were ER 
negative and over 99% of ER positive cases were EGFR negative (p<0.0001). All but 
one case of EGFR positive DCIS was positive for both proliferation markers Ki67 
(p=0.0294) and MCM2 (p=0.0254) EGFR positive DCIS was of higher cytonuclear 
grade and was more likely to have solid architecture with comedo-type necrosis and 
associated chronic inflammation present. 
3.9.8 Univariate Analysis and Recurrence of DCIS and/or Invasive Breast 
Disease 
Univariate paired analyses were carried out for all antibodies to determine any 
























Cty. Cor. Chi Square
Cty. Cor. P-Value
Fis her's Exact P-Value
Summary Table for REC Y/N, FINAL HER2 STATUS








Observed Frequencies for REC Y/N, FINAL HER2 STATUS




















Cty. Cor. Chi Square
Cty. Cor. P-Value
Fis her's Exact P-Value
Summary Table for FINAL EGFR STATUS, REC Y/N








Observed Frequencies for FINAL EGFR STATUS, REC Y/N























Cty. Cor. Chi Square
Cty. Cor. P-Value
Fis her's Exact P-Value
Summary Table for FINAL ER STATUS, REC Y/N








Observed Frequencies for FINAL ER STATUS, REC Y/N




















Cty. Cor. Chi Square
Cty. Cor. P-Value
Fis her's Exact P-Value
Summary Table for FINAL PR STATUS, REC Y/N








Observed Frequencies for FINAL PR STATUS, REC Y/N























Cty. Cor. Chi Square
Cty. Cor. P-Value
Fis her's Exact P-Value
Summary Table for FINAL CK5 (AT 1%), REC Y/N








Observed Frequencies for FINAL CK5 (AT 1%), REC Y/N




















Cty. Cor. Chi Square
Cty. Cor. P-Value
Fis her's Exact P-Value
Summary Table for FINAL CK5/6 (AT 1%), REC Y/N








Observed Frequencies for FINAL CK5/6 (AT 1%), REC Y/N























Cty. Cor. Chi Square
Cty. Cor. P-Value
Fis her's Exact P-Value
Summary Table for FINAL CK14 (AT 1%), REC Y/N








Observed Frequencies for FINAL CK14 (AT 1%), REC Y/N























Cty. Cor. Chi Square
Cty. Cor. P-Value
Fis her's Exact P-Value
Summary Table for FINAL KI67 (AT MEDIAN, 5%), REC Y/N








Observed Frequencies for FINAL KI67 (AT MEDIAN, 5%), REC Y/N




















Cty. Cor. Chi Square
Cty. Cor. P-Value
Fis her's Exact P-Value
Summary Table for FINAL MCM2 (AT MEDIAN, 27.5%), REC Y/N








Observed Frequencies for FINAL MCM2 (AT MEDIAN, 27.5%), REC Y/N
 Row exclusion: DCIS STATVIEW DATASET
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Summary Table for GRADE, REC Y/N










Observed Frequencies for GRADE, REC Y/N

















Summary Table for ARCH, REC Y/N












Observed Frequencies for ARCH, REC Y/N





















Summary Table for NECROSIS, REC Y/N












Observed Frequencies for NECROSIS, REC Y/N

















Summary Table for CI, REC Y/N












Observed Frequencies for CI, REC Y/N
























Cty. Cor. Chi Square
Cty. Cor. P-Value
Fis her's Exact P-Value
Summary Table for REC Y/N, SIZE RECODED AT MEDIAN (15)








Observed Frequencies for REC Y/N, SIZE RECODED AT MEDIAN (15)























Cty. Cor. Chi Square
Cty. Cor. P-Value
Fis her's Exact P-Value
Summary Table for AGE RECODED AT 50, REC Y/N





AGE 50 OR LESS
MORE THAN 50
Totals
Observed Frequencies for AGE RECODED AT 50, REC Y/N
























Cty. Cor. Chi Square
Cty. Cor. P-Value
Fis her's Exact P-Value
Summary Table for LUMINAL A, REC Y/N








Observed Frequencies for LUMINAL A, REC Y/N




















Cty. Cor. Chi Square
Cty. Cor. P-Value
Fis her's Exact P-Value
Summary Table for LUMINAL B, REC Y/N








Observed Frequencies for LUMINAL B, REC Y/N
























Cty. Cor. Chi Square
Cty. Cor. P-Value
Fis her's Exact P-Value
Summary Table for HER2 GROUP, REC Y/N








Observed Frequencies for HER2 GROUP, REC Y/N




















Cty. Cor. Chi Square
Cty. Cor. P-Value
Fis her's Exact P-Value
Summary Table for LUMINAL-HER2, REC Y/N








Observed Frequencies for LUMINAL-HER2, REC Y/N


























Cty. Cor. Chi Square
Cty. Cor. P-Value
Fis her's Exact P-Value
Summary Table for BASAL-LIKE GROUP, REC Y/N








Observed Frequencies for BASAL-LIKE GROUP, REC Y/N

























Cty. Cor. Chi Square
Cty. Cor. P-Value
Fis her's Exact P-Value
Summary Table for LUMINAL B1, REC Y/N








Observed Frequencies for LUMINAL B1, REC Y/N




















Cty. Cor. Chi Square
Cty. Cor. P-Value
Fis her's Exact P-Value
Summary Table for LUMINAL A1, REC Y/N








Observed Frequencies for LUMINAL A1, REC Y/N
 Row exclusion: DCIS STATVIEW DATASET
  
3.9.9 Histological Grade in DCIS 
Immunohistochemical expression of all markers in this study was compared to 
histological grade to determine any correlation between grade and specific markers.  
Table 21 gives the number of positive and negative cases expressing IHC markers in 





(% of total) 
Intermediate 
Grade  (n) 
Intermediate 





(% of total) 
Total     (n) 
ER -ve 35 90 4 10 0 0 39 
ER +ve 55 50 46 42 9 8 110 
Total 90  50  9  149 
PR -ve 54 70 23 30 0 0 77 
PR +ve 37 46 33 41 10 13 80 
Total 91  56  10  157 
EGFR -ve 81 57 53 37 8 6 142 
EGFR +ve 10 91 1 9 0 0 11 
Total 91  54  8  153 
HER2 -ve 60 49 51 41 12 10 123 
HER2 +ve 33 87 5 13 0 0 38 
Total 93  56  12  161 
Ki67 low 26 42 28 45 8 13 62 
Ki67 high 65 71 24 26 3 3 92 
Total 91  52  11  154 
MCM2 low 28 39 36 51 7 10 71 
MCM2 high 66 76 17 20 4 5 87 
Total 94  53  11  158 
CK5 -ve 73 57 46 36 10 8 129 
CK5 +ve 17 77 5 23 0 0 22 
Total 90  51  10  151 
CK5/6 -ve 56 54 42 41 5 5 103 
CK5/6 +ve 34 72 11 23 2 4 47 
Total 90  53  7  150 
CK14 -ve 69 55 49 39 7 6 125 
CK14 +ve 23 74 6 19 2 6 31 
Total 92  55  9  156 
Table 21: Biomarker expression by cytonuclear grade of DCIS.  
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Paired univariate analysis between the immunohistochemical markers and 
histological parameters such as cytonuclear grade, comedo type necrosis, chronic 



















Summary Table for GRADE, FINAL HER2 STATUS










Observed Frequencies for GRADE, FINAL HER2 STATUS

















Summary Table for FINAL EGFR STATUS, GRADE
 Row exclusion: DCIS STATVIEW DATASET
81 53 8 142
10 1 0 11
91 54 8 153




Observed Frequencies for FINAL EGFR STATUS, GRADE




















Summary Table for FINAL ER STATUS, GRADE
 Row exclusion: DCIS STATVIEW DATASET
35 4 0 39
55 46 9 110
90 50 9 149




Observed Frequencies for FINAL ER STATUS, GRADE

















Summary Table for FINAL PR STATUS, GRADE
 Row exclusion: DCIS STATVIEW DATASET
54 23 0 77
37 33 10 80
91 56 10 157




Observed Frequencies for FINAL PR STATUS, GRADE




















Summary Table for FINAL CK5 (AT 1%), GRADE
 Row exclusion: DCIS STATVIEW DATASET
73 46 10 129
17 5 0 22
90 51 10 151




Observed Frequencies for FINAL CK5 (AT 1%), GRADE

















Summary Table for FINAL CK5/6 (AT 1%), GRADE
 Row exclusion: DCIS STATVIEW DATASET
56 42 5 103
34 11 2 47
90 53 7 150




Observed Frequencies for FINAL CK5/6 (AT 1%), GRADE




















Summary Table for FINAL CK14 (AT 1%), GRADE
 Row exclusion: DCIS STATVIEW DATASET
69 49 7 125
23 6 2 31
92 55 9 156




Observed Frequencies for FINAL CK14 (AT 1%), GRADE




















Summary Table for FINAL KI67 (AT MEDIAN, 5%), GRADE
 Row exclusion: DCIS STATVIEW DATASET
26 28 8 62
65 24 3 92
91 52 11 154




Observed Frequencies for FINAL KI67 (AT MEDIAN, 5%), GRADE

















Summary Table for FINAL MCM2 (AT MEDIAN, 27.5%), GRADE
 Row exclusion: DCIS STATVIEW DATASET
28 36 7 71
66 17 4 87
94 53 11 158




Observed Frequencies for FINAL MCM2 (AT MEDIAN, 27.5%), GRADE




















Summary Table for ARCH, GRADE
 Row exclusion: DCIS STATVIEW DATASET
25 33 10 68
11 4 3 18
3 10 0 13
59 11 0 70
98 58 13 169






Observed Frequencies for ARCH, GRADE

















Summary Table for NECROSIS, GRADE
 Row exclusion: DCIS STATVIEW DATASET
39 3 0 42
22 24 1 47
28 10 0 38
9 21 12 42
98 58 13 169






Observed Frequencies for NECROSIS, GRADE


































Summary Table for CI, GRADE
 Row exclusion: DCIS STATVIEW DATASET
37 0 0 37
27 28 4 59
24 11 1 36
10 17 8 35
98 56 13 167






Observed Frequencies for CI, GRADE
 Row exclusion: DCIS STATVIEW DATASET
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3.9.10 Assignation of Molecular Subtypes to DCIS 
3.9.10.1 Molecular Subgrouping of DCIS 
Surrogate molecular subgroups (76) were assigned to the pure DCIS cohort using 
the criteria in Table 23. These groups broadly correlate to the five molecular subtypes 
proposed by Perou et al.  A subgroup which was both HER2 and ER positive was 
also identified within the series and categorised as luminal/HER2.  
DCIS subgroup  IHC Expression Pattern Number of Cases % of Cases  
































Table 23: Definitions for Surrogate Molecular Subgroups for DCIS:  
 
Additionally, the expression of Ki67 was examined in the ER positive and HER2 
negative DCIS cases in order to define luminal A and luminal B according to 
proliferation rate (Table 24).  Subgroups of luminal A1 and luminal B1 were defined 
as ER positive, Ki67 low and ER positive, Ki67 high respectively, in addition to the 
alternative method of defining cases according to ER and PR status, i.e. ER positive, 
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PR positive as luminal A and ER positive, PR negative as luminal B. Table 24 gives 
details of numbers of ER positive cases as assigned by high or low Ki67 expression.  
 
Group Definition No. Cases 
(TMA total n = 280, 
relevant (ER+) cases 
n= 158) 






















Table 24: Subgrouping of ER positive DCIS with Ki67 expression; cut-off defined at 
median, 5%. 
3.10 Immunophenotypic Subtypes of DCIS and Recurrence 
Three HER2 positive (HER2 group) cases recurred (n=47; 6.4%) and three of the 
basal-like group (n=50; 6%) had a recurrence (Table 20). In this cohort of pure DCIS 
the luminal A group (n=103), as defined above, showed no association with 
recurrence; nine of the recurrent cases belonged to the luminal A group. Only one of 
the recurrent cases was found in the luminal B group (n=55).  
For ER positive cases (n=95), 51% (n=48) had high Ki67 expression. High Ki67 status 
resulted in a 19% (n=18) shift from the luminal A (ER positive but low proliferation, 
defined as A1) to the luminal B1 (ER positive but high proliferation, defined as B1) 
group. In this series, seven of the luminal B1 group and four of the luminal A1 had a 
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recurrence. Overall, cases of DCIS that were ER and PR positive had a higher 
incidence of recurrence than cases which were ER positive with high Ki67 expression.  
In our series 74% of DCIS are ER positive. Approximately 70-80% of invasive ductal 
carcinomas of no special type (NOS) are ER positive according to the literature (188). 
This is related to cytonuclear grade of DCIS in the present series (p value < 0.001); 
61% of high grade cases (HG) are ER positive (n=90), 92% of intermediate grade 
(IG) (n=50) and 100% of low grade (LG) DCIS are ER positive n=9). Previous studies 
have demonstrated variation in ER expression in high grade DCIS, ranging from 
31.8% (189), 69% (190) to 72% (191). 
3.11 Discussion 
The genomic profiling of invasive breast cancers has revealed subtypes of invasive 
breast cancer, namely luminal A, luminal B, HER2, basal, normal and (subsequently) 
null. A search of the literature (Pubmed in 2014: search criteria; DCIS + molecular 
subtype, DCIS + IHC, DCIS + basal, DCIS + luminal, DCIS + phenotype) has yielded 
a small number of studies that examine the possibility of using IHC as a surrogate for 
genetic profiling to classify DCIS in a similar manner. To date only a few (82, 192) of 
these have taken a comparative approach by assigning the genetic molecular profile 
to samples then assessing the corresponding IHC as opposed to simply assigning 
groups by IHC expression alone.  
In this series immunohistochemistry (IHC) on “pure” DCIS was performed to ascertain 
if any potential marker or markers could be identified as a biological indicator of known 
progression to either a recurrence of DCIS or invasive disease. However, no 
association or predictor has been found for recurrence of DCIS with any of ER, PR, 
HER2, EGFR or the basal cytokeratins 5, 5/6 or 14, high or low expression of 
proliferative markers in univariate analysis. Unsurprisingly, a correlation is seen 
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between cytonuclear grade increased expression of proliferative markers (Ki67 and 
MCM2), which largely mirrors findings in invasive breast carcinoma.    
None of the IHC biomarkers evaluated in this cohort were significantly associated with 
recurrence of disease, although this may be due to the small numbers of patients in 
this series who suffered with recurrence. Additionally, the cohort for this study was 
based upon patients diagnosed with DCIS between 1995 and 2006 with 50% (n=71) 
of patients undergoing a mastectomy within 65 days of original histology report. 
Thomas et al (193) examined data from the Sloane Project, currently the largest 
prospective audit on DCIS. Examination of over 8000 cases indicates that 
mastectomy rates dropped to 26% between April 2003 and March 2012 with more 
women undergoing breast conserving surgery (BCS). They also highlight the 
significant degree of practice variation between institutions affecting patient outcome. 
These differences in practice should be considered when looking at data sets from 
an individual institution.  
Molecular profiling of invasive breast carcinomas gives subgroup frequencies of 
luminal A - 40%, luminal B - 20%, HER2 - 10-15% and basal-like - 15-20%. (76, 82, 
194, 195). In this series of DCIS the subgroup frequencies for DCIS as determined 
by IHC profiling were luminal A - 37%, luminal B - 20%, HER2 - 17%, luminal/HER2 
- 7% and basal-like - 18%, indicating an essentially similar frequency between the 
invasive carcinoma immunosub-types and that seen in DCIS.  
There is, however, no consensus agreement on assigning sub-type based on IHC 
panels for invasive disease, and this has not been satisfactorily addressed for DCIS. 
Whilst there is a increase in the frequency of HER2 positive DCIS compared to 
invasive breast carcinoma, 7% of these would be assigned to the luminal A group 
based on the surrogate panels suggested by some authors (82, 196, 197). In this 
cohort these patients are designated to a small group that is positive for both HER2 
and ER as thus as luminal/HER2.  
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Other studies have looked at the possibility of using IHC as a method of classifying 
DCIS, either to define potential molecular subtypes (86, 196-199) or specifically to 
identify a sub-set of basal-like DCIS, or to predict outcome or recurrence. Tamimi et 
al (200) identified subgroups in both invasive breast carcinomas (n=2897) and DCIS 
(n=272) noting that the luminal A group was more prevalent in the invasive cohort, 
whilst the HER2 and luminal B groups had a higher incidence in DCIS. Zhou et al 
(198) identified a basal–like subtype of DCIS with an increased risk of recurrence of 
disease. They constructed TMAs from 485 cases of primary DCIS found in Swedish 
women between 1986 and 2004. Using IHC markers (ER, PR, HER2, CK5/6 and 
EGFR) as surrogates for genomic profiling they defined groups as triple negative, 
non-triple negative and basal-like. Results for 392 women were available. Basal-like 
DCIS in their series (n=32) had a higher risk of local recurrence with hazard ratio (HR) 
of 1.8 (Confidence interval (CI) 95% 0.8 – 4.2) and also invasive risk recurrence of 
1.9 (CI 0.7 – 5.1) but these results were not statistically significant. They found no 
significantly increased risk of recurrence of disease for patients with triple negative 
DCIS. 
Meijenen et al (196) evaluated 16 IHC markers identifying six (ER, PR, androgen 
receptor, Bcl2, HER2 and p53) which they suggested were suitable for defining DCIS 
into two major groups, luminal and non-luminal, and 5 subgroups. They also noted 
that intermediate grade DCIS had more IHC similarities to well differentiated than 
poorly differentiated disease. Clark et al (197) also classified DCIS into molecular 
subgroups with IHC, suggesting a role for BCL2 as a possible identifier for good 
prognosis. Overall, therefore the present, and other, studies show that it is possible 
to identify differences between cases of DCIS using panels of IHC markers. Such 
markers show correlations with each other and with features of known clinico-
pathological relevance and can be combined into sub-groups equivalent to those in 
invasive breast cancer. However, no individual marker, or combination, shows a 
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strong association with recurrence of disease and thus to be of significant clinical 
value at this time. 
Few studies have looked directly at genomic and IHC parameters in the same lesions, 
either invasive or in situ. Nielsen et al (82) studied invasive breast carcinoma with 
both IHC and genomic profiling and identified a concordant set of basal-like tumours 
using four IHC markers (HER2, EGFR, CK5/6 and ER). In the present series we have 
defined a basal-like group by utilising three basal cytokeratin antibodies (CK14, CK5 
and CK5/6) in addition to EGFR, ER, PR and HER2, but we note that the frequencies 
of expression of CK5/6 and CK5 showed distinct disparity. This highlights one of the 
concerns in the definition of molecular subtypes using IHC; the variability of clones 
and the interpretation of scoring are parameters that currently have no defined values. 
What constitutes a positive CK score varies in the literature, with some researchers 
advocating any staining as positive (196, 200) and some using a threshold of ≥ 10% 
(197, 199). Indeed, one of the issues that requires addressing before a molecular 
taxonomy equivalent to genomic profiling, for either invasive or DCIS, can be adopted 
by application of IHC is the precise and globally acceptable definitions using specific 
antibodies, and possibly even clones. Robust scoring criteria and a need for 
standardisation of collection, fixation, processing and reporting are also fundamental 
to accurate assignation of molecular subtypes. Tang et al (201) reviewed the IHC 
classification of invasive breast cancers and advocated a molecular classification, 
which could be similarly used for DCIS. They suggest for invasive breast cancer 
subgrouping as luminal A (ER positive, HER2 negative), luminal B (ER positive, HER2 
positive), HER2 group (ER negative, HER2 positive), basal subgroup (ER negative, 
HER2 negative, CK5/6 and/ EGFR positive) and an unclassified group (ER negative, 




The present study aimed to identify the possibility of using IHC as a genomic 
surrogate to identify subgroups of DCIS and to investigate associations with patient 
outcome. We have found that molecular subgroups can be identified using an IHC 
approach. However, further work is required to evaluate the usefulness of such a 
system in DCIS, particularly with regard to prediction of recurrence. Retrospective 
studies will probably lack the statistical power or accuracy required to give reliable 
data, given the variation in clinical management in historical series, including the 
proportion of cases treatment by breast conserving surgery, differences in the 






Chapter 4. DCIS Associated with Invasive 
Breast Carcinoma 
4.1 Introduction 
The molecular profiling and immunohistochemical studies described in Chapter 3 
focused upon the IHC marker expression and the propensity for “pure” DCIS to 
become invasive or recur as further DCIS. However, DCIS may also be expressed 
alongside an invasive breast lesion. Previous genomic studies have demonstrated 
that similar genetic profiles exist between DCIS and synchronously expressed 
invasive breast disease (202-204). Conversely, there is some evidence of intra-
tumour heterogeneity between some DCIS and the respective invasive breast lesion 
given rise to the possibility of divergent clonal pathways within an individual tumour 
(202). This may indicate that, in synchronous DCIS and invasive breast disease at 
least, that DCIS is already at an advanced stage committed to invasive progression. 
We aimed therefore to explore the possibility of different IHC profiles or frequencies 
in a subset of DCIS with associated invasive carcinoma and to determine whether 
any potential difference existed between pure DCIS and DCIS lesions associated with 
invasive breast tumours. These would be stained with the same antibody panel as 
the pure DCIS in Chapter 3. This subset would also provide part of the cohort for 
further genomic studies (see Chapter 5).  
4.2 Materials and Methods 
DCIS and associated invasive tissue were provided by King’s Health Partners Tissue 
Bank (KHPB) with tissue microarrays constructed in the same manner as described 
in section 2.2. Similarly, TMA sections were stained with the same antibodies using 
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the similar conditions as set out in section 3.2. However, in this instance cores were 
taken from a minimum of two defined processes, namely DCIS and invasive 
components. For DCIS regions three 2mm cores were taken and for the invasive 
component three 0.6mm cores were taken. The DCIS component was identified by 
the presence of a complete basement membrane and myoepithelial layer surrounding 
the malignant epithelial cell islands by the author and consultant breast pathologist 
(SEP). In lesions where there was a doubt regarding the presence of an intact 
membrane, IHC for the marker smooth muscle myosin heavy chain (SMMHC) was 




Figure 30: SMMHC IHC showing intact myoepithelial cell layer around DCIS. 
 
A total of 41 cases dating between 1989 and 2004 with synchronous invasive breast 
disease and DCIS lesions was identified and stained with ER, PR, HER2, EGFR, 
CK5/6, CK14, MCM2 and Ki67. IHC scoring was carried out as per section 3.7. 
Molecular subgroups were assigned as defined by Perou et al using the following 
criteria: ER positive, PR positive, HER2 negative = luminal A; ER positive, PR 
negative, HER2 negative = luminal B; HER2 positive, ER negative = HER2 group; ER 
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negative, PR negative, HER2 negative with any/or EGFR,  CK5/6, CK14 = basal–like; 
no expression of any of ER, PR, HER2, basal CKs or EGFR = null. A subgroup of 
disease which was HER2 positive and ER positive was also noted within our series 
and designated luminal HER2. Additionally, the expression of proliferative markers 
was examined in ER positive cases to determine any association with prognosis and 
recurrence. Subgroups luminal A1 and luminal B1 were defined as ER positive, Ki67 
low and ER positive, Ki67 high respectively as opposed to ER positive, PR positive 
(luminal A) and ER positive PR negative (luminal B) within the HER2 negative sub-
set. 
4.3 Results 
4.3.1 Individual IHC Antibody Staining Concordance between Invasive 
Tumour and DCIS in the Same Case: 
The TMAs constructed and stained with IHC markers had scores generated for both 
the DCIS and invasive carcinoma components within each case. The DCIS and 
invasive component scores with each antibody were compared. Table 25 shows the 



































ER (Allred >3) 23 3 2 2 11 0 41 
PR (Allred >3) 9 1 3 8 20 0 41 
HER2 (HER2 
score 3+) 
8 0 7 13 13 0 41 
EGFR (HER2-
like score 3+) 
















9 1 6 2 20 3 41 
Table 25: Comparison of IHC scores between cases of admixed DCIS and invasive 
carcinoma 
4.3.2 Assignation of Molecular Subgroups 
Molecular subgroups were assigned according to both the invasive carcinoma IHC 
scores and DCIS IHC scores. Tables 26 and 27 give details of numbers and sub-
groups and concordance. Table 26 shows the number of cases assigned to each 
group according to DCIS or Invasive component. Table 27 shows the distribution 













DCIS Paired Cases 
 (Invasive carcinoma and 
DCIS match in same case) 
Unpaired cases 
 (Invasive carcinoma and 
DCIS do not match in the 
same case) 
Luminal A  
(ER positive, PR positive, 
HER2 negative) 
14 6 4 2 
Luminal B  
(ER positive, PR 
negative, HER2 negative) 
3 4 3 0 
HER2  
(HER2 positive, ER 
negative) 
0 4 1 3 
Basal-like 
(ER negative, PR 
negative, HER2 negative, 
EGFR /CK5/ CK5/6 
and/or CK14) 
12 9 4 5 
Luminal/ HER2 
(ER positive, HER2 
positive) 
7 11 7 0 
Null 
(All negative) 
1 1 0 1 
Total 37 35 18 12 





DCIS Paired Cases 
 (Invasive carcinoma and 
DCIS match in same case) 
Unpaired cases 
 (Invasive carcinoma and 
DCIS do Not match in the 
same case) 
Luminal A1  
ER positive, Ki67 
high expression 
10 9 6 3 
Luminal B1  
ER positive, Ki67 low 
expression 
10 16 6 4 
Total *20 25 12 7 
 *3 cases no Ki67 Score   
Table 27: IHC Molecular Subgroups for Invasive Carcinomas and Associated DCIS 






In this series of DCIS associated with invasive breast carcinoma several observations 
can be made. For ER positive DCIS and invasive breast disease there is a high 
degree of concordance with 83% (n=25/30) of cases showing a similar ER status. 
Analysis of the Allred scores also shows that cores have a similar degree of ER 
expression. A similar pattern is seen with PR, with 81% (n=17/21) having concordant 
scores.  
HER2 expression with IHC showed 75% concordance (n=21/28); although 25% of 
the DCIS was HER2 IHC positive whereas the invasive breast disease was negative, 
even in this small series.  
For EGFR there was no distinct pattern of correlation between DCIS and invasive 
breast disease; 3 cases were EGFR positive in both the invasive breast cancer and 
the DCIS, 3 cases showed positivity in the invasive disease only and 2 cases positivity 
in the DCIS only.  
Interestingly, there was also little similarity between invasive breast disease and DCIS 
with regard to basal cytokeratin expression; in 5 cases positive CK5/6 expression was 
seen in the invasive carcinoma whilst the DCIS was CK5/6 negative. Similarly, CK14 
positive invasive breast disease (n=4) was negative in the associated DCIS in 3 
cases. Conversely, DCIS was positive for CK14 in 3 cases and negative in the 
associated invasive cancer in two. One DCIS case was CK5/6 positive but negative 
in the invasive breast disease.  
Ki67 showed concordance (scores within 5% of each other) for 63% of admixed DCIS 
and invasive breast disease (n=22). Of note, the 37% (n=13) of discordant cases had 
elevated Ki67 in the invasive breast disease in all cases (range = 7-32% mean = 
10%). MCM2 expression was concordant in the DCIS and the invasive disease in 
37% of cases (n=7/19), 52% (n=10/19) of cases showed elevated MCM2 expression 
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(range = 7-73% mean = 38%) in the invasive tumour compared to the DCIS and 11% 
(n= 2/19) showing elevated MCM2 in the DCIS lesion (range= 12-49% mean =30%).  
Unlike the pure DCIS cohort, HER2 expression was associated with ER positivity in 
the DCIS component with 73% (n=11/15) showing positive staining for both. In the 
invasive component, unexpectedly, 100% of the HER2 positive disease was ER 
positive (n=7/7). Although there are many studies on ER positive HER2 negative 
breast cancer there are few articles addressing ER positive HER2 positive lesions.  
Ryden et al (205) describe HER2+ and ER+ breast cancer as a separate  subgroup 
of tumours with poor prognosis in premenopausal breast cancer. Alqaisi et al (206) 
found co-expression of ER-positive HER2 positive disease was found in younger age, 
had higher grade and increased visceral involvement in de novo metastasis.  
Unfortunately, in the DCIS TMA there was a marked loss of cores for ER, PR, EGFR, 
HER2 and MCM2 during the antigen retrieval step. The reason for this remains 
unclear as all TMAs were constructed with the same guidelines as other TMAs, 
including the invasive TMA from the same tissue samples, which retained tissue 
during antigen retrieval steps. The same cases for each antibody had tissue loss 
possibly indicating a fixation or necrotic tissue problem. It was possible therefore to 
assign only 35 cases to molecular subgroup for both the invasive and the in situ 
elements..  
Intriguingly, however, in this cohort such molecular subgrouping does not show 
perfect concordance between the DCIS and the associated invasive tumour for most 
groups. Only the luminal/HER2 group has complete concordance with all available 
samples being ER positive and HER2 positive in both the DCIS and HER2. 66% of 
luminal A, 0% of luminal B, 44% of basal-like and 0% of null had concurrent IHC 
staining in this series. This could be due to several factors: 
1. Tumour heterogeneity and, in particular, clonal expansion of particular cell 
types once invasion has occurred; 
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2. Synchronous development of unrelated tumour and DCIS within the same 
patient (highly unlikely); 
3. Down- or up-regulation of proteins once invasion has begun. 
The limitations of this experiment must be fully acknowledged before such 
conclusions can be drawn. The substantial loss of cores in the DCIS TMA during IHC 
staining has compromised the ability to group samples by more than one marker and 





Chapter 5. Genomic Studies on DCIS 
5.1 Introduction 
Understanding the genomic basis of DCIS and how it relates to invasive breast 
carcinoma may help elucidate the underlying mechanisms of progression to invasive 
disease or demonstrate that DCIS in certain instances may already represent a 
commitment to an invasive phenotype. The progression of DCIS to an invasive 
phenotype has been previously studied using gene expression profile analysis (203, 
207) and array comparative genomic hybridisation (aCGH) in small numbers of 
studies and cases (208-210). These studies have demonstrated that DCIS lesions of 
the same grade have similar genetic profiles to the concurrent invasive tumour, 
although qualitative differences such as prevalence are reported in matched series 
(211).  
Copy number variations (CNVs) are genomic variations of greater than one kilobase 
affecting the number of copies of genes possessed by an individual compared to a 
reference sample. First reported by Charles Lee in 2002 (212) CNVs represent 
deletions, insertions or duplications of DNA.  Shlien et al (213) described the 
importance of CNVs succinctly: 
“DNA copy number variations (CNVs) are an important component of genetic 
variation, affecting a greater fraction of the genome than single nucleotide 
polymorphisms (SNPs). The advent of high-resolution SNP arrays has made it 
possible to identify CNVs. Characterization of widespread constitutional (germline) 
CNVs has provided insight into their role in susceptibility to a wide spectrum of 
disease, and somatic CNVs can be used to identify regions of the genome involved 
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in disease phenotypes. The role of CNVs as risk factors for cancer is currently 
underappreciated.”  
Identification of CNVs in DCIS may provide clues to progression and help improve 
targeted treatment for both those with low and high risk invasive potential.  
5.2 Genetic Aberrations of DCIS and Invasive Breast Disease – Literature Review 
Changes in DNA copy numbers may be inherited or due to somatic mutations. Copy 
number variants (CNVs) usually refer to inherited variation whilst copy number 
aberrations (CNAs) refer to somatic mutation (214). Whilst beyond the scope of the 
thesis to identify every potential copy number gain or loss found in invasive breast 
disease in the literature, due to the vast array of data, commonly found copy number 
aberrations (CNAs) have been identified (215-219). These include gains on 1q, 6p, 
8q, 11q, 16p, 17q, 19, 20q and losses on 5q, 6q, 7p, 13q, 16q, 17p and 22q. In DCIS, 
several studies have identified a variety of CNAs (202, 207, 210, 220, 221). Copy 
number gains on 1q, 5q, 8q, 16p, 19q, 20 and losses on 1p, 3q, 6q, 8p, 9p, 11q, 
13q,16q, 17p and 17q are reported. These include known loci for HER2 (17q12), ER 
(6q25.1), EGFR (7p11) and p53 (17p1).   
In addition to the known CNAs there are many novel potential candidate genes 
identified in both DCIS and invasive breast disease that could be biomarkers for 
therapeutic intervention.  Hanneman et al (192) identified 35 genes which differed 
between DCIS and invasive breast disease and 43 genes that differed between low 
grade and high grade DCIS in 2006. Since then a few studies (210, 222-224) have 






5.3 Materials and Methods 
Several criteria were used for selections of MIP array samples. Due to the cost, it was 
deemed unfeasible to perform analysis on the whole cohort from the DCIS TMA set. 
Additionally, although only a comparatively small amount of tissue was required from 
the DCIS samples there was an issue of tissue availability. In general DCIS is not 
markedly cellular, TMAs had already been manufactured from the cases, and clearly 
one has a commitment not to exhaust a resource that must legally be retained as part 
of the patients’ diagnostic record.  Subsets for genomic analyses were therefore 
chosen to represent two groups, namely pure DCIS and DCIS associated with 
Invasive component. To further represent the larger cohort, DCIS lesions were 
chosen with the following IHC profiles: ER positive, HER2 positive and triple negative. 
Where a DCIS lesion was matched to invasive tissue samples were taken from both 
components and if possible a sample of adjacent normal tissue. Table 28 gives the 
number and type of sample selected for MIP array analysis.  
Specimen type Number of Cases 
Triple negative pure DCIS 12 
Triple negative DCIS associated with invasive breast disease* 
and 10 
Triple negative invasive breast disease associated with DCIS* 10 
    
ER positive pure DCIS  10 
ER positive DCIS associated with invasive breast disease^ and 9 
ER positive invasive breast disease associated with DCIS^ 9 
    
HER2 positive pure DCIS 8 
Matched normal from ER positive DCIS and invasive breast 
disease^ 7 
Matched normal from triple negative DCIS and invasive breast 
disease* 8 
Total number of samples 83 
Table 28: Sample Selection and Case Numbers for MIP Array Analysis.  
[* and ^ represent different microdissected components of the same cases] 
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5.4 Hypothesis for MIP Arrays Studies in DCIS and Invasive Breast Carcinoma 
Genomic analysis of tissue samples may provide additional knowledge in our 
understanding of breast cancer progression and help define treatments in the future. 
Whilst not exhaustive in sample size this does represent one of the largest studies on 
DCIS using MIP array to date. A comparison of the various groups may shed light on 
genomic differences found within the different disease states i.e. precursor versus 
invasive breast cancer. This could be used to determine if the expression the 
immunohistochemical markers used in Chapter 3 are present at the genomic level (as 
expected), for example, is there HER2 amplification in the HER2 positive IHC cases? 
It also creates a database of genomic data with to study alongside the 
immunohistochemical and demographic data. This database will provide a resource 
for further research beyond the scope of this thesis. The analysis will also provide 
insights into variations between genomic changes seen in DCIS and invasive breast 
cancers and may present novel genes not currently identified in the literature.  
Identification of genes that represent an underlying commitment to invasive potential 
established before the expression of a molecular subtype may also be found. To 
address these issues comparisons of different comparative analysis of the following 
groups was carried out to help elucidate possible genetic aberrations, for all cases of 
DCIS, both pure and that associated with invasive disease: 
 
1. ER+ DCIS compared to non ER+ DCIS  
2. ER+ pure DCIS compared to ER+ DCIS associated with invasive disease  
3. ER+ pure DCIS compared to ER+ invasive breast disease 
4. All ER+ DCIS (pure and matched) compared to all ER+ invasive disease  
5. Triple negative pure DCIS compared to triple negative invasive breast disease 
6. All triple negative DCIS compared to all non-triple negative DCIS 
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7. Triple negative pure DCIS compared to triple negative DCIS associated with 
invasive disease  
8. All triple negative DCIS compared to triple negative invasive disease 
9. HER2+ pure DCIS compared to non-HER2+ DCIS  
5.4.1 DNA Extraction 
DNA was extracted using a modified technique incorporating elements from the 
QIAGEN FFPE DNA kit (QIAGEN Ltd. Manchester UK) and protocols provided by Dr 
Jorge Reis-Filho (Cheaty Beatty Laboratories, London, UK).  4µm sections were cut 
from blocks already identified from the TMA cohorts, and H&E stained to ascertain 
the amount of available tissue. Where a suitable quantity of DCIS and/or invasive 
tumour/normal tissues was present, up to 20 sections were cut at 8µm and dried 
overnight at 37ºC. Sections were dewaxed in xylene then stained with nuclear fast 
red dye. Sections were viewed through a dissecting microscope and any areas of 
tissue not required for DNA analysis were scraped away using a fine aspirate needle 
(gauge 10). This included any stroma, lipid or connective tissue. Sections were 
immersed in sodium thiocyanate overnight to remove formalin fixation crosslinks. 
Slides were then rinsed in changes of ultra-pure H2O and sections examined under 
the dissecting microscope where components such as DCIS, invasive tumour and 
normal tissues were scraped into individual 1.5ml eppendorf tubes using individual 
aspirate needles for each component. Samples were immersed in proteinase K for 
48 hours at 40ºC to aid proteolysis, followed by DNA extraction using the QIAamp 
DSP DNA FFPE Tissue Kit (Qiagen, Manchester UK). DNA quality was initially 
assessed by taking a spectrophotometer reading (Nanodrop, Thermo Scientific 
Wilmington, Delaware, USA) to determine DNA presence. DNA absorbs light at 
260nm, a spectrophotometer can detect the amount of light absorbed in a sample, 
thus the more DNA the greater the absorbance of light. However, contaminants such 
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as proteins and RNA may also absorb light at 260nm so errors are possible.  Once 
the presence of DNA was confirmed by this approach, samples were then assessed 
using a fluorimeter (Qubit- Life Sciences, Paisley, UK). The Qubit system uses 
fluorescent dyes that bind to target molecules (e.g. DNA); these dyes have a minimal 
fluorescent signature which becomes greatly enhanced upon target binding. When 
compared to a standard sample of known concentration an accurate DNA 
concentration can be given. Protocols for DNA extraction are listed in Appendix 6.  
5.4.2 MIP Array 
DNA samples were shipped to AffyMetrix MIP laboratory (California, USA). Samples 
were allocated an anonymised number and all identifying data removed to ensure 
sample blinding, including the matched normal tissues. Using the OncoScan™ FFPE 
Express Service samples underwent MIP array assays.  
Data quality was assessed using the sample 2-point relative standard error. The 
majority (95%) of FFPE tumours samples applied to the MIP arrays passed the 2p-
RSE threshold (GSE31424).  
5.4.3 Statistical methods 
Tumour Aberration Prediction Suite (TAPS), a bioinformatics tool for the identification 
of allele-specific copy numbers in tumour samples using data from Affymetrix SNP arrays, 
was run on all samples to obtain allele specific absolute copy numbers at genomic 
segment level. Raw output tables from TAPS output are seen on the attached disc. 
Gene centric versions of these tables i.e. each row represents a gene and its 
respective CN and other parameters are directly copied from TAPS raw tables are 
also provided (attached disc). This shows gene level copy numbers for each sample. 
Using these gene centric tables, intra-group gene centric count/percentage tables 
were created according to the IHC groups (ER+, triple negative and HER2+) (also 
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see attached disc). These tables show counts/percentage for each gene and each 
CN type, as well as the respective sample IDs. 
To compare groups, Fisher’s exact tests were performed between two groups for 
each copy number type. For example, frequencies were calculated for "gains" for 
each segment among the two groups into a contingency table which was used to run 
Fisher’s test, resulting in a p-value for each segment for that copy number type. Files 
are stored on the attached disc and give Fisher tests output for all segments for each 
comparison respectively. Genome frequency plots for these tables are also provided 
(see attached disc). Significantly different segments between 2 groups i.e. based on 
p-values cut-off of <=0.05, are also presented on the attached disc, along with tables 
and genomic frequency plots for segments based on the above mentioned threshold. 
5.4.4 Analyses of Raw Data Tables 
The raw data (TAPS tables) produced a significant amount of data, which is too large 
for a single thesis to adequately analyse. Mining of the data to elicit possible key 
genes was determined to be a suitable way forward; this approach has been used by 
others previously (221).  
Data was compiled into groups for comparison e.g. ER positive pure DCIS compared 
to pure non ER positive DCIS (similarly all triple negative, HER2 etc.). 
Genomic regions were sorted into those with significant p-values for the various 
genomic states: amplification, deletion, copy neutral loss of heterozygosity (cnLOH), 
copy deletion loss of heterozygosity (cdLOH) and total loss.  
Of the samples with significant p values, genomic bands with the greatest difference 
between the number of samples (and the greatest percentage difference) were 
selected, e.g. in ER positive pure DCIS there is genomic band (region) where 5 
samples had amplification within this region compared to no amplification in any of 
the pure non ER positive samples.  
154 
 
In many instances there were multiple genetic aberrations listed in a general locus of 
a particular chromosome or arm. In others there were only one or two genetic 
aberrations identified. A rationale that the occurrence of the same genetic aberrations 
found in multiple samples are more likely to be key players than genetic aberrations 
found in any one individual sample representing heterogeneity or genetic plasticity in 
tumourigenesis was adopted. Although this concept may be potentially flawed, 
analysis of multiple genes on the same locus also produces very complex and varied 
biological processes when analysed by PANTHER (see 5.2.2).  
In addition to the above method, a literature search of genes associated with DCIS 
and invasive progression previously identified as potential drivers by other 
researchers was carried out.   
5.5.5 Analysis of MIP array Data Using “PANTHER” Classification System 
The large amount of genomic data generated, and subsequently analysed by the 
Breakthrough Breast Cancer/Research Oncology, King’s College London 
bioinformatics team, based upon the MIP array results requires further analysis in 
order to identify similarities and differences between groups. There are many gene 
analysis software packages available online (e.g. GeneOntology, Webgestalt, 
GeneGo, Pubgene, TopGeneSuite). It is beyond the scope of this thesis to determine 
the pros and cons of each individual package. Under advice from the Breakthrough 
Breast Cancer/Research Oncology, King’s College London bioinformatics team, and 
based upon the type of analysis required, the “protein annotation through evolutionary 
relationships” or PANTHER protein and gene analysis software was selected. In 2013 
Mi et al (225) described the analysis software thus: “PANTHER (protein annotation 
through evolutionary relationship) classification system (http://www.pantherdb.org/) is 
a comprehensive system that combines gene function, ontology, pathways and 
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statistical analysis tools that enable biologists to analyse large-scale, genome-wide 
data from sequencing, proteomics or gene expression experiments.” 
 
5.5.6 Analysis of DCIS and Invasive Breast Disease Subgroups. 
Groups were compared using the 7 copy number types (excluding undefined 
segments) shown below. Generalized copy number types of "gains" and "losses" 
were also included (Table 29). 
Cn mCn New CN Type Combined CN Type 
NA NA Undefined Undefined 
0 0 Total Loss Total loss 
2 NA Normal with unknown allele specificity 
Normal 
2 1 Allele specific normal 
1 NA/0 Copy deletion LoH Copy deletion LoH 
2 0 Copy neutral LoH Copy neutral LoH 
3 NA Single copy gain with unknown allele 
specificity Single copy gain 
3 0 Copy neutral single copy gain 




5.8.1 DNA Extraction for MIP Arrays 
For each of the 82 samples undergoing MIP array DNA quantities and Qubit 
fluorescence readings can be found in appendix 7. 
5.8.2 MIP Array Maps 
All MIP array data was analysed by the Bioinformatics Unit of King’s College London, 
Breakthrough Breast Cancer. MIP array data was analysed by three Independent 
researchers (AG, HM & SR).  A total of 73 cases (Table 30) were provided for analysis 
separated into the different phenotypic groups. These phenotypic groups were then 
compared with each other (Table 31).  
All MIP array chromosomal maps can be found in appendix 8 & 9. Representative 
figures are given below for ER positive pure DCIS (Figure 31), HER2 positive pure 
DCIS (Figure 32) and triple negative pure DCIS (Figure 33). Additionally, 
representative figures showing comparisons of normal breast tissue, DCIS and 
invasive breast disease for ER positive (Figure 34) and triple negative cases (Figure 
34) are given below. 
 
Specimen type Number of Cases 
ER positive pure DCIS 8/10 
ER positive DCIS associated with invasive disease 9/9 
ER positive invasive breast disease associated with DCIS 9/9 
  
Triple negative pure DCIS 9/12 
Triple negative DCIS associated with invasive breast 
disease 10/10 
Triple negative invasive disease associated with DCIS 7/10 
  
HER2 positive pure DCIS 7/8 
  




Title Group1 Group2 
ER+ DCIS compared to non ER+ 
DCIS 
ER Pure DCIS, ER DCIS 
with invasive disease 
(n=17) 
TN pure DCIS, TN DCIS with 
invasive disease, HER2 
positive pure DCIS (n=26) 
ER+ DCIS associated with invasive 
breast disease compared to ER+ 
pure DCIS 
ER+ DCIS with invasive 
disease (n=9) 
ER+ pure DCIS (n=8) 
ER+ invasive breast disease 
compared to all ER+ DCIS 
ER+ invasive breast 
disease (n=9) 
ER+ pure DCIS, ER DCIS 
with invasive disease (n=17) 
ER+ pure DCIS compared to ER+ 
invasive breast disease 
ER+ pure DCIS (n=8) 
ER+ invasive breast disease 
(n=9) 
Triple negative invasive breast 
disease compared to all triple 
negative DCIS 
TN invasive breast 
disease  (n=7) 
TN Pure DCIS, TN DCIS with 
invasive disease (n=19) 
Triple negative DCIS associated with 
invasive breast disease compared to 
triple negative pure DCIS 
TN DCIS with invasive 
disease (n=10) 
TN pure DCIS (n=9) 
Triple negative pure DCIS compared 
to triple negative invasive breast 
disease 
TN pure DCIS (n=9) 
TN invasive breast disease 
(n=7) 
HER2+ pure DCIS compared to ER+ 
pure DCIS 
HER2 positive pure 
DCIS (n=7) 
ER+ pure DCIS (n=8) 
HER2+ pure DCIS compared to TN 
pure DCIS and ER+ pure DCIS 
HER2 positive pure 
DCIS (n=7) 
TN pure DCIS, ER+ pure 
DCIS (n=17) 
Table 31: MIP Array Comparison Groups 





Figure 31: Chromosomal map for a ER Positive pure DCIS Case (DCISJPB10K 066). 
The X axis in the diagram refers to chromosome number (1-21 and X) and the Y axis is split into two sections. The upper section shows log of ratio of signal of 
the same probe from the tumour and normal samples. The lower section of the plot shows allelic-ratio. Usually, this represents the ratio of B-allele as compared 
to A-allele. The value always lies between 0 and 1. e.g. if there is one copy each of both allele then allele ratio would be 1 / 2 = 0.5 which represent the normal 
allele pairing.  Each probe represents the number of copies for a genomic region. The probe signal from the normal sample is subtracted from the tumour 













Figure 32: Chromosomal Map for a Pure DCIS Triple Negative Case (DCISJPB10K001) 
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5.8.3 Copy Number Aberrations for Oestrogen Receptor Positive DCIS Compared 
to Non Oestrogen Receptor DCIS  
These series examines the difference between oestrogen receptor positive DCIS and 
non oestrogen receptor positive DCIS. 
Frequency plots showing copy number aberrations between Oestrogen receptor 
positive DCIS and oestrogen receptor negative DCIS were provided by Breakthrough 
Breast Cancer/Research Oncology, King’s College London Bioinformatics 
Department (Figure 37).  
 
Figure 36: Frequency plots showing copy number aberrations between oestrogen 










5.8.3.1 Amplification in Oestrogen Receptor (ER) Positive DCIS and Oestrogen 
Receptor Negative DCIS  
There are amplifications found in ER positive DCIS (n=5/17) not observed in the 
majority of non ER DCIS (n=2/26). 
1. p-values < 0.05; 
2. A gene list is mapped from 16 genomic regions found on chromosomes 8, 11;  




5S_rRNA AC011626.1 AC021636.1 AC027238.1 AC090821.2 AC090821.3 AC090821.4 AC090821.5 AC103706.1 AC103764.1
 AC103863.1 AC107374.1 AC115836.1 AF130342.1 AF178030.2 AF186191.1 AF230666.2 AL031777.1 ANKRD46 AP003385.1
 AP003716.2 AP003716.4 AP003716.5 CCND1 CEBPD CHRAC1 CSMD3 CTC-458A3.1 CTD-2182N23.1
 DENND3 DEPDC6 EIF2C2 FGF19 FGF3 FGF4 GDAP1 HFE HIST1H1C HIST1H1D 
HIST1H1E HIST1H1PS1 HIST1H1T HIST1H2AB HIST1H2AC HIST1H2AD HIST1H2AE HIST1H2APS3
 HIST1H2APS4 HIST1H2BB HIST1H2BC HIST1H2BD HIST1H2BE HIST1H2BF HIST1H2BG HIST1H2BH HIST1H2BI 
HIST1H3A HIST1H3B HIST1H3C HIST1H3D HIST1H3E HIST1H3F HIST1H3G HIST1H4A HIST1H4B HIST1H4C
 HIST1H4D HIST1H4E HIST1H4F HIST1H4G hsa-mir-151 hsa-mir-30b hsa-mir-30d IKBKB KB-1615E4.1 KCNK9
 KIAA0146 KIAA0196 MYEOV NCALD NDRG1 NSMCE2 ORAOV1 PHF20L1 POLB PRKDC PTK2
 PXDNL RAD21 RNF19A RP11-1023P17.1 RP11-231D20.1 RP11-697N18.1 RP11-709P2.1 RP1-
221C16.7 RPS10P1 RRM2B SLA SLC45A4 SNORA40 SNORA7 SPAG1 SQLE ST18
 ST3GAL1 TG TMEM71 TRAPPC9 TRPS1 U6 U7 U91328.2 UNC93B5 WISP1
 Y_RNA ZFAT ZFATAS ZMAT4 
PANTHER analysis: 56 mapped ids are found, 62 mapped ids are not found.  
 
There are amplifications found in non ER DCIS (n=2/26) that are also present in some 
ER positive DCIS (n=6/17). 
1. p=values <0.05; 
2. A gene list is mapped from 13 genomic regions on chromosome 8; 
3. These regions encompass 49 genes altered in non ER DCIS; 
Genes:  
AC021636.1 AC090821.2 AC090821.3 AC090821.4 AC090821.5 AC103706.1 AC103764.1 AC107374.1 AC115836.1 AF186191.1
 AF230666.2 CEBPD CSMD3 CTC-458A3.1 CTD-2182N23.1 DENND3 DEPDC6 hsa-mir-30b hsa-
mir-30d IKBKB KCNK9 KIAA0146 KIAA0196 NDRG1 NSMCE2 PHF20L1 POLB PRKDC
 PTK2 PXDNL RP11-1023P17.1 RP11-231D20.1 RP11-697N18.1 RP11-709P2.1 SLA
 SLC45A4 SNORA40 SNORA7 SQLE ST18 ST3GAL1 TG TMEM71 TRAPPC9 U6
 WISP1 ZFAT ZFATAS ZMAT4 
PANTHER analysis: 25 mapped ids are found, 24 mapped ids are not found.  
 
5.8.3.2 Duplication in Oestrogen Receptor Positive DCIS and Oestrogen Receptor 
Negative DCIS  
There are no duplications in ER negative DCIS (check the status of the HER2 
positives) in this series.  




1. p-values < 0.05; 
2. A gene list is mapped from 4 genomic regions found on chromosomes 3, 6, 
16;  
3. These regions encompass 27 genes altered in ER positive DCIS; 
Genes:  
AC136443.1 AC138932.2 AL645941.2 AL669918.1 BFAR HLA-DMB HLA-DOB HLA-DQA2 HLA-DQB2 HLA-DQB3 HLA-
Z hsa-mir-1972 NIT2 NOMO1 NPIP PDXDC1 PLA2G10 PPP1R2P1 PSMB8 PSMB9 TAP1 TAP2 TBC1D23
 XXbac-BPG181M17.5 XXbac-BPG246D15.8 XXbac-BPG246D15.9 Y_RNA     
PANTHER analysis: 15 mapped ids are found, 12 mapped ids are not found.  
5.8.3.3 Genomic Gains in Oestrogen Receptor Positive DCIS and Non Oestrogen 
Receptor Positive DCIS  
There are genomic gains in ER positive DCIS (n=6/17) not observed in non ER 
positive DCIS (n=0/26). 
1. p-values < 0.05;  
2. A gene list is mapped from 10 genomic regions on chromosome 3;  
3. These regions encompass 75 genes altered in ER positive DCIS; 
Genes:  
5S_rRNA  AC096971.2 AC097359.1 AC097359.2 AC097359.3 AC099668.5 AC104186.1 AC104448.1 AC121252.1 AC121252.2
 AC126118.1 AC126118.2 AC141002.1 AMIGO3 APEH ATRIP C3orf35 C3orf54 CAMP CCDC51 CCDC72
 CDC25A CDH29 CELSR3 COL7A1 CTD-3211M3.1 FBXW12 FOXP1 GMPPB GOLGA4 hsa-mir-2115 hsa-
mir-711 IP6K1 IP6K2 LRRFIP2 MLH1 MST1 NCKIPSD NDUFB1P1 NME6 PFKFB4 PLXNB1
 PRKAR2A RNF123 RP11-20O23.1 RP11-24C3.2 RP11-391M1.3 RP11-430J3.1
 RP11-430J3.2 RP11-502L5.2 RP11-520A21.1 RP11-528N21.1 RP11-528N21.2
 RP11-528N21.3 RP11-905F6.1 RP13-1056D16.2 RP13-480C15.1 RPL14 SHISA5 SLC26A6
 snoU13 SPINK8 TMEM89 TREX1 U5 U6 U7 UBA7 UCN2 UQCRC1 Y_RNA
 ZNF589 ZNF619 ZNF620 ZNF621 
PANTHER analysis: 36 mapped ids are found, 39 mapped ids are not found.  
There were gains present in non ER DCIS (n=10/17) which are also present in ER 
positive DCIS (n=13/10). 
1. p-values < 0.05; 
2. A gene list is mapped from 16 genomic regions found on chromosomes 6, 8, 
10, 19;   
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3. These regions encompass 30 genes altered in both non ER DCIS and ER 
DCIS; 
Genes:  
5S_rRNA AC008734.2 AC090821.2 AC090821.3 AC090821.4 AC090821.5 AC103706.1 AF186191.1 AF216667.1 AF230666.2 AL713922.2
 CTC-458A3.1 CTD-2182N23.1 DIP2C IKBKB IL9RP2 LRRC6 MUC16 NDRG1
 PHF20L1 RP11-631M21.1 RP11-631M21.2 RP11-631M21.6 SLA SNORA40 ST3GAL1 TG
 TMEM71 WISP1 ZMYND11 
PANTHER analysis: 12 mapped ids are found, 18 mapped ids are not found. 
5.8.3.4 Genomic Sc Gains in Oestrogen Receptor Positive DCIS and Non Oestrogen 
Positive Receptor DCIS  
There are some overlaps in Sc gains found in ER positive DCIS (n=9/17) and non ER 
positive DCIS (n=4/26). 
1. p-values < 0.05; 
2. A gene list is mapped from 49 genomic regions found on chromosomes 3, 4, 
5, 7, 8, 10, 11, 12, 17, 20, 21;  
3. These regions encompass 180 genes altered in for ER positive DCIS and 
some non ER positive DCIS; 
Genes: 
 5S_rRNA ABCG1 ABHD12 AC004001.1 AC005355.1 AC008038.1 AC008264.4 AC008937.2 AC009365.4 AC009518.8 AC013434.1
 AC016831.7 AC018642.1 AC058791.1 AC058791.2 AC079595.1 AC079595.2 AC080112.3 AC087071.1 AC087071.2 AC092214.10
 AC097534.1 AC097534.2 AC105285.1 AC105285.2 AC121247.2 AC121252.2 AC135506.1 AC137630.1 AF213884.1 AL031666.1 
AL034548.1 AL034548.2 AL034548.3 AL109954.2 AL121894.1 AL157718.1 AL365356.1 AL713922.2 AL732437.1 ANKS1B
 AP002827.1 ARIH2 ARL1 ASB13 C10orf18 C12orf23 C20orf26 C21orf121 C21orf128 C2CD2 C3orf62 
 C3orf71  C5orf15 CALML3 CALML5 CCDC25 CCDC36 CCDC71 CDC6 CDKL3 CDKN2AIPNL
 CHCHD3 CRNKL1 CRY1 CST11 CST3 CST8 CST9 CST9L CSTL1 CTD-2410N18.1
 DALRD3 DIP2C DOCK4 EIF4E2P1 ENTPD6 EPHA1 GALNT7 GDPD4 GPX1 GZF1
 HMGB2 hsa-mir-191 hsa-mir-425 hsa-mir-620 IL9RP2 IMPDH2 KLHDC10 KLHDC8B LAMB2 MAP3K1
 MED13L MKLN1 MTERFD3 NAPB NAT5 NDUFAF3 NET1 NFKB1 NRSN2 NXT1
 P4HTM PAK1 PODXL PPIAP2 PPP2CA PRKAR2A PYGB QARS QRICH1 RALGAPA2 RARA
 RHOA RHOH RIN2 RP11-10K16.1 RP11-135F9.1 RP11-215P8.1 RP11-215P8.2
 RP11-215P8.3 RP11-215P8.4 RP11-218C14.2 RP11-218C14.6 RP11-218C14.7 RP11-23O13.1
 RP11-306G20.1 RP11-312A15.2 RP11-312A15.3 RP11-316M24.1 RP11-336A10.4
 RP11-336A10.5 RP11-336A10.7 RP11-395I6.2 RP11-3B7.1 RP11-3B7.6 RP1-148H17.1
 RP11-631M21.1 RP11-631M21.2 RP11-631M21.6 RP11-694I15.6 RP11-775D22.2 RP11-798M19.3
 RP13-131K19.1 RP13-131K19.2 RP13-463N16.6 RP3-322G13.5 RP3-333B15.2 RP4-569M23.2
 RP5-1002M8.4 RP5-1103G7.4 RPS27P23 SAP30 SKP1 SLC24A3 SLC25A20 snoU13 SOX12 SPIC
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 TCF7 TMTC2 TOP2A TRIB3 U5 U6 UBE2B UBE2H UMODL1 USP19 USP4
 UTP20 VDAC1 WDR6 Y_RNA ZC3HC1 ZCCHC3 ZMYND11 ZMYND8 ZNF295 
PANTHER analysis: 87 mapped ids are found, 92 mapped ids are not found.  
 
There are some overlaps in Sc gains for non ER positive DCIS (n=12/26) and ER 
positive DCIS (n=9/17).  
1. p-values < 0.05; 
2. A gene list is mapped from 25 genomic regions found on chromosomes 1, 7, 
10, 12, 17.  
3. These regions encompass 83 genes altered in non ER positive DCIS and ER 
positive DCIS. 
Genes:  
5S_rRNA AC013434.1 AC016182.1 AC018628.1 AC018628.3 AC058791.2 AC079595.1 AC079595.2 AC096947.1 AGBL4
 AL713922.2 ANKS1B ARMC7 BRIP1 C12orf23 C1orf123 C1orf185 C20orf26 CDKN2C
 CFLP2 CPT2 CRNKL1 CRY1 CSDA CYTH1 DIP2C DMRTA2 DNAH17 FAF1 HN1
 IL9RP2 INTS2 LRP8 MAGOH MED13 MKLN1 MTERFD3 NAT5 NFIA
 NT5C PRH1 PRH2 PRR4 RIN2 ROR1 RP11-117D22.1 RP11-183G22.2
 RP11-183G22.3 RP11-24J23.2 RP11-323N12.1 RP11-323N12.2 RP11-631M21.1
 RP11-631M21.2 RP11-631M21.6 RP4-784A16.1 RP4-784A16.2 RP4-784A16.3 RP4-
784A16.4 RP4-784A16.5 RP5-1002M8.4 RP5-1024G6.2 RP5-1024G6.5 RP5-833A20.1
 RP5-850O15.3 RP5-926E3.1 SLC16A5 TAS2R10 TAS2R13 TAS2R14 TAS2R19
 TAS2R20 TAS2R31 TAS2R50 TAS2R7 TAS2R8 TAS2R9 TIMP2 TMTC2 U6 USP36
 Y_RNA ZMYND11 ZNF859P 
PANTHER analysis: 46 mapped ids are found, 47 mapped ids are not found. 
5.8.3.5 Losses in Oestrogen Receptor Positive DCIS and Non Oestrogen Receptor 
Positive DCIS  
There are genomic losses found in ER positive DCIS (n=8/17) not observed in non 
ER positive DCIS (n=0/26). 
1. p-values < 0.05;  
2. A gene list is mapped from 25 genomic regions found on chromosomes 2, 7, 
9, 10, 11, 1; 
3.  These regions encompass 79 genes altered in ER positive DCIS; 
172 
 
Genes:   
AC006432.1 AC007403.1 AC007403.2 AC007537.1 AC007537.2 AC009474.1 AC009474.2 AC022882.1 AC036111.1 AC068339.1
 AC079920.1 ACSM4 AP000720.1 AP001482.1 AP002826.1 AP003065.3 AP006437.1 APLNR ARAP1 ARHGEF17
 BCL2L14 CACNA1C CD163L1 ETV6 FAM168A GRM5 LRP6 LRRC55 MANSC1 OR10AG1 OR5AK3P
 OR5AK4P OR5AQ1P OR5AS1 OR5BE1P OR5D13 OR5D14 OR5D16 OR5D18 OR5F1 OR5G3P OR5G5P
 OR5I1 OR5J1P OR5J2 OR5L1 OR5L2 OR5T1 OR5T2 OR5T3 OR5W1P OR5W2
 OR7E5P OR8H1 OR8H2 OR8H3 OR8I2 OR8J3 OR8K5 OR8V1P OR9M1P P2RX3
 PRG2 PRG3 PTPRD RELT RP11-267J23.1 RP11-31L22.2 SBDS SLC22A8
 SLC43A3 snoU13 SPRYD5 SSRP1 TNKS1BP1 TYR TYW1 U2 U6 
 
PANTHER analysis: 46 mapped ids are found, 33 mapped ids are not found.  
 
There are genomic losses found in non ER positive DCIS (n=11/26) not observed in 
ER positive DCIS (n=0/17). 
1. p-values < 0.05; 
2. A gene list is mapped from 17 genomic regions found on chromosomes 3, 4, 
5, 14, 15, 17, 22;   
3. These regions encompass 35 genes altered in non ER positive DCIS; 
Genes:  
AB019437.56 AC008772.1 AC008872.1 AC026202.1 AC026202.5 AC026214.2 AC092373.1 C22orf30 CD180 CNTN6
 FAT1 IGHV1-67 IGHV1-68 IGHV1-69 IGHV2-70 IGHV3-66 IGHV3-71 IGHV3-72 IGHV3-73 IGHV3-74 IGHVII-
67-1 IGHVIII-67-2 MAST4 PISD RAB27A RP11-173M1.1 RP11-287J9.1 RP11-287J9.2 RP11-308K2.1
 RP11-5P22.1 RP11-5P22.2 RP11-5P22.3 RP5-858B16.5 SFRS12 snoU13 
PANTHER analysis: 6 mapped ids are found, 29 mapped ids are not found. 
5.8.3.6 Total Losses in Oestrogen Receptor Positive DCIS and Non Oestrogen 
Receptor Positive DCIS 
There were total losses present in ER positive DCIS (n=13/17) not observed in non 
ER positive DCIS (n=0/26). 
1. p-values < 0.05; 
2. A gene list is mapped from 11 genomic regions found on chromosomes 8, 11, 
13, 17;  




 5S_rRNA AC005696.2 AC005696.3 AC006435.1 AC015799.1 AC015799.2 AC027763.1 AC027763.2 AC032044.1 AC055839.2 AC087742.1
 AC087742.2 AC090617.1 AC091153.4 AC116914.1 AC118754.2 AC118754.4 AC127521.1 AC130689.5 AIPL1 AL450226.1
 AL450226.2 ALOX12 ALOX15 AP001970.1 ARRB2 ASGR1 ASGR2 ATP2A3 BCL6B BHLHA9
 C17orf100 C17orf49 C17orf85 CAMKK1 CLEC10A CRKCSMD1 CTD-2545G14.1 DLG4 DPH1 FAM64A
 FBXO39 GAS7 GGT6 GSG2 HIC1 hsa-mir-132 hsa-mir-195 hsa-mir-212 hsa-mir-497 ITGAE
 KIAA0664 KIAA0753 MED31 METT10D MNT MYBBP1A OVCA2 P2RX1 PAFAH1B1 PELP1 PITPNM3
 RNASEK RP11-314A20.1 RP11-314A20.2 RP11-609D21.1 RP11-76K19.5 SGSM2
 SLC13A5 SLC16A11 SLC16A13 SMG6 SMTNL2 SNORD91 snoU13 SPNS2 SPNS3 SRR TEKT1
 TSR1 TUSC5 TXNDC17 U6 U8 UBE2G1 XAF1 YWHAE 
PANTHER analysis: 51 mapped ids are found, 37 mapped ids are not found.  
 
There were total losses present in non ER positive DCIS (n= 20/26) not observed in 
ER positive DCIS (n=0/17).  
1. p-values < 0.05; 
2. A gene list is mapped from 21 genomic regions from chromosome 17;  
3. These regions encompass 182 genes altered in non ER positive DCIS; 
Genes:  
5S_rRNA ABHD5 AC008734.2 AC011816.4 AC020626.1 AC025029.1 AC092038.1 AC092798.2 AC092798.3 AC093416.3
 AC098477.1 AC098477.2 AC098647.1 AC099539.1 AC099544.1 AC099544.2 AC099557.1 AC099778.3 AC104163.1 AC104184.1
 AC104307.1 AC104434.1 AC104434.2 AC104434.3 AC104445.1 AC105935.1 AC112512.1 AC115283.1 AC121251.1 AC121252.2 
AC124914.3 AC133141.1 AC133680.1 AC135966.1 ANO10 C3orf35 C3orf39 CACNA1D CADM2 CAMKV
 CDC25A CDCP1 CELSR3 CLEC3B CSPG5 CTNNB1 DHX30 EIF1B EIF4BP9 ENTPD3 EXOSC7 
FAM116A FAM198A FOXP1 FYCO1 GBE1 hsa-mir-1226 hsa-mir-564 ITGA9 KIF15 LARS2
 LIMD1 LRIG1 MAP4 MITF MLH1 MUC16 MYRIP NCKIPSD NGLY1 NKIRAS1
 NR1D2 OXSM PRICKLE2 RARB RP11-1029M24.1 RP11-1029M24.2 RP11-107O13.1 RP11-129B22.1 
RP11-129B22.2 RP11-129B22.4 RP11-129B22.5 RP11-136C24.1 RP11-136C24.2 RP11-141M3.2
 RP11-142L1.2 RP11-142L1.3 RP11-148G20.1 RP11-188P20.2 RP11-260O18.1 RP11-26G10.1
 RP11-272D20.2 RP11-30M20.1 RP11-341J3.1 RP11-353H3.1 RP11-372H2.1
 RP11-391M1.2 RP11-391M1.3 RP11-395P16.1 RP11-420K5.1 RP11-564P9.1 RP11-681O4.1
 RP11-697K23.1 RP11-755B10.3 RP11-814M22.1 RP11-88B8.2 RPL15 SACM1L
 SLC6A20 SLMAP SMARCC1 SNORA64 SNORD5 SNRK TGM4 TMEM42 TOP2B TRAIP U2
 U3 U5 U6 U7 UBE2E1 UBE2E2 ULK4 Y_RNA ZDHHC3 
PANTHER analysis: 50 mapped ids are found, 78 mapped ids are not found. 
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5.8.3.7 CdLOH in Oestrogen Receptor Positive DCIS and Non Oestrogen Receptor 
Positive DCIS  
There is CdLOH present in ER positive DCIS (n=8/17) not observed in non ER 
positive DCIS (n= 0/26). 
1. p-values < 0.05; 
2. A gene list is mapped from 13 genomic regions found on chromosomes 9, 11;  
3. These regions encompass 30 genes altered in ER positive DCIS; 
Genes: 
 AC022882.1 AC036111.1 AP000866.1 AP000866.2 AP006437.1 C11orf61 ESAM NRGN OR5D13 OR5D14 OR5D16
 OR5D18 OR5G3P OR5G5P OR5L1 OR5L2 OR5T1 OR5T2 OR5T3 OR8H1 OR8V1P
 P2RX3 PRG2 PRG3 PTPRD snoU13 SSRP1 TNKS1BP1 U2 VSIG2 
PANTHER analysis: 19 mapped ids are found, 11 mapped ids are not found.  
 
There is CdLOH in non ER positive DCIS (n=11/26) not observed in ER positive DCIS 
(n=0/17). 
1. P-values < 0.05; 
2. A gene list is mapped from 13 genomic regions found on chromosomes 8, 9, 
10, 11;   
3. These regions encompass 27 genes altered in non ER positive DCIS; 
Genes:  
AB019437.56 AC008772.1 AC026214.2 AC092373.1 CNTN6 FAT1 IGHV1-67 IGHV1-68 IGHV1-69 IGHV2-70
 IGHV3-66 IGHV3-71 IGHV3-72 IGHV3-73 IGHV3-74 IGHVII-67-1 IGHVIII-67-2 MAST4 RP11-173M1.1
 RP11-287J9.1 RP11-287J9.2 RP11-308K2.1 RP11-5P22.1 RP11-5P22.2
 RP11-5P22.3 SFRS12 snoU13 
PANTHER analysis: 3 mapped ids are found, 24 mapped ids are not found. 
5.8.3.8 CnLOH in Oestrogen Receptor Positive DCIS and Non Oestrogen Receptor 
Positive DCIS  
There is CnLOH in ER positive DCIS (n=15/17) not observed in non ER positive DCIS 
(n=0/26). 
1. p-values < 0.05; 
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2. A gene list is mapped from 40 genomic regions found on chromosomes 1, 2, 
3, 6, 7, 10, 12 19, 20;   
3. These regions encompass 200 genes altered in ER positive DCIS; 
Genes: 
 5S_rRNA 7SK AC004906.3 AC007040.5 AC008686.2 AC010733.4 AC012671.2 AC022021.2 AC062029.1 AC074389.1
 AC074389.6 AC074389.7 AC074389.9 AC078841.5 AC083864.3 AC083864.4 AC104134.2 AC104170.1 AC110781.3 AC110781.5
 ACOT11 AKIRIN1 AL031289.1 AL031985.1 AL139244.1 AL160287.2 AL161740.1 AL161932.2 AL929472.1 AL929472.3
 APBB1IP ARHGAP12 BAZ1B C10orf50 C1orf122 C1orf168 C1orf175 C1orf191 C1orf228 C2orf51 C8A
 C8B CARD11 CDCP2 CITED4 CST1 CST4 CSTP2 CTPS CYB5RL DAB1 DEM1
 DEPDC1 EDN2 EEPD1 EGFR EIF2AK3 ELFN1 EPHA10 EPS15 FAM151A FHL3 FOXI3
 FOXO6 GLIS1 GLUDP5 GRIK3 HEYL HIVEP3 HPCAL4 hsa-mir-23a hsa-mir-24-2 hsa-mir-27a hsa-mir-30c-1
 hsa-mir-30e IL20RB INPP5B KCNQ4 KIF2C KIF5B MAD1L1 MANEAL MPP7 MRPL37 MTF1
 NCK1 NDUFS5 NFYC NRP1 NT5C1A OMA1 OSBPL3 OSBPL9 OVCH1 PABPC4 PARS2 PDSS1
 PPAP2B PPIE PRKAA2 RET RIMS3 RNF220 RP11-109P14.1 RP11-109P14.10
 RP11-109P14.2 RP11-109P14.8 RP11-109P14.9 RP11-128B16.3 RP11-15J6.1 RP11-167O6.2
 RP11-191G24.1 RP11-191G24.2 RP11-213P13.1 RP11-240D10.2 RP11-240D10.4 RP11-241I20.1
 RP11-241I20.3 RP11-241I20.4 RP11-241I20.5 RP11-253A20.1 RP11-269F19.2
 RP11-275F13.1 RP11-275F13.3 RP11-342D11.2 RP11-348A7.1 RP11-348A7.2
 RP11-351M16.1 RP11-351M16.2 RP11-351M16.3 RP11-377K22.2 RP11-377K22.3
 RP11-378I13.1 RP11-399E6.1 RP11-399E6.4 RP1-144F13.3 RP11-472N13.3 RP11-
486B10.3 RP11-486B10.4 RP11-524K22.1 RP11-575C1.1 RP11-656D10.3 RP11-656D10.5
 RP11-656D10.6 RP11-781D11.1 RP11-85F14.1 RP11-85F14.6 RP1-28O17.1
 RP13-16H11.1 RP13-16H11.2 RP13-16H11.5 RP13-16H11.6 RP13-16H11.7 RP1-63P18.2
 RP4-614N24.1 RP4-678E16.4 RP4-694A7.2 RP4-694A7.3 RP4-694A7.4 RP4-705F19.1
 RP4-705F19.2 RP4-710M16.2 RP4-739H11.1 RP4-739H11.3 RP4-783C10.3 RP5-
1033K19.2 RP5-1066H13.4 RP5-1103B4.3 RP5-866L20.1 RP5-866L20.2 RP5-866L20.3
 RP5-997D24.3 RP5-997D24.5 RP6-239D12.1 RPE65 RPIA SDK1 SF3A3 SNORA63
 SNORD112 snoU13 SSBP3 TCEB1P18 TMEM53 TMTC1 TTC39A TTC4 U3 U5 U6
 U7 UTP11L VAX2 WAC Y_RNA YRDC ZNF642 ZNF643 ZNF684 ZSWIM4 
PANTHER analysis: 77 mapped ids are found, 123 mapped ids are not found. 
 
There is CnLOH present in non ER positive DCIS (n=24/26) not observed in ER 
positive DCIS (n=0/17).  
1. p-values < 0.05; 
2. A gene list is mapped from 38 genomic regions found on chromosomes 1, 3, 
6, 10, 12, 21;  




5S_rRNA 7SK AACS ABI3BP AC078811.1 AC083805.1 AC083805.2 AC106728.2 AC108739.1 AC117377.1
 ADPRHL2 AF015262.1 AF015262.2 AL008732.1 AL034372.1 AL136180.1 AL136230.1 AL138724.3 AL138889.1 AL139044.1
 AL139286.1 AL590403.1 AL773603.1 AL844908.5 ANKS1B AP000304.12 AP000313.1 AP000313.2 AP000318.2 AP000320.6
 AP000322.53 AP000322.54 AP000569.2 AP000569.8 AP001630.1 AP001630.5 AP001631.9 ARHGAP9 ATP5O
 C21orf51 C21orf67 C21orf70 C6orf125 CAP2 CBS CLDND1 CLIC6 COL8A2 CPOX CTD-2021J15.1
 CTD-2021J15.2 DCBLD2 DCTN2 EIF2C1 EIF2C3 EIF2C4 FAM8A1 GNL1 GPR15 GRM4 hsa-mir-1275 hsa-
mir-548a-1 IFNGR2 IMPG2 IP6K3 ITGB2 ITPR3 ITSN1 KCNE1 KCNE2 KIF13A KIF5A
 LEMD2 MARS MGAT4C MIP MLN MRPL51P2 NCRNA00160 NDUFV3 NUP153 OR5K2 PKNOX1
 PRKG1 PRR3 PTTG1IP RCAN1 RNF144B RP11-14H3.3 RP11-204E9.1 RP11-227H4.1
 RP11-227H4.4 RP11-227H4.5 RP11-254A17.1 RP11-301G23.1 RP11-319J24.1 RP11-319J24.3 
RP11-377N20.1 RP11-40M23.1 RP11-524C21.1 RP11-569H14.1 RP11-663C11.1 RP11-686D16.1
 RP11-686D16.2 RP1-273P12.3 RP1-67M12.1 RP3-322L4.2 RP3-468B3.2 RP4-665N4.4
 RP4-665N4.5 RUNX1 SNORA11 snoU13 SOX4 ST3GAL6 SYT1 TEKT2 TIMELESS
 TMEM50B TMTC2 TRIM38 U2AF1 U6 U7 Y_RNA  
PANTHER analysis: 56 mapped ids are found, 70 mapped ids are not found.  
5.8.4 Copy Number Aberrations for Oestrogen Receptor Positive Pure DCIS 
Compared to Oestrogen Receptor Positive DCIS Associated with Invasive 
Breast Disease 
These series examines the difference between oestrogen receptor positive pure 
DCIS and oestrogen receptor positive DCIS associated with invasive breast disease 
i.e. the DCIS component and not the invasive breast disease. 
Frequency plots showing copy number aberrations between oestrogen receptor 
positive pure DCIS and oestrogen receptor positive DCIS associated with invasive 
breast disease were provided by Breakthrough Breast Cancer/Research Oncology, 




Figure 37: Frequency plots showing copy number aberrations between oestrogen 
positive pure DCIS and oestrogen positive DCIS associated with tumour 
(amplifications, duplications, gains, Sc gains, losses, total losses CdLOH and 

















5.8.4.1 Amplification in Oestrogen Receptor Positive Pure DCIS Compared to 
Oestrogen Receptor Positive DCIS Associated with Invasive Breast Disease 
There were no amplifications in ER positive pure DCIS (n=0/8) in this series. 
However, there were amplifications present in cases of ER positive DCIS associated 
with invasive breast disease (n=5/9).  
1. p-values < 0.05; 
2. A gene list is mapped from 7 genomic regions found on chromosomes 6, 8.  
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3. These regions encompass 69 genes altered in ER positive DCIS associated 
with invasive breast disease; 
Genes: 
5S_rRNA AC025647.3 AC103863.1 AF130342.1 AL031777.1 ANKRD46 AP001207.1 AP001208.1 AP001208.2 AP002852.1
 AP002907.1 CHRAC1 DENND3 EIF2C2 FBXO43 GRHL2 HFE HIST1H1C HIST1H1D HIST1H1E HIST1H1PS1
 HIST1H1T HIST1H2AB HIST1H2AC HIST1H2AD HIST1H2AE HIST1H2APS3 HIST1H2APS4 HIST1H2BB
 HIST1H2BC HIST1H2BD HIST1H2BE HIST1H2BF HIST1H2BG HIST1H2BH HIST1H2BI HIST1H3A HIST1H3B HIST1H3C
 HIST1H3D HIST1H3E HIST1H3F HIST1H3G HIST1H4A HIST1H4B HIST1H4C HIST1H4D HIST1H4E HIST1H4F
 HIST1H4G hsa-mir-1273 hsa-mir-151 KB-1615E4.1 NCALD PTK2 RGS22 RNF19A RP1-221C16.7 RPS10P1 RRM2B
 SNORD77 snoU13 SPAG1 TRAPPC9 U6atac U7 U91328.2 UBR5 Y_RNA 
PANTHER analysis: 29 mapped ids are found, 40 mapped ids are not found.  
5.8.4.2 Duplication in Oestrogen Receptor Positive Pure DCIS Compared to 
Oestrogen Receptor Positive DCIS Associated with Invasive Breast Disease 
There were no duplications present in ER positive DCIS associated with invasive 
breast disease in this series. However, there were duplications identified in ER 
positive pure DCIS (n=4/8). 
1.  p-values < 0.05; 
2. A gene list is mapped from 1 genomic region and chromosome 8;  
3. These regions encompass 2 genes altered in ER positive pure DCIS; 
Gene:  ASPH 7SK 
PANTHER analysis: 1 mapped id is found. 
Gene ID: ENSG00000198363  
Protein ID: Q12797  
Gene Name: Aspartyl/asparaginyl beta-hydroxylase  
Gene Symbol(s):  ASPH 
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5.8.4.3 Genomic Gains in Oestrogen Receptor Positive Pure DCIS Compared to 
Oestrogen Receptor Positive DCIS Associated with Invasive Breast Disease 
There were gains associated with both ER positive pure DCIS (n=4/8) and ER positive 
DCIS associated with invasive breast disease (n=9/9).  
1. p-values < 0.05; 
2. A gene list is mapped from 43 genomic regions found on chromosomes 1, 3, 
5, 6, 7, 10, 11, 16, 17, 18, 19, 20;  
3. These regions encompass 283 genes altered in both ER positive pure DCIS 
and ER positive DCIS associated with invasive breast disease; 
Genes:  
5S_rRNA 7SK AC005220.3 AC006076.1 AC006486.1 AC007431.1 AC007431.2 AC009362.2 AC013434.1 AC016831.7
 AC018642.1 AC018816.3 AC058791.1 AC058791.2 AC090625.1 AC090821.2 AC090821.3 AC090821.4 AC090821.5 AC090955.3
 AC103706.1 ACAP3 ADIG AGRN AL021394.1 AL021578.1 AL096828.1 AL109823.2 AL109840.1 AL118506.1
 AL118506.3 AL121673.1 AL121673.2 AL121827.1 AL133330.1 AL136532.1 AL139348.1 AL162505.1 AL365229.1 AL390719.1
 AL669831.3 AL713922.2 ARF4P2 ARFGAP1 ARFRP1 ARL6IP1 ATP5E AURKAIP1 B3GALT6 BCAS1
 BCAS4 BCL2 BCL2L1 BHLHE23 BIRC7 C1orf159 C1orf170 C20orf11 C20orf135 C20orf166
 C20orf181 C20orf195 C20orf20 C20orf200 C20orf83 C20orf90 CANT1 CBFA2T2 CD44 CDH4
 CHRNA4 CIC COL20A1 COL9A3 COX4I2 CPSF3L CST3 CTD-3184A7.4 CTSZ DBNDD2
 DENND3 DIDO1 DIP2C DNAJC5 DPH3B DVL1 EDN3 EEF1A2 EGOT ERF F3
 FAM132A FAM41C FAM65C GATA5 GLTPD1 GMEB2 GNAS GNASAS GPR20 GSK3A
 HAR1A HAR1B HAR1F HES4 HM13 hsa-mir-1-1 hsa-mir-124-3 hsa-mir-133a-2 hsa-mir-1914
 hsa-mir-200a hsa-mir-200b hsa-mir-296 hsa-mir-298 hsa-mir-429 hsa-mir-647 hsa-mir-941-1 hsa-mir-941-3 hsa-
mir-941-4 ID1 IL9RP2 ISG15 ITPR1 KCND2 KCNQ2 KDSR KIAA0406 KLHL17 LGALS3BP LIME1 
MKLN1 MRPS16P MSI2 MXRA8 NCOA3 NCRNA00029 NKAIN4 NOC2L NTSR1
 NXT1 OGFR OSMR PAFAH1B3 PARD6B PDHX PHACTR3 PIGT PLEKHN1 PPDPF
 PRPF6 PTK6 PUSL1 RALGAPB RBPJL RICTOR RP11-164D18.2 RP11-206L10.13
 RP11-243J16.7 RP11-261N11.8 RP11-305P22.5 RP11-358D14.2 RP11-429E11.2
 RP11-429E11.3 RP11-465B22.3 RP11-465B22.5 RP11-465B22.6 RP11-54O7.1
 RP11-54O7.10 RP11-54O7.11 RP11-54O7.14 RP11-54O7.2 RP11-54O7.3
 RP11-631M21.1 RP11-631M21.2 RP11-631M21.6 RP11-86H7.6 RP11-93B14.4 RP11-93B14.5
 RP11-93B14.6 RP1-1J6.2 RP1-290I10.2 RP1-290I10.3 RP1-290I10.6 RP1-290I10.7 RP1-
290I10.8 RP1-309F20.2 RP1-309F20.3 RP13-30A9.1 RP13-30A9.2 RP3-322G13.7 RP3-
324O17.2 RP3-324O17.4 RP3-324O17.5 RP3-453C12.8 RP3-461P17.10 RP4-530I15.6 RP4-
543J19.8 RP4-564F22.2 RP4-564F22.5 RP4-583P15.10 RP4-583P15.11 RP4-614C15.2
 RP4-614C15.3 RP4-697K14.12 RP4-697K14.3 RP4-697K14.7 RP4-719C8.1 RP4-
724E16.2 RP4-797C5.2 RP4-806M20.2 RP5-1049G16.4 RP5-1100H13.3 RP5-827L5.1 RP5-827L5.2 RP5-
885L7.10 RP5-885L7.11 RP5-890O3.3 RP5-890O3.9 RP5-902P8.10 RP5-963E22.4
 RPL7P3 RPRD1B RPS3P2 RTEL1 SAMD10 SAMD11 SCNN1D SDC4 SDF4 SFRS1
 SLC17A9 SLC1A2 SLC2A4RG SLC45A4 SLCO4A1 SLMO2 SMG1 SNHG11 SNORA40 SNORA71 
SNORA71A SNORA71B snoU13 SNTA1 SRMS ST3GAL1 STMN3 SULF2 SUMO1P1 SYCP2
 SYS1 TAF4 TAS1R3 TCFL5 TFAP2A TGM2 TH1L TMSL6 TNFRSF18 TNFRSF4
183 
 
 TNFRSF6B TOP1 TP53TG5 TPD52L2 TPX2 TSPAN12 TTLL10 TUBB1 U1 U6 U7
 UBE2J2 UCKL1 VSTM2L WFDC2 Y_RNA YTHDF1 ZBTB46 ZGPAT ZMYND11 ZNF217
 ZNF512B ZNF831 
PANTHER analysis: 131 mapped ids are found, 152 mapped ids are not found. 
 
There were gains present in ER positive DCIS associated with invasive breast 
disease (n=5/9) not observed in ER positive pure DCIS (n=0/8).  
1. p-values < 0.05 
2. A gene list is mapped from 35 genomic regions found on chromosomes 1, 2, 
4, 5, 6, 7, 9, 11, 12, 14, 18, 19, 20, 22; 
3. These regions encompass 147 genes altered in ER positive DCIS associated 
with invasive breast disease; 
Genes: 
 5S_rRNA 7SK AC000032.1 AC010442.1 AC012305.1 AC022724.2 AC026740.1 AC027097.1 AC064834.2 AC064834.3
 AC064834.4 AC091609.1 AGAP1 AHRR AIM1 AL031963.1 AL031963.2 AL031963.3 AL031963.5 AL109754.1
 AL117692.1 AL117692.2 AL133351.1 AL136164.1 AL139092.1 AL161626.1 AL356735.1 AMIGO1 AMPD2 ANKRD5
 AP000769.1 AP000944.1 AP002478.2 AP002478.4 ATG5 ATP5F1 ATP8B1 ATXN7L2 BPHL C14orf182
 C14orf183 C5orf55 C6orf155 C6orf195 CCDC127 CELSR2 CEP72 CTD-2083E4.4 CTD-2083E4.5
 CTD-2083E4.6 CTD-2228K2.1 CTD-2228K2.2 CTD-2228K2.5 CTD-2231H16.1
 CTD-2589H19.4 CYB561D1 DLGAP1 ETS1 EXOC3 FAM136B FRMD8 GCNT1 GNAI3
 GNAT2 GPR61 GSK3A GSTM2 GSTM3 GSTM4 GSTM5 hsa-mir-197 hsa-mir-30a hsa-mir-30c-2
 hsa-mir-612 KDSR LRRC14B MYBPHL MYLK4 NQO2 OGFRL1 OVGP1 PDCD6 PLEKHG4B
 PRDM1 PRUNE2 PSMA5 PSRC1 RIPK1 RP11-101C11.1 RP11-109I2.3 RP11-145H9.3
 RP11-154D6.1 RP11-214N16.2 RP11-218C14.5 RP11-310P5.1 RP11-310P5.2
 RP11-404H14.1 RP11-416N4.1 RP11-416N4.4 RP11-420G6.3 RP11-420G6.4
 RP11-422N19.3 RP11-552M11.2 RP11-552M11.4 RP11-58E21.1 RP11-66C24.1
 RP11-811I15.1 RP11-94F13.1 RP1-40E16.11 RP1-40E16.2 RP1-40E16.3 RP1-
40E16.4 RP1-40E16.8 RP1-40E16.9 RP1-90J20.10 RP1-90J20.2 RP1-90J20.7 RP1-90J20.8 RP3-
331H24.4 RP4-630J13.1 RP4-735C1.4 RP5-1160K1.1 RP5-1160K1.3 RP5-1160K1.6
 RP5-839B4.7 RP5-839B4.8 RSL24D1P11 SDHA SERPINB1 SERPINB6 SERPINB9
 SLC39A10 SLC9A3 SNAP25 SORT1 SYPL2 TPPP TUBB2A U6 USP24 WDR77 WI2-




5.8.4.4 Genomic Sc Gains in Oestrogen Receptor Positive Pure DCIS Compared to 
Oestrogen Receptor Positive DCIS Associated with Invasive Breast Disease 
There were Sc gains present in ER positive pure DCIS (n=4/8) not observed in any 
ER positive DCIS associated with invasive breast disease (n=0/9) in this series. 
1. p-values < 0.05;  
2. A gene list is mapped from 6 genomic regions found on chromosomes 1, 8;  
3. These regions encompass 16 genes altered in ER positive pure DCIS; 
Genes:  
AC018442.1 AC023933.1 AL590138.1 CD244 CSMD3 F11R hsa-mir-151  ITLN1 ITLN2 PLXNA2 PTK2
 RP11-312J18.5 RP11-312J18.6 RP11-312J18.7 RP11-544M22.1 VPS13B 
PANTHER analysis: 8 mapped ids are found, 8 mapped ids are not found. 
 
There were Sc gains present in ER positive DCIS associated with invasive breast 
disease (n=6/9) not observed in ER positive pure DCIS (n=0/8). 
1. p-values < 0.05; 
2. A gene list is mapped from 23 genomic regions found on chromosomes 1, 2, 
11, 12, 17, 19, 20;  
3. These regions encompass 143 genes altered in ER positive DCIS associated 
with invasive breast disease; 
Genes:  
ABCC3 AC005220.3 AC007431.1 AC012305.1 AC091062.2 AC092066.6 ACAP3 AGAP1 AGRN AL049736.1
 AL109754.1 AL109840.1 AL136532.1 AL139348.1 AL365229.1 AL390719.1 AL669831.3 ANKRD5 ATP5E AURKAIP1
 B3GALT6 BCAS1 BCAS4 BCL3 C17orf73 C1orf159 C1orf170 C20orf177 C20orf83 CBLC
 CDH26 CDH4 CPSF3L CTB-22K21.2 CTSZ CYP24A1 DOK5 DVL1 FAM132A
 FAM41C FAM65C GLTPD1 GNAS HES4 HOXB3 HOXB4 HOXB5 hsa-mir-10a hsa-mir-200a hsa-
mir-200b hsa-mir-429 ISG15 KLHL17 LUC7L3 MRPS16P MSI2 MXRA8 NOC2L NXT1 PARD6B
 PFDN4 PHACTR3 PLEKHN1 PPP1R3D PTPRT PUSL1 RNFT1 RP11-164D18.2 RP11-206L10.13
 RP11-294J22.5 RP11-357H14.7 RP11-416N4.1 RP11-416N4.4 RP11-429E11.2
 RP11-429E11.3 RP11-465B22.3 RP11-465B22.5 RP11-465B22.6 RP11-506D12.1
 RP11-506D12.3 RP11-54O7.1 RP11-54O7.10 RP11-54O7.11 RP11-54O7.14 RP11-54O7.2
 RP11-54O7.3 RP11-700H6.1 RP11-700H6.2 RP1-232N11.2 RP1-309F20.2 RP1-309F20.3
 RP3-322G13.7 RP4-530I15.6 RP4-543J19.8 RP4-583K8.1 RP4-614C15.2 RP4-614C15.3
 RP4-715N11.2 RP4-719C8.1 RP4-723E3.1 RP4-724E16.2 RP4-730D4.1 RP5-1022J11.1 
RP5-1022J11.2 RP5-1030M6.2 RP5-1073F15.1 RP5-827L5.1 RP5-827L5.2 RP5-839B4.7 RP5-839B4.8
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 RP5-890O3.3 RP5-890O3.9 RP5-902P8.10 RPL12P4 RPS6KB1 SAMD11 SCNN1D
 SDF4 SLC39A11 SLMO2 SNAP25 SNORA70 snoZ6 SYCP2 TAS1R3 TH1L TMSL6
 TNFRSF18 TNFRSF4 TOB1 TTLL10 TUBB1 U4atac U6 U7 UBE2J2 WFIKKN2
 Y_RNA ZFP64 ZNF217 ZNF831 
PANTHER analysis: 62 mapped ids are found, 79 mapped ids are not found. 
5.8.4.5 Losses in Oestrogen Receptor Positive Pure DCIS Compared to Oestrogen 
Receptor Positive DCIS Associated with Invasive Breast Disease 
There is some overlap in the losses found in ER positive pure DCIS (n=5/8) compared 
to ER positive DCIS associated with invasive breast disease (n=1/9). DCIS. 
1. p-values < 0.05;  
2. A gene list is mapped from 35 genomic regions found on chromosomes 3, 9, 
11;  
3. These regions encompass 510 genes altered in ER positive pure DCIS; 
Genes:  
5S_rRNA 7SK ABCG4 AC015689.1 AC019227.1 AC019227.2 AC025029.1 AC087441.1 AC090587.2 AC090587.4
 AC090587.5 AC090804.1 AC108448.2 AC108448.3 AC109309.4 AC132217.4 ACA59 ACAD8 ADAMTS15 ADAMTS8 
AMICA1 AMOTL1 ANKK1 ANKRD42 ANKRD49 AP000560.1 AP000619.1 AP000620.1 AP000620.2 AP000642.1
 AP000654.1 AP000654.2 AP000757.1 AP000767.1 AP000769.1 AP000787.1 AP000797.1 AP000797.2 AP000843.2 AP000844.1
 AP000866.1 AP000866.2 AP000873.1 AP000880.1 AP000892.4 AP000907.1 AP000907.2 AP000907.3 AP000908.1 AP000911.1 
AP000925.2 AP000936.1 AP000936.3 AP000936.4 AP000936.5 AP000944.1 AP001007.1 AP001007.3 AP001122.1 AP001267.1
 AP001267.2 AP001528.1 AP001582.1 AP001767.1 AP001781.1 AP001830.1 AP001891.1 AP001922.1 AP001972.1 AP001979.1
 AP001992.2 AP001999.1 AP002364.1 AP002364.2 AP002380.1 AP002380.2 AP002451.1 AP002754.1 AP002783.1 AP002783.2 
AP002783.3 AP002783.4 AP002783.5 AP002783.6 AP002802.1 AP002884.4 AP002886.2 AP002956.4 AP002962.1 AP002986.1
 AP002991.1 AP003025.2 AP003039.3 AP003039.4 AP003041.1 AP003070.1 AP003072.1 AP003122.1 AP003175.1 AP003304.2
 AP003392.1 AP003392.3 AP003402.1 AP003402.2 AP003461.1 AP003461.10 AP003461.11 AP003461.2
 AP003461.3 AP003461.4 AP003461.5 AP003461.6 AP003461.7 AP003461.8 AP003461.9 AP003499.3 AP003500.1 AP003774.4
 AP003774.5 AP003774.7 AP003780.2 AP003781.1 AP003971.1 AP004242.1 AP004242.2 AP004248.4 AP004372.1 AP004607.1 
AP004607.2 AP004607.3 AP004609.2 AP004609.4 AP005273.1 AP005435.1 AP005597.1 AP005638.1 AP005638.3 AP005718.1
 AP005814.1 AP006216.10 AP006216.11 AP006216.12 AP006216.5 AP006288.1 APLP2 APOA1
 APOA4 APOA5 APOC3 ARCN1 ARHGAP32 ARHGAP42 ARHGEF12 ARHGEF17 ARRB1 ATM
 ATP5L B3GAT1 BACE1 BARX2 BCL9L BCO2 BEST1 BIRC2 BIRC3 BTG4 BUD13
 C11orf1 C11orf10 C11orf2 C11orf30 C11orf36 C11orf45 C11orf52 C11orf53 C11orf54 C11orf57 
C11orf61 C11orf63 C11orf65 C11orf66 C11orf71 C11orf75 C11orf82 C11orf84 C11orf88 C11orf9
 C11orf90 C11orf92 C11orf93 CADM1 CAPN1 CARS CBL CCDC15 CCDC153 CCDC67
 CCDC82 CCDC83 CCDC84 CCDC89 CCDC90B CD3D CD3E CD3G CDC42EP2 CEP164 CEP57
 CHEK1 CHORDC1 CHRM1 CLDN25 CNTN5 CREBZF CRTAM CRYAB CTSC CUL5 CWC15
 CXCR5 DAGLA DCUN1D5 DDI1 DDX25 DDX6 DGAT2 DIXDC1 DLAT DLG2
 DPF2 DRD2 DSCAML1 DYNC2H1 EI24 EIF3F ENDOD1 ESAM ETS1 EXPH5
 FADS1 FADS2 FADS3 FAM168A FAM181B FAM55A FAM55B FAM55D FAM76B FAU
 FCHSD2 FDX1 FDXACB1 FEN1 FLI1 FOLH1B FOLR4 FOXR1 FRMD8 FTH1 FUT4
186 
 
 FXYD2 FXYD6 FZD4 GBE1 GLB1L2 GLB1L3 GPR83 GUCY1A2 HEPACAM HEPN1
 HRASLS5 hsa-mir-1304 hsa-mir-1908 hsa-mir-34b hsa-mir-34c hsa-mir-483 hsa-mir-548l hsa-mir-611 hsa-mir-612 HSPB2 HTR3A 
HTR3B HYLS1 IFT46 IGF2 IGF2AS IGSF9B IL10RA IL18 INS JAM3 JRKL
 KCNJ1 KCNJ5 KDELC2 KDM4D KDM4DL KIAA1731 LAYN LRRC10B MALAT1 MAML2
 MAP6 MARK2 ME3 MED17 MLL MMP1 MMP10 MMP12 MMP13 MMP20 MMP27
 MMP3 MMP7 MMP8 MOGAT2 MPZL2 MPZL3 MRE11A MRGPRE MRGPRG MRPL49
 MTMR2 MYLKP1 NAALAD2 NCAM1 NCAPD3 NCRNA00167 NEU3 NFRKB NLRX1 NNMT
 NOX4 NPAT NRGN NUP98 OPCML OR10V1 OR2AT2P OR2AT4 OR4A15 OR4A16
 OR55B1P OR8A1 OR8B12 OR8B9P OSBP OSBPL5 P2RY2 P2RY6 PAFAH1B2 PANX3 PATL1
 PCF11 PCSK7 PDGFD PDZD3 PGAP2 PGR PHLDB1 PICALM PIH1D2 PIWIL4
 PKNOX2 POLA2 POU2AF1 PPIHP1 PPP2R1B PRCP PRDM10 PTPRD PUS3 RAB30
 RAB38 RAB39 RAB3IL1 RBM7 RDX RELT REXO2 RHOG RNF169 RNF214
 ROBO3 ROBO4 RP11-142L1.1 RP11-142L1.2 RP11-142L1.3 RP11-147I3.1 RP11-160H12.1
 RP11-237N19.1 RP11-358N4.2 RP11-359D24.1 RP11-399J13.1 RP11-438N5.1
 RP11-447G14.1 RP11-567M21.1 RP11-657K20.1 RP11-659G9.1 RP11-667M19.1
 RP11-690D19.1 RP11-727A23.1 RP11-742N3.1 RP11-810P12.1 RP11-832N8.1
 RP11-861M13.1 RP11-864G5.1 RP11-959F10.1 RPL23AP64 RPL37AP8 RPLP0P2 RRM1 
SCARNA11 SCN2B SCN4B SDHD SESN3 SFRS2B SIAE SIDT2 SIK2 SIK3 SLC22A10
 SLC22A20 SLC22A24 SLC22A25 SLC22A9 SLC25A45 SLC35F2 SLC36A4 SLC37A2 SLCO2B1 SNORA1 
SNORA18 SNORA25 SNORA32 SNORA40 SNORA7 SNORA70 SNORA8 SNORD112 SNORD5 SNORD56
 snoU13 snoU2_19 snoU2-30 snoZ40 SORL1 SPA17 SPATA19 SPCS2 SPDYC ST14 STIM1
 STT3A SYT7 SYTL2 SYVN1 TAF1D TAGLN TBRG1 TEX12 THYN1 TIGD3
 TIMM8B TM7SF2 TMEM123 TMEM126A TMEM126B TMEM135 TMEM136 TMEM218 TMEM25 TMEM45B
 TMPRSS13 TMPRSS4 TMPRSS5 TP53AIP1 TREH TRIM48 TRIM49 TRIM49L TRIM53 TRIM53B
 TRIM64 TRIM64B TRIM77 TTC12 TTC36 U2 U6 U7 UBASH3B UBE4A UBTFL2
 UBTFL3 UPK2 USP28 UVRAG VPS26B VSIG2 XRRA1 Y_RNA ZBTB16 ZBTB44 
ZC3H12C ZNF259 ZNHIT2 ZW10 
PANTHER analysis: 286 mapped ids are found, 224 mapped ids are not found.  
 
There were losses present in ER positive DCIS associated with invasive breast 
disease (n=6/9) not observed in ER positive pure DCIS (n=0/8). 
1. p-values < 0.05; 
2. A gene list is mapped from 56 genomic regions found on chromosomes 5, 8, 
10, 16, 19, X;  
3. These regions encompass 149 genes altered in ER positive DCIS associated 
with invasive breast disease; 
Genes: 5S_rRNA AC002366.3 AC003666.1 AC009055.1 AC009110.1 AC009120.1 AC009161.1 AC010546.1 AC018558.1 AC022164.1
 AC023824.2 AC025287.1 AC025287.2 AC025287.3 AC025287.4 AC069278.1 AC073493.1 AC073493.2 AC073493.3 AC135776.1
 ADAM3A ADAM5P AGTR2 AKR1B1P8 AL035443.1 AL133512.1 AL353698.1 AL591398.1 AMELX ANKRD26P1 
ARHGAP6 ARHGEF9 ASPDH BMP15 BX119964.1 BX119964.2 BX119964.3 BX119964.4 C5orf50 CCNYL3 CDH11
 CDH8 CLCN4 CTD-2503H21.1 CXorf29 DHRSX DMD EFHC2 EIF2S3 FAAH2 FAM48B2 FDPSL5
187 
 
 FMR1 FMR1NB FRMPD4 GPR112 GPR64 GS1-256O22.1 GS1-256O22.5 GS1-466O4.2
 GS1-466O4.3 GS1-466O4.5 GS1-541M1.2 JOSD2 KLF8 L29074.1 L29074.2 L29074.3
 L29074.5 LRRC4B MAGEB18 MAGEB5 MAGEB6 MAGEB6B MAGED4 MAGEE1 MAP3K7IP3 NRG3
 PSMD7 RP11-104D21.1 RP11-104D21.2 RP11-104D21.3 RP11-121C22.1 RP11-156J23.1
 RP11-1A15.2 RP11-357C3.2 RP11-357C3.3 RP11-363G10.2 RP1-137H15.2 RP1-
138A5.1 RP11-38O23.3 RP11-38O23.4 RP11-38O23.5 RP11-38O23.7 RP11-3D23.1
 RP11-434J24.2 RP11-467P22.4 RP11-479I1.4 RP11-517D11.3 RP11-54I5.1 RP11-552E4.2
 RP11-617O8.1 RP11-637B23.1 RP11-637B23.3 RP11-702C7.1 RP11-702C7.2
 RP11-761E20.1 RP11-81C12.1 RP11-93B10.3 RP1-20J23.1 RP1-267M5.1 RP1-267M5.2 RP1-
290C9.2 RP13-188A5.1 RP13-346H10.2 RP13-348B13.1 RP13-348B13.2 RP13-34C21.1 RP13-60P5.2
 RP1-54B20.7 RP3-433G13.1 RP4-551E13.2 RP5-1145L23.2 RP5-849L7.1 RP6-1O2.1 SHROOM4 
SLITRK4 SNORA11 SNORA68 snoU13 SPACA5B SPANXN3 SPIN4 SSX5 SSX6 U40455.1 U6 VENTXP1
 WWOX Y_RNA Z98304.1 ZFP112 ZFRP1 ZFX ZIC3 ZNF180 ZNF229 ZNF285 
PANTHER analysis: 42 mapped ids are found, 106 mapped ids are not found. 
5.8.4.6 Total Loss in Oestrogen Receptor Positive Pure DCIS Compared to 
Oestrogen Receptor Positive DCIS Associated with Invasive Breast Disease 
There were total losses present in ER positive pure DCIS (n=5/8) not observed in ER 
positive DCIS associated with invasive breast disease (n=0/9). 
1. p-values < 0.05; 
2. A gene list is mapped from 13 genomic regions found on chromosomes 9, 11, 
13, 15, 19;  
3. These regions encompass 25 genes altered in for ER positive pure DCIS; 
Genes:  
7SK AC025678.1 AC027139.2 AC027139.3 AP000720.1 AP001482.1 AP003072.1 CCDC67 CTSC GOLGA8B GRM5 hsa-
mir-1233 KDM4C LPAR6 NOX4 OR10V1 OSBP PATL1 RB1 RP11-657K20.1 SLC36A4 TYR
 U7 ZNF208 ZNF257 
PANTHER analysis: 15 mapped ids are found, 10 mapped ids are not found.  
 
There were total losses present in ER positive DCIS associated with invasive breast 
disease (n= 9/9) not observed in ER positive pure DCIS (n=0/8). 
1. p-values < 0.05; 
2. A gene list is mapped from 91 genomic regions found on chromosomes 11, 
13, 16, 17, X; 
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3. These regions encompass genes altered in ER positive DCIS associated with 
invasive breast disease; 
Genes:  
5S_rRNA 7SK ABCC12 ABR AC000003.1 AC002347.1 AC002347.2 AC002366.3 AC003658.1 AC004070.1
 AC004478.2 AC005277.1 AC005284.1 AC005323.1 AC005358.1 AC005358.3 AC005548.1 AC005548.2 AC005696.2 AC005696.3
 AC005725.1 AC006435.1 AC007225.1 AC007339.1 AC009053.1 AC009110.1 AC009120.1 AC009120.3 AC009161.1 AC010546.1
 AC015799.1 AC015799.2 AC015908.2 AC016292.1 AC016292.3 AC025287.1 AC025287.2 AC025287.3 AC025287.4 AC025518.1
 AC027045.1 AC027763.1 AC027763.2 AC032044.1 AC055839.2 AC073493.1 AC073493.2 AC073493.3 AC087498.1 AC087501.1
 AC087742.1 AC087742.2 AC090282.1 AC090617.1 AC091153.4 AC097370.1 AC099508.1 AC099684.1 AC100748.2 AC104581.1 
AC109599.1 AC116914.1 AC118754.2 AC118754.4 AC127521.1 AC130343.2 AC130689.5 AC135178.7 ACA64 ADAT1
 AIPL1 AL136160.1 AL355852.1 AL390738.2 AL450226.1 AL450226.2 AL589987.1 ALOX12 ALOX15 AMAC1L3
 AMELX ANKFY1 ANKRD26P1 AP001970.1 ARHGAP6 ARHGEF15 ARHGEF9 ARRB2 ASB12 ASGR1 ASGR2
 ASMT ASPA ATP2A3 ATP5EP2 BCAR1 BCL6B BHLHA9 BMP15 BRWD3 BX004827.1 BX649443.1
 C13orf36 C16orf78 C16orf87 C17orf100 C17orf44 C17orf48 C17orf49 C17orf68 C17orf85 C17orf91
 CAMKK1 CBLN1 CCDC42 CDH13 CDH8 CFDP1 CHD3 CHRNB1 CHST5 CHST6
 CLEC10A CLEC18B CRK CRLF2 CTD-2503H21.1 CTD-2545G14.1 CTNS CTRB1 -CTRB2
 CYB5D1 CYB5D2 DDX26B DHRS7C DHRSX DLG4 DNAH2 DNAH9 DNAJA2 DPH1 EEF1AL1
 EIF4A1P10 ERN2 FA2H FAM123B FAM46D FAM64A FANCB FBXO39 FRMPD4 GABARAPL2 GAPDHP34
 GAS7 GGT6 GLG1 GLP2R GLRA2 GPT2 GS1-466O4.2 GS1-466O4.3 GS1-466O4.5
 GS1-541M1.1 GS1-541M1.2 GSG2 GTPBP6 HCCS HDHD1A HIC1 HK2P1
 HMGA1L1 hsa-mir-1253 hsa-mir-132 hsa-mir-1468 hsa-mir-195 hsa-mir-212 hsa-mir-22 hsa-mir-497 INPP5K ITGAE KARS
 KDM6B KIAA0664 KIAA0753 KRBA2 LDHD LL0YNC03-3F3.1 LSMD1 MAGEB18 MAGEB5 MAGEB6
 MAGEB6B MAGED1 MAGED4 MAGED4B MAGEE1 MAP2K4 MED31 METT10D MFSD6L MLKL MNT
 MTMR8 MTUS2 MYBBP1A MYH1 MYH10 MYH13 MYH2 MYH3 MYH4 MYH8
 MYLK3 MYO1C MYOCD NCRNA00086 NCRNA00107 NCRNA00108 NDEL1 NETO2
 NPIPL2 NTN1 NXN ODF4 OR1A1 OR1A2 OR1D2 OR1D5 OR1E1 OR1E2 OR1G1
 OR3A1 OR3A2 OR3A3 OR3A4 ORC6L OVCA2 P2RX1  P2RX5 P2RY8  PAFAH1B1 PAN3
 PCDH11X PDX1 PELP1 PFAS PHKB PIK3R5 PIK3R6 PIRT PITPNA PITPNM3
 PLCXD1 PLK1 POLR2A PPP2R3B PRPF8 PRPSAP2 PSMD7 RAB43P1 RANGRF RAP1GAP2
 RCVRN RFWD3 RILP RNASEK RNF222 RP1-107N3.1 RP1-107N3.2 RP11-114H20.1
 RP11-120D5.1 RP11-145B3.2 RP11-151A2.2 RP11-16L6.3 RP11-197L7.2 RP11-217H19.1
 RP11-234P3.2 RP11-234P3.3 RP11-234P3.4 RP11-234P3.5 RP11-265D19.5 RP11-265D19.6
 RP11-284B18.3 RP11-2N21.2 RP11-309M23.1 RP11-309M23.2 RP11-311P8.1 RP11-311P8.2
 RP11-314A20.1 RP11-314A20.2 RP11-325E14.1 RP11-325E14.2 RP11-325E14.5 RP11-331F4.1
 RP11-331F4.4 RP11-33N11.1 RP11-342C20.3 RP11-344N17.11 RP11-344N17.2 RP11-344N17.3
 RP11-344N17.6 RP11-344N17.7 RP11-344N17.8 RP11-357C3.2 RP11-357C3.3
 RP11-360A9.1 RP11-363G10.2 RP11-364B14.1 RP11-364B14.2 RP11-364B14.3
 RP11-403E24.1 RP11-432N13.2 RP11-432N13.3 RP11-459A10.1 RP11-459A10.2
 RP11-459A10.3 RP11-462C21.1 RP11-471M2.1 RP11-471M2.2 RP11-481F23.1
 RP11-483M24.2 RP11-48B14.1 RP11-51C14.1 RP11-51C14.2 RP11-520F9.2
 RP11-552E4.3 RP11-552E4.4 RP11-552E4.5 RP11-565F19.1 RP11-572F4.1 RP11-609D21.1
 RP11-617O8.1 RP11-637B23.1 RP11-637B23.3 RP11-647I17.1 RP11-702C7.1
 RP11-702C7.2 RP11-713H12.1 RP11-93B10.3 RP11-963H4.1 RP11-963H4.2 RP1-
279N11.1 RP13-210D15.1 RP13-210D15.4 RP13-210D15.6 RP13-297E16.3 RP13-297E16.4
 RP13-297E16.5 RP13-34C21.1 RP13-465B17.2 RP13-465B17.3 RP13-565O16.2
 RP13-60P5.2 RP13-858C7.1 RP13-926M18.1 RP3-428A13.1 RP4-710L4.1 RPA1
 RPL26 RTN4RL1 SCARF1 SCARNA21 SCO1 SERPINF1 SERPINF2 SFRS17A SGSM2 SHCBP1
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 SHISA6 SHOX SHPK SHROOM4 SLC13A5 SLC16A11 SLC16A13 SLC25A35 SLC43A2 SLITRK5 SMG6 
SMTNL2 SMYD4 SNORA11 SNORA69 SNORA76 SNORD91 snoU13 SOX3 SPATA22 SPDYE4
 SPIN4 SPNS2 SPNS3 SRR SSX1 SSX3 SSX9 STX8 TAX1BP3 TBX22 TEKT1
 TERF2IP TIMM22 TLCD2 TMEM170A TMEM220 TMEM231 TMEM88 TMEM93 TNFSF12 TNFSF12-TNFSF13
 TNFSF13 TRPV1 TRPV3 TSR1 TUSC5 TXNDC17 U1 U6 U7 U70984.1 U8
 UBE2G1 UPRT USP43 VAT1L VENTXP1 VPS35 WDR16 WDR59 WDR81 WSCD1 XAF1
 Y_RNA YWHAE ZBTB4 ZDHHC15 ZFP1 ZNF423 ZNF449 ZNF75D ZNRF1 ZZEF1 
PANTHER analysis: 219 mapped ids are found, 223 mapped ids are not found. 
5.8.4.7 CdLOH in Oestrogen Receptor Positive Pure DCIS Compared to Oestrogen 
Receptor Positive DCIS Associated with Invasive Breast Disease 
There is CdLOH present in ER positive pure DCIS (n=6/8) not observed in any ER 
positive DCIS associated with invasive breast disease (n=0/9). 
1. p-values < 0.05; 
2. A gene list is mapped from 54 genomic regions found on chromosomes 3, 9, 11;  
3. These regions encompass 333 genes altered in ER positive pure DCIS; 
Genes: 
 5S_rRNA ABCG4 AC015689.1 AC025029.1 AC087441.1 AC090587.2 AC090587.4 AC090587.5 AC090804.1 AC108448.2 AC108448.3
 AC109309.4 AC132217.4 AC133041.1 ACAD8 AMOTL1 ANKRD42 ANKRD49 AP000438.1 AP000560.1 AP000619.1
 AP000620.1 AP000620.2 AP000642.1 AP000654.1 AP000654.2 AP000767.1 AP000769.1 AP000787.1 AP000873.1 AP000911.1
 AP000944.1 AP001267.1 AP001267.2 AP001528.1 AP001767.1 AP001922.1 AP001972.1 AP001979.1 AP001992.2 AP001999.1
 AP002364.1 AP002364.2 AP002380.1 AP002380.2 AP002754.1 AP002783.1 AP002783.2 AP002783.3 AP002783.4 AP002783.5
 AP002783.6 AP002802.1 AP002956.4 AP002991.1 AP003122.1 AP003175.1 AP003304.2 AP003392.1 AP003392.3 AP003461.1
 AP003461.10 AP003461.11 AP003461.4 AP003461.5 AP003461.7 AP003499.3 AP003774.4 AP003774.5
 AP003774.7 AP003780.2 AP003781.1 AP003971.1 AP004242.1 AP004242.2 AP004607.1 AP004607.2 AP004607.3 AP004609.2
 AP004609.4 AP005273.1 AP005435.1 AP005718.1 AP005814.1 AP006288.1 ARCN1 ARHGAP42 ARHGEF12 ARHGEF17
 ARRB1 ATM ATP5L B3GAT1 BCL9L BEST1 BIRC2 BIRC3 C11orf10 C11orf2 C11orf30 
C11orf36 C11orf54 C11orf65 C11orf66 C11orf75 C11orf82 C11orf84 C11orf9 C11orf90 CADM1 CAPN1
 CARS CBL CCDC153 CCDC67 CCDC82 CCDC83 CCDC84 CCDC89 CCDC90B CD3G
 CDC42EP2 CEP57 CHORDC1 CHRM1 CNTN5 CREBZF CTD-2026G6.1 CTD-2026G6.2 CWC15
 CXCR5 DAGLA DCUN1D5 DDI1 DDX6 DGAT2 DLG2 DPF2 DYNC2H1 EIF3F
 ENDOD1 EXPH5 FADS1 FADS2 FADS3 FAM168A FAM181B FAM76B FAM86D FAU
 FCHSD2 FEN1 FOLH1B FOLR4 FOXR1 FRMD8 FTH1 FUT4 FZD4 GBE1 GLB1L2
 GLB1L3 GPR83 GUCY1A2 HRASLS5 hsa-mir-1304 hsa-mir-1324 hsa-mir-1908 hsa-mir-483 hsa-mir-548l hsa-mir-611 hsa-
mir-612 IFT46 IGF2 IGF2AS IGSF9B INS JAM3 JRKL KDELC2 KDM4D KDM4DL
 KIAA1731 LRRC10B MALAT1 MAML2 MAP6 MARK2 ME3 MED17 MLL MMP1 MMP10
 MMP12 MMP13 MMP20 MMP27 MMP3 MMP7 MMP8 MOGAT2 MRE11A MRGPRE 
MRGPRG MRPL49 MTMR2 MYLKP1 NAALAD2 NCAPD3 NEU3 NLRX1 NOX4 NPAT NUP98 OR2AT2P
 OR2AT4 OR55B1P OSBPL5 P2RY2 P2RY6 PCF11 PDGFD PDZD3 PGAP2 PGR PHLDB1
 PICALM PIWIL4 POLA2 PRCP PTPRD RAB30 RAB38 RAB3IL1 RELT RHOG RNF169
 RP11-142L1.1 RP11-142L1.2 RP11-142L1.3 RP11-147I3.1 RP11-160H12.1 RP11-241K7.1
 RP11-241K7.2 RP11-358N4.2 RP11-359D24.1 RP11-399J13.1 RP11-413E6.1 RP11-413E6.2
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 RP11-413E6.3 RP11-438N5.1 RP11-447G14.1 RP11-642N14.3 RP11-659G9.1
 RP11-690D19.1 RP11-727A23.1 RP11-742N3.1 RP11-803B1.1 RP11-803B1.2
 RP11-803B1.3 RP11-803B1.4 RP11-803B1.5 RP11-803B1.7 RP11-810P12.1
 RP11-861M13.1 RP11-864G5.1 RP11-959F10.1 RPL23AP64 RPLP0P2 RRM1 SESN3
 SFRS2B SLC22A10 SLC22A20 SLC22A24 SLC22A25 SLC22A6 SLC22A8 SLC22A9 SLC25A45 SLCO2B1
 SNORA1 SNORA18 SNORA25 SNORA32 SNORA40 SNORA7 SNORA70 SNORA8 SNORD112 SNORD5 
SNORD56 snoU13 snoU2_19 snoU2-30 snoZ40 SPATA19 SPCS2 SPDYC STIM1 SYT7 SYTL2 SYVN1
 TAF1D THYN1 TIGD3 TM7SF2 TMEM123 TMEM126A TMEM126B TMEM135 TMEM136 TMEM25 TREH 
TRIM49 TRIM49L TRIM53 TRIM53B TRIM64 TRIM64 TRIM77 TTC36 U2 U6 UBE4A UBTFL2
 UBTFL3 UPK2 UVRAG VPS26B XRRA1 Y_RNA ZNHIT2 
PANTHER analysis: 167 mapped ids are found, 166 mapped ids are not found.  
 
There is CdLOH found in ER positive DCIS associated with invasive breast disease. 
(n=8/9) with some overlap in ER positive pure DCIS (n=1/8). 
1. p-values < 0.05; 
2. A gene list is mapped from 36 genomic regions found on chromosomes 5, 7, 
10, 12, 16, 19, X; 
3. These regions encompass 61 genes, 2 and 59 genes altered in ER positive 
DCIS associated with invasive breast disease; 
Genes:  
AC002519.2 AC005774.2 AC009055.1 AC009120.1 AC018558.1 AC022164.1 AC023824.2 AC025287.2 AC069278.1 AC073057.5
 AC135776.1 ARHGEF9 ASPDH BX649443.1 C16orf67 C5orf50 CCNYL3 CDH11 DHRSX EFHC2 EIF2S3
 FAM48B2 FDPSL5 FRMPD4 GPR64 JOSD2 LRRC4B MAGED4 NRG3 RP11-114G11.2 RP11-1217F2.15
 RP11-133M24.1 RP11-357C3.2 RP11-357C3.3 RP11-363G10.2 RP11-479I1.4
 RP11-617O8.1 RP11-93B10.3 RP1-290C9.2 RP13-297E16.4 RP13-297E16.5 RP13-34C21.1
 RP13-858C7.1 RP4-551E13.2 SNORA11 SNORA68 SORCS3 SPIN4 U7 VN1R66P Y_RNA
 ZFP112 ZFX ZNF180 ZNF229 ZNF285 ZNF716 ZNF720 ZNF720P1 
PANTHER analysis: 41 mapped ids are found, 28 mapped ids are not found. 
5.8.4.8 CnLOH in Oestrogen Receptor Positive Pure DCIS Compared to Oestrogen 
Receptor Positive DCIS Associated with Invasive Breast Disease 
There is CnLOH present in ER positive pure DCIS (n=8/8) not observed in ER positive 
DCIS associated with invasive breast disease (n=0/9). 
1. p-values < 0.05; 
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2. A gene list is mapped from 98 genomic regions found on chromosomes 1, 2, 
3, 4, 6, 10, 11, 12, 16, 19, 20, 21;  
3. These regions encompass 627 genes altered in ER positive pure DCIS; 
Genes: 
 5S_rRNA 7SK ABI3BP ABT1 AC000032.1 AC002485.1 AC004699.1 AC012154.1 AC018809.6 AC021749.1
 AC021749.2 AC021749.3 AC022007.1 AC022007.2 AC022007.4 AC022007.5 AC023085.1 AC025423.2 AC027288.1 AC027288.2
 AC034102.1 AC034193.5 AC034193.7 AC063962.1 AC073366.1 AC078917.1 AC079598.1 AC079598.2 AC087521.1 AC087521.2
 AC087521.3 AC087521.4 AC087521.5 AC093028.1 AC096649.1 AC096649.2 AC096649.3 AC124890.1 AC131263.1 AC131263.2
 AC137628.1 AC137834.2 ACCS ACCSL ADAM30 ADAMTS14 ADH5P4 AF254982.1 AF254982.2 AF254982.3 
AGAP10 AGAP6 AGAP7 AGAP8 AHCYL1 AL021807.2 AL021808.1 AL021808.2 AL021808.3 AL023913.1
 AL031178.1 AL035045.1 AL035456.1 AL035467.1 AL035661.3 AL050321.1 AL050321.2 AL050322.1 AL050335.1 AL050335.2
 AL109754.1 AL109922.1 AL118509.1 AL133255.1 AL136164.1 AL138850.1 AL139429.1 AL354680.1 AL354933.1 AL355344.1 
AL359752.1 AL391137.2 AL442003.2 AL442003.3 AL450342.1 AL450342.2 AL512288.1 AL512503.1 AL590062.1 AL591034.2
 AL591044.1 AL591044.2 AL591044.3 AL591044.4 AL672187.3 AL672187.4 AL713998.1 ALKBH3 ALX3 AMBRA1 ANKRD5
 ANKRD52 ANO3 ANXA8L1 AP000302.58 AP000303.1 AP000304.12 AP000304.2 AP001992.2 APOF
 ARHGAP1 ARHGAP9 ASAH2 ATF2 ATP5G3 B3GAT2 BANF2 BDNF BDNFOS BMS1P2 BTBD3
 BYSL C10orf53 C11orf91 C1orf127 C1orf167 C1orf216 C20orf12 C20orf187 C20orf3 C20orf61
 C20orf72 C20orf78 C20orf79 C20orf94 C22orf30 C3orf10 C3orf24 C6orf155 C6orf205 C6orf57
 CASP14 CCDC34 CCT2 CD59 CD82 CDK2 CFLP6 CHRM4 CHST1 CIDECP
 CLCN6 CLSPN CNPY2 COMTD1 COQ10A CR381653.1 CR381653.2 CR381653.3 CR381670.1 CR381670.2
 CR382285.2 CR382287.1 CR392039.1 CR392039.2 CR392039.3 CREB3L1 CRELD1 CRYZL1 CS CSF1
 CSRP2BP CST1 CST2 CST3 CST4 CST5 CST7 CSTF3 CSTP1 CSTP2 CTA-215D11.3
 CTA-215D11.4 CTSLL7 CYCSP41 DEFB110 DEFB112 DEFB113 DEFB114 DEFB133 DEK DEPDC7
 DGKZ DIP2C DNAJC28 DONSON DPCR1 DTNBP1 DUPD1 DUSP13 ELOVL5 ENO1
 EPHA6 EPS8L3 ERBB3 ERRFI1 ESYT1 EXT2 EYA3 EYS F2 FAM135A
 FAM21A FAM21D FAM25B FAM25D FAM35B2 FAM40A FAM72B FANCD2 FAT1P1 FBXO3
 FBXO9 FCGR1B FRS2 FRS3 GART GCLC GCM1 GGTLA4 GLI1 GLUDP8 GMPR
 GPR182 GSTM2 GSTM3 GSTM3P GSTM5 GUSBL1 HARBI1 HCG21 HIPK3 HIST1H2AH
 HIST1H2BJ HIST1H2BK HIST1H4I HIST2H2BA HIST2H2BB HMGA1L5 HNRNPM hsa-mir-1228 hsa-mir-1252 hsa-mir-129-2
 hsa-mir-30a hsa-mir-30c-2 hsa-mir-670 hsa-mir-933 HSD17B12 ICK IFNGR2 IGHV1OR15-5 IKZF4 IL17RC
 IL23A INHBC INHBE IRAK2 ITSN1 JAG1 JARID2 KDM1B KHDRBS2 KIAA0319L
 KIAA0652 KIAA1274 KIF16B LGR4 LIN28AP3 LIN7C LRP1 LRRC10 MACROD2 Mar02 MDK
 MDM2 MED20 MKKS MRPS11P1 MTHFR MYCL1 MYL6 MYL6B MYLIP MYO1A MYST4 
NAB2 NCDN NCOA4 NCRNA00240 NDUFA4L2 NEU3 NKX22 NKX2-4 NODAL NOTCH2 NTS
 NXPH4 NXT1 OBFC2B OGDHL OGFRL1 OTOR OVOL2 PA2G4 PA2G4P2 PAK7 PAN2
 PANK4 PARG PARK7 PGAM3P PGC PHACTR1 PHF21A PIP5K2A PISD PLCH2
 PLK1S1 POM121L1P POM121L2 POM121L3P PPIAP13 PPIAP17 PPYR1 PRAM1 PRF1 PRICKLE4 PRPF19
 PRRT3 PRSS16 PSMB2 PTMAP3 QSER1 R3HDM2 RAB5B RASSF9 RDH16 RERE
 RFX4 RIC8B RIMS1 RNF144B RNF41 RP11-102J14.1 RP11-104F15.7 RP11-109G10.2
 RP11-134K13.2 RP11-144G6.10 RP11-144G6.4 RP11-144G6.9 RP11-146I2.1
 RP11-154D6.1 RP11-157E14.1 RP11-157E14.3 RP11-159H22.1 RP11-160A9.1 RP11-160A9.2
 RP11-185B14.1 RP1-118J21.5 RP11-195M16.1 RP11-209A2.1 RP11-218C14.5 RP11-227D2.3
 RP11-239L20.3 RP11-239L20.4 RP11-239L20.5 RP11-244C20.1 RP11-263F15.1
 RP11-281P11.1 RP11-292F22.3 RP11-292F22.4 RP11-292F22.5 RP11-298J23.5
 RP11-298J23.6 RP1-129L7.1 RP11-307F22.2 RP11-314P12.2 RP11-314P12.3 RP11-324H6.5
 RP11-324H6.6 RP11-324H6.7 RP11-348A11.1 RP11-397G17.1 RP11-399K21.2
192 
 
 RP11-399K21.4 RP11-399K21.5 RP11-399K21.6 RP1-13D10.2 RP1-13D10.3 RP1-
13D10.4 RP1-13D10.5 RP11-401E14.1 RP11-401E14.2 RP11-416N4.1 RP11-416N4.4
 RP11-425L10.1 RP11-431K24.1 RP11-431K24.2 RP11-431K24.3 RP11-431K24.4 RP11-435D7.3
 RP11-439A17.10 RP11-439A17.2 RP11-439A17.4 RP11-439A17.5 RP11-439A17.7
 RP11-439A17.9 RP11-448N11.1 RP11-448N11.2 RP11-457M11.2 RP11-460I13.5
 RP11-460I13.6 RP11-462G2.1 RP11-462G2.2 RP11-466G11.1 RP11-472I20.1
 RP11-481A12.2 RP11-481A12.5 RP11-481A12.6 RP11-487I5.4 RP11-506E9.1 RP11-507K13.4
 RP11-507K13.6 RP11-526K17.2 RP11-526K21.2 RP11-528A10.1 RP11-528A10.2 RP11-542F9.1
 RP11-560J1.1 RP11-56A21.4 RP11-56N19.5 RP11-575L16.2 RP11-587D21.1 RP11-592B15.3
 RP11-592B15.4 RP11-592B15.6 RP11-69I22.2 RP11-69I22.3 RP11-707M13.1 RP11-
710A11.2 RP11-74E24.2 RP11-77G23.2 RP11-77G23.5 RP11-789A7.1 RP1-190J20.2
 RP11-96J19.1 RP11-96J19.2 RP11-96J19.3 RP1-198K11.3 RP1-20N4.1 RP1-240B8.3
 RP1-278O22.1 RP1-278O22.2 RP1-27K12.4 RP1-288M22.1 RP1-288M22.2 RP1-298M8.1
 RP13-15M17.1 RP13-392I16.1 RP1-34L19.1 RP1-34L19.2 RP1-89D4.1 RP3-322G13.7 RP3-331H24.4
 RP3-395M20.2 RP3-395M20.3 RP3-410C9.1 RP3-410C9.2 RP3-477M7.2 RP3-477M7.3
 RP3-477M7.4 RP3-483K16.2 RP3-483K16.3 RP3-527G5.1 RP4-564O4.1 RP4-568F9.3 RP4-
568F9.6 RP4-568F9.7 RP4-580G13.1 RP4-633I8.1 RP4-633I8.2 RP4-633I8.3 RP4-633I8.4 RP4-697P8.2 RP4-
697P8.3 RP4-705D16.3 RP4-717M23.2 RP4-718D20.3 RP4-726N1.2 RP4-728D4.2 RP4-
728D4.3 RP4-734C18.1 RP4-735C1.4 RP4-735C1.5 RP4-735C1.6 RP4-737E23.2
 RP4-737E23.4 RP4-742J24.2 RP4-777D9.2 RP4-796I8.1 RP5-1018A4.3 RP5-1042I8.6 RP5-
1053E7.1 RP5-1053E7.2 RP5-1068E13.3 RP5-1068F16.3 RP5-1069C8.1 RP5-1069C8.2 RP5-1099D15.1
 RP5-1100I6.1 RP5-1100I6.2 RP5-1115A15.1 RP5-1177M21.1 RP5-1195D24.1 RP5-839B4.7
 RP5-839B4.8 RP5-858B16.5 RP5-860P4.2 RP5-872K7.2 RP5-872K7.7 RP5-
905G11.3 RP5-931K24.1 RP5-973N23.4 RP5-983H21.3 RP5-984P4.1 RP5-984P4.4
 RPL15P1 RPL23AP6 RPL24P2 RPL41 RPL7AL3 RPLP0P1 RPS11P1 RPS15AP1 RPS26 RPS5L
 RRBP1 SAMD8 SDR9C7 SFTA2 SHMT2 SILV SLC15A3 SLC24A3 SLC25A33 SLC39A5
 SLC45A1 SLC9A3P1 SLC9A3P3 SMAP1 SMARCC2 SMCHD1 SNAP25 SNORA48 SNORA70 SNORA74 
SNORA77 SNORA8 SNORD17 snoU13 SNRPB2 SNX5 SON SPCS2 SPDEF SPTLC3 STAC3
 STAT2 STAT6 SUOX SYT1 TAC3 TCP1 L1 TFAP2E TFEB TIMELESS TIMM23
 TIMM23B TMEM109 TMEM111 TMEM132A TMEM132B TMEM194A TMEM50B TMEM90B TOMM6 TP53I11
 TPMT TPTE TRIT1 TSPAN18 TTC17 U1 U2 U3 U4 U6 U7
 USP49 VARSL VDAC2 VN1R11P VN1R12P VN1R13P VN1R14P XRN2 XRRA1 XXbac-
BPG118E17.9 XXyac YR14BB7.1 XXyac-YX60D10.1 Y_RNA ZBTB39 ZC3H10 ZNF133 ZNF322A
 ZNF408 ZPLD1 
PANTHER analysis: 248 mapped ids are found, 379 mapped ids are not found.  
 
There is CnLOH in ER positive DCIS associated with invasive breast disease not 
observed in ER positive pure DCIS. 
1. p-values < 0.05; 




3. These regions encompass 149 genes altered in ER positive DCIS associated 
with invasive breast disease; 
Genes: 
 7SK AB019439.2 AC008659.1 AC008659.2 AC009997.1 AC010674.2 AC010724.1 AC010724.2 AC010724.3 AC010724.4 AC010724.5
 AC010724.6 AC010724.7 AC011295.1 AC011295.2 AC011295.3 AC011295.4 AC011295.5 AC011944.1 AC012050.1 AC018926.1
 AC018926.2 AC022748.1 AC025580.2 AC025917.1 AC026624.1 AC026956.1 AC026956.2 AC039057.1 AC039057.3 AC044907.1 
AC068870.1 AC069082.1 AC084882.1 AC087738.2 AC092373.1 AC104115.1 AC105339.1 AC105339.2 AC116903.1 AC116903.2
 AC126339.1 AC126339.2 AC126339.3 AC126339.4 AC135995.1 AC135995.2 AC135995.3 AC135995.4 AC135995.5 AC136940.3
 ADAMTS7 AGXT2L2 ANKRD34C AP3B2 ARPP19 BCL2L10 C15orf26 C15orf32 C15orf48 CCPG1
 CHRNB4 CLK4 COL23A1 CPEB1 CTB-129O4.1 CTD-2184D3.1 CTD-2270N23.1 CTSH CYP19A1
 DYX1C1 EFTUD1 F2RL1 FAM153C FAM154B FAM174B FSD2 GFPT2 GNB5 GOLGA6L10
 GOLGA6L3 GOLGA6L5 GOLGA6L9 HNRNPAB HNRNPH1 HOMER2 hsa-mir-1266 hsa-mir-147b hsa-mir-184 hsa-mir-628 IGHD 
IL16 KIAA1024 KIAA1199 KIAA1370 MAPK9 MAST4 MESDC1 MESDC2 MEX3B MORF4L1 MYO5A
 MYO5C NEDD4 NHP2 ODZ2 PIGB PRTG PYGO1 RAB27A RASGEF1C RASGRF1 RFX7 RMND5B
 RP11-1001M11.1 RP11-252I14.1 RP11-287J9.1 RP11-335K5.1 RP11-5P22.1 RP11-5P22.2
 RP11-5P22.3 RP11-889L3.1 RP11-889L3.3 RP11-889L3.4 RP11-96J23.1 RP13-608F4.1
 RP13-996F3.1 RPS17 S100Z SCARNA15 SEMA6D SH3GL3 SLC30A4 snoU109 snoU13
 SPATA5L1 ST8SIA2 STARD5 TEX9 TMC3 TMED3 U1 U2 U7 UBE2Q2P2 UNC13C
 WDR72 WHAMM 
PANTHER analysis: 64 mapped ids are found, 84 mapped ids are not found. 
5.8.5 Copy Number Aberrations for Oestrogen Receptor Positive Pure DCIS 
Compared to Oestrogen Positive Invasive Breast Disease 
These series examines the difference between oestrogen receptor positive pure 
DCIS and oestrogen receptor positive invasive breast cancer. 
 
Frequency plots showing copy number aberrations between oestrogen receptor 
positive pure DCIS and oestrogen receptor positive invasive breast disease were 
provided by Breakthrough Breast Cancer/Research Oncology, King’s College London 
Bioinformatics Department (Figure 38). 
Figure 38: Frequency plots showing copy number aberrations between oestrogen 
receptor positive pure DCIS and oestrogen positive invasive breast disease 
(amplifications, duplications, gains, Sc gains, losses, total losses CdLOH and 


















5.8.5.1 Amplification in Oestrogen Receptor Positive Pure DCIS Compared to 
Oestrogen Receptor Positive Invasive Breast Disease 
There were no amplifications in ER positive pure DCIS (n=0/8) in this series. 
However, there were amplifications in ER positive invasive breast disease (n=5/9) not 
present in the ER positive pure DCIS.  
1. p-values < 0.05; 
2. A gene list is mapped from 2 genomic regions on chromosome 8; 
3. These regions encompass 3 gene altered in ER positive invasive breast 
disease; 
Genes: 
 AC103863.1 AF130342.1 EIF3H 
PANTHER analysis: 1 mapped id is found, 2 mapped ids are not found.  
Gene Information: ENSG00000147677   Protein ID: O15372   
Gene Name: Eukaryotic translation initiation factor 3 subunit H Gene Symbol(s):  
EIF3H 




ENSG00000147677 (Ensembl) 4503515(GI) IPI00977658 (IPI) EIF3H (Synonym)  
603912(MIM) ENST00000521861(Ensembl_TRS)  HGNC:3273(HGNC) 
ENSP00000429931(Ensembl_PRO) 
 
5.8.5.2 Duplication in Oestrogen Receptor Positive Pure DCIS Compared to 
Oestrogen Receptor Positive Invasive Breast Disease 
No duplications were found in either ER positive pure DCIS or ER positive invasive 
breast disease. 
5.8.5.3 Genomic Gains in Oestrogen Receptor Positive Pure DCIS Compared to 
Oestrogen Receptor Positive Invasive Breast Disease 
Gains present in ER positive pure DCIS (n=1/8) were present in gains found in ER 
positive invasive breast disease (n=7/9). This represents gains in both ER positive 
pure DCIS and ER positive invasive breast disease. 
1. p-values < 0.05; 
2. A gene list is mapped from 16 genomic regions found on chromosomes 6, 16, 
20; 
3. These regions encompass 91 genes altered in ER positive invasive breast 
disease and ER positive DCIS;  
Genes:  
AC006076.1 AC106739.1 AL109840.1 AL121583.1 AL121673.1 AL136532.1 ARF4P2 ASXL1 ATP5E C20orf11
 C20orf112 C20orf166 C20orf195 C20orf20 C20orf200 C20orf90 C6orf48 COL9A3 CTD-3184A7.4 CTSZ
 DIDO1 DNMT3B DPH3B EEF1A2 GATA5 GCNT2 GMEB2 GNAS GNASAS HLA-DQA1 HLA-DQB1 HLA-
DRB1 hsa-mir-1-1 hsa-mir-133a-2 HSPA1A HSPA1B HSPA1L IL4R JMJD5 KCNQ2 KIF3B LSM2
 NSMCE1 NTSR1 OGFR PPDPF PTK6 RP11-11M20.2 RP11-358D14.2 RP11-360O19.1
 RP11-360O19.4 RP11-93B14.4 RP11-93B14.5 RP11-93B14.6 RP1-1J6.2 RP1-290I10.3
 RP1-290I10.4 RP1-290I10.5 RP1-290I10.6 RP1-290I10.7 RP1-290I10.8 RP1-
309F20.2 RP1-309F20.3 RP13-30A9.1 RP13-30A9.2 RP4-543J19.8 RP4-697K14.12 RP4-
697K14.3 RP4-697K14.7 RP4-724E16.2 RP5-1184F4.5 RP5-885L7.10 RP5-885L7.11
 RPL7P3 RTEL1 SLC17A9 SLCO4A1 SLMO2 SNTA1 SRMS STMN3 TAF4 TCFL5 TFAP2A
 TH1L TOP1 TUBB1 VARS XXbac-BPG254F23.5 XXbac BPG254F23.6 ZNF217 




There were gains present in ER positive invasive breast disease (n=6/9) not observed 
in ER positive pure DCIS (n=0/8). 
1. p-values < 0.05; 
2. A gene list is mapped from 12 genomic regions found on chromosomes 6, 18, 
20:  
3. These regions encompass 91 genes altered in ER positive invasive breast 
disease; 
Genes:  
5S_rRNA 7SK AIM1 AL031963.1 AL031963.2 AL031963.3 AL031963.5 AL033383.2 AL033523.1 AL109754.1
 AL133351.1 AL133509.1 AL138831.1 AL139092.1 AL160398.1 AL445309.1 AL445309.2 ANKRD5 AP005058.2 AP005482.1
 AP006565.1 ATG5 BPHL C6orf145 C6orf146 C6orf195 C6orf201 CDYL CEP76 FAM136B
 FAM50B FOXO3 LACE1 MYLK4 NQO2 PECI PRDM1 PRPF4B PSMG2 PSMG4
 RIPK1 RP11-145H9.3 RP11-404H14.1 RP1-140K8.1 RP1-140K8.2 RP1-140K8.3
 RP1-140K8.4 RP11-416N4.1 RP11-416N4.4 RP11-420G6.3 RP11-420G6.4
 RP11-420L9.2 RP11-420L9.4 RP11-428J1.2 RP11-620A17.1 RP11-625P7.1
 RP11-697G4.3 RP1-223B1.1 RP1-40E16.11 RP1-40E16.2 RP1-40E16.3 RP1-40E16.4
 RP1-40E16.8 RP1-40E16.9 RP1-90J20.10 RP1-90J20.2 RP1-90J20.7 RP1-90J20.8 RP3-359N14.1
 RP3-359N14.2 RP3-400B16.1 RP3-400B16.2 RP3-400B16.3 RP3-406P24.1 RP3-406P24.3 
RP3-430A16.1 RP3-527G5.1 RP4-529N6.1 RP5-839B4.7 RP5-839B4.8 SERPINB1 
SERPINB6 SERPINB9 SLC22A23 SNAP25 snoU13 SPIRE1 TUBB2A TUBB2B U6 WRNIP1 Y_RNA 
PANTHER analysis: 26 mapped ids are found, 66 mapped ids are not found. 
5.8.5.4 Genomic Sc Gains in Oestrogen Receptor Positive Pure DCIS Compared to 
Oestrogen Receptor Positive Invasive Breast Disease 
Sc gains in ER positive pure DCIS (n=5/8) show some overlap with Sc gains in ER 
positive invasive breast disease (1/9). 
1. p-values < 0.05;  
2. A gene list is mapped from 6 genomic regions found on chromosomes 1, 8;  
3. These regions encompass 28 genes altered in ER positive pure DCIS;  
Genes:  
ACBD6   AL359853.1 AL359853.3 AL390718.1 C1orf192 CEP350 FMO2 FMO3 FMO6P hsa-mir-1295 LHX4
 QSOX1 RP11-122G18.5 RP11-12M5.4 RP11-145A3.1 RP11-145A3.2 RP11-216N21.1
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 RP1-127D3.4 RP11-502H18.2 RP11-52I18.1 RP11-533E19.2 RP11-533E19.3 RP1-45C12.1
 RP5-1180C10.2 SDHC TOR1AIP1 TOR1AIP2 U6 
PANTHER analysis: 11 mapped ids are found, 17 mapped ids are not found.  
 
Sc gains in ER positive invasive breast disease (6/9) show some overlap with the Sc 
gains in ER positive pure DCIS (n=1/8). 
1. p-values < 0.05; 
2. A gene list is mapped from 10 genomic regions found on chromosomes 6, 20;  
3. These regions encompass 67 genes altered in ER positive invasive breast 
disease; 
Genes: 
AL031963.1 AL031963.2 AL031963.5 AL109754.1 AL109840.1 AL121583.1 AL121673.1 AL133343.1 AL136532.1 ANKRD5
 ARF4P2 ASXL1 ATP5E  
BPHL C20orf11 C20orf112 C20orf166 C20orf20 C20orf200 C20orf90 COL9A3 CTSZ DIDO1 DNMT3B
 DPH3B GATA5 GNAS GNASAS hsa-mir-1-1 hsa-mir-133a-2 KIF3B NTSR1 OGFR
 RP11-11M20.2 RP11-410N8.1 RP11-410N8.3 RP11-410N8.4 RP11-416N4.1 RP11-416N4.4
 RP11-93B14.4 RP11-93B14.5 RP11-93B14.6 RP1-1J6.2 RP1-309F20.2 RP1-309F20.3
 RP13-30A9.1 RP13-30A9.2 RP1-40E16.11 RP1-40E16.8 RP1-40E16.9 RP4-
543J19.8 RP5-1184F4.5 RP5-839B4.7 RP5-839B4.8 RP5-885L7.10 RP5-885L7.11 RPL7P3
 SLC17A9 SLCO4A1 SLMO2 SNAP25 TAF4 TCFL5 TH1L TOP1 TUBB1 TUBB2A 
PANTHER analysis: 23 mapped ids are found, 44 mapped ids are not found. 
5.8.5.5 Losses in Oestrogen Receptor Positive Pure DCIS Compared to Oestrogen 
Receptor Positive Invasive Breast Disease 
Genomic losses in ER positive pure DCIS (n=6/8) show some overlap with genomic 
losses in ER positive invasive breast disease (1/9). 
1. p-values < 0.05; 
2. A gene list is mapped from 32 genomic regions on chromosome 11;  
3. These regions encompass 225 genes altered in ER positive pure DCIS; 
Genes: 
 5S_rRNA 7SK AC009294.1 AC019227.1 AC019227.2 ACA59 ACAD8 ACRV1 ADAMTS15 ADAMTS8
 AMICA1 ANKK1 AP000757.1 AP000770.1 AP000797.1 AP000797.2 AP000843.2 AP000844.1 AP000880.1 AP000892.4 
AP000907.1 AP000907.2 AP000907.3 AP000908.1 AP000911.1 AP000925.2 AP000926.1 AP000936.1 AP000936.3 AP000936.4
 AP000936.5 AP001122.1 AP001267.1 AP001267.2 AP001582.1 AP001781.1 AP001891.1 AP001979.1 AP001992.2 AP001998.1
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 AP002451.1 AP002806.1 AP002806.2 AP002856.4 AP002856.5 AP002856.6 AP002856.7 AP002884.4 AP002886.2 AP002962.1 
AP002986.1 AP002991.1 AP003025.2 AP003039.3 AP003039.4 AP003040.1 AP003040.2 AP003041.1 AP003070.1 AP003402.1
 AP003402.2 AP003500.1 AP003730.1 AP003730.2 AP004248.4 AP004372.1 AP005597.1 AP005638.1 AP005638.3 AP005639.1
 AP006216.10 AP006216.11 AP006216.12 AP006216.5 APLP2 APOA1 APOA4
 APOA5 APOC3 ARHGAP20 ARHGAP32 ARHGEF17 ATP5L B3GAT1 BACE1 BAK1P2 BARX2
 BCO2 BSX BTG4 BUD13 C11orf1 C11orf44 C11orf45 C11orf52 C11orf57 C11orf63 C11orf71
 C11orf88 CADM1 CD3D CD3E CD3G CEP164 CHEK1 CLDN25 CRTAM CRYAB
 CUL5 DDX10 DDX25 DDX6 DIXDC1 DLAT DRD2 DSCAML1 EI24 ETS1
 FAM168A FAM55A FAM55B FAM55D FDX1 FDXACB1 FLI1 FXYD2 FXYD6 GLB1L2
 GLB1L3 hsa-mir-34b hsa-mir-34c HSPA8 HSPB2 HTR3A HTR3B HYLS1 IGSF9B IL10RA IL18
 JAM3 KCNJ1 KCNJ5 LAYN MLL MPZL2 MPZL3 NCAM1 NCAPD3 NCRNA00167
 NEU3 NFRKB NNMT OPCML OR4A15 OR4A16 PAFAH1B2 PATE1 PATE2 PATE3 PATE4
 PCSK7 PIH1D2 POU2AF1 PPIHP1 PPP2R1B PRDM10 PUS3 RAB39 RBM7 RDX RELT 
REXO2 RNF214 RP11-237N19.1 RP11-567M21.1 RP11-667M19.1 RP11-762B21.1 RP11-762B21.2
 RP11-762B21.3 RP11-801G16.1 RP11-832N8.1 RPL37AP8 SCARNA11 SCN2B SCN4B SDHD
 SIDT2 SIK2 SIK3 SLC35F2 SNORD14 snoU13 SNX19 SPATA19 SPCS2 ST14 STT3A TAGLN
 TEX12 THYN1 TIMM8B TMEM225 TMEM45B TMPRSS13 TMPRSS4 TMPRSS5 TP53AIP1 TRIM48
 TTC12 U2 U4 U4atac U6 U6atac UBASH3B UBE4A USP28 VPS26B XRRA1 Y_RNA 
ZBTB16 ZBTB44 ZC3H12C ZNF259 ZW10 
PANTHER analysis: 129 mapped ids are found, 96 mapped ids are not found.  
 
There is a degree of overlap of the genomic losses in ER positive invasive breast 
disease (n=8/9) compared to ER positive pure DCIS (n=3/8). 
1. p-values < 0.05; 
2. A gene list is mapped from 51 genomic regions found on chromosomes 8, 9, 
13, 15, 16, 19, X;  
3. These regions encompass 84 genes altered in both ER positive invasive 
breast disease and ER positive pure DCIS; 
Genes: 
 5S_rRNA 7SK AC009707.1 AC011445.1 AC019176.2 AC022559.1  AC022716.1 AC073493.1 AC073493.2 AC073493.3
 AC090204.1 AC090204.10  AC090204.2 AC090204.3 AC090204.4 AC090204.5 AC090204.6 AC090204.7  AC090204.8
 AC090204.9 AC090420.1 AC100800.1 AC129915.1 AF238378.1 AL135784.1 AL590131.1 AL611925.1 ARHGEF10 BX649443.1
 C8orf68 CACNA1B CLN8 CSMD1 DEFA5 DHRSX DLC1 DLGAP2 EHMT1 FREQ
 FRMPD4 GANC GFRA2 hsa-mir-596 hsa-mir-627 IGSF1 IL28A IL28B IL29 JPH3 KBTBD11
 MAGED1 MAGED4B MRRFP MYOM2 NCCRP1 NLGN4X OR11N1P OR1AA1P OR5BH1P PCDH19 
PLA2G4F PSD3 RP11-114H20.1 RP11-133M24.1 RP11-234P3.2 RP11-234P3.3 RP11-234P3.4
 RP11-2N21.2 RP11-346L6.1 RP1-154J13.2 RP1-154J13.3 RP11-647I17.1
 RP13-858C7.1 RP5-1168A5.1 RP5-1170D6.1 RP5-964N17.1 SNORA11 SNORA70
 SYCN TMEM87A U3 U6 VPS39 Y_RNA 
PANTHER analysis: 25 mapped ids are found, 59 mapped ids are not found. 
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5.8.5.6 Total Loss in Oestrogen Receptor Positive Pure DCIS Compared to 
Oestrogen Receptor Positive Invasive Breast Disease 
There are total losses for ER positive pure DCIS (n=5/8) not observed in ER positive 
invasive breast disease (n=0/9). 
1. p-values < 0.05; 
2. A gene list is mapped from 12 genomic regions found on chromosomes 9, 11, 
15, 19; 
3. These regions encompass 22 genes altered in ER positive pure DCIS; 
Genes: 
 7SK AC025678.1 AC027139.2 AC027139.3 AP000720.1 AP001482.1 AP003072.1 CCDC67 CTSC GOLGA8B GRM5 hsa-
mir-1233 KDM4C NOX4 OR10V1 OSBP PATL1 RP11-657K20.1 SLC36A4 TYR U7
 ZNF208 ZNF257 
PANTHER analysis: 13 mapped ids are found, 10 mapped ids are not found.  
There were total losses present for ER positive invasive breast disease (n=9/9) not 
observed in ER positive pure DCIS (n=0/8). 
1. p-values < 0.05; 
2. A gene list is mapped from 84 genomic regions found on chromosomes 8, 13, 
14, 16, 17, X;  
3. These regions encompass 443 genes altered in ER positive invasive breast 
disease; 
Genes: 
 5S_rRNA 7SK AC000003.1 AC001226.2 AC002347.1 AC002366.3 AC002504.1 AC005284.1 AC005323.1 AC005410.2
 AC005548.1 AC005548.2 AC005696.2 AC005696.3 AC005725.1 AC007333.1 AC007333.2 AC015799.1 AC015799.2 AC015908.2
 AC016292.3 AC022716.1 AC025518.1 AC026462.1 AC027045.1 AC027763.1 AC027763.2 AC073493.1 AC073493.2 AC073493.3
 AC074035.1 AC087498.1 AC090282.1 AC097370.1 AC099684.1 AC112778.1 AC112778.2 AC144838.1 AIPL1 AL136001.1
 AL136160.1 AL136219.1 AL136359.1 AL138690.1 AL138815.1 AL138815.3 AL139002.1 AL139034.1 AL139082.1 AL158032.2 
AL162377.1 AL162377.2 AL163544.1 AL355611.1 AL355611.2 AL355611.3 AL356863.1 AL359180.1 AL391384.1 AL442203.2 
AL445989.1 AL450423.1 AL450447.1 AL512362.1 AL512652.1 AL589987.1 AL590007.2 AL596092.1 ALOX12 AMAC1L3
 ARHGAP6 ARX ASGR1 ASGR2 ASPA ASPG ASS1P4 ATP7B ATP8A2 ATXN8OS B3GALTL BCL6B
 BTF3L1 BX649443.1 BX890604.1 BX890604.2 C13orf23 C13orf34 C13orf36 C13orf37 C14orf180 C17orf100
 C17orf49 C17orf51 C17orf61 C17orf74 C17orf91 CCDC42 CCDC70 CCNA1 CDK8 CHRNB1 CLEC10A
 CLN5 CRYL1 CTD-2545G14.1 CTNS DACH1 DGKH DHRS7C DHRSX DHX9P1
 DIAPH3 DIS3 DLC1 DLG4 DNAH9 DPH1 DUSP21 EBF2 EDNRB EFHA1
 EIF4A1P6 FAM123A FAM64A FBXL3 FBXO39 FGF11 FGF9 FLT1 FOXO1 FREM2 FREQ
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 GAPDHP34 GAS7 GFRA2 GJA3 GJB2 GJB6 GLP2R GPR12 HDHD1A HMCN2 HNF4GP1 hsa-mir-1253 hsa-
mir-195 hsa-mir-203 hsa-mir-22 hsa-mir-497 hsa-mir-744 hsa-mir-759 IFT88 IL17D IRG1 KCNJ12
 KDM6A KIAA0564 KIAA0664 KIAA0753 KIF26A KLF12 KLF5 KLHL1 LHFP LIN28AP2 MAP2K3
 MAP2K4 MED31 METT10D MFSD6L MTUS2 MXRA5 MYH1 MYH10 MYH13 MYH2 MYH3 MYH4
 MYH8 N6AMT2 NDEL1 NEFL NEFM NEK3 NEK5 NFYAP1 NHLRC3 NLGN2
 NLGN4X NTN1 NXN OLFM4 OR1A1 OR1A2 OR1D2 OR1D5 OR1E1 OR1E2 OR1G1
 OR3A1 OR3A2 OR3A3 OR3A4 OVCA2 PABPC3 PAFAH1B1 PARP4 PCDH8 PIBF1 PIK3R5
 PIK3R6 PIRT PITPNM3 PLSCR3 POLA1 POLR2A POU4F1 PRKX PSPC1 RAP1GAP2 RCVRN
 RFXAP RNASEK RNF17 RNF219 RNF6 RP11-101P17.10 RP11-101P17.11 RP11-101P17.5 RP11-101P17.6 
RP11-101P17.7 RP11-101P17.8 RP11-101P17.9 RP11-107B1.1 RP11-110K18.2 RP11-110K8.1
 RP11-117N4.1 RP11-11C5.1 RP11-12I24.2 RP11-12I24.3 RP11-133M24.1 RP11-137M6.2 
RP11-149B7.1 RP11-149B7.3 RP11-149B7.4 RP11-149B7.5 RP11-165I9.3 RP11-165I9.4 
RP11-165I9.6 RP11-165I9.8 RP11-169O17.1 RP11-169O17.5 RP11-16D22.1 RP11-16L6.3 RP11-172E9.2
 RP11-172H24.3 RP11-181D10.2 RP11-187A9.2 RP11-187A9.3 RP11-196I2.1 RP11-196P2.1
 RP11-197L7.2 RP11-1M18.1 RP11-203P2.1 RP11-203P2.2 RP11-206H15.2 RP11-206L1.2
 RP11-209P2.1 RP11-214O11.1 RP11-214O11.2 RP11-218I21.1 RP11-248G5.3
 RP11-24H2.1 RP11-24H2.2 RP11-252B20.1 RP11-261P13.3 RP11-264J4.4 RP11-264J4.5
 RP11-264J4.6 RP11-266E6.2 RP11-267I18.1 RP11-271B5.1 RP11-279N8.1 RP11-304M3.2
 RP11-30C8.1 RP11-30C8.2 RP11-318G21.2 RP11-318G21.3 RP11-318G21.4 RP11-
323P14.2 RP11-325D5.3 RP11-327P2.3 RP11-335N6.1 RP11-342C20.2 RP11-342C20.3
 RP11-349O10.1 RP11-350A18.1 RP11-351N4.3 RP11-360A9.1 RP11-364B14.1
 RP11-364B14.2 RP11-364B14.3 RP11-367C11.2 RP11-380N8.1 RP11-380N8.3 RP11-380N8.4
 RP11-381L18.2 RP11-388E20.1 RP11-393H6.2 RP11-393H6.3 RP11-394A14.1
 RP11-394A14.2 RP11-394A14.3 RP11-398O19.3 RP11-408O13.2 RP11-408O13.3 RP11-
421P11.5 RP11-430I3.2 RP11-430K22.1 RP11-430K22.2 RP11-431O22.2 RP11-442F12.2
 RP11-459A10.1 RP11-459A10.2 RP11-459A10.3 RP11-459J23.1 RP11-459J23.2
 RP11-462C21.1 RP11-463M3.1 RP11-467D10.2 RP11-471M2.1 RP11-471M2.2 RP11-473M10.1
 RP11-473M10.2 RP11-473M10.3 RP11-474L7.4 RP11-483M24.2 RP11-501G6.1 RP11-505F3.2
 RP11-505F3.4 RP11-518D7.1 RP11-51B13.2 RP11-520F24.1 RP11-520F24.2 RP11-520F24.3
 RP11-520F9.2 RP11-521H3.1 RP11-523H24.5 RP11-527F15.1 RP11-52L5.4 RP11-534K14.1
 RP11-534K14.2 RP11-545M8.1 RP11-545M8.2 RP11-545M8.3 RP11-556N21.4 RP11-56M2.1 RP11-570F6.1
 RP11-571G1.1 RP11-571G1.2 RP11-609D21.1 RP11-61K9.2 RP11-629E24.2 RP11-629O4.1 
RP11-706O15.1 RP11-706O15.3 RP11-706O15.5 RP11-706O15.7 RP11-706O15.8 RP11-707P20.1
 RP11-713H12.1 RP11-76N11.2 RP11-77P3.1 RP11-7B3.2 RP11-7B3.3 RP11-7B3.4 RP11-822E23.1
 RP11-88G17.6 RP11-90M5.1 RP11-963H4.1 RP1-258N20.3 RP13-858C7.1 RP13-926M18.1 
RPA1 RTN4RL1 SCEL SCO1 SERPINF1 SERPINF2 SHISA6 SHPK SLAIN1 SLC13A5 SLC16A11
 SLC16A13 SLITRK5 SMAD9 SMYD4 SNORA25 SNORA48 SNORA68 SNORA9 SNORD116 SNORD37 
snoU13 SPATA22 SPDYE4 SPEM1 STOML3 STX8 TCEB1P23 TDRD3 TDRD9 TEKT1 TLCD2
 TMEM102 TMEM179 TMEM46 TNK1 TOX3 TRPC4 TRPV1 TRPV3 TXNDC17 U2 U3 U4 
U6 U7 UFM1 UTP14C VCX3A WASF3 WDR81 WSCD1 XAF1 XPO4 Y_RNA ZBED1
 ZBTB4 ZDHHC20 ZMYM2 ZMYM5 




5.8.5.7 CdLOH in Oestrogen Receptor Positive Pure DCIS Compared to Oestrogen 
Receptor Positive Invasive Breast Disease 
There are similarities between CdLOH in ER positive pure DCIS (n=7/8) and CdLOH 
in ER positive invasive breast disease (n=3/9). 
1. p-values < 0.05; 
2. A gene list is mapped from 38 genomic regions found on chromosomes 9, 11, 
17;  
3. These regions encompass 281 genes altered in ER positive invasive breast 
disease and ER positive pure DCIS; 
Genes:  
5S_rRNA 7SK AC004148.1 AC006435.1 AC009294.1 AC019227.1 AC019227.2 AC055839.2 AC087500.1 AC087742.1
 AC116914.1 AC129492.6 ACA59 ACAD8 ACRV1 ADAMTS15 ADAMTS8 ALOX12B ALOX15B ALOXE3 AMICA1 
ANKFY1 ANKK1 AP000757.1 AP000770.1 AP000797.1 AP000797.2 AP000843.2 AP000844.1 AP000880.1 AP000892.4
 AP000907.1 AP000907.2 AP000907.3 AP000908.1 AP000911.1 AP000925.2 AP000926.1 AP000936.1 AP000936.3 AP000936.4
 AP000936.5 AP001122.1 AP001267.1 AP001267.2 AP001582.1 AP001781.1 AP001891.1 AP001979.1 AP001992.2 AP001998.1 
AP002451.1 AP002806.1 AP002806.2 AP002856.4 AP002856.5 AP002856.6 AP002856.7 AP002884.4 AP002886.2 AP002962.1
 AP002986.1 AP002991.1 AP003025.2 AP003039.3 AP003039.4 AP003040.1 AP003040.2 AP003041.1 AP003070.1 AP003402.1
 AP003402.2 AP003500.1 AP003730.1 AP003730.2 AP004248.4 AP004372.1 AP005597.1 AP005638.1 AP005638.3 AP005639.1 
AP006216.10 AP006216.11 AP006216.12 AP006216.5 APLP2 APOA1 APOA4 APOA5
 APOC3 ARHGAP20 ARHGAP32 ARHGEF17 ATP2A3 ATP5L AURKB B3GAT1 BACE1 BAK1P2 BARX2
 BCO2 BSX BTG4 BUD13 C11orf1 C11orf44 C11orf45 C11orf52 C11orf57 C11orf63 C11orf71
 C11orf88 C17orf44 C17orf59 C17orf68 C17orf85 C17orf87 C1QBP CADM1 CAMKK1 CD3D
 CD3E CD3G CEP164 CHEK1 CLDN25 CNTROB CRTAM CRYAB CTNS CUL5 CYB5D2
 DDX10 DDX25 DDX6 DERL2 DHX33 DIXDC1 DLAT DRD2 DSCAML1 EI24
 ETS1 FAM168A FAM55A FAM55B FAM55D FDX1 FDXACB1 FLI1 FXYD2 FXYD6
 GLB1L2 GLB1L3 GSG2 GUCY2D HES7 HIC1 hsa-mir-132 hsa-mir-212 hsa-mir-34b hsa-mir-34c
 HSPA8 HSPB2 HTR3A HTR3B HYLS1 IGSF9B IL10RA IL18 ITGAE JAM3 KCNJ1
 KCNJ5 LAYN METT10D MIS12 MLL MPZL2 MPZL3 NCAM1 NCAPD3 NCRNA00167 NEU3
 NFRKB NLRP1  NNMT  NUP88  OPCML OR4A15 OR4A16  P2RX1 P2RX5  PAFAH1B2 PATE1  
PATE2 PATE3  PATE4  PCSK7 PER1 PFAS PIH1D2 POU2AF1 PPIHP1 PPP2R1B PRDM10
 PTPRD PUS3 RAB39  RABEP1 RANGRF RBM7 RDX RELT REXO2 RNF214 RP11-
237N19.1 RP11-48B14.1 RP11-567M21.1 RP11-667M19.1 RP11-762B21.1 RP11-762B21.2
 RP11-762B21.3 RP11-801G16.1 RP11-832N8.1 RPAIN  RPL37AP8 SCARNA11 SCN2B
 SCN4B SDHD SIDT2 SIK2 SIK3 SLC25A35 SLC35F2 SMG6 SNORD14 snoU13 SNX19 SPATA19
 SPCS2 ST14 STT3A TAGLN TAX1BP3 TEX12 THYN1 TIMM8B TMEM107 TMEM225
 TMEM45B TMEM93 TMPRSS13 TMPRSS4 TMPRSS5 TP53AIP1 TRIM48 TTC12 U2 U4
 U4atac U6 U6atac U7 U8 UBASH3B UBE4A USP28 USP6 VAMP2 VPS26B XRRA1
 Y_RNA ZBTB16 ZBTB44 ZC3H12C ZNF259 ZNF594 ZW10 ZZEF1 




There are some similarities between CdLOH in ER positive invasive breast disease 
(n=7/9) and CdLOH in ER positive pure DCIS (n=1/8). 
1. p-values < 0.05; 
2. A gene list is mapped from 34 genomic regions found on chromosomes 1, 8, 
9, 15, 16, 19, 22, X; 
3. These regions encompass 51 genes altered in ER positive invasive breast 
disease and ER positive pure DCIS; 
Genes: 
 5S_rRNA 7SK AC011445.1 AC018558.1 AC019176.2 AC022716.1 AC023824.2 AC073493.1 AC073493.2 AC073493.3
 AF238378.1 AL611925.1 AP000351.4 BMP15 BX649443.1 CACNA1B CSMD1 DDT DEFA5 DHRSX
 EHMT1 FRMPD4 GABRB3 GANC GFRA2 GSTT2 GSTTP1 hsa-mir-627 IL28A IL28B IL29
 LARGE MAGED1 NCCRP1 PLA2G4F PRKCZ RP11-104D21.1 RP11-104D21.2 RP11-104D21.3
 RP11-637B23.1 RP11-637B23.3 RP13-346H10.2 RP13-858C7.1 RP5-1168A5.1 RP5-
1170D6.1 RP5-964N17.1 SNORA70 SYCN TMEM87A U3 VPS39 
PANTHER analysis: 20 mapped ids are found, 31 mapped ids are not found.  
5.8.5.8 CnLOH in Oestrogen Receptor Positive Pure DCIS Compared to Oestrogen 
Receptor Positive Invasive Breast Disease 
There are similarities between ER positive pure DCIS (n=8/8) and ER positive 
invasive breast disease (n=4/9). 
1. p-values < 0.05; 
2. A gene list is mapped from 67 genomic regions found on chromosomes 1, 3, 
4, 5, 6, 10, 11, 12, 18, 19, 20, 22;  
3. These regions encompass 357 genes altered in ER positive pure DCIS; 
Genes: 
 5S_rRNA 7SK ABT1 AC000032.1 AC002485.1 AC005399.1 AC025423.2 AC034193.1 AC099680.1 AC124890.1
 RP11-209A2.1  ADH5P4 AGAP10 AHCYL1 AK3L1 AKD1 AL021807.2 AL021808.1 AL021808.2 AL021808.3
 AL023913.1 AL035045.1 AL035661.3 AL050321.1 AL050321.2 AL050322.1 AL050335.1 AL050335.2 AL109754.1 AL109922.1
 AL109947.1 AL109947.2 AL118509.1 AL121584.1 AL121988.1 AL132996.1 AL133255.1 AL133472.1 AL138850.1 AL139429.1 
AL354680.1 AL391137.2 AL391559.1 AL589723.1 AL590062.1 AL591044.1 AL591044.2 AL591044.3 AL591044.4 AL691432.2
 AL713998.1 ANKRD5 ANXA8L1 AP001029.1 AP001992.2 AP005482.1 APBB2 ASPHD2 BACH2 BANF2
 BEND6 BMS1P2 BTBD3 BX255972.1 C1orf212 C20orf12 C20orf187 C20orf3 C20orf61 C20orf72
 C20orf78 C20orf79 C20orf82 C20orf94 C3orf10 C6orf1 C6orf140 C6orf184 CD164 CDH12 CDK11A
 CECR2 CECR9 CENPM CEP76 CRYBB2P1 CSF1 CSRP2BP CST1 CST2 CST3 CST4
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 CST5 CST7 CSTP1 CSTP2 CTA-221G9.9 CTA-246H3.11 CTA-246H3.7
 CTA-246H3.8 CTA-250D10.15 CTA-250D10.19 CTB-1048E9.7 CTSLL7 CYP2S1 DEK
 DHFRP2 DLGAP3 DTNBP1 ELAVL4 ENSAP1 EPS8L3 EYS FAM25B FAM35B2 FAM40A
 FAT1P1 FGFR3P FIG4 FLOT1 GAPDP2 GGTLA4 GJA4 GJB3 GJB4 GJB5 GLS2 GLUDP8
 GMPR GSTM2 GSTM3 GSTM3P GSTM5 GUSBL1 HCP5 HIST1H2AH HIST1H2BJ HIST1H2BK HIST1H4I HLA-B
 HLA-S HMGA1 HNRNPM HPS4 hsa-mir-33a IRAK2 JARID2 KDM1B KHDRBS2 KIF13A KIF16B LGSN
 LIN28AP3 LRP5L MACROD2 MAP3K7 MAR02 MDC1 MDM2 MICA MICAL1 MKKS
 MMP23A MRPS11P1 MYLIP MYO1F N4BP2 NAV3 NCRNA00227  NCRNA00240 NEU3 NHLRC1
 NKX2-2 NKX2-4 NUDT3 NXT1 OTOR OVOL2 PA2G4P2 PACSIN1 PAK7 PGAM3P PHACTR1
 PLK1S1 POM121L1P POM121L2 POM121L3P PPIAP17 PPIL6 PPYR1 PRAM1 PRSS16 PSMG2
 PTMAP3 PTPN2 RBMS2 RNF11B RNF144B RP11-102J14.1 RP11-124A7.2 RP11-129K24.4
 RP11-144G6.10 RP11-144G6.4 RP11-144G6.9 RP11-146I2.1 RP11-157E14.1
 RP11-157E14.3 RP11-195M16.1 RP11-218C14.5 RP11-227D2.3 RP11-239L20.3 RP11-239L20.4 RP11-239L20.5
 RP11-292F22.3 RP11-292F22.4 RP11-292F22.5 RP1-129L7.1 RP11-307F22.2 RP11-314P12.2 
RP11-314P12.3 RP11-388K2.1 RP1-13D10.2 RP1-13D10.3 RP1-13D10.4 RP1-13D10.5
 RP11-401E14.1 RP11-401E14.2 RP11-416N4.1 RP11-416N4.4 RP11-457M11.2 RP11-492I2.1
 RP11-513I15.3 RP11-513I15.5 RP11-513I15.6 RP11-526K17.2 RP11-528A10.1 RP11-528A10.2 
RP11-542F9.1 RP11-560J1.1 RP11-575L16.2 RP11-69I22.2 RP11-69I22.3 RP11-707M13.1
 RP11-74E24.2 RP1-187N21.2 RP1-190J20.2 RP1-198K11.3RP1-240B8.3 RP1-298M8.1
 RP3-322G13.7 RP3-453I5.2 RP3-462D8.2 RP3-525L6.2 RP4-564O4.1 RP4-568F9.3 RP4-568F9.6 RP4-
568F9.7RP4-580G13.1 RP4-697P8.2 RP4-697P8.3 RP4-705D16.3 RP4-717M23.2RP4-718D20.3
 RP4-726N1.2 RP4-734C18.1 RP4-735C1.4 RP4-735C1.5 RP4-735C1.6 RP4-
737E23.2 RP4-737E23.4 RP4-742J24.2 RP4-777D9.2RP4-794H19.4 RP4-796I8.1 RP5-1018A4.3 RP5-
1068E13.3RP5-1068F16.3 RP5-1069C8.1 RP5-1069C8.2 RP5-1077I2.3 RP5-1077I2.4RP5-1100I6.1
 RP5-1100I6.2 RP5-1177M21.1 RP5-1195D24.1RP5-839B4.7 RP5-839B4.8 RP5-860P4.2
 RP5-872K7.2 RP5-872K7.7 RP5-905G11.3RP5-919F19.5 RP5-931K24.1 RP5-984P4.1 RP5-
984P4.4 RP5-997D16.2 RPL13P RPL15P1 RPL23AP6 RPL24P2 RPL7AL3 RPLP0P1 RPS10
 RPS10P2 RPS11P1 RPS15AP1 RRBP1 SEP03 SEZ6L  SHISA8 SLC24A3 SMCHD1 SMPD2 SNAP25 
SNORD17 SNORD83 snoU13 SNRPB2 SNX5 SPCS2 SPDEF SPIRE1 SPRYD4 SPTLC3
 SREBF2 TASP1 TMEM90B TNFRSF13C TPMT TUBB U1 U2 U3 U6 U7 VHL
 VN1R11P VN1R12P VN1R13P VN1R14P XRN2 XRRA1 XXbac-BPG181B23.4 XXbac-BPG181B23.6 XXbac-
BPG248L24.11 XXbac-BPG248L24.12 XXbac-BPG27H4.7 XXbac-BPG308K3.6 XXyac-YR14BB7.1 XXyac-
YX60D10.1 Y_RNA Z99716.2 ZBTB24 ZDHHC20P2 ZNF133 ZNF322A ZNF414 
PANTHER analysis: 120 mapped ids are found, 237 mapped ids are not found.  
 
There are similarities between ER positive invasive breast disease (n=4/9) and ER 
positive pure DCIS (n=8/8). 
1. p-values < 0.05; 
2. A gene list is mapped from 34 genomic regions found on chromosomes 3, 4, 
5, 7, 8, 10, 11, 12, 15, 17, 18, 19;  





5S_rRNA AAAS ABHD14A ABHD14B AC002347.1 AC002481.5 AC005323.1 AC008021.1 AC008590.1 AC009271.1
 AC009704.1 AC009779.1 AC010297.1 AC011260.2 AC011385.1 AC011385.3 AC012379.1 AC012379.2 AC013558.1 AC015689.1
 AC021066.1 AC022031.1 AC023055.2 AC023509.1 AC025165.2 AC025165.7 AC025165.8 AC026689.1 AC040963.1 AC044839.1
 AC044839.2 AC055715.1 AC068473.1 AC068888.1 AC068987.1 AC068988.1 AC069209.1 AC073573.1 AC078778.1 AC078864.1
 AC079600.1 AC087893.3 AC090398.1 AC090666.1 AC091103.1 AC091551.1 AC091934.1 AC091934.2 AC097359.1 AC097359.2
 AC097359.3 AC099557.1 AC100783.1 AC103681.1 AC103681.2 AC104186.1 AC104448.1 AC104850.1 AC105105.1 AC105316.1
 AC107016.1 AC107016.2 AC112205.1 AC112215.2 AC112215.4 AC116904.1 AC116917.2 AC126118.1 AC126118.2 AC132217.4
 AC156455.1 AC190387.1 ACACB ACVR1B ACVRL1 ACY1 ALAS1 ALDOAP1 ALKBH2 ALPK2 AMHR2
 ANAPC5 ANKRD33 AP005273.1 AP006288.1 ARHGEF3 ATCAY ATF7 ATP5G2 ATP9B ATRIP
 ATXN2  ATXN7 B4G ALNT1 BAP1 BCL7A BIN2 BLOC1S1 BMP3 C11orf94 C12orf10 C12orf44
 C18orf26 C18orf54 C18orf55 C3orf45 C3orf49 C3orf63 C3orf78 C4orf22 C4orf39 CACNA2D2 CACNA2D3
 CAMKK2 CAMP CBX5 CCDC51 CCDC66 CCDC72  CCDC99 CCNG1 CCR8 CD63
 CDC25A CELA1 CHST11 CNDP1 CNDP2 COPZ1 CPE CRY2 CSAD CSRNP1
 CSRNP2 CTB-164L20.1 CTB-95B16.1 CTD-3211M3.1 CTDP1 CTNNA1 CUX2 CX3CR1
 CYB561D2 CYB5A DAO DAPK3 DAZAP2 DCD DCTN2 DNAH1 DNAJC14 DOCK2 DTX3
 DUSP7 DYM EEF1A1P24 EEF2 EIF1B EIF4B EIF4E1B ENTPD3 ESPL1 ETF1
 FAF2 FAM109A FAM196B FAM69C FBLL1 FBXW12 FGFR4 FHIT GABRG2 GALNT6
 GAS7 GDF11 GK3P GLP2R GLYCAM1 GLYCTK GNAI2 GOLGA4 GPR84 GPRIN1
 GRASP GRP GTSF1 GYLTL1B HIGD1C HIGD1DP HMMR HNRNPA1 hsa-let-7g hsa-mir-103-1
 hsa-mir-122 hsa-mir-135a-1 hsa-mir-148b hsa-mir-1979 hsa-mir-2115 hsa-mir-218-2 hsa-mir-483 hsa-mir-578 hsa-mir-637
 HSPA9 HYAL1  HYAL2  HYAL3 IFRD2 IGF2 IGF2AS IGFBP6 IL31 INS
 ITGA5 ITGA7 ITGB1BP3 ITGB7 KDM2B KIF5A KLHL2  KRT1 KRT2 KRT3 KRT4
 KRT5 KRT6A  KRT6B KRT6C  KRT7  KRT71  KRT72 KRT73  KRT74  KRT75 KRT76  KRT77
  KRT78   KRT79 KRT8 KRT80  KRT81  KRT82  KRT83  KRT84  KRT85  KRT86
 LACRT LETMD1 LMO1 LRRC43 LRRFIP2 MAP2K2 MAP3K12 MAPK8IP1 MAT2B MBD2
 METTL7B MEX3C MFSD5 MIP MLH1 MLXIP MMP19 MXI1 MYH1 MYH13 MYH2 MYH4
 MYH8 MYRIP NACA3P NAT6 NCKAP1L NDUFB1P1 NEDD4L NEFL NEFM NFATC1 NFE2
 NISCH  NME6 NPFF NR4A1  NSD1 NT5DC2 NUDCD2 OR10P1 ORMDL2 P2RX4
 P2RX7 PANK3 PBRM1 PCBP2 PCBP4 PCDH24 PDE1B PDZRN4 PEX16 PFDN5 PHF21A PHF7
 PIAS4 PLXNB1 POLI POU6F1 PPM1M PPP1R1A PPTC7 PRDM11 PRICKLE1 PRKG2
 PRR13 PSMD9 RAD9B RAPGEF2 RARG RARS RASSF1 RCVRN RDH5 RNF34
 RNF44 RP11-100N20.1 RP11-1029M24.1 RP11-1029M24.2 RP11-138A23.1 RP11-138A23.2
 RP11-153F5.1 RP11-155D18.11 RP11-168J18.4 RP11-168J18.6 RP11-219C20.1
 RP11-241K18.1 RP11-241K18.2 RP11-24C3.2 RP11-25I15.1 RP11-285B24.1 RP11-294O2.2
 RP11-330H6.5 RP11-331G2.4 RP11-366M4.1 RP11-366M4.11 RP11-366M4.12 RP11-366M4.13
 RP11-366M4.14 RP11-366M4.15 RP11-366M4.17 RP11-366M4.2 RP11-366M4.3
 RP11-366M4.4 RP11-366M4.5 RP11-366M4.6 RP11-366M4.8 RP11-391M1.2
 RP11-391M1.3 RP11-416A17.1 RP11-438N5.1 RP11-462C21.1 RP11-469O11.2
 RP11-502L5.2 RP11-504H5.1 RP11-50F24.3 RP11-51O17.1 RP11-528N21.2 RP11-528N21.3
 RP11-541P9.3 RP11-554O1.1 RP11-644A7.1 RP11-727C1.1 RP11-834C11.3
 RP11-834C11.4 RP11-834C11.5 RP11-834C11.6 RP11-834C11.7 RP11-834C11.8
 RP11-972K6.1 RP5-1157M23.2 RPL14 RPL29 RPSA RRM1 SARNP SC4MOL
 SCN8A SEC11C SEMA3B SEMA3E SEMA3G SH2B3 SHC4 SIL1 SLC11A2 SLC25A38
 SLC26A10 SLC35C1 SLC38A3 SLC4A8 SLIT3 SMAD4 SMAGP SMNDC1 SMUG1 SNCB
 SNORA30 SNORA62 SNORA64 SNORD28 SNORD37 SNORD63 snoU13 SOAT2 SOCS6 SP1 SP7
 SPATA12 SPINK8 SPRYD3 STAB1 STARD6 STIM1 SVOP SYT13 TARBP2 TCF4
 TCTN1 TENC1 TFCP2 THOC7 TIMELESS TLR9 TMEM115 TMEM192 TNNC1 TP53I11
 TRIM60 TRIM61 TRIM75 TSPAN18 TTC21A TUSC2 TUSC4 TWF2 TXNL1 U1 U4 U5
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 U6 U6atac U7 U73166.1 U73166.2 U73167.7 U73169.1 UNG USP30 WDR51A
 WDR66 WDR7 WDR82 WWC1 XIRP1 Y_RNA ZBTB7A ZMYND10 ZNF346 ZNF385A ZNF407
 ZNF589 ZNF619 ZNF620 ZNF621 ZNF740 
PANTHER analysis: 285 mapped ids are found, 185 mapped ids are not found. 
5.8.6 Copy Number Aberrations for All Oestrogen Receptor Positive DCIS 
Compared to Oestrogen Receptor Positive Invasive Breast Disease 
These series examines the difference between all oestrogen receptor positive DCIS 
(i.e. both pure and that associated with invasion) and oestrogen receptor positive 
invasive breast disease. 
Frequency plots showing copy number aberrations between oestrogen receptor 
positive DCIS and oestrogen receptor positive invasive breast disease were provided 
by Breakthrough Breast Cancer/Research Oncology, King’s College London 
Bioinformatics Department (Figure 39).  
 
Figure 39: Frequency plots showing copy number aberrations between oestrogen 
positive DCIS and oestrogen positive invasive breast disease (amplifications, 
















5.8.6.1 Amplification in Oestrogen Receptor Positive DCIS Compared to Oestrogen 
Receptor Positive Invasive Breast Disease 
No amplifications in either ER positive DCIS or ER positive invasive breast disease 
are found in this series.  
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5.8.6.2 Duplication in Oestrogen Receptor Positive DCIS Compared to Oestrogen 
Receptor Positive Invasive Breast Disease 
There are some overlaps in the duplications present in ER positive DCIS (n=4/17) 
and in ER positive invasive breast disease (n=1/9).  
1. p-values < 0.05; 
2. A gene list is mapped from 2 genomic regions on chromosome 1;  
3. These regions encompass 18 genes altered in ER positive DCIS and some 
ER positive invasive breast disease; 
Genes: 
AL592307.2 HFE2 TXNIP POLR3GL ANKRD34A LIX1L RBM8A GNRHR2 PEX11B ITGA10
 ANKRD35 PIAS3 RP11-458D21.2 RP11-458D21.1 RP11-315I20.1 RP11-315I20.3 U1
 PDE4DIP 
PANTHER analysis: 12 mapped ids are found, 6 mapped ids are not found.  
 
There are duplications found in ER positive invasive disease (n=4/9) not present in 
ER positive DCIS (n=0/17).  
1. p-values < 0.05;  
2. A gene list is mapped from 17 genomic regions found on chromosomes 1, 8, 
9, 10, 17, 21;  
3. These regions encompass 255 genes altered in ER positive invasive breast 
disease; 
Genes: 
 ADAM15 5S_rRNA 7SK AC046185.1 AC046185.2 AC110921.1 ADAR AF216667.1 AL359758.1 AL589764.2
 AL589765.1 AL589986.2 AL590431.1 AL590431.2 AL590431.3 AL590666.2 AL591893.1 AL591893.2 AL591893.3 AL592307.1
 AL592492.2 AL606500.1 AL713999.1 ANTXRL AP000304.12 AP000313.1 AP000313.2 AP000569.2 AP000569.8 APOA1BP
 AQP10 ASH1L ATP5O ATP8B2 BCAN BCL9 C1orf104 C1orf189 C1orf230 C1orf43 C1orf46
 C1orf61 C1orf68 CAPN2 CCDC47 CCT3 CGN CHD1L CHRNB2 CKS1B CLK2 CRABP2
 CRCT1 CRNN DAP3 DCST1 DCST2 DDX42 DPM3 EFNA1 EFNA3 EFNA4 FAM189B FDPS 
FLAD1 FLG FLG2 FTSJ3 GABPB2 GBA GBAP GPATCH4 HAPLN2 HAX1 HCN3
 HDHD1CP HELZ HRNR hsa-mir-190b hsa-mir-548d-2 hsa-mir-554 hsa-mir-555 hsa-mir-9-1 hsa-mir-92b IL6R
 IQGAP3 ITSN1 KCNH6 KCNN3 KPRP KRTCAP2 LCE1D LCE1E LCE1F LCE2A LCE2B
 LCE2C LCE2D LCE3A LCE3B LCE3C LCE3D LCE3E LCE4A LCE5A LELP1
 LENEP LIMD2 LINGO4 LOR LRRC6 LYSMD1 MAP3K3 MEF2D MLLT11 MRPL9 MSTO1 MTX1
 MTX1P1 MUC1 NBPF10 NBPF15 NBPF16 NES NOTCH2NL NUP210L OAZ3 OR13Z1P
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 PBXIP1 PGLYRP3 PGLYRP4 PI4KB PIP5K1A PITPNC1 PKLR PMVK POGZ PRR9
 PSMB4 PSMC5 PSMD12 PSMD4 PTPRD PYGO2 RAG1AP1 RFX5 RHBG RP11-107M16.2 RP11-126K1.2
 RP11-126K1.6 RP11-126K1.8 RP11-139I14.2 RP11-201K10.1 RP11-21N7.2 RP11-21N7.6
 RP11-21N7.7 RP11-243J18.2 RP11-263K19.4 RP11-263K19.6 RP11-274N19.2
 RP11-284F21.5 RP11-284F21.7 RP11-289I10.1 RP11-289I10.2 RP11-292F22.2
 RP11-292F22.3 RP11-29H23.1 RP11-29H23.2 RP11-29H23.4 RP11-29H23.5
 RP11-29H23.6 RP11-307C12.11 RP11-316M1.11 RP11-337C18.4 RP11-350G8.3
 RP11-350G8.4 RP11-350G8.5 RP11-350G8.7 RP11-404E16.1 RP1-140J1.1 RP1-140J1.4
 RP11-441L11.1 RP1-14N1.2 RP11-540D14.6 RP11-540D14.8 RP11-61L14.2 RP11-61L14.6
 RP11-666A1.1 RP11-666A1.2 RP11-666A1.3 RP11-666A1.4 RP11-666A1.5
 RP11-66D17.3 RP11-66D17.5 RP11-68I18.2 RP11-74C1.2 RP11-74C1.4 RP11-763B22.2
 RP11-763B22.3 RP11-763B22.4 RP11-89F3.2 RP11-89F3.3 RP11-98D18.1 RP11-98D18.2
 RP11-98D18.3 RP11-98D18.7 RP11-98D18.9 RP11-98G7.1 RP1-43O17.1 RP1-43O17.2
 RP1-52J10.9 RP1-91G5.1 RP1-91G5.3 RPTN RUSC1 SCAMP3 SCNM1 SEC22B SELENBP1 SEMA6C
 SHC1 SHE SMARCD2 SNORA44 SNORA58 SNORA8 SNORD59 snoU13 SNX27 STRADA
 TACO1 TCAM1 TCHH TCHHL1 TDRD10 TDRKH THBS3 TMEM71 TMOD4 TNFAIP8L2
 TNRC4 TPM3 TRIM46 TTC24 TUFT1 U2 U6 U7 UBAP2L UBE2Q1 VPS72
 Y_RNA YY1AP1 ZBTB7B ZNF687 
PANTHER analysis: 137 mapped ids are found, 118 mapped ids are not found.  
5.8.6.3 Genomic Gains in Oestrogen Receptor Positive DCIS Compared to 
Oestrogen Receptor Positive Invasive Breast Disease 
There were gains present in both ER positive DCIS (n=5/17) and ER positive invasive 
breast disease (n=7/9) with considerable overlap in this series. 
1. p-values < 0.05; 
2. A gene list is mapped from 3 genomic regions found on chromosomes 6, 16;  
3. These regions encompass 16 genes altered in both ER positive DCIS and ER 
positive invasive breast disease; 
Genes:  
AC106739.1 AL031963.1 AL031963.2 AL031963.5 BPHL HLA-DQA1 HLA-DQB1 IL4R JMJD5 NSMCE1 RP1-
40E16.11   RP1-40E16.8 RP1-40E16.9  
PANTHER analysis: 10 mapped ids are found, 6 mapped ids are not found.  
5.8.6.4 Genomic Sc Gains in Oestrogen Receptor Positive DCIS Compared to 
Oestrogen Receptor Positive Invasive Breast Disease 
There are similar Sc gains in both ER positive DCIS (n=4/17) and ER positive invasive 
breast disease (n=6/9) in this series. 
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1. p-values < 0.05;  
2. A gene list is mapped from 16 genomic regions found on chromosomes 6, 12, 
16, 18, 20;  
3. These regions encompass 63 genes altered in both ER positive invasive 
breast disease and ER positive DCIS; 
Genes:  
ASXL1 5S_rRNA ABCC11 AC106739.1 AC125494.2 AL031963.1 AL031963.2 AL031963.3 AL031963.5 AL121935.1
 AL133343.1 ATN1 BPHL C12orf57  C20orf112 CD4 COPS7A EMG1 ENO2 FAM136B
 GNB3 GPR162 HLA-DQA2 HLA-DQB2 HLA-DQB3 hsa-mir-141 hsa-mir-200c IL4R JMJD5 LAG3 LEPREL2
 LONP2 LRRC23 MACROD2 MLF2 NQO2 NSMCE1 PHB2 PTMS PTPN6 RIPK1 RP11-356I2.2
 RP11-356I2.4 RP11-410N8.1 RP11-410N8.3 RP11-410N8.4 RP11-568A7.1 RP1-1J6.2 RP1-
40E16.11 RP1-40E16.2 RP1-40E16.3 RP1-40E16.4 RP1-40E16.8 RP1-40E16.9
 RP1-90J20.8 RP5-1184F4.5 snoU89 TCP10L2 TNFAIP3 TOP1 TUBB2A U47924.1 U7 
PANTHER analysis: 30 mapped ids are found, 33 mapped ids are not found.  
5.8.6.5 Losses in Oestrogen Receptor Positive DCIS Compared to Oestrogen 
Receptor Positive Invasive Breast Disease 
There are similar losses in both ER positive DCIS (n=7/17) and ER positive invasive 
breast disease (n=8/9) in this series.  
1. p-values < 0.05; 
2. A gene list is mapped from 29 genomic regions found on chromosomes 1, 8, 
13, 15, 16, 22, X;  
3. These regions encompass 114 genes altered in both ER positive invasive 
breast disease and ER positive DCIS; 
Genes: 
5S_rRNA AC022716.1 AC039056.1 AP000351.4 AP000553.1 AP000555.1 ARHGEF10 ATXN8OS CCDC116 CLN8
 CSMD1 CT45A1 CT45A2 CT45A3 CT45A4 DDT DLC1 EHMT1 EIF4A1P6 F8A3
 GANC GFRA2 GSTT1 GSTT2 GSTTP1 H2AFB3 hsa-mir-1184 hsa-mir-130b hsa-mir-301b hsa-
mir-596 hsa-mir-627 JPH3 KB-1027C11.4 KLHL1 LARGE MAPK1 MRRFP PAK3
 PLA2G4D PLA2G4E PLA2G4F PPIL2 PRKCZ RP11-110K18.2 RP11-206H15.2 RP11-218L14.4
 RP11-264J4.5 RP11-264J4.6 RP11-520F24.1 RP11-520F24.2 RP11-520F24.3 RP11-521H3.1
 RP11-77P3.1 RP11-954J6.3 RP13-36C9.4 RP13-36C9.5 RP5-1168A5.1 RP5-
1170D6.1 RP5-964N17.1 SDF2L1 TDRD3 TMEM87A TMLHE TOP3B U3 U6
 UBE2L3 VPS39 Y_RNA YDJC YPEL1 ZMYM2 
PANTHER analysis: 35 mapped ids are found, 37 mapped ids are not found.  
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5.8.6.6 Total Loss in Oestrogen Receptor Positive DCIS Compared to Oestrogen 
Receptor Positive Invasive Breast Disease 
There were total losses present in ER positive DCIS (n=13/17) not observed in ER 
positive invasive breast disease (n=0/9). 
1. p-values < 0.05; 
2. A gene list is mapped from 29 genomic regions found on chromosomes 3, 4, 
8, 9, 10, 11, 13, 15, 16;  
3. These regions encompass 60 genes altered in ER positive DCIS; 
Genes:  
7SK AC025678.1 AC090947.1 AC108056.1 AC133041.1 AL596092.1 AP000720.1 AP001482.1 AP001970.1 ATP8A2 CEP164
 CTD-2026G6.1 CTD-2026G6.2 DSCAML1 ERN2 GRM5 hsa-mir-1324 LHFP MTUS2
 NEFL NEFM NOX4 NUPL1 OR10D1P OR10D3P OR10V1 OR8B1P OR8B2 OR8B3 OR8B4
 OR8C1P OR8D1 OR8D2 OR8F1P OR8G2P OR8G5 OSBP PATL1 PLK1 PPARG RP11-206I15.2
 RP11-241K7.1 RP11-241K7.2 RP11-351N4.3 RP11-413E6.1 RP11-413E6.2 RP11-413E6.3
 RP11-468L18.1 RP11-527F15.1 RP11-642N14.3 RP11-803B1.1 RP11-803B1.2
 RP11-803B1.3 RP11-803B1.4 SNORA31 TYR U6 U7 U8 VWA5A 
PANTHER analysis: 22 mapped ids are found, 38 mapped ids are not found. 
 
There were total losses present in ER positive invasive breast disease (n=9/9) not 
observed in ER positive DCIS (n=0/17). 
1. p-values < 0.05; 
2. A gene list is mapped from 23 genomic regions found on chromosomes 9, 13, 
14, 16, X;  
3. These regions encompass 120 genes altered in ER positive invasive breast 
disease; 
Genes: 5S_rRNA AC002504.1 AC112778.1 AC112778.2 AL136001.1 AL136359.1 AL138690.1 AL139082.1 AL162377.1
 AL162377.2 AL163544.1 AL355611.1 AL355611.2 AL355611.3 AL356863.1 AL359180.1 AL391384.1 AL442203.2 AL450423.1
 AL512362.1 AL590007.2 ARX ASPG ATP7B ATXN8OS C13orf23 C13orf34 C13orf36 C13orf37
 C14orf180 CCDC70 CCNA1 DACH1 DGKH DIS3 DUSP21 FOXO1 FREM2 FREQ HMCN2 hsa-
mir-203 hsa-mir-759 KDM6A KIAA0564 KIF26A KLF12 KLF5 KLHL1 NEK3 NEK5 NHLRC3
 OLFM4 PCDH8 PIBF1 POLA1 RP11-117N4.1 RP11-11C5.1 RP11-12I24.2 RP11-12I24.3
 RP11-133M24.1 RP11-16D22.1 RP11-187A9.2 RP11-187A9.3 RP11-196I2.1 RP11-206H15.2
 RP11-206L1.2 RP11-209P2.1 RP11-214O11.1 RP11-214O11.2 RP11-218I21.1 RP11-248G5.3
 RP11-24H2.1 RP11-24H2.2 RP11-266E6.2 RP11-279N8.1 RP11-30C8.1 RP11-30C8.2
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 RP11-327P2.3 RP11-335N6.1 RP11-349O10.1 RP11-381L18.2 RP11-393H6.2 RP11-393H6.3
 RP11-430K22.1 RP11-430K22.2 RP11-431O22.2 RP11-459J23.1 RP11-459J23.2
 RP11-474L7.4 RP11-501G6.1 RP11-505F3.2 RP11-505F3.4 RP11-520F24.1 RP11-
520F24.2 RP11-520F24.3 RP11-56M2.1 RP11-571G1.1 RP11-571G1.2 RP11-629O4.1
 RP11-76N11.2 RP11-77P3.1 RP11-7B3.2 RP11-7B3.3 RP11-7B3.4 RP11-88G17.6 RP1-258N20.3
 SNORA25 SNORA68 SNORA9 SNORD37 STOML3 TDRD9 TMEM179 TRPC4 U4 U6 U7
 UFM1 UTP14C Y_RNA 
PANTHER analysis: 31 mapped ids are found, 89 mapped ids are not found.  
 
5.8.6.7 CdLOH in Oestrogen Receptor Positive DCIS Compared to Oestrogen 
Receptor Positive Invasive Breast Disease 
There is similar CdLOH present in both ER positive DCIS (n=10/17) and ER positive 
invasive breast disease (n=7/9).  
1. p-values < 0.05;  
2. A gene list is mapped from 67 genomic regions found on chromosomes 1, 2, 
5, 7, 8, 9, 11, 13, 15, 19, 22, X; 
3. These regions encompass 215 genes altered in both ER positive DCIS and 
ER positive invasive breast disease; 
Genes: 
5S_rRNA 7SK AC000035.3 AC000041.8 AC002472.8 AC002472.9 AC004019.10 AC004019.16 AC004019.17
 AC005300.5 AC006946.12 AC006946.15 AC008162.1 AC011890.1 AC019176.2 AC022613.1 AC022716.1 AC027807.1 
AC039056.1 AC068286.1 AC074389.1 AC074389.6 AC074389.7 AC074389.9 AC090510.1 AC102941.1 AC103965.1 AC110781.3
 AC110781.5 ACRV1 ADAMTSL3 ADRBK2 AIFM3 AL022323.1 AL121825.1 AL451005.1 AP000347.2 AP000350.10
 AP000350.6 AP000350.7 AP000350.8 AP000351.3 AP000351.4 AP000553.1 AP000555.1 AP1B1 AP3B1 ATP1B4
 BPIL2 C1GALT1C1 C22orf28 C22orf30 CCDC116 CDAN1 CECR1 CECR2 CECR3 CECR4 CECR5
 CECR6 CFP CHEK1 CPXCR1 CSMD1 CT45A1 CT45A2 CT45A3 CT45A4 CT47B1
 CTA-211A9.5 CTA-221G9.11 CTA-256D12.11 CTA-256D12.12 CTA-292E10.6 CTA-292E10.7 
CTA-407F11.6 CTA-407F11.7 CTA-407F11.8 CTA-85E5.7 CTA-984G1.5 CTD-2037K23.1 CTD-2037K23.2
 CTD-2254N19.1 CUL4B CXorf25 CXorf64 DDT DDTL DLC1 EFCAB6 EHMT1 EIF4A1P6
 ELFN1 ELK1 EMID1 FAM189A1 FAM32B FAM70A FBXO7 GANC GFRA2 GRIA3 GSTT1
 GSTT2 GSTT2B GSTTP1 HAUS2 HMGN2L9 HORMAD2 hsa-mir-130b hsa-mir-301b hsa-mir-627 IGLV10-67
 IGLV1-62 IGLVI-63 IGLVIV-64 IGLVIV-65 IGLVIV-66-1 IGLVV-66 IL17RA KB-1027C11.4 KIAA1671 LAMP2
 LARGE LL22NC03-23C6.15 LL22NC03-28H9.5 LRRC57 LZTR1 MAD1L1 MAPK1 MCTS1 MRRFP
 MTMR3 NEFH NF2 NIPSNAP1 PA2G4P1 PAK3 PATE1 PATE2 PDE4D PLA2G4D
 PLA2G4E PLA2G4F PNPLA5 PPIL2 PRAMEL PRKCZ RFPL1 RFPL1S RFPL3 RFPL3S RGL4
 RHBDD3 RP11-137D19.1 RP11-442I12.1 RP11-45J1.1 RP1-149A16.12 RP1-149A16.15 RP1-
149A16.16 RP1-149A16.17 RP1-149A16.3 RP11-521H3.1 RP1-212G6.4 RP1-222H5.1 RP1-
302D9.2 RP1-302D9.3 RP1-302D9.4 RP1-302D9.5 RP1-30E17.1 RP1-30E17.2
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 RP13-36C9.4 RP13-36C9.5 RP3-388M5.8 RP3-393P12.1 RP4-655L22.2 RP4-655L22.4
 RP5-1168A5.1 RP5-1170D6.1 RP5-964N17.1 SC22CB-1D7.1 SCAMP1 SDF2L1
 SGSM1 SLC27A6 SNAP23 SNORA70 SNORD56 snoU13 STARD9 SULT4A1 SYN1 SYN3
 TDRD3 THAP7 THOC5 TJP1 TMEM211 TMEM87A TOP3B TTBK2 TTC28 U3 U6
 UBE2L3 UBR1 UXT VPS39 XXbac-B135H6.15 Y_RNA YDJC YPEL1 Z71183.1 ZBTB33 
ZNRF3 
PANTHER analysis: 96 mapped ids are found, 115 mapped ids are not found.  
5.8.6.8 CnLOH in Oestrogen Receptor Positive DCIS Compared to Oestrogen 
Receptor Positive Invasive Breast Disease 
There is CnLOH in ER positive DCIS (n 16/17) not observed in ER positive invasive 
breast disease (n=0/9). 
1. p-values < 0.05; 
2. A gene list is mapped from 36 genomic regions found on chromosomes 1, 3, 
4, 12, 19, 20; 
3. These regions encompass 85 genes altered in ER positive; 
Genes: 
 Mar-02  5S_rRNA 7SK AC003111.1 AC003111.2 AC006128.1 AC008764.1 AC022506.2 AC024075.1 AC027667.1 AC027667.2
 AC034193.1 AC099680.1 AGAP2 AK3L1 AKAP8 AKAP8L AL121988.1 BRD4 C19orf42 C19orf44 
C1orf212 C3orf10 CALR3 CHERP CST1 CST2 CST4 CST5 CSTP1 CSTP2 CTD-2356P16.1
 CYP2A13 CYP2F1 CYP2S1 DLGAP3 ELAVL4 EPHX3 GJA4 GJB3 GJB4 GJB5 GSTM3P
 HNRNPM hsa-mir-1470 IRAK2 KIF5A MACROD2 MED26 NKX2-2 NKX2-4 NOTCH3 OS9 PGLYRP2
 PIP4K2C PLK1S1 PRAM1 RASAL3 RP11-227D2.3 RP11-415I12.1 RP11-492I2.1 RP11-766N7.1
 RP1-198K11.3 RP4-777D9.2 RP5-1177M21.1 RP5-872K7.2 RP5-872K7.7 RP5-
984P4.1 RP5-984P4.4 RP5-997D16.2 RPL24P2 RPS15AP1 SLC35E1 snoU13 TBC1D30 TMEM38A U1
 U6 U6atac VHL WIBG WIF1 WIZ XRN2 XXyac-YX60D10.1 
PANTHER analysis: 42 mapped ids are found, 43 mapped ids are not found. 
 
There is CnLOH present in ER positive invasive breast disease (n=9/9) not observed 
in ER positive DCIS (n=0/17). 
1. p-values < 0.05;  
2. A gene list is mapped from 16 genomic regions found on chromosomes 1, 3, 
11, 12;  




 5S_rRNA AC012598.1 AC044839.1 AC044839.2 AC061999.1 AC092910.1 AC092910.2 AC103681.1 AC103681.2 AC117377.1
 AC119795.1 ADPRHL2 ALX4 ANKS1B C11orf74 C11orf94 C3orf15 COL8A2 COX17 CRY1 CRY2 DCTN2
 DDIT3 EIF2C3 EXT2 GAP43 GSK3B GYLTL1B hsa-mir-616 KIF5A LSAMP MAPK8IP1
 MARS MBD6 MGAT4C MIP NR1I2 PEX16 PHF21A POPDC2 PRDM11 RAG1 RAG2
 RP11-169N13.1 RP11-169N13.4 RP11-18H7.1 RP11-190C22.1 RP11-326J18.1 RP11-767L7.1 
RP11-767L7.2 RP4-665N4.4 RP4-665N4.5 SLC35C1 SYT13 TEKT2 TIMELESS TP53I11
 TRAF6 TSPAN18 U6 
PANTHER analysis: 37 mapped ids are found, 23 mapped ids are not found 
 
5.8.7 Copy Number Aberrations for Triple Negative DCIS Compared to Non Triple 
negative DCIS 
This series examines the differences between pure triple negative DCIS and all other 
types of DCIS (e.g. ER+, HER2+) (pure and in the presence of invasive disease).  
Frequency plots showing copy number aberrations between TN DCIS and non TN 
DCIS are given in Figure 40. 
 
Figure 40: Frequency plots for copy number aberrations for triple negative DCIS 
versus non triple negative DCIS (amplifications, duplications, gains, Sc gains, losses, 
total losses CdLOH and CnLOH, pages 220-223).  
 
Frequency plots below show the relative copy number gains and losses for an entire 
sample set compared to its counterpart e.g. the first plot in Figure 36 shows 
amplification for all triple negative DCIS and invasive breast disease compared to all 
non triple negative DCIS and invasive breast disease in this series. The number on 
the y axis refers to the number of cases showing a genomic difference. The x axis 
refers to the chromosome number. The lower half of the y axis represents the non 
triple negative and the upper half the triple negative. Amplification on chromosome 8 
is apparent on several regions for non triple negative DCIS and invasive breast 
disease and is also present at a lower frequency on fewer loci for triple negative DCIS 
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and invasive breast disease. Amplification is present on chromosomes 6 (n=24), 
11(n=25) and 17 (n=26) for non triple negative DCIS and invasive breast disease but 





















PANTHER Analysis is used to provide the following information the above copy 
number scenarios for all groups listed in sections 5.3.3 to 5.3.8 
1. p-values- a significant p-value showing the genomic aberrations are not 
defined by chance and that the null hypothesis is correct, as an example – 
duplications found in triple negative DCIS compared to triple negative DCIS- 
a p-value of 0.5 showing that the there is a 5% chance that these duplication 
differences and found by random chance alone within our series.  
2. The gene list mapped from different genomic regions on each chromosome. 
Each chromosome has been divided into overlapping genomic regions which 
are assessed for amplifications, duplications etc. Genes are identified in each 
region from different chromosomes. For each analysis the number of gene 
regions and chromosomes is given. 
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3. A list of genes is created from an online database (ESEMBL) and these genes 
are listed in the results section as gene ids. 
4. The gene list (ids) are uploaded to the PANTHER analysis software, homo 
sapiens is the species genome selected and a functional analysis is 
requested. The Software provides a list of mapped genes with known 
biological, molecular and protein functions. Those genes entered into the 
software with established functions are returned as “mapped ids found” and 
those without are returned as “mapped ids not found”. The mapped ids are 
used to create pie charts showing biological processes, molecular functions 
and  radar graphs for protein classes (representative charts and graphs are 
found in 5.3.7 the majority are stored on the accompanying disc. 
Genomic data and subsequent PANTHER analysis for TN negative DCIS and non 
triple negative DCIS is given below. 
5.8.7.1 Amplification in Triple Negative DCIS Compared to Amplification in Non Triple 
Negative DCIS  
The comparison of amplifications in TN DCIS (n=3/26) compared to non TN DCIS 
(n=12/33) shows considerable overlap between those amplifications found in TN 
DCIS also found in non TN DCIS.  
1. p-values < 0.05; 
2. A gene list is mapped from 19 genomic regions found on chromosomes 6, 8, 
11, 17;   
3. These regions encompass 39 genes altered in TN DCIS and non TN DCIS; 
Genes: 
 AC107374.1 ADCY8 AF216667.1 CCND1 CEBPD CRKRS CSMD3 DENN DENND3 HIST1H2AB HIST1H3A HIST1H3B HIST1H4A 
HIST1H4B hsa-mir-151 IKBKB KIAA0146 KIAA1429 LRRC6 MYEOV ORAOV1 POLB PRKDC PTK2 PTK2 PTK2 PXDNL RP11-231D20.1 
RP11697N18.1 SLC45A4 SNORA7 U6 U6 




Amplifications are found in non TN DCIS (n=8/33) that are not observed in TN DCIS 
(n=0/26)  
1. p-values < 0.05;  
2. A gene list is mapped from 18 genomic regions found on chromosomes 8, 11, 
17;   
3. These regions encompass 39 genes altered in non TN DCIS; 
Genes: 
7SK AC013300.1 AC022973.1 AC103833.1 AC109322.1 ADCY8 C8orf4 CRKRS CSMD3 CYC1 DEPDC6 EFR3A EXOSC4 
FAM49B FGF19 FGF3 FGF4 GPAA1 GPR20 GRINA GSDMC KCNQ3 KIAA1875 LRRC6 MAF1 OC90 OPLAH PARP10 PLEC PTK2 RP11-
1023P17.1 RP11274M4.1 RP11473O4.1 SHARPIN SLC45A4 SNORA25 SPATC1 ST18 TMEM71 
PANTHER analysis: 27 genes mapped, 1 id is not found. 
5.4.1.1 Duplication of Triple Negative DCIS Compared to Duplication in Non Triple 
Negative DCIS  
Duplications are found in TN DCIS (n=5/26) that are not observed in non TN DCIS 
(n=0/33)  
1. p-values < 0.05; 
2. A gene list is mapped from 18 genomic regions found on chromosomes 3, 6, 
12;  
3. These regions encompass 17 genes altered in TN DCIS; 
Genes: 
 5S_rRNA AC004671.1 AC106722.1 AL096711.1 C6orf174 ECHDC1 MBNL1 NTF3 RNF146 RP11362A9.3 RP1-177A13.1 RP3-
351K20.3 RP3-351K20.4 RP3-403A15.1 RSPO3 TMEM14E Y_RNA 
PANTHER analysis: 6 mapped ids found, 11 mapped ids are not found. 
 
Duplications are found in non TN DCIS (n=0/33) that are not observed in TN DCIS 
(n=7/26).  
1. p-values  < 0.05; 
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2. A gene list is mapped from 20 genomic regions found on chromosomes 3, 8, 
10, 16, 17, 20, 22; 
3. These regions encompass 54 genes altered in non TN DCIS; 
Genes: AC015813.2 AC020688.1 AC090922.1 AC092291.1 AC124319.3 AC136443.1 AC138932.2 AL031661.1 AL391421.1
 AL391421.2 AL391421.3 AL391421.4 AP003355.2 ATG3P1 BFAR CTD-2561B21.1 CUEDC1 DLG5 FAM18A 
GSTTP2 H2AFZP5 hsamir-1972 HSPEP1 KCNS2 MAFB MRPS23 NIT2 NOMO1 NPIP NUBP1 OXR1 PARN PDXDC1 PLA2G10
 POLR3A RALGAPB RP11-101E14.2 RP11-101E14.3 RP11126H7.3 RP1-191L6.2 RP4-564F22.2 RP4 564F22.5
 RP5-1031J8.1 RPS24 SNHG11 SNORA71 SNORA71A SNORA71B SNORD112 TBC1D23 U6 U7 VEZF1 
Y_RNA 
PANTHER analysis: 19 mapped ids are found, 35 mapped ids are not found. 
5.8.7.2 Genomic Gains in Triple Negative DCIS Compared to Genomic Gains in Non 
Triple Negative DCIS  
Gains found in TN DCIS (n=10/26) have some overlap with gains found in non TN 
DCIS (n=3/33). 
1. p-values < 0.05; 
2. A gene list is mapped from 17 genomic regions found on chromosomes 3, 4, 
5, 10, 10; 
3. These regions encompass 77 genes altered in non TN DCIS; 
 Genes:  
5S_rRNA AC006296.3 AC022400.3 AC096971.2 AC103560.1 ACADSB AGAP5APC BMS1P4 BUB3 C10orf55 CAMK2G CHCHD1 
COQ6CTC-459M5.1 CTC-459M5.2 CTC-493D22.1 CTD2077I5.1 CTD 2192A1.1CTD-2201G3.1 ENTPD5 EPB41L4A FAM161B FHIT 
FOXP1 FTHL23 FUT11 GLT8D4 GLUDP3 HMX2 HMX3 IKZF5 KIAA0913 MCC MYOZ1 NCRNA00219 NDST2 PLAU 
PPP4R2 PSTK PTGR2 RNase_MRP RP11-162A23.5 RP11-282I1.1 RP11-417O11.5 RP11430J3.1 RP11-
430J3.2 RP11-458B24.2 RP11-464F9.1 RP11-464F9.19 RP11-464F9.9 RP11526F3.1 RP11-574K11.12 RP11-574K11.16 RP11-574K11.18 
RP11-574K11.20 RP11-574K11.5 RP11-574K11.8 RP11-624D20.1 RP11-654C22.1 RP11-728B21.2 RP11-905F6.1 SEC24C SHQ1
 SNORA13 snoU13 SYNPO2L TSSK1B U1 U4atac U6 U7 USP54 VCL Y_RNA YTHDC2 ZNF410 
 
There were gains found in non TN DCIS (n=8/33) that are not observed in TN DCIS 
(n=0/26). 
1. p-values < 0.05; 
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2. A gene list is mapped from 36 genomic regions found on chromosomes 2, 6, 
7, 9, 10, 17, 18, 19;   
3. These regions encompass 99 genes altered in non TN DCIS; 
Genes: 
AC004603.4 AC005176.1 AC005205.2 AC005205.3 AC005205.4  AC005239.1 AC006133.3 AC007842.1 AC008555.5 AC008655.1 
AC009711.1 AC011443.1 AC011445.1 AC011455.1 AC011496.1 AC011500.1 AC011500.2 AC012309.4 AC012309.5 AC080032.1
 AC091078.1 AC091078.2  AC092296.1 AC092296.3 AC093063.1 AC103996.1 ACAN ASPDH C19orf63 CDKN2BAS
 CEACAMP7 CLC DENND4C DLL3 DYRK1B EID2 EID2B FAM71E1 FBL FBXO27 FCGBP GMFG IL28A 
IL28B  IL29 JOSD2 KCNC3 KCTD15 LEUTX LGALS13 LGALS14 LRFN1 LRRC4B MED29 MLLT3
 MRPS12 MTAP MYBPC2 MYH14 NAPSA NAPSB NCCRP1 NFKBIB NR1H2 PAF1  PAK4 PLEKHG2
 POLD1 PSG1 PSG10 PSG11 PSG6 PSG7 PSMC4 RINL RP11513M16.5 RPS16
 RPS6 SAMD4BSARS2 SIRT2 snoU13 SPIB SUPT5H SYCN SYT3 TIMM50 VN1R96P Y_RNA ZFP14  ZFP36  
ZFP82 ZNF146 ZNF30 ZNF383 ZNF546 ZNF565 ZNF780A ZNF780B 
PANTHER analysis: 59 mapped ids found, 40 mapped ids are not found. 
5.8.7.3 Genomic Sc Gains in Triple Negative DCIS Compared to Genomic Sc Gains 
in Non Triple Negative DCIS  
There are Sc Gains found in TN DCIS (n=7/26) that are not observed from non TN 
DCIS (n=0/33). 
1. p-values < 0.05; 
2. A gene list is mapped from 21 genomic regions on 6 chromosomes 1, 2, 6, 9, 
16, 19;  
3. These regions encompass 86 genes altered in TN DCIS; 
Genes:  
5S_rRNA AC016699.1 AC017099.3 AC018892.1 AC018892.3 AC018892.4 AC018892.5 AC018892.6 AC018892.7 AC018892.8
 AC018892.9 AC079337.1 AC079395.1 AC092683.1 AC092683.2 AC092683.3 AC106785.1 AC106785.10 AC106785.14 AC106785.18
 AC106785.20 AC106785.22 AC106785.25 AC106785.27 AC106785.28 AC106785.6
 AC116553.1 AC137932.1 AC137932.3 AC159540.1 AC159540.14 AC159540.2 AC159540.3 ACTR1B AL391807.1 AL445568.1 
AL590785.1 ANKRD11 ANKRD36 ANKRD36B B3GAT2 BAI3 CDKN2BAS CEBPG CHST8 COX5B CTD-2329C7.1 DBIP1 ELOVL4 FAHD2B 
FAM178B IRAK1BP1 KCNQ5 KCTD15 MTAP PEPD PHIP RIMS1 RP11-135M8__A.1 RP11-173D14.3 RP11-321C1.1
 RP11-35J1.1 RP11-361F19.1 RP11-380M3.1 RP11-406O16.1 RP11-789A7.1 RP1-20N4.1 RP1-232L24.3 RP3-357D13.1 
RP3-357D13.3 RP3-390M24.1 RP3-474G15.1 RP3-474G15.2 RP3-485C17.1 RP3-485C17.2 RP3-525N10.2 SNORD112 snoU13
 TMEM131 U3 U4 U6 U7 UBTFL6 VWA3B ZAP70 
PANTHER analysis: 21 mapped ids are found, 65 mapped ids are not found. 
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There are Sc Gains in non TN (n=8/33) not observed in TN DCIS (n=0/26). 
1. p-values < 0.05; 
2. A gene list is mapped from 36 genomic regions found on chromosomes 3, 4, 
5, 9, 14, 17; 
3. These regions encompass 93 genes altered in TN DCIS; 
Genes:  
7SK AC006296.3 AC068400.1 AC098869.1 AC099668.5 AC104996.1 AC105935.1 AC121252.2 AC126327.1 AC126327.4 AL117692.1
 AL117692.2 AL136294.1 AL161626.1 AMIGO3 APC APEH ATP6V0A1 BLMH C14orf135 C14orf182 C14orf183 C3orf54 C9orf40 C9orf41 
C9orf95 CAMKV  CCDC55 CDCP1 CDH29 COASY CPD CTB-75G16.1 CTC-459M5.1 CTC-459M5.2 CTD-2184C24.1 CTD-2192A1.1
 DDX52 DHRS11 DHRS7 DUSP14 EFCAB5 EPB41L4A FAM134C GCNT1 GGNBP2 GMPPB hsa-mir-423 HSD17B1
 HSD17B1P1 IP6K1 LRRC9 MLX MRM1 MST1 MYO19 NAGLU NCRNA00219 NTRK2 OSTF1 PIGW PLEKHH3 
PPM1A PRKAR2A PRUNE2 PSMC3IP RAD51L1 RBM47 RNF123 RP11-197P3.1 RP11-197P3.4 RP11-197P3.5
 RP11-214N16.2 RP11-422N19.3 RP11-458B24.2 RP11-526F3.1 RP11-58E21.1 RP11-66C24.1 RP13-1056D16.2
 RP13-480C15.1 SLC6A4 SNORA13 SNORD63 SYNRG TADA2A TMIGD1 TRAIP TRPM6 TUBG1 TUBG2 U6 UBA7 Y_RNA 
PANTHER analysis: 50 mapped ids are found, 43 mapped ids are not found. 
5.8.7.4 Losses in in Triple Negative DCIS Compared to Genomic Total Loss in Non 
Triple Negative DCIS  
There are losses found in TN DCIS (n=11/26) that are not observed in non TN DCIS 
(n=0/33). 
1. p-values <0.0001; 
2. A gene list is mapped from 23 genomic regions on chromosome 4;  
3. These regions encompass 94 altered genes in TN DCIS; 
Genes: 
 MAR01 7SK AC079349.1 AC095046.1 AC095047.1 AC096766.1 AC097534.1 AC097534.2 AC104082.1 AC104082.2
 AC105285.2 AGPAT9 ANXA3  ARHGAP24 C4orf12  C4orf39 C4orf43 CDS1 CPE FAM175A FGF5 FRAS1
 GALNT7 GALNTL6 GK2 GK3P HMGB2 hsa-mir-1979 hsa-mir-578 KLHL2 NACA3P NKX6-1 NPY5R OR7E94P RP11-10K16.1 
RP11112L18.1 RP11-147K21.1 RP11-218C23.1 RP11-219C20.1 RP11-234K19.1 RP11-234K19.2 RP11-
274J2.1 RP11-294O2.1 RP11-294O2.2 RP11-366M4.1 RP11-366M4.11 RP11-366M4.12 RP11-366M4.13 RP11-
366M4.14 RP11-366M4.15 RP11-366M4.17 RP11-366M4.2 RP11-366M4.3 RP11-366M4.4 RP11-366M4.5 RP11-366M4.6
 RP11-366M4.8 RP11-42A4.1 RP11-436A7.1 RP11-443J23.1 RP11-452C8.1 RP11-469O11.1
 RP11-469O11.2 RP11-485C11.1 RP11-489G11.1 RP11-502M1.1 RP11-502M1.2 RP11-51G24.1
 RP11-606P2.1 RP11-610O8.1 RP11-689K5.2 RP11-689K5.3 RP11-722P15.1
 RP11-75A5.1 RP11-767N15.1 RP11-798M19.3 RP11-8L2.1 RPL35AP12 SAP30 SC4MOL SCRG1 
SNORA31 SNORA75 SPOCK3 TKTL2 TMEM192 TRIM60 TRIM61 TRIM75 U4 U5 U6 WDFY3 Y_RNA 
PANTHER analysis: 23 mapped ids are found, 71 mapped ids are not found. 
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There are losses in non TN DCIS (n=10/33) that are not observed in TN DCIS 
(n=0/26) represents losses for non TN DCIS (N=10/24). 
1. P values < 0.05; 
2. A gene list is mapped from 35 genomic regions found on chromosomes 1, 2, 
3, 6, 9, 10, 17, 18, 19; 
3.  These regions encompass 127 altered genes in TN DCIS; 
Genes: 
 5S_rRNA AC002539.1 AC003051.1 AC004562.1 AC005176.1 AC005205.2 AC005205.3 AC005205.4 AC005208.1 AC005239.1
 AC005307.1 AC005616.1 AC006133.3 AC007392.3 AC007392.4 AC007403.1 AC007403.2 AC007403.3 AC009474.1
 AC009474.2 AC011443.1 AC011500.1 AC011500.2 AC023115.3 AC078941.1 AC091038.2 AC092155.1 AC092155.2
 AC092155.4 AC093063.1 AL162419.2 AL356957.10 AL356957.2 AL356957.3 AL356957.4 AL356957.6 AL356957.7
 AL356957.9 AL359836.1 AL732363.1 C9orf68 CAPN12 CDH2 CLCDLL3 DYRK1B EHBP1 EID2
 EID2B EMX2OS FAM98C FBL FBXO27 FCGBP FSHR GLIS3 GMFG hsa-mir-1-2 hsa-mir-133a-1 
KCNJ16 KCNJ2 KCNK18 KIAA1598 LEUTX LGALS13 LGALS14 LGALS7 LRFN1 MAP4K1 MED29
 MEIS1 MIB1 NT5E PAF1 PAK4 PDZD8 PLEKHG2 RASGRP4 RP11-14N7.1
 RP11-14N7.2 RP11-268I9.1 RP11321N4.3 RP11-33E24.1 RP11-33E24.3
 RP11-358M14.2RP11-403I13.1 RP11403I13.2 RP11-403I13.4 RP11-403I13.5 RP11-403I13.6
 RP11-403I13.7 RP11403I13.8RP11-501J20.2 RP11-501J20.3 RP11-501J20.5 RP11-5G18.2 RP11-70J12.1 
RP11-744H18.1 RP11-744H18.2 RP11-763B22.5 RP11-763B22.6 RP11-763B22.7 RP11-763B22.8
 RP11-763B22.9 RP1-3J17.3 RPS16 RSL24D1P2 RYR1 SAMD4B SARS2 SLC18A2 SLC1A1
 SNHG5 SNORA73 SNORA81 SNORD50 snoU13 SNX14 SPRED3 SUPT5H SYNCRIP TIMM50 U1 U6 VAX1 
Y_RNA ZFP36 
PANTHER analysis: 41 mapped ids are found, 86 mapped ids are not found. 
5.8.7.5 Total Loss in Triple Negative DCIS Compared to Genomic Total Loss in Non 
Triple Negative DCIS  
There are total losses found in TN DCIS (n=17/26) that are not observed in non TN 
DCIS (n=0/33). 
1. p-values = 0.05; 
2. A gene list is mapped from 58 genomic regions found on chromosomes 3, 
4,14,15,17; 
3. These regions encompass 223 genes altered in Non TN DCIS; 
Genes: 
 5S_rRNA 7SK ABCD4 AC002117.1 AC003043.1 AC003043.2 AC003102.3 AC003963.2 AC004222.1 AC004596.1
 AC004968.1 AC004968.2 AC006349.1 AC007056.1 AC007686.1 AC007722.1 AC008045.1 AC008105.1 AC012409.1
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 AC015936.1 AC015936.3 AC016251.1 AC019131.2 AC020704.1 AC026202.1 AC026202.5 AC026882.1 AC027708.1
 AC027807.1 AC036222.1 AC055813.1 AC055873.1 AC068400.1 AC079915.1 AC084809.2 AC084809.3 AC090043.1
 AC090283.1 AC090283.3 AC091199.1 AC096750.1 AC102948.1 AC102948.2 AC103702.1 AC103965.1 AC104260.1
 AC113211.1 AC124789.1 AC134669.1 AC135724.1 AC138150.3 AC138150.4 AC183087.1 AC183087.2 ACBD4
 ACCN1 ADAM11 ADAMTSL3 ADCK1 ADH1A ADH1B ADH1C ADH4 ADH5
 ADH6 AF111168.1 AF111168.3 AHSA1 ALKBH1 ARHGAP23 ARRDC4 ASB16 ATXN7L3
 C14orf148 C14orf156 C14orf174 C14orf178 C17orf104 C17orf105 C17orf46 C17orf53 C17orf65
 C17orf93 C1QL1 C4orf37 CA10 CCDC103 CCDC43 CD300LG CDC6 CNTN4
 CNTN6 COX6B1P2 CTD-2175M1.1 CTD-2377D24.1 CTD-2377D24.2 CTD-2377D24.4
 CTD-2377D24.6 DBF4B DCAKD DDX52 DHX8 DUSP3 DYNLL1P1 EFTUD2
 EIF4E ETV4 EVI2A EVI2B FAM149B2 FAM169B FAM171A2 FAM177A2 FAM187A
 FMNL1 FZD2 G6PC3 GFAP GJC1 GPATCH8 GPR179 GRN GSTZ1
 HDAC5 HEXIM1 HEXIM2 HIGD1B HNF1B HOXB13 HOXB7 HOXB9 hsa-mir-1260 hsa-
mir-1469 hsa-mir-196a-1 hsa-mir-2117 ISM2 ITGA2B KIAA1737 KIF18B KRT222 KRT24
 KRT25 LIN52 LSM12 MAP3K14 MCTP2 MEOX1 METAP1 MPP2 MPP3
 MRPL45 MYO1D NAGS NF1 NGB NMT1 NR2F2 NRXN3 OMG
 PCNAP1 PLCD3 POMT2 PPY PRAC PYY RAB11FIP4 RGS6 RP11-1072C15.1
 RP11-15B17.1 RP11-176P14.1 RP11-187O7.1 RP11-204C23.1 RP11-299L17.1
 RP11-332E19.1 RP11-352E6.1 RP11-352E6.2 RP11-357H14.4 RP11-369I16.1
 RP11-428B4.2 RP11-522B15.1 RP11-522B15.2 RP11-571L19.2 RP11-571L19.4
 RP11-624A4.1 RP11-696N14.1 RP11-765K14.1 RP11-799A12.1 RP11-799A12.2
 RUNDC3A SIPA1L1 SLC25A39 SLC4A1 SMARCE1 SNORA32 SNORA46 SNORD56 snoZ178
 SNW1 SOCS7 SOST SPACA3 SPATA8 SPRED1 SPTLC2 SRCIN1 STON2
 SYNRG TBC1D3 TMED8 TMEM101 TMEM63C TMEM98 TMUB2 U3 U6 U7
 UBTF VEGFC VIPAR VSX2 WIPF2 Y_RNA ZDHHC22 
PANTHER analysis: 115 mapped ids are found, 108 mapped ids are not found. 
 
There are total losses found in non TN DCIS (n=27/33) that are not observed in TN 
DCIS (n=0/26). 
1. p-values  <0.0001; 
2. A gene list is mapped from 18 genomic regions on 1 chromosome (17) ; 
3. These regions encompass 46 genes altered in TN DCIS; 
Genes:  
AC000003.1 AC027763.1 AC027763.2 AIPL1 ALOX12 AMAC1L3 ASGR1 ASGR2 BCL6B C17orf49 C17orf61 C17orf74 CCDC42 CHRNB1 
CLEC10A CTD-2545G14.1 DLG4 DPH1 FBXO39 FGF11 GAS7 hsa-mir-195 hsa-mir-497 MFSD6L NLGN2 OVCA2 PIK3R5 PIK3R6 
PLSCR3 POLR2A RNASEK RNF222 RP11-609D21.1 SLC16A11 SLC16A13 SPDYE4 SPEM1 TEKT1 TMEM102 TNFSF12 TNFSF12-TNFSF13 
TNFSF13 TNK1 U6 Y_RNA ZBTB4 
PANTHER analysis: 33 mapped ids are found, 13 mapped ids are not found. 
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5.8.7.6 CdLOH in Triple Negative DCIS Compared to with CdLOH in Non Triple 
Negative DCIS 
There is CdLOH found in TN DCIS (n=11/26) that are not present in non TN DCIS 
(n=0/33).  
1. p-values  <0.0001; 
2. A gene list is mapped from 24 genomic regions on 2 chromosomes (4 and 5);  
3. These regions encompass 91 genes altered in TN DCIS; 
Genes: Mar01  7SK AC023355.1 AC023355.3 AC079349.1 AC095047.1 AC096766.1 AC097534.1 AC097534.2 AC104082.1 
AC104082.2 AC105285.2 AGPAT9 ANXA3 ARHGAP24 C4orf39 C4orf43 CDS1 CPE DUT FBN1 FGF5
 FRAS1 GALNT7 GALNTL6 GK2 GK3P HMGB2 hsa-mir-1979 hsa-mir-578 KLHL2 NACA3P NKX6-1 NPY5R 
OR7E94P RP11-10K16.1RP11-112L18.1 RP11-218C23.1 RP11-219C20.1 RP11-234K19.1 RP11-234K19.2 RP11-274J2.1 RP11294O2.1 RP11-
294O2.2 RP11-366M4.1 RP11-366M4.11 RP11-366M4.12 RP11-366M4.13 RP11-366M4.14 RP11-366M4.15 RP11-366M4.17 
RP11-366M4.2 RP11-366M4.3 RP11-366M4.4 RP11-366M4.5 RP11-366M4.6 RP11-366M4.8 RP11-42A4.1
 RP11-436A7.1 RP11-443J23.1 RP11-469O11.1 RP11-469O11.2 RP11-485C11.1 RP11-489G11.1 RP11-502M1.1 RP11-
502M1.2 RP11-51G24.1 RP11-606P2.1 RP11-689K5.2 RP11-689K5.3 RP11-75A5.1
 RP11-767N15.1 RP11-798M19.3 RP11-8L2.1 RPL35AP12 SAP30 SC4MOL SCRG1 SLC12A1 SNORA31 SPOCK3 TKTL2 TMEM192 
TRIM60 TRIM61 TRIM75 U4 U5 U6 WDFY3 Y_RNA 
PANTHER analysis: 25 mapped ids are found, 66 mapped ids are not found. 
There is CdLOH found in non TN DCIS (n=10/26) that are not observed in TN DCIS 
(0/26)  
1. p-values < 0.05; 
2. A gene list is mapped from 36 genomic regions found on chromosomes 2, 6, 
7, 9, 10, 17, 18, 19; 
3. These regions encompass 107 genes altered in TN DCIS; 
Genes: 5S_rRNA AC002539.1 AC003051.1 AC004562.1 AC005176.1 AC005205.2 AC005205.3 AC005205.4 AC005208.1 
AC005239.1 AC005307.1 AC005616.1 AC006133.3 AC007392.3 AC007392.4 AC007403.1 AC007403.2 AC009474.1 AC009474.2 
AC011443.1 AC011500.1 AC011500.2 AC091038.2 AC092155.4 AC093063.1 AL133476.1 AL359836.1 ATP8B5P C6orf161
 CAPN12 CDH2 CLC DLL3 DYRK1B EHBP1 EID2 EID2B EMX2OS FAM98C FBL FBXO27 FCGBP GLIS3 GMFG
 hsa-mir-1-2 hsa-mir-133a-1 KCNJ16 KCNJ2 KCNK18 KIAA1598 LEUTX LGALS13 LGALS14 LGALS7 LRFN1 
MAP4K1 MED29 MEIS1 MIB1 NT5E PAF1 PAK4 PDZD8 PLEKHG2 RASGRP4 RP11-207F8.1 RP11-268I9.1
 RP11-30P6.1 RP11-30P6.2 RP11-30P6.3 RP11-30P6.4 RP11-30P6.6 RP11-321N4.3
 RP11-33E24.1 RP11-33E24.3 RP11-424A16.1 RP11-501J20.2 RP11 501J20.3 RP11-501J20.5 
RP11-5G18.2 RP1-161C16.1 RP11-70J12.1 RP1-263J7.1 RP1263J7.2 RP1-3J17.3 RP3-455E7.1 RYR1 
SAMD4B SARS2 SLC18A2 SNHG5 SNORA73 SNORA81 SNORD50 snoU13 SNX14 SPRED3 SUPT5H SYNCRIP TEK 
TIMM50 U4 U6 UNC13B VAX1 Y_RNA ZFP36 
PANTHER analysis: 51 mapped ids are found, 104 mapped ids are not found. 
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5.8.7.7 CnLOH in Non Triple Negative DCIS Compared with CnLOH in Triple 
Negative DCIS  
There is CnLOH found in TN DCIS (23/26) that are not observed in non TN DCIS 
(0/33). 
1. p-values < 0.05; 
2. A gene list is mapped from 31 genomic regions found on chromosomes 
6,10,19, 20;   
3. These regions encompass 145 genes altered in TN DCIS; 
Genes: 
 Mar02 5S_rRNA 7SK AC010323.1 AC114273.1 AL023583.1 AL024498.1 AL031123.1 AL031123.2 AL033539.1
 AL033539.2 AL136305.1 AL136307.1 AL136307.2 AL139807.1 AL158198.1 AL158817.1 AL357054.1 AL357497.1 AL662797.1
 ANGPTL4 ATP5GP1 BMP6 C6orf134 C6orf136 C6orf52 CAGE1 CAP2 CCDC90A CD320
 CD83 DHX16 DSP DTD1 EDN1 EEF1A1P34 EEF1E1 ELOVL2 F13A1 FARS2
 GCM2 GCNT2 GCNT6 HDGFL1 HIVEP1 KANK3 KIAA1949 KLF6 LASS4 LPCAT3
 LY86 MAK MRPS18B MUTED NDUFA7 NEDD9 NOL7 NRM NRN1 OFCC1
 PAK1IP1 PIP5K1P1 PPP1R10 PRL PTMAP1 RAB11B RANBP9 RBM24 RIOK1 RNF182
 RP11-125M16.1 RP11-127P7.2 RP11-146I2.1 RP11-184A2.2 RP11-239H6.2
 RP11-239H6.3 RP11-288G3.2 RP11-288G3.3 RP11-288G3.4 RP11-320C15.1
 RP11-339A7.1 RP11-359N11.1 RP11-359N11.2 RP11-360O19.1 RP11-360O19.4
 RP11-360O19.5 RP11-379J5.4 RP11-379J5.5 RP11-405O10.2 RP11-456H18.1
 RP11-456H18.2 RP11-464C19.2 RP11-464C19.3 RP11-556O15.1 RP11-637O19.2
 RP11-69L16.4 RP11-69L16.5 RP11-69L16.6 RP11-716O23.1 RP11-716O23.2 RP1-
182O16.1 RP1-182O16.2 RP1-23O21.1 RP1-273P12.1 RP1-290I10.2 RP1-290I10.3
 RP1-290I10.4 RP1-290I10.5 RP1-290I10.6 RP1-290I10.7 RP1-290I10.8 RP1-
303A1.1 RP1-309H15.2 RP1-62D2.3 RP1-80N2.2 RP3-336K20__B.2 RP3-380B8.1 RP3-380B8.3
 RP3-380B8.4 RP3-380E11.2 RP3-398D13.2 RP3-398D13.3 RP3-429O6.1 RP3-
451B15.3 RP3-470L22.1 RP3-486D24.1 RP3-510L9.1 RP4-761I2.2 RP4-761I2.4 RP5-1068E13.3
 RPL15P3 RPS28 RREB1 snoU13 SNRNP48 SSR1 SYCP2L TFAP2A TMEM14B TMEM14C
 TXNDC5 U1 U6atac U7 Y_RNA 
PANTHER analysis: 51 mapped ids are found, 104 mapped ids are not found. 
 
There is CnLOH found in non TN DCIS (29/33) that are not observed in TN DCIS 
(0/26).  
1. p-values < 0.05; 
2. A gene list is mapped from 70 genomic regions on chromosomes 1, 2, 3, 7, 
10, 19, 20;  
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3. These regions encompass 244 genes altered in non TN DCIS; 
Genes:  
5S_rRNA AC005034.2 AC006039.1 AC007040.5 AC007099.1 AC007099.2 AC007878.1 AC010733.2 AC010733.4 AC010733.7
 AC010744.1 AC010975.1 AC011245.1 AC011455.1 AC012494.1 AC012671.1 AC012671.2 AC016747.3 AC023881.1
 AC062029.1 AC064872.1 AC073628.1 AC078841.5 AC083864.3 AC083864.4 AC084149.1 AC084149.2 AC092660.1
 AC093616.1 AC096540.1 AC098581.1 AC104134.2 AC104135.2 AC104135.3 AC104135.4 AC104170.1 AC108479.1
 AC108479.2 AC110491.1 AC117444.2 AC117444.3 ACOT11 ACPL2 ADARB2 AHSA2 AKIRIN1
 AL031289.1 AL031985.1 AL110502.1 AL161740.1 AL592166.1 AL929472.1 AL929472.3 ARL6 ATP1B3P1
 ATP6V1B1 BAZ1B BEST4 BMP8B BTBD19 C1orf122 C1orf168 C1orf175 C1orf228
 C2orf51 C2orf74 C8A C8B CCDC163P CITED4 CRYBG3 CST1 CST4
 CSTP2 CTNNA2 CTPS DAB1 DEM1 DYSF EBNA1BP2 EDN2 EEPD1
 EGFR EIF2AK3 EIF2B3 EPHA10 EPHA6 EPS15 FABP1 FAM126A FAM151A
 FAM176A FAM183A FHL3 FOXI3 FOXJ3 FOXO6 GABRR3 GRIK3 GUCA2A
 GUCA2B HEYL HIVEP3 HK2 HPCAL4 hsa-mir-30c-1 hsa-mir-30e INPP5B
 KCNQ4 KIAA1841 KIF2C KRCC1 LRRTM4 MANEAL MINA MMACHC MRPS12 MT-
ATP8 MTF1 MYCL1 NDUFA4P2 NDUFS5 NFKBIB NFYC NT5C1A OMA1 OR5AC1
 OR5AC1P OR5AC2 OR5AC4P OR5H1 OR5H14 OR5H15 OR5H2 OR5H3P OR5H4P
 OR5H5P OR5H6 OR5H7P OR5H8P OR5K3 OR5K4 OSBPL9 OXCT2 PABPC4
 PAIP2B PAPOLG PEX13 PLK3 POLE4 POU5F1P7 PPAP2B PPIE PRKAA2
 PTCH2 PUS10 RASA2 RGPD2 RIMS3 RINL RNF220 RP11-109P14.1
 RP11-109P14.10 RP11-109P14.2 RP11-109P14.8 RP11-109P14.9 RP11-124D9.1
 RP11-15J6.1 RP1-118J21.24 RP1-118J21.5 RP11-191G24.1 RP11-191G24.2
 RP11-213P13.1 RP11-215L17.1 RP11-223A3.1 RP11-231L11.1 RP11-231L11.3
 RP11-240D10.2 RP11-240D10.4 RP11-253A20.1 RP11-269F19.2 RP11-269F19.4
 RP11-275F13.1 RP11-275F13.3 RP11-282K6.3 RP11-316C10.1 RP11-319C21.1
 RP11-325B23.2 RP11-343D2.11 RP11-346M10.1 RP11-346M10.2 RP11-348A7.1
 RP11-348A7.2 RP11-377K22.2 RP11-377K22.3 RP11-378I13.1 RP11-399E6.1
 RP11-399E6.2 RP11-399E6.4 RP11-416L21.1 RP11-438D8.2 RP11-438D8.3
 RP11-438D8.4 RP1-144F13.3 RP1-144F13.4 RP11-486B10.3 RP11-486B10.4
 RP11-4H14.1 RP11-526K17.2 RP1-158P9.1 RP11-656D10.3 RP11-656D10.5
 RP11-656D10.6 RP11-764I5.1 RP11-781D11.1 RP11-789L4.1 RP1-21K4.1 RP1-
63P18.2 RP4-564O4.1 RP4-580G13.1 RP4-614N24.1 RP4-635E8.1 RP4-657D16.4
 RP4-657D16.5 RP4-678E16.4 RP4-705F19.1 RP4-705F19.2 RP4-710M16.1
 RP4-710M16.2 RP4-739H11.1 RP4-739H11.3 RP4-783C10.3 RP5-1066H13.4
 RP5-1090E8.1 RP5-1103B4.3 RP5-1180C18.1 RP5-860P4.2 RP5-866L20.1
 RP5-866L20.2 RP5-866L20.3 RP5-882O7.1 RP5-882O7.3 RP5-882O7.4
 RP6-239D12.1 RPIA RPL38 RPS8 SARS2 SCMH1 SF3A3 SIRT2
 SLC25A36 SLFNL1 SMYD1 SNORA26 SNORA63 SNORD112 SNORD38 SNORD46 snosnR61
 snoU109 snoU13 SPSB4 SSBP3 TACR1 TCTEX1D4 TESK2 THNSL2 TMEM53
 TMEM90B TRIT1 TTC39A U2 U5 U6 U7 USP34 UTP11L
 VAX2 WDR65 Y_RNA YRDC ZBTB38 ZNF638 ZNF642 ZNF643 ZNF684
 ZPLD1 
PANTHER analysis: 118 mapped ids are found, 170 mapped ids are not found.  
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5.8.8 Copy Number Aberrations for Pure Triple Negative DCIS Compared to Triple 
Negative DCIS Associated with Invasive Breast Disease 
These series examines the differences between pure triple negative DCIS and triple 
negative DCIS associated with invasive breast disease, i.e. the DCIS component not 
the invasive breast disease.  
Frequency plots showing copy number aberrations between Pure TN DCIS and TN 
DCIS associated with invasive breast disease were provided by Breakthrough Breast 
Cancer/Research Oncology, King’s College London Bioinformatics Department 
(Figure 41). 
 
Figure 41: frequency plots showing copy number aberrations between pure triple 
negative dcis and triple negative DCIS associated with invasive breast disease 
(amplifications, duplications, gains, Sc gains, losses, total losses CdLOH and 
















5.8.8.1 Amplification of Pure Triple Negative DCIS and Triple Negative DCIS 
Associated with Invasive Breast Disease 
No amplifications in TN pure DCIS or TN DCIS associated with invasive breast 
disease were found in this series.  
5.8.8.2 Duplication of TN pure DCIS and TN DCIS Associated with Invasive Breast 
Disease 
No Duplications in TN pure DCIS or TN DCIS associated with invasive breast disease 
found in this series.  
5.8.8.3 Genomic Gains of TN pure DCIS and TN DCIS Associated with Invasive 
breast disease 
There is considerable overlap between the genomic gains seen in TN pure DCIS 
(n=5/9) and TN DCIS associated with invasive breast disease (n=10/10). 
1. p-values < 0.05; 




3. These regions encompass 67 genes altered in TN pure DCIS and TN DCIS 
associated with invasive breast disease; 
Genes:  
5S_rRNA 7SK AC108925.1 ACTN2 AL513363.1 AP000351.1 AP000351.10 AP000351.2 AP000351.6
 AP000351.7 AP000351.8 AP000351.9 CFLP4 CHML CHRM3 CSMD3 EDARADD ENO1P1
 EXO1 FH GSTT1 GSTTP1 GSTTP2 HEATR1 hsa-mir-1204 KMO KRT18P32
 LGALS8 MAP1LC3C MTR NCRNA00210 OPN3 PLD5 PVT1 RP11-149J18.1
 RP11-152L7.1 RP11-152L7.2 RP11-177F15.1 RP11-182B22.2 RP11-307O1.1
 RP11-323D18.1 RP11-323D18.4 RP11-323D18.5 RP11-362H12.1 RP11-371I1.2
 RP11-385F5.2 RP11-385F5.4 RP11-397A15.4 RP11-400N13.1 RP11-439E19.3
 RP11-439E19.5 RP11-439E19.6 RP11-439E19.8 RP11-463J7.2 RP11-488L18.1
 RP11-488L18.8 RP11-544D21.1 RP11-553N16.1 RP11-561I11.2 RP11-561I11.3
 SCCPDH SNORD112 SPATA17 U6 VN1R17P VN1R5 WDR64 
PANTHER analysis: 18 mapped ids are found, 49 mapped ids are not found.  
 
There were gains present in TN DCIS associated with invasive breast disease (n=7/7) 
not observed in pure DCIS (n=0/9). 
1. p-values < 0.05; 
2. A gene list is mapped from 13 genomic regions found on chromosomes 1, 2, 
6, 9;  
3. These regions encompass 69 genes altered in TN DCIS associated with 
invasive breast disease; 
Genes:  
AC002485.1 AC096583.1 AC139712.2 AL158147.1 AL161450.1 AL161450.10 AL161450.11 AL161450.13 AL161450.16
 AL161450.2 AL161450.3 AL161450.4 AL161450.8 AL161450.9 C9orf146 C9orf46 C9orf66 CBWD1 CD274 DMRTA2
 DOCK8 ELAVL4 FAF1 FAM138C FOXD4 hsa-mir-101-2 hsa-mir-1302-2 JAK2
 LAMA2 NFIB PDCD1LG2 PTPRD RCL1 RLN1 RP11-125K10.2 RP11-125K10.4 RP11-125K10.5
 RP11-12D24.6 RP11-12D24.7 RP11-143M1.2 RP11-143M1.3 RP11-143M1.4 RP11-143M1.7
 RP11-183G22.1 RP11-183G22.2 RP11-183G22.3 RP11-25O10.1 RP11-280O24.1
 RP11-284P20.2 RP11-284P20.3 RP11-284P20.4 RP11-32F11.2 RP11-39K24.11
 RP11-39K24.14 RP11-39K24.2 RP11-39K24.4 RP11-39K24.5 RP11-39K24.9 RP11-492I2.1
 RP11-560D2.2 RP11-567C20.2 RP11-567C20.3 RP11-572H4.1 RP11-59O6.3 U6
 XXyac-YRM2039.1 XXyac-YRM2039.2 XXyac-YRM2039.3 ZCCHC11  
PANTHER analysis:  16 mapped ids are found, 53 mapped ids are not found.  
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5.8.8.4 Genomic Sc Gains of TN pure DCIS and TN DCIS Associated with Invasive 
Breast Disease 
There are no significant Sc gains found in pure DCIS in this series. There are Sc gain 
found in TN DCIS associated with invasive breast disease (n=7/10) that mapped ids 
in TN pure DCIS (n=0/9). 
1. p-values<  0.05; 
2. A gene list is mapped from 49 genomic regions found on chromosomes 1, 5, 
6, 8, 9, 20;  
3. These regions encompass 350 genes altered in TN DCIS associated with 
invasive breast disease; 
Genes:  
5S_rRNA 7SK AC008949.1 AC010455.1 AC010491.1 AC010627.1 AC012640.3 AC016553.1 AC016575.1 AC024589.2
 AC025181.1 AC025472.1 AC025647.3 AC034229.1 AC091878.1 AC099784.2 AC106774.1 AC108925.1 AC112200.1 
AC114981.1 AC138409.1 AC138409.2 AC138951.3 AC139783.1 ADAMTS12 AGBL4 AL034429.1 AL035467.1 AL133230.2
 AL136164.1 AL136310.1 AL354933.1 AL357519.1 AL390776.1 AL592166.1 AL596225.1 AL645730.1 AL645730.2 
AMACR ANKH ANKRD33B ANKRD46 BASP1 BEST4 BTBD19 C1orf123 C1orf163 C1orf185
 C1orf228 C1QTNF3 C5orf17 C5orf22 C5orf23 C6orf155 CC2D1B CCT5 CDH12 CDH18
 CDH6 CDH9 CDKN2C CFLP2 CMBL COX6CP2 CPT2 CTB-40H15.1
 CTB-40H15.2 CTB-40H15.3 CTB-55B8.1 CTC-305H11.1 CTC-461F20.1
 CTD-2001E22.1 CTD-2001E22.2 CTD-2004A9.1 CTD-2008E3.1 CTD-2010I22.1
 CTD-2010I22.2 CTD-2011G10.1 CTD-2011G17.1 CTD-2017D15.1 CTD-2023M8.1
 CTD-2057J6.1 CTD-2057J6.2 CTD-2061E9.1 CTD-2066L21.1 CTD-2066L21.2 
CTD-2066L21.3 CTD-2134P3.1 CTD-2138O14.1 CTD-2139B15.1 CTD-2139B15.2 CTD-2139B15.4
 CTD-2139B15.5 CTD-2143L24.1 CTD-2151L9.1 CTD-2151L9.2 CTD-2154B17.1
 CTD-2165H16.1 CTD-2165H16.2 CTD-2165H16.3 CTD-2194F12.1 CTD-2197O4.1
 CTD-2199O4.1 CTD-2201E9.1 CTD-2201E9.2 CTD-2201E9.3 CTD-2201E9.4
 CTD-2203K17.1 CTD-2206G10.1 CTD-2206G10.2 CTD-2215L10.1 CTD-2218G20.1
 CTD-2218G20.2 CTD-2233C11.2 CTD-2233C11.3 CTD-2256P15.1 CTD-2269E23.1
 CTD-2269E23.2 CTD-2290C23.1 CTD-2290C23.2 CTD-2290C23.3 CTD-2290P7.1
 CTD-2313D3.1 CTD-2351A8.1 CTD-2533K21.1 CTD-2533K21.2 CTD-2533K21.3
 CTD-2533K21.4 CTD-3007L5.1 CTD-3065A13.1 CTNND2 DAP DMRTA2
 DMRTB1 ECHDC2 EIF2B3 ELAVL4 ERI3 FAF1 FAM105A FAM105B FAM134B FAM159A
 FAM173B FBXL7 FBXO43 FTHL10 GPX7 GRHL2 GUCA2A GUCA2B HIVEP3 hsa-
mir-30a hsa-mir-30c-2 hsa-mir-579 KB-1615E4.1 KIF2C LAMA2 LRP8 MAGOH Mar11 Mar6
 MTMR12 MYCL1 MYO10 NCALD NPR3 OGFRL1 ORC1L PDZD2 PLK3
 PMCHL1 PRDM9 PRPF38A PTCH2 PTPN1 REV3L RGS22 RIMS1 RNASEN
 RNF19A RNF220 ROPN1L RP11-1023L17.1 RP11-1023L17.2 RP11-1084J3.1 RP11-1084J3.2 
RP11-1084J3.3 RP11-113I22.1 RP11-117D22.1 RP11-117D22.2 RP11-124N3.1
 RP11-124N3.2 RP11-124N3.3 RP11-1250I15.1 RP11-1250I15.2 RP11-1325J9.1
 RP11-154D6.1 RP11-155O18.3 RP11-159C21.3 RP11-159C21.4 RP11-183G22.1
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 RP11-183G22.2 RP11-183G22.3 RP1-118J21.5 RP11-197O8.1 RP11-19O2.1
 RP11-19O2.2 RP11-19O2.4 RP11-1C1.1 RP11-1C1.3 RP11-1C1.4 RP11-1C1.5 RP11-1C1.6 
RP11-1C1.7 RP11-215G15.2 RP11-215G15.3 RP11-215G15.4 RP11-25O10.1 RP11-260E18.1
 RP11-263F15.1 RP11-269F19.2 RP11-269F19.4 RP11-275B7.1 RP11-291J9.1
 RP11-291J9.2 RP11-308B16.1 RP11-308B16.2 RP11-319C21.1 RP11-321E2.10
 RP11-321E2.11 RP11-321E2.12 RP11-321E2.13 RP11-321E2.2 RP11-321E2.3
 RP11-321E2.4 RP11-321E2.5 RP11-321E2.6 RP11-321E2.7 RP11-321E2.8
 RP11-321E2.9 RP11-32F11.2 RP11-36C20.1 RP1-137K24.1 RP11-419C19.1
 RP11-419C19.2 RP11-419C19.3 RP11-42L13.1 RP11-42L13.2 RP11-432M8.1
 RP11-432M8.10 RP11-432M8.11 RP11-432M8.12 RP11-432M8.13 RP11-432M8.14
 RP11-432M8.15 RP11-432M8.16 RP11-432M8.17 RP11-432M8.18 RP11-432M8.19
 RP11-432M8.2 RP11-432M8.3 RP11-432M8.4 RP11-432M8.5 RP11-432M8.6
 RP11-432M8.7 RP11-432M8.8 RP11-432M8.9 RP11-447B18.1 RP11-454P21.1
 RP11-463J7.1 RP11-463J7.2 RP11-463J7.3 RP11-46C20.1 RP11-478A7.1
 RP11-492I2.1 RP11-54F2.1 RP11-560A7.1 RP11-560D2.2 RP11-567C20.2 RP11-567C20.3
 RP11-572H4.1 RP11-572H4.2 RP11-5N11.1 RP11-5N11.2 RP11-5N11.3
 RP11-5N11.4 RP11-5N11.5 RP11-5N11.6 RP11-5N11.7 RP1-167G20.1 RP1-
167G20.2 RP11-81B23.1 RP11-823P9.1 RP11-823P9.3 RP11-93G23.1 RP11-93N19.1 RP11-93N19.2
 RP11-93N19.3 RP1-21K4.1 RP1-251I12.1 RP1-288M22.1 RP1-288M22.2 RP3-331H24.4
 RP3-415N12.1 RP3-487J7.2 RP4-631H13.2 RP4-784A16.1 RP4-784A16.2 RP4-784A16.3
 RP4-784A16.4 RP4-784A16.5 RP4-795A5.1 RP4-796B4.1 RP5-1024G6.2 RP5-
1024G6.5 RP5-850O15.3 RP5-882O7.1 RP5-926E3.1 RPS8 RXFP3 SEMA5A SLC45A2 
SNORA18 SNORA40 SNORD123 SNORD38 SNORD46 snosnR61 snoU13 SPAG1 SUB1 TARS TAS2R1
 TCTEX1D4 TMEM53 TRIO TRIT1 U2 U4 U5 U6 U8 Y_RNA
 ZCCHC11 ZFR ZNF622 ZNF859P ZYG11A ZYG11B 
PANTHER analysis: 84 mapped ids are found, 266 mapped ids are not found.  
5.8.8.5 Losses in TN pure DCIS and TN DCIS Associated with Invasive Breast 
Disease 
There are genomic losses in TN pure DCIS (n=4/9) which were not observed in TN 
DCIS associated with invasive breast disease (n=0/10). 
1. p-values < 0.05; 
2. A gene list is mapped from 7 genomic regions found on chromosomes 7, 16, 
17, 19;  
3. These regions encompass 29 genes altered in TN pure DCIS; 
Genes:  
AC006013.1 AC006480.2 AC008734.1 AC067941.1 AC099758.1 AC131384.1 CALN1 KRT14 KRT16 KRT17
 KRT42P PMS2L4 RP11-166O4.1 RP11-166O4.4 RP11-166O4.5 RP11-166O4.6
 RP11-358M3.1 RP11-421N10.1 RP4-635O5.1 RP4-736H5.1 RP4-736H5.2




PANTHER analysis: 6 mapped ids are found, 23 mapped ids are not found. 
 
There are some similarities in genomic losses in TN DCIS associated with invasive 
breast disease (n=7/10) compared to TN pure DCIS (n=1/9). 
1. p-values < 0.05; 
2. A gene list is mapped from 19 genomic regions found on chromosomes 3, 4, 
5, 13, 14;  
3. These regions encompass 49 genes altered in TN DCIS associated with 
invasive breast disease; 
Genes:  
AC006427.1 AC006427.2 AC006427.3 AC093848.1 AC106868.1 AC107394.1 AC109351.1 AC110766.1 AL590102.1 AL596329.1
 CCKAR CTC-507E12.1 FHIT GPHB5 GPHN KCNH5 KCNIP4 LDB2 MAGI1 PACRGL
 PCDH7 PPP2R5E RHOJ RP11-120A1.1 RP11-141E13.1 RP11-174E22.1 RP11-
174E22.2 RP11-293A21.1 RP11-293A21.2 RP11-308K2.1 RP11-315A17.1 RP11-390C19.1
 RP11-415C15.1 RP11-417M17.1 RP11-429G17.1 RP11-495L18.2 RP11-543A18.1
 RP11-617I14.1 RP11-619J20.1 RP11-93M12.1 SCARNA20 SLIT2 SNORD74
 snoU13 STIM2 SYNE2 TAPT1 TBC1D19 U6 
 
PANTHER analysis: 16 mapped ids are found, 33 mapped ids are not found.  
5.8.8.6 TN DCIS Associated with Invasive breast disease 
There were total losses present in TN pure DCIS (n=8/9) which were not observed in 
TN DCIS associated with invasive breast disease (n=0/10). 
1. p-value<0.05; 
2. A gene list is mapped from 25 genomic regions found on chromosomes 6, 8, 
11, 13, 14, 16, 17, 19, 22;  
3. These regions encompass 72 genes altered in TN pure DCIS; 
Genes:  
AARSD1 ABCC12 ABCC4 AC004019.10 AC004019.17 AC004659.1 AC005513.1 AC008734.1
 AC008734.2 AC087650.1 AC087650.8 AC090427.1 AC100793.2 ADAM5P AL136359.1 AL137001.1 AOC2 AOC3
 ARL4D BRCA1 CACNA1A CCDC105 CECR2 CTD-3199J23.2 DNAH9 EMR2 EMR3 FBXO33
 G6PC GPC5 hsa-mir-2117 IFI35 MBD3L1 MUC16 OLFM4 OR4C3 OR4C45 OR4C5 OR4S1
 OR4X1 OR4X2 OR7A10 OR7A11P OR7A17 OR7A2P OR7A5 OR7C1 OR7C2 PARK2 PSME3
 RND2 RP11-24H2.1 RP11-24H2.2 RP11-301J16.2 RP11-301J16.3 RP11-301J16.5
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 RP11-301J16.7 RP11-442J17.4 RPL27 RTN1 RUNDC1 SLC1A6 SNORA40 U2 U6
 VAT1 Y_RNA ZNF333 ZNF558 
PANTHER analysis: 40 mapped ids are found, 29 mapped ids are not found. 
 
There were total losses present in TN DCIS associated with invasive breast disease 
(n=8/10) which were not observed in TN pure DCIS (n=0/9). 
1. p-values < 0.05; 
2. A gene list is mapped from 32 genomic regions found on chromosomes 3, 4, 
5, 8, 9, 13, 14, 15, 17, 18;  
3. These regions encompass 56 genes altered in TN DCIS associated with 
invasive breast disease; 
Genes: 
 7SK AC021860.1 AC022559.1 AC023385.1 AC034111.1 AC084882.1 AC091133.1 AC096750.1 AC103702.1 AC114477.1
 AC139426.1 AC139426.3 AC139426.4  ACTR10 AL079307.3 AL079307.4 AL079307.5 AL121579.1 AL132989.2 
AL138995.1 AL139021.2 AL163952.2 ARAP2 ARID4A ASPN B4GALNT2 C14orf166 C14orf181 CENPP
 CSMD1 CTD-2015H6.1 CTD-2015H6.2 CTD-2015H6.3 CTD-2244F11.2
 CTD-2325P2.2 DTHD1 ECM2 FAM151B FAM7A1 FMN1 FRMD6 GIP
 GNG2 GREM1 HMGB1L14 HOXB7 HOXB9 IGF2BP1 KIAA0586 KLB KLF3 KLHL5 LIAS
 MITF MSRA MTUS1 OMD PDCD6IP PDS5B PELI2 PRSS55 PSMA3
 RAD51L1 RFC1 RP11-1000B6.2 RP11-212F11.1 RP11-213G21.1 RP11-213G21.2
 RP11-22A3.2 RP11-360F5.1 RP11-360F5.2 RP11-360F5.3 RP11-380B4.2
 RP11-431M7.2 RP11-431M7.3 RP11-501C14.5 RP11-501C14.6 RP11-501C14.7
 RP11-617D20.1 RP11-708H21.1 RP11-83C7.1 RP11-83C7.2 RP13-395E19.1
 RP1L1 RPL9 SCG5 SNF8 SNORA18 snoU13 SPRED1 TIMM9 TMEM156 TOMM20L U1 
U3 U6 U8 UBE2Z WDR19 Y_RNA ZFP36L1 ZFYVE16 
 
5.8.8.7 CdLOH of TN pure DCIS and TN DCIS Associated with Invasive breast 
disease 
There is CdLOH present in TN pure DCIS (n=4/9) which were not observed in TN 
DCIS associated with invasive breast disease (n=0/10) 
1. p-values < 0.05; 




3. These regions encompass 12 genes altered in TN pure DCIS; 
Genes:  
AC006013.1 AC131384.1 CALN1 KRT14 KRT16 KRT17 KRT42P RP11-358M3.1 RP4-635O5.1 RP5-945F2.1 RP5-
945F2.2 RP5-945F2.3 
PANTHER analysis: 4 mapped ids are found, 8 mapped ids are not found.  
 
There is CdLOH present in TN DCIS associated with invasive disease (n=7/10) not 
observed in TN pure DCIS (n=0/9). 
1. p-values < 0.05;  
2. A gene list is mapped from 37 genomic regions found on chromosomes 3, 4, 
5, 8, 13, 14, 15, 17;  
3. These regions encompass 96 genes altered in TN DCIS associated with 
invasive breast disease; 
Genes: 
7SK AC006160.1 AC006160.2 AC006160.4 AC006160.5 AC006445.6 AC006445.7 AC007126.1 AC015688.1 AC020698.1
 AC093848.1 AC098830.1 AC106868.1 AC107394.1 AC110766.1 AC111152.1 ADH1A ADH1B ADH1C 
AL110292.1 BOD1L C14orf53 C4orf47 C5orf13 CCDC110 CDCA2 CLRN2 CTC-459M5.1 CTC-459M5.2
 CTD-2022H16.1 CTD-2192A1.1 EPB41L4A FAM184B FAM189A1 FAM19A4 GBA3 GPM6A
 GPR125 KCNH5 KCNIP4 KSR1 LAP3 LDB2 LGALS9 MED28 MTNR1A 
NCRNA00219 PCDH7 PDLIM3 PPARGC1A PTPRG QDPR RP11-103J17.1 RP11-10G12.1
 RP11-10G12.2 RP11-120A1.1 RP11-141E13.1 RP11-17E2.2 RP11-196P2.1
 RP11-215A19.1 RP11-24D11.1 RP11-279O9.4 RP11-301L8.2 RP11-315A17.1
 RP11-333E5.1 RP11-333E5.2 RP11-341G5.1 RP11-380P13.1 RP11-380P13.2
 RP11-495L18.2 RP11-540E16.2 RP11-556G22.1 RP11-556G22.2 RP11-556G22.3
 RP11-576E20.1 RP11-598O12.1 RP11-598O12.2 RP11-617I14.1 RP11-619J20.1
 RP11-626E13.1 RP11-665I14.1 RP11-696N14.1 RP11-722M1.1 RP11-806K15.1
 RP11-93M12.1 RP13-497K6.1 RPL10AP6 SNORA13 SNORA51 SNORA75 snoU13 SORBS2 
TJP1 U6 WDR17 Y_RNA 
PANTHER analysis: 28 mapped ids are found, 68 mapped ids are not found. 
5.8.8.8 CnLOH of TN pure DCIS and TN DCIS Associated with Invasive Breast 
Disease 
There is CnLOH present in TN pure DCIS (n=9/9) which were not observed in TN 
DCIS associated with invasive breast disease (n=0/10).  
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1. p-values < 0.05; 
2. A gene list is mapped from 74 genomic regions found on chromosomes 1, 2, 
3, 6, 7, 10, 11, 19;  
3. These regions encompass 574 genes altered in TN pure DCIS; 
Genes: 
5S_rRNA 7SK AC002066.1 AC005487.2 AC005779.1 AC010087.1 AC010087.4 AC010087.5 AC011489.2 AC011489.3
 AC013251.1 AC013251.2 AC017083.1  AC017083.2 AC017083.3 AC022210.2 AC023165.1 AC067950.1 AC073130.3 
AC073210.1 AC079112.1 AC084193.1 AC092958.1 AC099680.1 AC104073.1  AC105342.1 AC108697.1 AC117508.1 ACTG2
 ADAM22 ADCY5 AGTR1 AKR1A1 AL008729.1 AL023583.1 AL023807.1 AL023807.2 AL024498.1 AL031785.1
 AL031905.1 AL034372.1 AL035464.1 AL035555.2 AL035670.1 AL049710.1 AL049710.2 AL049710.4 AL050335.1
 AL050335.2 AL079341.1 AL109918.1 AL117340.2 AL117340.3 AL121946.1 AL135912.1 AL136230.1 AL136305.1
 AL137003.1 AL138724.3 AL157773.1 AL162579.1 AL354680.1 AL357079.1 AL357079.2 AL357497.1 AL359316.1
 AL391839.1 AL391839.3 AL445669.2 AL590068.1 AL603888.1 AL604028.1 AL604028.2 ALG1L AP003774.4
 AP003774.5 AP003774.6 AP003774.7 APBB1IP APLNR ARTN ATP5LP5 ATP6V0B ATXN1 B4GALT2
 BCL7B BLOC1S3 BMP5 BPESC1 BRAF BTBD9 BTF3L4 C10orf68 C1D
 C1orf210 C1orf50 C2orf89 C3orf16 C3orf72 C6orf114 C6orf142 C6orf52 C6orf64 CAP2 
CAV2 CCDC14 CCDC17 CCDC23 CCDC24 CCDC30 CCDC88B CCDC90A CCT6P3 CD2AP
 CD83 CEP70 CLDN19 CNRIP1 COL21A1 COL9A2 COMMD2 CTB-54D4.1 CYP26B1
 CYP39A1 DAAM2 DEFB110 DEFB112 DEFB113 DEFB114 DEFB133 DEK DNAH6 DNAH8
 DNAJB9 DNAJC30 DPH2 EBNA1BP2 EDN1 EEF1A1P25 EFHC1 ELOVL2 EPC1
 ERMAP ERV3 ESYT3 EXOC3L2 FAIM FAM8A1 FOXL2 GAPDHP39 GCLC
 GCM2 GCNT2 GCNT6 GEMIN7 GFOD1 GFRAL GJA9 GLO1 GLP1R
 GMPR GPBP1L1 GPR110 GPR111 GPR115 GPR116 GSTA1 GSTA2 GSTA3 GSTA5 
GSTA6P HCRTR2 HIVEP1 HMGCLL1 hsa-mir-1237 hsa-mir-133b hsa-mir-206 hsa-mir-548a-1 hsa-mir-761
 IL17A IL17F INTS4L1 IPO13 IPP IQCJ ITGB1 JAK1 KCNK16 KCNK17
 KCNK5 KDM1B KDM4A KIF13A KIF6 KLHL31 KTI12 LEPRE1 LRFN2
 LRRC1 LRRC55 LRRC68 LTBP4 LYZL2 MAK MAST2 MCM3 MEP1A
 MLXIPL MME MRAS MRPS22 MYCBP MYLIP MYLK NASP NEDD9 NKPD1 NOL7 
NRCAM NRD1 NRP1 NUP153 OFCC1 OSBPL9 P2RY1 PABPC1P10 PAK1IP1 PAQR8
 PDIA5 PFN2 PHACTR1 PIK3CB PIK3R3 PKHD1 PLA2G7 PNO1 PNPLA8 PPCS
 PPIH PPP3R1 PRIM2 PRR23A PRR23B PRR23C PTPLB PTPRF RAB3B
 RAB7A RANBP9 RARRES1 RAVER2 RBM24 RCAN2 RELB RHBDL2 RIMKLA
 RNF13 RNF144B RNF182 RP11-10O22.2 RP11-117F22.1 RP11-121P10.1 RP11-125M16.1
 RP11-127P7.2 RP11-135A24.2 RP11-135A24.4 RP11-146I2.1 RP11-146I2.2
 RP11-14C22.5 RP11-14H3.3 RP11-157D18.2 RP11-163G10.2 RP11-163G10.3
 RP11-163G10.4 RP11-166N17.1 RP11-166N17.3 RP11-167H9.3 RP11-167H9.4
 RP11-184I16.2 RP11-184I16.3 RP11-184I16.4 RP11-192K2.3 RP11-192P3.1
 RP11-192P3.3 RP11-202D20.1 RP11-203H2.1 RP11-203H2.2 RP11-204E9.1
 RP11-221E20.3 RP11-221E20.4 RP11-221E20.5 RP11-228O6.2 RP11-232M24.1
 RP11-253D19.1 RP11-253D19.2 RP11-255N4.2 RP11-255N4.3 RP11-268F1.2
 RP11-268F1.3 RP11-282K6.3 RP11-306L14.1 RP11-322N21.2 RP11-323I14__A.1 RP11-
328P23.2 RP11-330A16.1 RP11-330O11.2 RP11-342D11.3 RP11-342M1.2 RP11-342M1.3
 RP11-342M1.4 RP11-345L23.1 RP11-354I10.1 RP11-359N11.1 RP11-359N11.2
 RP11-360O19.1 RP11-360O19.4 RP11-360O19.5 RP11-379B18.4 RP11-379B18.5
 RP1-137F1.3 RP11-385F7.2 RP11-38P22.2 RP11-392A23.4 RP11-392A23.5 RP11-
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397G17.1 RP1-13D10.2 RP1-13D10.3 RP1-13D10.4 RP1-13D10.5 RP11-401E14.1
 RP11-401E14.2 RP11-411K7.1 RP11-411K7.2 RP11-411K7.4 RP11-411K7.5
 RP11-418B12.1 RP11-420A21.1 RP1-142O9.2 RP11-430C17.1 RP11-446F17.3
 RP11-451G4.2 RP11-451G4.3 RP11-460H18.1 RP11-460H18.2 RP11-460N20.3
 RP11-460N20.4 RP11-460N20.5 RP11-462L8.1 RP11-462L8.2 RP11-466L17.1 
RP11-470H9.1 RP11-472N13.2 RP11-479G22.3 RP11-479G22.5 RP11-479G22.6
 RP11-479G22.7 RP11-501I19.3 RP11-501I19.4 RP11-501O2.1 RP11-501O2.2
 RP11-501O2.3 RP11-501O2.4 RP11-501O2.5 RP11-505J9.1 RP1-151F17.1
 RP11-529G21.4 RP1-152L7.1 RP1-152L7.3 RP1-152L7.5 RP1-152L7.6 RP11-548O1.1 RP11-548O1.3 
RP11-550C4.6 RP11-590C23.1 RP11-598F17.1 RP11-630I5.1 RP11-635I10.1 RP11-637O19.2
 RP11-639B1.1 RP11-63E16.1 RP11-649A16.1 RP11-649A16.5 RP11-651P23.2
 RP11-651P23.3 RP11-651P23.4 RP11-651P23.5 RP11-651P23.6 RP11-666A20.1
 RP11-666A20.3 RP11-666A20.4 RP11-689D3.4 RP11-71N10.1 RP11-722C17.1
 RP11-723O4.2 RP11-735A5.1 RP11-746P2.5 RP11-767N6.2 RP11-767N6.7
 RP11-771D21.2 RP11-788A4.1 RP11-788A4.2 RP11-793K1.1 RP11-795J1.1
 RP11-795J1.2 RP11-797H7.1 RP11-797H7.2 RP11-797H7.3 RP11-797H7.5
 RP11-79N23.1 RP11-7O11.3 RP1-180E22.3 RP11-812I20.2 RP11-90C4.1
 RP11-90C4.2 RP11-90C4.3 RP11-90C4.4 RP1-190J20.2 RP11-91A18.1
 RP11-91A18.4 RP11-91A18.5 RP11-9N20.1 RP1-202I21.3 RP1-202I21.5
 RP1-207H1.2 RP1-207H1.3 RP1-217P22.2 RP1-228H13.1 RP1-228H13.2 RP1-
257A7.4 RP1-273P12.1 RP1-273P12.3 RP1-27K12.2 RP1-27K12.4 RP1-290I10.4 RP1-
290I10.5 RP1-290I10.7 RP1-295F6.2 RP1-304B14.3 RP1-319M7.2 RP13-469O16.1
 RP13-476E20.1 RP1-62D2.3 RP1-71H19.2 RP3-322I12.2 RP3-322L4.2 RP3-335N17.2
 RP3-347E1.2 RP3-365O12.2 RP3-380E11.2 RP3-437C15.1 RP3-445N2.1 RP3-
448I9.1 RP3-448I9.2 RP3-451B15.3 RP3-462C17.1 RP3-486B10.1 RP3-486D24.1 RP3-503A6.2
 RP3-510L9.1 RP4-533D7.3 RP4-533D7.4 RP4-533D7.5 RP4-633H17.2 RP4-
657D16.3 RP4-724P12.1 RP4-753D5.3 RP4-753D5.4 RP4-761I2.2 RP4-761I2.4 RP5-1043E3.1
 RP5-864K19.4 RP5-994D16.3 RP5-994D16.7 RP5-994D16.9 RPL15P3 RPN1
 RPS15AP10 RPS15AP16 RPS17P5 RPS6KA4 RRAGC SEC22A SFRS16 SHKBP1 SHMT1P1
 SIRT5 SLC25A20P1 SLC25A27 SLC35B3 SLC6A9 SMAP2 SNORA15 SNORA22
 SNORA24 SNORA5 SNORA8 SNORD45 SNORD66 snoU13 SOX4 SPTBN4 ST3GAL3 STX1A
 SUCLA2P2 SYCP2L TBC1D7 TBL2 TDRD6 TFAP2B TFAP2D TFEC THAP5 TMEM125
 TMEM14A TMEM14B TMEM14C TMEM69 TMSB10 TNFRSF21 TPMT TRAM2 TRAPPC6A
 TSPAN1 TXNDC12 U1 U3 U6 U7 USP34 VPS37D WBSCR22 WDR92
 WWTR1 Y_RNA YBX1 ZEB1 ZFAND3 ZIC1 ZIC4 ZMYND12 ZNF117
 ZNF138 ZNF273 ZNF296 ZNF438 ZNF643 ZNF691 
PANTHER analysis: 126 mapped ids are found, 331 mapped ids are not found.  
 
There is some overlap in CnLOH in TN DCIS associated with invasive breast cancer 
(n=10/10) and CnLOH in TN pure DCIS (n=5/9). 
This represents CnLOH for TN DCIS associated with invasive breast disease. 
1. p-values < 0.05; 
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2. A gene list is mapped from 49 genomic regions found on chromosomes 1, 2, 
3, 7,10,12,17, 19, 20, 21, X; 
3. These regions encompass 309 genes altered in TN DCIS associated with 
invasive breast disease; 
Genes:  
5S_rRNA AC004455.1 AC004691.5 AC005189.6 AC005537.2 AC005879.1 AC006466.5 AC006960.7 AC006978.1 AC010789.1
 AC015923.1 AC016706.1 AC063927.2 AC063927.3 AC063927.4 AC063927.5 AC063927.6 AC063927.7 AC063927.8
 AC063927.9 AC063944.1 AC068765.1 AC073585.1 AC087069.2 AC113554.1 AC114788.1 AC114788.2 AC138128.1
 ACADSB ACE ACE2 ADCYAP1R1 ADRB1 AF015262.1 AF015262.2 AF015720.3 AF015726.1
 AF020802.1 AF020802.2 AF020802.3 AF020802.4 AL133215.1 AL133387.2 AL135794.1 AL157788.1 AL158014.1
 AL162407.1 AL353664.1 AL355598.1 AL355861.1 AL359747.1 AL359836.1 AL591845.1 AL603764.1 AL731543.1
 ANLN AOAH AP000688.8 AQP1 ARMS2 ATE1 BBX BLVRA BMX
 BRIP1 BTBD16 BTRC BUB3 C10orf118 C10orf119 C10orf120 C10orf2 C10orf46
 C10orf76 C10orf84 C10orf88 C10orf90 C1orf113 C7orf44 CA5B CA5BP CASC2
 CCDC54 CD3EAP CSF3R CUZD1 CYB561 DCAF7 DCLRE1A DLGAP3 DMBT1
 DNMBP DOCK1 DPCD EIF3A ELOVL3 EMX2 EMX2OS ERCC1 FAM176B
 FAM178A FAM188B FAM24A FAM24B FAM45A FBXW4 FGF8 FGFR2 FOSB
 FTLP18 GBF1 GHRHR GLI3 GPAM GRK5 GS1-594A7.3 GS1-594A7.5
 HDAC4 HECW1 HMX2 HMX3 HPS6 hsa-mir-608 hsa-mir-802 HTRA1 IKZF5
 INMT INPP5F INTS2 JAKMIP3 KAZALD1 KCNH6 KCNIP2 KCNK18 KIAA1598
 LBX1 LDB1 LSM10 LZTS2 MGEA5 MRPL43 MRPS15 MRPS24 MT-ATP6 MT-
CO1 MT-CO3 MT-ND1 MT-ND2 MT-ND3 MT-ND4 MT-ND4L MT-ND5 MT-ND6 NANOS1
 NCRNA00093 NHLRC2 NKX2-3 NOLC1 NPM3 NSMCE4A OSCP1 PDZD7
 PDZD8 PITX3 PLEKHA1 POLL PPM1N PPP1R13L PPP1R2P2 PPRC1 PRDX3
 PRLHR PSTK RAB11FIP2 RGS9 RP11-107C16.2 RP11-107I14.1 RP11-107I14.2
 RP11-107I14.4 RP11-107I14.5 RP11-108L7.4 RP11-108L7.7 RP11-129J12.1
 RP11-153N17.1 RP11-162A23.5 RP11-179H18.8 RP11-181E22.1 RP11-190J1.10
 RP11-190J1.3 RP11-190J1.7 RP11-198M6.2 RP11-198M6.5 RP11-214N15.5
 RP11-215A21.2 RP11-223P11.2 RP11-223P11.3 RP11-244H3.1 RP11-244H3.2
 RP11-245J24.1 RP11-248I9.2 RP11-25C19.1 RP11-25C19.3 RP11-280F2.1
 RP11-280F2.2 RP11-282I1.1 RP11-298H24.1 RP11-302K17.3 RP11-302K17.4
 RP11-302K17.7 RP11-309P22.1 RP11-319I23.2 RP11-319I23.3 RP11-31L23.3
 RP11-324L3.1 RP11-328K15.1 RP11-338O1.2 RP11-354M20.3 RP11-36N22.1
 RP11-36N22.3 RP11-381K7.1 RP11-381K7.2 RP11-411P18.2 RP11-446H18.1
 RP11-446H18.3 RP11-446H18.5 RP11-45P22.1 RP11-45P22.2 RP11-462G8.2
 RP11-462G8.3 RP11-498J9.1 RP11-498J9.2 RP11-498J9.4 RP11-500G22.2
 RP11-501J20.2 RP11-501J20.3 RP11-501J20.5 RP11-561O4.1 RP11-564D11.3
 RP11-567J24.4 RP11-56I23.1 RP11-57H14.3 RP11-5G18.2 RP11-781P14.3
 RP11-78C6.1 RP11-79M19.2 RP11-93B21.1 RP13-314C10.5 RP5-1158B12.1
 RP5-877J2.1 RPL23AP3 RPL34P3 RPS20P1 RTN2 RUNX1 SAT1 SCN4A SEC23IP
 SEMA4G SETD4 SFPQ SFXN3 SFXN4 SLC18A2 SNORA19 SNORA63 SNORD112
 SNORD60 snoU13 SORCS3 STK40 TACC2 TANC2 TCERG1L THRAP3 TLX1
 TLX1NB TMEM27 TWIST2 U2 U3 U4 U6 URGCP USP29
 VASP VAX1 VTI1A Y_RNA ZIM3 ZMYM1 ZMYM6 
PANTHER analysis: 134 mapped ids are found, 157 mapped ids are not found. 
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5.8.9 Copy Number Aberrations for Triple Negative Pure DCIS Compared to Triple 
Negative Invasive Breast Disease 
These series examines the difference between pure triple negative DCIS only and TN 
invasive breast disease. 
 
Frequency plots showing copy number aberrations between Pure TN DCIS and TN 
invasive breast disease were provided by Breakthrough Breast Cancer/Research 
Oncology, King’s College London Bioinformatics Department (Figure 42).  
 
Figure 42: Frequency plots showing copy number aberrations between pure triple 
negative DCIS and triple negative invasive breast disease (amplifications, 
















5.8.9.1 Amplification of Pure Triple Negative DCIS and Triple Negative Invasive 
Breast Disease 
No amplifications are found in TN pure DCIS or TN invasive breast disease in this 
series. 
5.8.9.2 Duplication in Pure Triple Negative DCIS and Triple Negative Invasive Breast 
Disease 
There are duplications are found in TN pure DCIS (n=1/9) and TN invasive breast 
disease (n=3/7). 
1. p-values < 0.05; 
2. A gene list is mapped from 13 genomic regions found on chromosomes 2, 6, 
8, 12;  
3. These regions encompass 181 genes altered in TN pure DCIS and TN 
invasive breast disease; 
Genes:  
5S_rRNA 7SK ABCC10 AC012494.1 AC079600.1 AL080315.3 AL096711.1 AL121959.1 AL136304.1 AL136304.2
 AL136304.3 AL451073.1 AL583834.1 ARG1 BMP5 BYSL C6orf108 C6orf132 C6orf15_2 C6orf154
 C6orf174 C6orf192 C6orf226 C6orf58 C8orf85 CCND3 CENPW CLIC5 CNPY3 COL21A1 CRIP3
 CTAGE9 CTGF CUL7 CUL9 DLK2 ECHDC1 EEF1A1P36 EEF1DP5 ENPP1 ENPP3
257 
 
 ENPP4 ENPP5 EYA4 FRS3 GFRAL GNMT GUCA1A GUCA1B HCRTR2 HEY2 HINT3 
HMGB1L13 HMGCLL1 hsa-mir-588 KIAA0240 KLC4 KLHDC3 LAMA2 LRFN2 MEA1 MED20
 MED23 MOXD1 MRPL2 MRPS10 NCOA7 OR2A4 PEX6 PGC POLR1C PPP2R5D PRB2
 PRICKLE1 PRICKLE4 PTCRA PTK7 PTPRK RNF146 RP11-103C16.2 RP11-121P10.1 RP11-
123H21.1 RP11-151M7.1 RP11-162L10.1 RP11-203B4.1 RP11-213N20.1 RP11-228O6.2
 RP11-25I15.1 RP11-295F4.4 RP11-298J23.5 RP11-298J23.6 RP11-314E23.1 RP1-131F15.2
 RP11-325O24.1 RP11-325O24.2 RP11-357P24.2 RP1-139D8.6 RP11-480N24.3 RP11-480N24.4
 RP11-480N24.6 RP11-527F13.1 RP11-527F13.2 RP11-533O20.2 RP11-570K4.1
 RP11-624M8.1 RP11-69I8.2 RP11-69I8.3 RP11-753G20.1 RP11-775I22.2 RP1-177A13.1 RP1-179E13.1
 RP1-283K11.3 RP1-293L8.2 RP1-293L8.5 RP13-469O16.1 RP1-55C23.4 RP1-55C23.5 RP1-
55C23.7 RP1-6P5.2 RP1-78N10.2 RP1-86D1.2 RP1-86D1.3 RP1-86D1.4 RP1-86D1.5 RP1-8B1.4 RP3-323K23.3
 RP3-330M21.5 RP3-337H4.6 RP3-351K20.3 RP3-351K20.4 RP3-403A15.1 RP3-
416F10.1 RP3-447E21.3 RP3-462C17.1 RP3-475N16.1 RP3-523C21.1 RP3-523C21.2 RP5-973N23.4
 RP5-988G15.1 RPL24P4 RPL7L1 RPS12 RSPO3 SCARNA15 SLC22A7 SLC30A8 SNORA33
 SNORA8 SNORD100 SNORD101 snoU13 SRF STX7 TAAR1 TAAR2 TAAR3 TAAR4P
 TAAR5 TAAR6 TAAR7P TAAR8 TAAR9 TAF8 TFEB THEMIS TJAP1 TOMM6 TRERF1 
TRMT11 TTBK1 U4 U6 U7 USP49 VNN1 VNN2 VNN3 XPO5
 Y_RNA YIPF3 ZNF318 
PANTHER analysis: 83 mapped ids are found, 98 mapped ids are not found.  
5.8.9.3 Genomic Gains of Pure Triple Negative DCIS and Triple Negative Invasive 
Breast Disease 
There is overlap in the genomic gains present in TN pure DCIS (n=2/9) and TN 
Invasive breast disease (n=6/7). 
1. p-values < 0.05; 
2. A gene list is mapped from 11 genomic regions found on chromosomes 1, 6, 
8, 10;   
3. These regions encompass 133 genes altered in TN pure DCIS and TN 
invasive breast disease; 
Genes: 
 5S_rRNA 7SK AC099805.1 AL139392.1 AL359983.1 AP001207.1 C1orf150 CAPN11 CFLP4 CHML
 EXO1 EYA1 FH FMN2 GREM2 GRHL2 HSD17B7P1 KIF26B KMO MAP1LC3C
 MRPL14 NCALD NLRP3 OPN3 OR11L1 OR13G1 OR14A16 OR14A2 OR14C36 OR14K1 
OR14L1P OR1C1 OR2AJ1 OR2AK2 OR2B11 OR2C3 OR2G2 OR2G3 OR2G6 OR2L13 OR2L1P
 OR2L2 OR2L3 OR2L5 OR2L8 OR2M1P OR2M2 OR2M3 OR2M4 OR2M5 OR2M7 OR2T1 
OR2T10 OR2T11 OR2T12 OR2T2 OR2T29 OR2T3 OR2T33 OR2T34 OR2T35 OR2T4 OR2T5
 OR2T6 OR2T8 OR2W3 OR2W5 OR6F1 OR9H1P PLD5 RGS7 RP11-132G10.2
 RP11-177F11.1 RP11-314P12.2 RP11-323D18.1 RP11-323D18.4 RP11-323D18.5
 RP11-331N16.1 RP11-397A15.4 RP11-407H12.4 RP11-407H12.8 RP11-430I15.2
 RP11-430I15.4 RP11-435F13.1 RP11-435F13.2 RP11-438F14.1 RP11-438F14.3
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 RP11-438H8.3 RP11-438H8.8 RP11-438H8.9 RP11-439E19.3 RP11-439E19.5
 RP11-439E19.6 RP11-439E19.8 RP11-463J7.1 RP11-463J7.2 RP11-463J7.3
 RP11-467I20.2 RP11-467I20.3 RP11-467I20.4 RP11-467I20.5 RP11-467I20.6 RP11-488L18.1
 RP11-488L18.8 RP11-513D4.1 RP11-513D4.2 RP11-513D4.3 RP11-553N16.1
 RP11-561I11.2 RP11-561I11.3 RP11-634B7.1 RP11-634B7.4 RP11-634B7.5
 RP11-80B9.1 RP11-80B9.2 RP11-80B9.4 RP11-80B9.5 RP11-978I15.10
 RP11-978I15.9 RSL24D1P4 SCCPDH SLC29A1 SNORD112 snoU13 TMEM63B TRIM58 U5 U6
 VN1R17P VN1R5 WDR64 XXyac-YR14BB7.1 Y_RNA 
PANTHER analysis: 62 mapped ids are found, 71 mapped ids are not found. 
 
There are genomic gains present in some samples of TN invasive breast disease 
(n=2/9), none of which are observed in TN pure DCIS (n=0/9). 
1. p-values < 0.005; 
2. A gene list is mapped from 2 genomic regions on chromosome 3;  
3. These regions encompass 17 genes altered in TN invasive breast disease; 
Genes: 
AC133435.2 AC112504.2 RNF7 GRK7 ATP1B3 TFDP2 AC128648.1 GK5 RP11-340E6.1 RP11-340E6.2
 RP11-144C9.1 RP11-271K21.2 RP11-271K21.4 RP11-271K21.7 RP11-343B5.1 AC133435.1 U6 
PANTHER analysis: Number of mapped IDs found 5, 12 mapped ids are not found.  
Genomic Sc Gains in TN pure DCIS and TN Invasive Breast Disease 
There are no Sc gains in TN pure DCIS in this series (n=0/9). Sc gains are, however,  
present in TN invasive breast disease (n=4/7).  
1. p-values < 0.05;  
2. A gene list is mapped from 14 genomic regions found on chromosomes 1, 3, 
8;  
3. These regions encompass 143 genes altered in TN invasive breast disease; 
Genes: 
5S_rRNA AC023165.1 AC092898.1 AC092902.1 AC099805.1 AC112484.1 AC112504.2 AC117401.1 AC117508.1 AC128648.1
 AC133435.1 AC133435.2 ACAD9 ADCY5 ALDH1L1 ALG1L ATP1B3 C3orf15 C3orf22 C3orf37
 CCDC14 CCDC48 CHCHD6 CHST13 CNBP COPG COX17 ENO1P3 EYA1 GK5 GP9
 GRAMD1C GRK7 GS1-388B5.1 GS1-388B5.2 GS1-388B5.3 GS1-388B5.4 GS1-388B5.5
 GS1-388B5.6 GS1-388B5.7 GS1-388B5.8 GSK3B H1FX HEG1 hsa-mir-548i-1 ISY1
 ITGB5 KALRN KIAA1257 KIAA1407 MUC13 MYLK NR1I2 OSBPL11 PLXNA1 POPDC2 PTPLB 
QTRTD1 RAB43 RAB7A RNF7 ROPN1 ROPN1B RP11-124N2.1 RP11-124N2.2 RP11-124N2.3
 RP11-144C9.1 RP11-158I23.1 RP11-169N13.1 RP11-169N13.4 RP11-18H7.1 RP11-190C22.1
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 RP11-197K3.1 RP11-202D20.1 RP11-221E20.3 RP11-221E20.4 RP11-221E20.5 RP11-255E6.1
 RP11-271K21.2 RP11-271K21.4 RP11-271K21.7 RP11-290K4.2 RP11-340E6.1
 RP11-340E6.2 RP11-343B5.1 RP11-379B18.1 RP11-379B18.2 RP11-379B18.3
 RP11-379B18.4 RP11-379B18.5 RP11-390G14.1 RP11-434H6.2 RP11-435F17.1
 RP11-435F17.3 RP11-463J7.1 RP11-463J7.2 RP11-463J7.3 RP11-521J5.1
 RP11-529F4.1 RP11-605F14.1 RP11-605F14.2 RP11-605F14.3 RP11-666A20.1 RP11-666A20.3
 RP11-666A20.4 RP11-689D3.4 RP11-71H17.1 RP11-71H17.6 RP11-722C17.1
 RP11-723O4.2 RP11-723O4.3 RP11-723O4.6 RP11-723O4.7 RP11-723O4.8
 RP11-767L7.1 RP11-767L7.2 RP11-775J23.1 RP11-775J23.2 RP11-9N20.1 RP13-685P2.4
 RP13-685P2.5 RPS15AP16 RPS27P12 RSRC1 SHOX2 SLC12A8 SLC41A3 SNORA24 SNORA5
 snoU13 SNX4 TFDP2 TXNRD3 TXNRD3IT1 U1 U6 UMPS UROC1 Y_RNA
 ZBTB20 ZDHHC23 ZNF148 ZXDC 
PANTHER analysis: 51 mapped ids are found, 92 mapped ids are not found.  
5.8.9.4 Genomic Losses in TN pure DCIS and TN Invasive Breast Disease 
There are genomic losses found in TN pure DCIS (n=1/9) also present in TN invasive 
breast disease (n=5/7).  
1. p-values >0.05; 
2. A gene list is mapped from 28 genomic regions found on chromosomes 4, 14, 
15, 19;  
3. These regions encompass 165 genes altered in TN pure DCIS and TN 
invasive breast disease;  
Genes:  
Y_RNA 5S_rRNA 7SK ABLIM2 AC011912.1 AC012379.1 AC012379.2 AC013452.1 AC013452.2 AC018926.1
 AC084882.1 AC090427.1 AC093680.1 AC093827.1 AC093848.1 AC097381.1 AC104059.1 AC104650.2 AC106868.1 AC107394.1
 AC108516.1 AC109351.1 AC110766.1 ACOX3 ADH1A ADH1B ADH1C ADH7 AF146191.4 AF250324.2
 AFAP1 AFF1 AGPAT9 AIMP1 AL133444.1 AL160471.2 AL160471.3 ANXA3 AP001962.3 ARD1B
 ARHGAP24 ARHGEF38 C15orf33 C4orf12 C4orf17 C4orf23 C4orf36 C4orf6 CCPG1 CEP152
 CGRRF1 COPS2 CPZ CRMP1 DAPP1 DNAJB14 DTWD1 EMR2 EVC EVC2
 FAM175A FAM190A FBN1 FGF5 FGF7 FOXA1 FRAS1 FRG1 FRMD6 GALK2
 GCH1 GK2 GMPSP GPR78 GSTCD H2AFZ hsa-mir-95 HSD17B11 HSD17B13 HTRA3
 INTS12 KLHL8 MAPK10 MAPKSP1 MIPOL1 MTTP NID2 NPNT NUDT9 OR7E94P
 PCDH7 PIGB PRDM8 PTPN13 RAB27A RASGEF1B RG9MTD2 RP11-112L18.1 RP11-11N6.1
 RP11-1258F18.1 RP11-15B17.1 RP11-15B17.4 RP11-162K6.1 RP11-174E22.1
 RP11-174E22.2 RP11-218C23.1 RP11-234K19.1 RP11-234K19.2 RP11-274J2.1
 RP11-311D14.1 RP11-311D14.2 RP11-377G16.2 RP11-390C19.1 RP11-397E7.1
 RP11-397E7.2 RP11-397E7.3 RP11-397E7.4 RP11-417M17.1 RP11-42A4.1
 RP11-438E5.1 RP11-452C8.1 RP11-45L9.1 RP11-463J17.1 RP11-476C8.1 RP11-476C8.2
 RP11-476C8.3 RP11-529H2.1 RP11-610O8.1 RP11-617I14.1 RP11-656C2.1
 RP11-689K5.3 RP11-689P11.2 RP11-689P11.3 RP11-696N14.1 RP11-696N14.3
 RP11-710E1.1 RP11-710F7.2 RP11-710F7.3 RP11-722P15.1 RP11-766F14.1
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 RP11-766F14.2 RP11-767N15.1 RP11-774O3.1 RP11-774O3.2 RP11-774O3.3
 RP11-778J15.1 RP11-792D21.1 RP11-792D21.2 RP11-8L2.1 RP11-93M12.1 RP13-612N21.1
 RSL24D1 SAMD4A SH3TC1 SHC4 SLC10A6 SNORA75 snoU13 SPARCL1 STK32B TBCK U5
 U6 U6atac WDFY3         
PANTHER analysis: 67 mapped ids are found, 98 mapped ids are not found. 
 
There are genomic losses found in TN invasive breast disease (5/7) not observed in 
TN pure DCIS (0/9). 
1. p-values < 0.05;  
2. A gene list is mapped from 8 genomic regions found on chromosomes 4, 8,14, 
18, X;  
3. These regions encompass 33 genes altered in TN invasive breast disease; 
Genes:  
 AC018797.3 AF196969.5 AF196972.1 AF196972.9 AF213884.1 AF224669.3 AKAP6 AL592043.1 BMX EBP
 FAM47A FTSJ1 MANBA NFKB1 PIR PORCN RBM3 RP11-10L12.1 RP11-10L12.2
 RP11-10L12.4 RP11-10L12.5 RP11-10L12.6 RP11-1148L6.5 RP11-1148L6.6
 RP11-281B1.2 RP11-305F18.1 RP11-545D19.1 RP13-202B6.2 SMAD4 snoU13
 TBC1D25 UBE2D3 WDR13        
       
PANTHER analysis: 14 mapped ids are found, 19 mapped ids are not found.  
 
5.8.9.5 Total Loss in TN pure DCIS and TN Invasive Breast Disease 
There are total genomic losses present in TN pure DCIS (n=8/9) not observed in TN 
invasive breast disease (n=0/7). 
1. p-values < 0.05; 
2. A gene list is mapped from 23 genomic regions found on chromosomes 6, 
8, 11, 13, 14, 17, 19;   
3. These regions encompass 69 genes altered in TN pure DCIS; 
Genes: 
 AARSD1 ABCC4 AC004659.1 AC005513.1 AC008734.1 AC008734.2 AC087650.1 AC087650.8 AC090427.1 AC100793.2
 ACTL9 ADAM5P ADAMTS10 AL136359.1 AL137001.1 AOC2 AOC3 ARL4D BRCA1
 CACNA1A CCDC105 CTD-2557P19.1 CTD-3199J23.2 EMR2 EMR3 FBXO33
 G6PC GPC5 hsa-mir-2117 IFI35 MBD3L1 MUC16 MYO1F OLFM4 OR2Z1
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 OR4C3 OR4C45 OR4C5 OR4S1 OR4X1 OR4X2 OR7A10 OR7A11P OR7A17
 OR7A2P OR7A5 OR7C1 OR7C2 PARK2 PSME3 RND2 RP11-24H2.1 RP11-24H2.2
 RP11-301J16.2 RP11-301J16.3 RP11-301J16.5 RP11-301J16.7 RP11-442J17.4
 RPL27 RTN1 RUNDC1 SLC1A6 SNORA40 U2 U6 VAT1 Y_RNA
 ZNF333 ZNF558 
PANTHER analysis: 41 mapped ids are found, 28 mapped ids are not found. 
 
There are total genomic losses present in TN invasive breast disease (n=7/7) not 
observed in TN pure DCIS (n=0/9). 
1.  p-values < 0.05;  
2. A gene list is mapped from 30 genomic regions found on chromosomes 4, 8, 
13, 14, 15, 17;  
3. These regions encompass 112 genes altered in TN invasive breast disease; 
Genes:  
5S_rRNA AC005324.1 AC005324.2 AC005324.4 AC005324.6 AC005324.7 AC007686.1 AC015922.1 AC015922.2 AC015922.7
 AC090283.1 AC090283.3 AC096750.1 AC098487.1 ADCK1 AF111168.1 AF111168.3 AHSA1 AL049775.1 AL136160.1
 AL357172.1 AL359180.1 ALKBH1 ARD1B ATP5C1P1 C13orf23 C13orf36 C14orf148 C14orf156 C14orf174
 C14orf178 C14orf184 CACNA1G CATSPERB CNOT6L CTD-2175M1.1 DDIT4L DYNLL1P1 FLRT2
 GAPDHP34 GK2 GNG5P5 GSTZ1 hsa-mir-1260 IL6STP1 ISM2 KIAA1737 KRT222 KRT24
 KRT25 LHFP LMO7 MEIS3P1 MTUS1 NGB NHLRC3 NRXN3 OR7E94P POMT2 RASGEF1B
 RFXAP RP11-15B17.1 RP11-16L6.3 RP11-197L7.2 RP11-226P1.1 RP11-234K19.1 RP11-234K19.2
 RP11-299L17.1 RP11-352E6.1 RP11-352E6.2 RP11-421P11.5 RP11-438E5.1 RP11-452C8.1
 RP11-478K15.1 RP11-478K15.2 RP11-478K15.3 RP11-478K15.4 RP11-478K15.5
 RP11-499E18.1 RP11-527F15.1 RP11-588P8.1 RP11-610O8.1 RP11-624A4.1
 RP11-689K5.3 RP11-765K14.1 RP11-94C24.10 RP11-94C24.11 SLC39A8 SMAD9
 SMARCE1 SNORA32 SNORA46 SNORA75 snoU13 SNW1 SPTLC2 STOML3 STON2 TBC1D26 TMED8
 TMEM63C TRIM16 U3 U7 UBE2Z VEGFC VIPAR Y_RNA ZDHHC22 ZNF286
 ZNF29P 
PANTHER analysis: 39 mapped ids are found, 72 mapped ids are not found.  
5.8.9.6 CdLOH of TN pure DCIS and TN Invasive Breast Disease 
There is CdLOH present in TN pure DCIS (n=1/9) also present in TN invasive breast 
disease (n=5/7). 
1. p-values>0.05; 




3. These regions encompass 128 genes altered in TN pure DCIS and TN 
invasive breast disease; 
Genes:  
5S_rRNA 7SK ABLIM2 AC011912.1 AC012379.1 AC012379.2 AC013452.1 AC013452.2 AC018926.1 AC084882.1
 AC093680.1 AC093827.1 AC093848.1 AC097381.1 AC104059.1 AC106868.1 AC108516.1 AC109351.1 ACOX3 AF146191.4
 AF250324.2 AFAP1 AFF1 AGPAT9 AIMP1 AL133444.1 AL160471.2 AL160471.3 ANXA3 AP001962.3
 ARHGAP24 ARHGEF38 C15orf33 C4orf23 C4orf36 C4orf6 CCPG1 CEP152 CGRRF1 COPS2 CPZ
 CRMP1 DAPP1 DNAJB14 DTWD1 EVC EVC2 FBN1 FGF5 FGF7 FOXA1
 FRAS1 FRG1 FRMD6 GALK2 GCH1 GPR78 GSTCD H2AFZ HSD17B11 HSD17B13
 HTRA3 INTS12 KLHL8 MAPK10 MAPKSP1 MIPOL1 NID2 NPNT NUDT9 PIGB
 PRDM8 PTPN13 RAB27A RASGEF1B RP11-112L18.1 RP11-15B17.1 RP11-15B17.4
 RP11-162K6.1 RP11-174E22.1 RP11-174E22.2 RP11-218C23.1 RP11-274J2.1
 RP11-311D14.1 RP11-311D14.2 RP11-377G16.2 RP11-390C19.1 RP11-397E7.1
 RP11-397E7.2 RP11-397E7.3 RP11-397E7.4 RP11-417M17.1 RP11-42A4.1
 RP11-45L9.1 RP11-463J17.1 RP11-476C8.1 RP11-476C8.2 RP11-476C8.3 RP11-529H2.1
 RP11-656C2.1 RP11-689K5.3 RP11-689P11.2 RP11-689P11.3 RP11-710E1.1
 RP11-710F7.2 RP11-710F7.3 RP11-766F14.2 RP11-767N15.1 RP11-774O3.1
 RP11-774O3.2 RP11-774O3.3 RP11-778J15.1 RP11-792D21.1 RP11-792D21.2
 RP11-8L2.1 RP13-612N21.1 RSL24D1 SAMD4A SHC4 SLC10A6 snoU13 SPARCL1 STK32B
 TBCK U5 U6 U6atac Y_RNA+AA1:A128 
PANTHER analysis: 56 mapped ids are found, 72 mapped ids are not found.  
 
There is CdLOH present in TN invasive breast disease (n=4/7) not observed in TN 
pure DCIS (0/9). 
1. p-values < 0.05; 
2. A gene list is mapped from 103 genomic regions found on chromosomes 4, 5, 
8, 9, 10, 12, 13, 14, 15, 16, 18, X;  
3. These regions encompass 433 genes altered in TN invasive breast disease; 
Genes:  
5S_rRNA AC003658.1 AC004053.1 AC006160.1 AC006160.2 AC006160.4 AC006160.5 AC006445.1 AC006445.6 AC006445.7
 AC006445.8 AC007126.1 AC007956.2 AC008245.1 AC010296.1 AC013558.1 AC018413.1 AC018558.1 AC019131.2 AC020698.1
 AC023824.2 AC034110.1 AC034110.2 AC068473.1 AC090360.1 AC091551.1 AC091602.1 AC091646.1 AC092621.1 AC092846.1
 AC093628.1 AC093848.1 AC096742.1 AC098830.1 AC105423.1 AC106785.1 AC106785.10 AC106785.14
 AC106785.18 AC106785.20 AC106785.22 AC106785.25 AC106785.27
 AC106785.28 AC106785.6 AC106868.1 AC111152.1 AC114688.1 AC116553.1 AC134978.1 AC139100.1 ACTBP1
 ACYP1 ADH1A ADH1B ADH1C ADH4 ADH5 ADH7 ADNP2 AF196970.3 AF196972.3
 AF196972.4 AF213884.1 AF241726.2 AF241726.4 AF241726.6 AKAP6 AL096700.1 AL096700.2 AL121578.2 AL132716.1
 AL132716.2 AL132777.1 AL132777.2 AL132988.1 AL132988.2 AL132988.3 AL132988.4 AL359219.1 AL445487.1 AL591394.1
 AL929101.1 ANXA10 AP002075.1 ARAF ASB5 ATP8A1 ATP9B B3GALTL BANK1 BCL2
 BDH2 BOD1L C13orf26 C13orf33 C14orf149 C14orf38 C14orf53 C15orf43 C18orf22 C4orf37
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 C8orf75 CDH7 CENPE CENPVL1 CFP CHST7 CISD2 CLRN2 COMMD10 CTB-118N6.3
 CTC-339F2.2 CTD-2022H16.1 CTD-2522E6.4 CTDP1 CXorf24 CXorf25 CXorf31
 CXXC4 CYP4V2 DCTN2 DDIT3 DDX60 DDX60L DLST DUOX1 DUOX2 DUOXA1
 DUOXA2 DUSP4 EEF1DP3 EGLN3 EIF2B2 EIF4E ELK1 EMCN FAM149A FAM164C
 FAM177A2 FAM184B FANCB FCF1 FRY FTLP16 FTSJ1 GALR1 GBA3 GLRA2
 GPR125 GPR64 GSPT2 hsa-mir-1255a hsa-mir-221 hsa-mir-222 hsa-mir-616 HSBP1L1 HSP90AB2P
 HSPH1 INE1 JKAMP KCNG2 KCNH5 KCNIP4 KIAA0317 KIF5A KLF12 KLHL4
 KLKB1 KRT8P14 LAP3 LDB2 LRRC9 LTBP2 MAGED1 MAGED4 MAGED4B MAP3K15
 MARS MBD6 MBP MED28 METAP1 MEX3C MLH3 MNAT1 MOSPD2 MTNR1A
 NDUFB11 NEK9 NFATC1 NFKB1 NHEDC1 NHEDC2 NKX3-2 NOVA1 NPAS3 NUS1P1 OTC
 PARD6G PCDH7 PCTK1 PDHA1 PGF PHF16 PHKA2 PPARGC1A PPEF1 PPP3CA
 PQLC1 PROX2 QDPR RAB28 RAD23B RBM10 RGN RP11-109E24.1 RP11-10G12.1
 RP11-10G12.2 RP11-10L12.4 RP11-1148L6.6 RP11-114H20.1 RP11-120A1.1
 RP11-123O22.1 RP11-1299A16.1 RP11-1299A16.2 RP11-141E13.1 RP11-159J2.1
 RP11-159J2.2 RP11-162A12.1 RP11-167N19.1 RP11-167N19.2 RP11-173M11.1
 RP11-173M11.2 RP11-173P16.2 RP11-17E2.2 RP11-196I18.2 RP11-196I18.3
 RP11-196I18.4 RP11-198M15.1 RP11-200A24.1 RP11-207N4.2 RP11-207N4.3
 RP11-215A19.1 RP11-22B10.3 RP11-234P3.2 RP11-234P3.3 RP11-234P3.4
 RP11-234P3.5 RP11-245M24.1 RP11-24D11.1 RP11-252M21.1 RP11-252M21.3
 RP11-252M21.4 RP11-252M21.6 RP11-252M21.7 RP11-289C17.1 RP11-289C17.2
 RP11-292B1.1 RP11-292B1.2 RP11-297P16.1 RP11-297P16.3 RP11-297P16.4
 RP11-305F18.1 RP11-30C8.1 RP11-30C8.2 RP11-310I9.1 RP11-311P8.1
 RP11-311P8.2 RP11-315A17.1 RP11-324B6.1 RP11-328K4.1 RP11-333E5.1
 RP11-333E5.2 RP11-341G5.1 RP11-367C11.2 RP11-380P13.1 RP11-380P13.2 RP1-
138A5.1 RP11-38O23.3 RP11-38O23.4 RP11-38O23.5 RP11-38O23.7 RP11-417L14.1
 RP11-428B4.2 RP11-433O3.1 RP11-451L9.2 RP11-451L9.3 RP11-45F23.1
 RP11-462G22.1 RP11-473D24.1 RP11-474L7.4 RP11-495L18.2 RP11-498M5.2
 RP11-499E18.1 RP11-49F1.1 RP11-508N12.2 RP11-508N12.3 RP11-508N12.4 RP11-552E4.2
 RP11-552E4.3 RP11-552E4.4 RP11-556G22.1 RP11-556G22.2 RP11-556G22.3
 RP11-56H2.1 RP11-571E6.1 RP11-571E6.3 RP11-571E6.4 RP11-571L19.2
 RP11-571L19.4 RP11-576E20.1 RP11-617I14.1 RP11-619J20.1 RP11-644A7.1
 RP11-655M19.1 RP11-665C14.1 RP11-665C14.2 RP11-665I14.1 RP11-692P14.1
 RP11-696N14.1 RP11-696N14.3 RP11-6C14.1 RP11-703G6.1 RP11-729M20.1
 RP11-75A9.1 RP11-75A9.2 RP11-75A9.3 RP11-769N22.1 RP11-799A12.1
 RP11-799A12.2 RP11-87F15.2 RP1-212G6.4 RP1-30G7.2 RP13-43E11.1 RP13-479F17.2
 RP13-497K6.1 RP13-928P6.3 RP1-54B20.7 RP1-71L16.1 RP1-71L16.2 RP1-71L16.3 RP1-71L16.6 RP2
 RP3-393P12.1 RP3-393P12.2 RP3-393P12.3 RP3-436M11.3 RP3-499B10.3 RP3-
499B10.4 RP3-499B10.5 RP4-733D15.1 RP4-774G10.1 RP5-1158E12.1 RP5-1158E12.2
 RP5-1158E12.3 RP5-972B16.2 RP6-227L5.1 RP6-227L5.2 RP6-99M1.1 RPGR RPS6KL1 RTN1
 RXFP2 SALL3 SEMA6A SLC25A21 SLC38A5 SLC38A6 SLC7A1 SLC9A7 SMAD4 SNORA11
 SNORA25 SNORA31 SNORA7 SNORA75 SNORD37 snosnR60_Z15 snoU13 SOCS6 SORD
 SPACA5 SPACA5B SPCS3 SRPX SSX5 SSX6 STAMBPL1 SUV39H1 SYN1 SYTL5
 TACR3 TIMP1 TJP1 TLR3 TMED10 TRMT5 TSHZ1 TSPAN5 TSPAN7 TXNL4A U1
 U12 U2 U3 U4atac U6 U7 U70984.1 UBA1 UBE2D3 UNC13C
 UPRT USP11 UXT WAS WDR72 Y_RNA YLPM1 Z98304.1 ZADH2 ZDHHC15
 ZNF157 ZNF182 ZNF236 ZNF41 ZNF462 ZNF516 ZNF630 ZNF673 ZNF674 ZNF81 
PANTHER analysis: 163 mapped ids are found, 270 mapped ids are not found.  
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5.8.9.7 CnLOH of TN pure DCIS and TN Invasive Breast Disease 
There is CnLOH present in TN pure DCIS (n=9/9) not observed in TN invasive breast 
disease (n=0/7). 
1. p-values < 0.05; 
2. A gene list is mapped from 110 genomic regions found on chromosomes 1, 2, 
3, 6, 7, 10, 11, 12, 20, 21;  
3. These regions encompass 891 genes altered in TN pure DCIS; 
Genes: 
 5S_rRNA 7SK ABHD11 AC004975.1 AC004979.1 AC004979.2 AC004979.3 AC004979.4 AC004979.5 AC004979.6 AC004979.7
 AC005537.2 AC005586.2 AC006021.1 AC007092.1 AC007238.1 AC007560.1 AC007680.2 AC007682.1 AC007682.2 AC008173.1
 AC010087.1 AC010087.4 AC010087.5 AC012361.1 AC012368.1 AC012368.2 AC013251.1 AC013251.2 AC016727.3 AC016894.1
 AC017083.1 AC017083.2 AC017083.3 AC018462.2 AC018462.3 AC022210.2 AC023115.1 AC023115.3 AC023165.1 AC025594.1
 AC025594.2 AC064868.1 AC067950.1 AC069304.1 AC073422.1 AC073464.11 AC073464.9 AC073846.1 AC073846.2 
AC073846.3 AC074289.1 AC078811.1 AC078941.1 AC079112.1 AC079807.4 AC083868.1 AC083883.1 AC092898.1 AC092902.1
 AC092910.1 AC092910.2 AC092958.1 AC093087.1 AC093168.1 AC097463.1 AC097463.2 AC106874.1 AC106874.3 AC107081.1
 AC107081.2 AC107081.5 AC108039.1 AC108039.2 AC108039.3 AC108462.1 AC108697.1 AC108729.1 AC108739.1 AC112484.1 -
AC112694.1 AC114752.1 AC114808.2 AC114808.3 AC117401.1 AC117472.1 AC117472.2 AC117508.1 AC126182.1 AC131571.1
 AC131571.2 AC138655.4 AC144441.1 ACAD9 ACTG2 ACTGP9 ACTR3C ADCY5 AF131217.1 AF227510.7 AGK
 AGTR1 AKR1A1 AL008729.1 AL022170.1 AL023583.1 AL023807.1 AL023807.2 AL024498.1 AL034372.1 AL035670.1 
AL049635.1 AL049635.2 AL049710.1 AL049710.2 AL049710.4 AL050335.1 AL050335.2 AL109918.1 AL121946.1 AL133268.1
 AL136230.1 AL136305.1 AL137003.1 AL138724.3 AL139044.2 AL157773.1 AL160037.2 AL160400.1 AL160400.2 AL162579.1
 AL354680.1 AL357079.1 AL357079.2 AL357497.1 AL359316.1 AL445669.2 AL589723.1 AL590062.1 AL603888.1 AL604028.1 
AL604028.2 AL645811.1 ALG1L ALK ANKRD20B APOB ARGFX ARTN ASB3 ASS1P1 ATP5LP2
 ATP5LP5 ATP6V0B ATP6V1F ATXN1 B3GNT1 B4GALT2 BAK1 BBS9 BCL7B BMP5
 BPESC1 BTF3L4 C1D C1orf210 C1orf50 C1orf84 C2orf43 C2orf89 C3orf16 C3orf22 C3orf33 C3orf37
 C3orf72 C6orf114 C6orf142 C6orf227 C6orf52 C7orf29 C7orf55 CAP1 CAP2 CCDC136 CCDC14
 CCDC17 CCDC23 CCDC24 CCDC30 CCDC48 CCDC90A CCT4 CD2AP CD83 CD96 CEP70
 CHCHD6 CHST13 CLDN19 CLDN3 CLDN4 CLEC5A CMAH CNBP COL21A1 COL9A2 COMMD1
 COMMD2 COPG COX6B1P1 CTD-2021J15.1 CTD-2021J15.2 CYP26B1 CYP39A1 DEFB110
 DEFB112 DEFB113 DEFB114 DEFB133 DEK DNAH6 DNAJB6 DNAJC30 DPH2 EBNA1BP2
 EDN1 EEF1A1P25 EFHC1 ELOVL2 ELP4 ENO1P3 EPCAM ERBB3 ERMAP ESYT3 FABP7
 FAIM FAM161A FAM65B FAM8A1 FBXO40 FLNC FOXL2 FOXN2 FSTL1 GAPDHP39
 GCLC GCM2 GCNT2 GCNT6 GFOD1 GFRAL GGNBP1 GIMAP2 GIMAP4 GIMAP6 GIMAP7
 GIMAP8 GJA9 GMNN GMPR GMPS GP9 GPBP1L1 GPR110 GPR111 GPR115
 GPR116 GPR156 GRM8 GS1-388B5.1 GS1-388B5.2 GS1-388B5.3 GS1-388B5.4
 GS1-388B5.5 GS1-388B5.6 GS1-388B5.7 GS1-388B5.8 GSK3B GSTA1 GSTA2 
GSTA3 GSTA5 GSTA6P GTF2E1 GTF2H1 H1FX HCRTR2 HEG1 HGD HIPK2
 HIVEP1 HLA-DQA1 HLA-DQB1 HMGCLL1 HMGCS2 hsa-mir-133b hsa-mir-206 hsa-mir-548a-1 hsa-mir-548i-1
 hsa-mir-559 hsa-mir-761 HSPDP7 HYI IGSF22 IL17A IL17F IMMP1L IPO13 IPP IQCJ IRF5
 ISY1 ITGB5 ITPR3 JARID2 JHDM1D KALRN KCNK12 KCP KDM1B KDM4A KIAA0319L
 KIAA0467 KIAA1147 KIAA1257 KIF13A KLHL31 KLRAQ1 KLRG2 KTI12 LDHA LDHAL6A
 LDHC LEPRE1 LRFN2 LRRC1 LRRC16A LRRC4C LRRC58 LRRC61 LUC7L2 MAK
 MAST2 MCM3 MED8 MEP1A MFSD2A MGAM MKRN1 MLXIPL MME MRAS MRPL32
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 MRPS22 MSH2 MTCO3P1 MUC13 MUTYH MYCBP MYL6P4 MYLIP MYLK N6AMT1
 NAP1L1P3 NASP NCDN NCRNA00240 NEDD9 NHLRC1 NOL7 NRD1 NRXN1 NUP153 OFCC1 
OR5AK2 OR9A1P OR9A3P OR9A4 OSBPL11 OSBPL9 P2RY1 PABPC1P10 PAK1IP1 PAQR8
 PARP12 PAX6 PDIA4 PDIA5 PELI1 PFN2 PHACTR1 PHGDH PIK3CB PIK3R3 PKHD1 PKIB 
PLA2G7 PLCH1 PLCXD2 PLXNA1 PNO1 PPCS PPIH PPP3R1 PPT1 PRIM2 PRR23A
 PRR23B PRR23C PRSS37 PSMB2 PTPLB PTPN5 PTPRF RAB19 RAB3B RAB43
 RAB7A RABL3 RANBP9 RARRES1 RARRES2 RBM24 RCAN2 REPIN1 RHBDL2 RIMKLA RLF
 RNF13 RNF144B RNF160 RNF182 ROPN1 RP11-100F22.1 RP11-10O22.2 RP11-115D7.3
 RP11-117F22.1 RP11-117L15.1 RP11-117L15.3 RP11-121P10.1 RP11-1220K2.2 RP11-125M16.1
 RP11-127P7.2 RP11-128A6.2 RP11-128A6.3 RP11-138N21.1 RP11-146I2.1 RP11-146I2.2 RP11-14H3.3
 RP11-157D18.2 RP11-163G10.2 RP11-163G10.3 RP11-163G10.4 RP11-167H9.3 RP11-167H9.4
 RP11-174O3.1 RP11-174O3.3 RP11-174O3.4 RP11-184I16.2 RP11-184I16.3 RP11-184I16.4
 RP11-18H7.1 RP11-191A15.1 RP11-191A15.2 RP11-191A15.3 RP11-191A15.4 RP11-192K2.3
 RP11-197K3.1 RP11-202D20.1 RP11-219E24.1 RP11-221E20.3 RP11-221E20.4 RP11-221E20.5
 RP11-228O6.2 RP11-232M24.1 RP11-255N4.2 RP11-255N4.3 RP11-268F1.2
 RP11-268F1.3 RP11-280H21.1 RP11-282K6.3 RP11-290K4.1 RP11-290K4.2 RP11-291L19.1
 RP11-306L14.1 RP11-309L24.2 RP11-309L24.4 RP11-309L24.6 RP11-310F12.1
 RP11-311B18.1 RP11-321G3.1 RP11-322N21.2 RP11-330A16.1 RP11-33K5.1
 RP11-342M1.2 RP11-342M1.3 RP11-342M1.4 RP11-345L23.1 RP11-359H3.1 RP11-359H3.4 
RP11-359N11.1 RP11-359N11.2 RP11-360O19.1 RP11-360O19.4 RP11-360O19.5 RP11-365F18.1
 RP11-365F18.3 RP11-367G6.1 RP11-379B18.1 RP11-379B18.2 RP11-379B18.3
 RP11-379B18.4 RP11-379B18.5 RP11-383F6.1 RP11-384F7.1 RP11-384F7.2
 RP11-385F7.2 RP11-38P22.2 RP11-390G14.1 RP11-392A23.4 RP11-392A23.5 RP11-397G17.1 
RP1-13D10.2 RP1-13D10.3 RP1-13D10.4 RP1-13D10.5 RP11-401E14.1 RP11-401E14.2
 RP11-402J7.2 RP11-402J7.3 RP11-40M23.1 RP11-411K7.1 RP11-411K7.2 RP11-411K7.4
 RP11-411K7.5 RP11-418B12.1 RP11-428L9.1 RP1-142O9.1 RP1-142O9.2
 RP11-434H6.2 RP11-446F17.3 RP11-446F3.2 RP11-451G4.2 RP11-451G4.3 RP11-466L17.1
 RP11-470H9.1 RP11-500K19.1 RP11-501I19.3 RP11-501I19.4 RP11-501O2.1
 RP11-501O2.2 RP11-501O2.3 RP11-501O2.4 RP11-501O2.5 RP11-505J9.1
 RP11-506B15.4 RP11-506B15.6 RP11-511P7.2 RP1-151F17.1 RP11-521J5.1 RP11-526P5.1
 RP11-526P5.2 RP11-529F4.1 RP11-529G21.4 RP1-152L7.1 RP1-152L7.3 RP1-152L7.5 RP1-152L7.6 RP11-543F8.1
 RP11-543F8.2 RP11-548O1.1 RP11-548O1.3 RP11-550C4.6 RP11-560J1.1 RP11-567P17.1
 RP11-567P17.2 RP11-585F20.1 RP11-598F17.1 RP11-605F14.1 RP11-605F14.2
 RP11-605F14.3 RP11-622P13.2 RP11-630I5.1 RP11-632K21.1 RP11-632K21.3
 RP11-635I10.1 RP11-637O19.2 RP11-639B1.1 RP11-639F1.1 RP11-639F1.2 RP11-639F1.3 
RP11-63E16.1 RP11-649A16.1 RP11-649A16.5 RP11-651P23.2 RP11-651P23.3 RP11-651P23.4
 RP11-651P23.5 RP11-651P23.6 RP11-666A20.1 RP11-666A20.3 RP11-666A20.4
 RP11-674E16.1 RP11-681L4.1 RP11-689D3.4 RP11-69C17.3 RP11-69C17.4
 RP11-71H17.1 RP11-71H17.6 RP11-71N10.1 RP11-722C17.1 RP11-723C11.2
 RP11-723O4.2 RP11-723O4.3 RP11-723O4.6 RP11-723O4.7 RP11-723O4.8
 RP11-735A5.1 RP11-767N6.2 RP11-767N6.7 RP11-771D21.2 RP11-775J23.1
 RP11-775J23.2 RP11-779P15.1 RP11-779P15.2 RP11-785H2.1 RP11-788A4.1
 RP11-788A4.2 RP11-793K1.1 RP11-795J1.1 RP11-795J1.2 RP11-79N23.1 RP11-7O11.3
 RP1-180E22.3 RP11-812I20.2 RP11-90C4.1 RP11-90C4.2 RP11-90C4.3 RP11-90C4.4
 RP1-190J20.2 RP11-91A18.1 RP11-91A18.4 RP11-91A18.5 RP11-9N20.1 RP1-228H13.1
 RP1-228H13.2 RP1-245M18.2 RP1-257A7.4 RP1-273P12.1 RP1-273P12.3 RP1-27K12.2
 RP1-27K12.4 RP1-290I10.4 RP1-290I10.5 RP1-290I10.7 RP1-304B14.3 RP13-476E20.1 
RP13-685P2.4 RP13-685P2.5 RP1-39G22.4 RP1-39G22.5 RP1-62D2.3 RP1-71H19.2 RP1-
92O14.6 RP3-335N17.2 RP3-342P20.2 RP3-347E1.2 RP3-365O12.2 RP3-380E11.2 RP3-
425P12.1 RP3-425P12.2 RP3-425P12.4 RP3-425P12.5 RP3-437C15.1 RP3-448I9.1 RP3-448I9.2 RP3-
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451B15.3 RP3-462C17.1 RP3-486B10.1 RP3-486D24.1 RP3-501N12.3 RP3-510L9.1 RP3-
522P13.1 RP3-522P13.2 RP3-522P13.3 RP3-525L6.2 RP4-533D7.3 RP4-533D7.4 RP4-
533D7.5 RP4-584D14.5 RP4-584D14.6 RP4-633H17.2 RP4-657D16.3 RP4-724P12.1
 RP4-728D4.2 RP4-728D4.3 RP4-753D5.3 RP4-753D5.4 RP4-761I2.2 RP4-761I2.4 RP4-
765A10.1 RP4-765A10.2 RP5-1142J19.1 RP5-1142J19.2 RP5-1154E9.5 RP5-1154E9.6
 RP5-1154E9.7 RP5-864K19.4 RP5-894A10.2 RP5-894A10.5 RP5-983H21.3 RP5-
994D16.3 RP5-994D16.7 RP5-994D16.9 RPL15P3 RPN1 RPS15AP10 RPS15AP16 RPS17P5
 RPS27P12 RRAGC SCGN SEC22A SEMA5B SHMT1P1 SIRT5 SLC12A8 SLC25A20P1
 SLC25A27 SLC33A1 SLC37A3 SLC6A9 SMAP2 SMPDL3A SNORA24 SNORA5 SNORA70 SNORD66 
SNORD78 snoU13 SNTG2 SNX4 SOX6 SPTY2D1 SSBP1 ST3GAL3 STX1A SUCLA2P2
 SUCLG1 SYCP2L TAS2R3 TAS2R38 TAS2R4 TAS2R5 TBC1D7 TBL2 TBXAS1 TDRD6
 TESK2 TFAP2B TFAP2D TFAP2E TGFBR3 TIE1 TMCO2 TMEM125 TMEM14A TMEM14B TMEM14C
 TMEM69 TMEM86A TMSB10 TNFRSF21 TNPO3 TOE1 TPI1P2 TPMT TPO TRAM2 TRIM38
 TSG101 TSPAN1 TTC26 TXNDC12 TXNRD3 TXNRD3IT1 U1 U3 U4 U6 U7
 UBE3C UBN2 UEVLD UMPS UROC1 USP34 VN1R11P VN1R12P VN1R13P VPS37D
 WBSCR22 WBSCR26 WBSCR27 WBSCR28 WDR92 WEE2 WWTR1 XPO1 XXbac-BPG254F23.5 XXbac-
BPG254F23.6 XXbac-BPG254F23.7 Y_RNA YBX1 Z83001.1 Z93017.1 ZBTB20 ZC3HAV1 ZC3HAV1L ZIC1
 ZIC4 ZMPSTE24 ZMYM4 ZMYND12 ZNF148 ZNF398 ZNF425 ZNF643 ZNF691 ZNF775 ZNF786 
PANTHER analysis: 335 mapped ids are found, 497 mapped ids are not found.  
 
There is CnLOH present in TN invasive breast disease (n=7/7) not observed in TN 
pure DCIS (n=0/9). 
1. p-values < 0.05;  
2. A gene list is mapped from 30 genomic regions found on chromosomes 1, 4, 
7, 10, 14, 18, 21;   
3. These regions encompass 379 genes altered in TN invasive breast disease; 
Genes:  
5S_rRNA 7SK  ABCA4   ABCD3  ABLIM1  AC005071.1 AC005071.2 AC005071.3 AC005879.1 AC006557.1 AC007922.2 AC007956.2
 AC016839.1 AC018797.3 AC022884.1 AC023983.1 AC069281.1 AC069281.2 AC073585.1 AC073588.1 AC073842.18 AC073842.19
 AC090363.1 AC091588.1 AC093577.3 AC093577.5 AC093577.7 AC093577.8 AC096947.1 AC104961.1 AC105247.1 ACADSB ACTL6B 
AFAP1L2 AFG3L2 AGFG2 AL109761.3 AL109761.5 AL117351.1 AL117351.2 AL117351.3 AL117351.4 AL117351.5
 AL117351.6 AL117351.7 AL133384.1 AL157788.1 AL158014.1 AL353664.1 AL355598.1 AL355861.1 AL359747.1 AL359836.1
 AL603764.1 AL731543.1 ALG14 AMAC1L1 ANKRD62 AP000431.1 AP000431.2 AP000432.2 AP000457.1 AP000568.2
 AP000745.1 AP000855.4 AP000946.2 AP000963.2 AP000963.3 AP000998.1 AP000998.2 AP001029.1 AP001120.1 AP001171.1
 AP001439.2 AP001441.1 AP001442.2 AP001525.1 AP001525.2 AP001604.3 AP001605.4 AP001605.6 AP001607.1 AP002414.1
 AP002414.2 AP005264.2 AP4M1 APP ARHGAP29 ARMS2 ATE1 BAG3 BCAR3 BTBD16
 BTG3 BUB3 C10orf119 C10orf120 C10orf46 C10orf82 C10orf84 C10orf88 C10orf96 C18orf1 C18orf19 
C18orf45 C1orf87 C1QBPP C21orf131 C21orf37 C21orf91 C7orf43 C7orf47 C7orf51 C7orf59 C7orf61
 CABLES1 CACNA2D1 CASC2 CCDC18 CDH2 CELF4 CHODL CHST9 CIDEA CNN3 CNPY4
 COPS6 CTA-109P11.1 CTAGE1 CTB-161A2.2 CTB-161A2.3 CTB-161A2.4
 CUZD1 CXADR CYP2J2 DLST DMBT1 DNMBP DNTTIP2 DR1 EIF3A EIF4A1P
 EMX2 EMX2OS ENO4 F3 FAM24A FAM24B FAM45A FAM69A FBXO24 FCF1 FDPSP FGFR2
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 FGGY FNBP1L GAL3ST4 GAPDHP29 GATA6 GATS GCLM GFRA1 GIGYF1 GNAL GNB2
 GPC2 GRK5 HMX2 HMX3 HOOK1 HRH4 hsa-mir-106b hsa-mir-1-2 hsa-mir-133a-1 hsa-
mir-25 hsa-mir-320c-2 hsa-mir-760 hsa-mir-93 HSPA12A HTR7 HTRA1 IKZF5 IMPA2 IMPACT INADL
 INPP5F KCNK18 KCTD1 KIAA0317 KIAA1598 KRT18P2 LRCH4 LTBP2 MANBA MBLAC1
 MC2R MC5R MCM7 MEPCE MIB1 MIR1255B1 MOSPD3 MPPE1 MTF2 NANOS1 NCAM2 
NCRNA00093 NCRNA00113  NCRNA00157 NFIA NFKB1 NSMCE4A ORC5L OSBPL1A PCOLCE
 PDZD8 PILRA PILRB PLEKHA1 PMS2L1 PNLIP PNLIPRP1 PNLIPRP2 PNLIPRP3 PPIAP
 PRDX3 PRLHR PROX2 PRSS7 PSMA8 PSTK PVRIG RAB11FIP2 RELN RGS10
 RNMT RP11-107C16.2 RP11-10L12.1 RP11-10L12.2 RP11-10L12.4 RP11-10L12.5
 RP11-10L12.6 RP11-145M4.2 RP11-145M4.3 RP11-148B18.1 RP11-148B18.3 RP11-148B18.4 
RP11-162A23.5 RP11-179H18.2 RP11-179H18.4 RP11-179H18.5 RP11-179H18.7 RP11-179H18.8
 RP11-198M6.2 RP11-198M6.5 RP11-215A21.2 RP11-245J24.1 RP11-268I9.1
 RP11-26N15.1 RP11-282I1.1 RP11-295O23.2 RP11-295O23.4 RP11-313A24.1 RP11-317F20.2 
RP11-319I23.2 RP11-319I23.3 RP11-328K15.1 RP11-33D13.2 RP11-354M20.3 RP11-366L18.1
 RP11-36N22.1 RP11-36N22.3 RP11-430G17.1 RP11-436K8.1 RP11-44M6.1
 RP11-44M6.3 RP11-465K1.2 RP11-470E16.1 RP11-488P3.1 RP11-498B4.2 RP11-498B4.5
 RP11-498B4.7 RP11-498J9.1 RP11-498J9.2 RP11-498J9.4 RP11-500G22.2
 RP11-501J20.2 RP11-501J20.3 RP11-501J20.5 RP11-506M12.1 RP11-539I5.1
 RP11-539I5.2 RP11-564D11.3 RP11-567J24.4 RP11-575B7.2 RP11-575B7.3 RP11-57H12.2
 RP11-5G18.2 RP11-62L18.3 RP11-681N23.1 RP11-758P17.2 RP11-758P17.3 RP11-781P14.3
 RP11-786F14.1 RP11-78A18.2 RP11-78O9.1 RP11-79M19.2 RP11-86H7.1 RP11-86H7.2
 RP11-86H7.3 RP11-86H7.6 RP11-86H7.7 RP13-530H6.2 RP4-612C19.1 RP4-
612C19.2 RP4-639F20.1 RP4-639F20.3 RP4-668G5.1 RP4-713B5.2 RP4-717I23.2 
RP4-717I23.3 RP4-782L23.1 RP4-782L23.2 RP5-1033H22.2 RP5-833A20.1 RP5-837O21.1 RP5-
837O21.2 RP5-837O21.3 RP5-837O21.4 RP5-837O21.5 RP5-837O21.6 RP5-837O21.7
 RP5-837O21.8 RP5-837O21.9 RPL10P1 RPL37P3 RPL37P4 RPS15AP5 RPS3AP1 RPS6KL1
 SEC23IP SFXN4 SLC18A2 SLC44A3 SLC6A6P SLMO1 SNORA19 SNORA7 SNORA73 snoU13
 SPDYE3 SPIRE1 SS18 STAG3 TACC2 TAF4B TAF6 TFR2 TGFBR3 TIAL1 TM2D1 TMED5 
TMEM56 TSC22D4 TUBB6 U1 U3 U6 U6atac U7 UBE2D3 VAX1 Y_RNA
 YLPM1 ZCWPW1 ZNF3 ZNF519 ZNF521 ZSCAN21 
PANTHER analysis: 152 mapped ids are found, 227 mapped ids are not found. 
5.8.10 Copy Number Aberrations in All Triple Negative DCIS compared to Triple 
Negative Invasive breast disease 
This series examines the difference between TN DCIS and TN invasive breast 
disease.  
Frequency plots showing copy number aberrations between TN DCIS and TN 
invasive breast disease were provided by King’s College London Bioinformatics 




Figure 43: Frequency plots showing copy number aberrations between triple negative 
DCIS and triple negative invasive disease (amplifications, duplications, gains, Sc 
















5.8.10.1 Amplification of Triple Negative DCIS and Triple negative Invasive 
Breast Disease 
No amplifications were present in triple negative DCIS (n=0/19) or triple negative 
invasive breast disease (n=0/7). 
5.8.10.2 Duplication of Triple Negative DCIS Compared to Duplication in Triple 
Negative Invasive Breast Disease 
Duplicated genes found in TN DCIS (1/19) were also present in TN invasive breast 
disease (n=3/7). 
1. p-values < 0.05; 
2. The gene list is created from 5 genomic regions found on chromosomes 2, 6, 
12;  
3. These regions encompass 57 genes altered in TN DCIS; 
Genes: 
 7SK AC012494.1 AC079600.1 AL121959.1 ARG1 C6orf192 CTAGE9 CTGF EEF1A1P36 ENPP1 ENPP3
 EYA4 HCRTR2 HMGB1L13 LRFN2 MED23 MOXD1 OR2A4 PRICKLE1 RP11-121P10.1 RP11-123H21.1
 RP11-203B4.1 RP11-25I15.1 RP11-295F4.4 RP11-314E23.1 RP1-131F15.2 RP11-69I8.2
 RP11-69I8.3 RP1-283K11.3 RP1-55C23.4 RP1-55C23.5 RP1-55C23.7 RP1-78N10.2 RP3-
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323K23.3 RP3-416F10.1 RP3-462C17.1 RP3-523C21.1 RP3-523C21.2 RP5-988G15.1
 RPS12 SNORA33 SNORD100 SNORD101 STX7 TAAR1 TAAR2 TAAR3 TAAR4P TAAR5 TAAR6 
TAAR7P TAAR8 TAAR9 U4 VNN1 VNN2 VNN3 
PANTHER analysis: 22 mapped ids are found, 35 mapped ids are not found.  
 
Duplication of genes found in TN invasive breast disease (n=3/7) which are not 
observed in TN DCIS (n=0/19): 
1. p-values < 0.05; 
2. The gene list is created from 8 genomic regions found on chromosomes 6, 8, 
12;  
3. These regions encompass 126 genes altered in TN invasive breast disease; 
Genes:  
5S_rRNA 7SK ABCC10 AL080315.3 AL096711.1 AL136304.1 AL136304.2 AL136304.3 AL451073.1 AL583834.1 BMP5
 BYSL C6orf108 C6orf132 C6orf15_2 C6orf154 C6orf174 C6orf226 C6orf58  C8orf85 CCND3 CENPW CLIC5 CNPY3 
COL21A1 CRIP3 CUL7 CUL9 DLK2 ECHDC1 EEF1DP5 ENPP4 ENPP5 FRS3 GFRAL GNMT GUCA1A GUCA1B HCRTR2 HEY2 
HINT3 HMGCLL1 hsa-mir-588 KIAA0240 KLC4 KLHDC3 LAMA2 MEA1 MED20 MRPL2 MRPS10 NCOA7 PEX6 PGC
 POLR1C PPP2R5D PRB2 PRICKLE4 PTCRA PTK7 PTPRK RNF146 RP11-103C16.2 RP11-151M7.1
 RP11-162L10.1 RP11-213N20.1 RP11-228O6.2 RP11-298J23.5 RP11-298J23.6 RP11-325O24.1 RP11-
325O24.2 RP11-357P24.2 RP1-139D8.6 RP11480N24.3 RP11-480N24.4 RP11-480N24.6 RP11-527F13.1 RP11-527F13.2 RP11-533O20.2 RP11-
570K4.1 RP11-624M8.1 RP11-753G20.1 RP11-775I22.2 RP1-177A13.1 RP1-179E13.1 RP1-293L8.2 
RP1-293L8.5 RP13-469O16.1 RP1-6P5.2 RP1-86D1.2 RP1-86D1.3 RP1-86D1.4 RP1-86D1.5 RP1-8B1.4 RP3-330M21.5 RP3-337H4.6 RP3-
351K20.3 RP3-351K20.4 RP3-403A15.1 RP3-447E21.3 RP3-475N16.1 RP5-973N23.4
 RPL24P4 RPL7L1 RSPO3 SCARNA15 SLC22A7 SLC30A8 SNORA8 snoU13 SRF TAF8 TFEB THEMIS 
TJAP1 TOMM6 TRERF1 TRMT11 TTBK1 U6 U7 USP49 XPO5 Y_RNA YIPF3 ZNF318 
PANTHER analysis: 62 mapped ids are found, 64 mapped ids are not found.  
 
5.8.10.3 Genomic Gains of Triple Negative DCIS Compared to Genomic Gains 
in Non Triple Negative DCIS  
Gene gains for TN DCIS (n= 4/19) and TN invasive breast disease (n=5/7) show 
considerable overlap, i.e. genes are present in both groups.  
1. p-values < 0.05; 
2. A gene list is mapped from 25 genomic regions found on chromosomes 1, 3, 
6, 9, 10, 20, 21, X;  
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3. These regions encompass 232 genes altered in TN DCIS and TN invasive 
breast disease; 
Genes: 
 5S_rRNA 7SK AC055758.1 AC072028.2 AC092898.1 AC107021.1 AC108729.1 AC112504.2 AC128648.1 AC133435.1 
AC133435.2 AKAP12 AL096840.2 AL133260.1 AL158155.2 AL356137.1 AL357514.2 AL357561.2 AL365214.2 AL450307.1
 AL583849.1 ATP1B3 ATR BNIP3 C1orf135 C3orf16 C3orf58  C3orf70 CCDC39 CCIN CHCHD6 CLIC6 CLTA COMMD2 
CTD-2501O3.1 CTD-2501O3.2 CTD-2501O3.3 DCAF10 DHX36 EEF1A1P25 EHHADH EIF2S2P2 ESR1 EXOSC3 EXTL1 FAM54B 
FBXO10 FLYWCH1P1 FRMPD1 FXR1 GK5 GLIPR2 GM2AP1 GNE GPR149 GRHPR GRK7  HRCT1 IPCEF1 IYD JAKMIP3
 MACROD2 MAN1C1 MAP3K13 MELK MFN2  MIIP MME MTHFD1L NCRNA00160 OPRM1 OR2S2 PABPC1P10 
PAFAH2 PAQR7  PAX5 PCOLCE2 PDIK1L PFN2 PIK3CB PLCH1 PLEKHG1 PLOD2 PLS1 PLSCR1 PLSCR2 PLSCR4 PLSCR5 PLXNA1 
POLR1E PPP1R14C PPP2R2D RAB1C RECK RFPL4B RG9MTD3 RNF13  RNF38 RNF7 RP1-105O18.1 RP11-
110C15.4 RP11-113A10.1 RP11-113A10.2 RP11-113A10.3 RP11-113A10.5 RP11-117F22.1 RP11-117L15.1
 RP11-136K14.1 RP11-136K14.2 RP11-136K14.3 RP11-144C9.1 RP11-167H9.2 RP11-167H9.3
 RP11-167H9.4 RP11-167H9.5 RP11-167H9.6 RP11-190C21.3 RP11-190C21.4 RP11-217E22.1
 RP11-217E22.2 RP11-217E22.5 RP11-21M4.2 RP11-220I1.1 RP11-220I1.2
 RP11-220I1.4 RP11-232M24.1 RP1123D24.1 RP11-23D24.2 RP11-255N4.2 RP11-255N4.3
 RP11-259P15.1 RP11-259P15.3 RP1-125I3.2 RP1-125I3.3 RP1-125I3.4 RP1-125I3.7 RP11-270G15.2 RP11271K21.2 
RP11-271K21.4 RP11-271K21.7 RP11-274H2.2 RP11-274H2.3 RP11-291C6.1 RP11-297B17.2 RP11-29A1.3
 RP11-317B3.2 RP11-327L3.1 RP11-327L3.3 RP11-327L3.4 RP11-327L3.5 
RP11-340E6.1 RP11-340E6.2 RP11-343B5.1 RP11-383G6.3 RP11-383G6.4 RP11-397D12.4 
RP11-397D12.6 RP11-397D12.7 RP11-405L18.1 RP11-405L18.2 RP11-405L18.4 RP11427D1.1 RP11-439C8.1
 RP11-439C8.2 RP11-451G4.1 RP11-451G4.2 RP11-451G4.3 RP11-465M18.1 RP11-
471B18.1 RP11-483E7.1 RP11-506B6.1 RP11-506B6.2 RP11-506B6.3 RP11-548O1.1 RP1-159M24.1
 RP11-605F14.3 RP11-613F7.1 RP11-613M10.6 RP11-622L21.1 RP11639F1.1 RP11-639F1.2
 RP11-639F1.3 RP11-63E16.1 RP11-649A16.1 RP11-651P23.2 RP11651P23.3 
RP11-651P23.4 RP11-651P23.5 RP11-651P23.6 RP11-656A15.1 RP11-65C6.1
 RP11-758I14.2 RP11-758I14.3 RP11-785G3.1 RP11-84P7.1 RP11-84P7.2
 RP11-84P7.3 RP11-88H10.1 RP1188H10.2 RP11-88H10.3 RP1-197O17.3 RP1-292B18.1 RP1-
292B18.3 RP1-292B18.4 RP1-297M16.2 RP1-317E23.3 RP1-44A20.4 RP1-99E18.2 RP3-422F24.2 RP3-
460G2.2 SCARNA17 SCARNA18 SEPN1 SLC30A2 SLC35F1 snoU13 STMN1 TFDP2 TOMM5 TRIM63 TRPC1 U1 U3 U4 U6 U7 U8
 WWTR1 XRN1 Y_RNA ZBTB5 ZCCHC7 
PANTHER analysis: 77 mapped ids are found, 155 mapped ids are not found. 
5.8.10.4 Sc Gains of Triple Negative DCIS Compared to Sc Gains in Triple 
Negative Invasive Breast Disease  
The comparison of values for Sc gains in TN invasive breast disease (n=3/7) and TN 
DCIS (n=0/19)  
1. p-values  <0.05; 
2. A gene list is mapped from 32 genomic regions found on chromosomes 1, 2, 
3, 6, 10, 16, 20. This represents Sc gains for TN Invasive breast disease; 
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3. These regions encompass 209 genes altered in TN invasive breast disease; 
Genes: 
 5S_rRNA 7SK AADAC AADACL2 AC007392.3 AC007403.1 AC007403.2 AC009086.1 AC009086.3 AC009086.4
 AC009474.1 AC009474.2 AC025279.1 AC055758.1 AC072028.2 AC078784.1 AC107021.1 AC107027.2 AC108729.1 
AC121332.1 AC128648.1 AC133435.1 AC133435.2 AC133555.1 AC133555.2 AC133555.3 AC133555.4 AC133555.6 AC133555.7
 ACPL2 AL357561.2 AL450307.1 ARHGAP31 ASTE1 ATP2C1 ATP5LP5 ATR B4GALT4 BNIP3 BOLA2 
C1orf135 C2orf86 C3orf16 C3orf30  C3orf58 CCDC39 COMMD2 CPNE4 CTD-2501O3.1 CTD-2501O3.2
 CTD-2501O3.3 DHX36 EEF1A1P25 EXTL1 FAM54B GIYD1 GK5 GM2AP1 GPR149 GSTO3P IGSF11 IYD JAKMIP3 
LSAMP MACROD2 MAN1C1 MME MRPL3 NEK11 NUDT16 NUDT16P OPRM1 P2RY1 PABPC1P10 
PAFAH2 PAQR7 PARK2 PCOLCE2 PDIK1L PFN2 PIK3CB PLCH1 PLOD2 PLS1 PLSCR1
 PLSCR2 PLSCR4 PLSCR5 PPP1R14C PPP2R2D QPRT RASA2 RNF13 RP11-117F22.1
 RP11-117L15.1 RP11-167H9.2 RP11-167H9.3 RP11167H9.4 RP11-167H9.5 RP11-167H9.6
 RP11-190C21.3 RP11-190C21.4 RP11-217E22.1 RP11217E22.2 RP11-217E22.5 RP11-21M4.2 RP11-
232M24.1 RP11-23D24.1 RP11-23D24.2 RP11255N4.2 RP11-255N4.3 RP1-125I3.2 RP1-125I3.3 RP1-125I3.4 RP1-
125I3.7 RP11265F19.1 RP11-270G15.2 RP11-274H2.2 RP11-274H2.3 RP11-291C6.1 RP11-305I9.1 
RP11-316C10.1 RP11-340E6.1 RP11-343B5.1 RP11-383G6.3 RP11-383G6.4
 RP11-38P22.2 RP11-39E3.3 RP11-39E3.4 RP11-39E3.5 RP11-39E3.6 RP11-402E20.1
 RP11-420J11.2 RP11-427D1.1 RP11-438D8.2 RP11-438D8.3 RP11-438D8.4 RP11-439C8.1 
RP11-439C8.2 RP11-451G4.1 RP11-451G4.2 RP11-451G4.3 RP11-454C18.2 RP11-483E7.1
 RP11-484M3.4 RP11-484M3.5 RP11-496B10.1 RP11-496B10.3 RP11-496B10.5
 RP11-517B11.2 RP11-517B11.4 RP11-517B11.6 RP11-548O1.1 RP11-622L21.1
 RP11-639F1.1 RP11-639F1.2 RP11-639F1.3 RP11-63E16.1 RP11-63L4.1 RP11-649A16.1
 RP11-64D22.1 RP11-64D22.2 RP11-64D22.5 RP11-651P23.2 RP11-651P23.3
 RP11-651P23.4 RP11-651P23.5 RP11-651P23.6 RP11-656A15.1 RP11-758I14.2
 RP11-758I14.3 RP11-785G3.1 RP11-788A4.1 RP11-788A4.2 RP11-789L4.1 
RP11-88H10.1 RP11-88H10.2 RP11-88H10.3 RP11-933H2.4 RP1-317E23.3 RP3-422F24.2 RP4-635B5.1 
RUNDC2B SCARNA17 SCARNA18 SEPN1 SLC30A2 SNORA58 snoU13 SPN STMN1 SUCNR1 SULT1A4 TFDP2 TM4SF4 
TRIM63 TRPC1 TTC14 U1 U3 U4 U6 U7 U8 UPK1B WWTR1 XRN1 Y_RNA 
ZBTB38 
PANTHER analysis: 64 mapped ids are found, 145 mapped ids are not found.  
5.8.10.5 Losses in Triple Negative DCIS Compared to Losses in Triple 
Negative Invasive Breast Disease  
Losses in TN DCIS (n=1/19) show similarities with losses in TN invasive breast 
disease (n=3/7). This represents losses for TN DCIS and TN invasive breast disease. 
1. p-values  <0.05; 
2. The gene list is created from 31 genomic regions found on chromosomes 1, 
2, 3, 6, 10, 16, 20; 




5S_rRNA 7SK AADAC AADACL2 AC007392.3 AC007403.1 AC007403.2 AC009086.1 AC009086.3 AC009086.4
 AC009474.1 AC009474.2 AC025279.1 AC055758.1 AC072028.2 AC078784.1 AC107021.1 AC107027.2 AC108729.1 AC121332.1
 AC133555.1 AC133555.2 AC133555.3 AC133555.4 AC133555.6 AC133555.7 ACPL2 AL357561.2 AL450307.1 ARHGAP31
 ASTE1 ATP2C1 ATP5LP5 ATR B4GALT4 BNIP3 BOLA2 C1orf135 C2orf86 C3orf16 C3orf30
 C3orf58 CCDC39 COMMD2 CPNE4 CTD-2501O3.1 CTD-2501O3.2 CTD-2501O3.3 DHX36
 EEF1A1P25 EXTL1 FAM54B GIYD1 GM2AP1 GPR149 GSTO3P IGSF11 IYD JAKMIP3 LSAMP 
MACROD2 MAN1C1 MME MRPL3 NEK11 NUDT16 NUDT16P OPRM1 P2RY1 PABPC1P10
 PAFAH2 PAQR7 PARK2 PCOLCE2 PDIK1L PFN2 PIK3CB PLCH1 PLOD2 PLS1
 PLSCR1 PLSCR2 PLSCR4 PLSCR5 PPP1R14C PPP2R2D QPRT RASA2 RNF13 RP11-117F22.1
 RP11-117L15.1 RP11-167H9.2 RP11-167H9.3 RP11-167H9.4 RP11-167H9.5 RP11-167H9.6
 RP11-190C21.3 RP11-190C21.4 RP11-217E22.1 RP11-217E22.2 RP11-217E22.5
 RP11-21M4.2 RP11-232M24.1 RP11-23D24.1 RP11-23D24.2 RP11-255N4.2
 RP11-255N4.3 RP1-125I3.2 RP1-125I3.3 RP1-125I3.4 RP1-125I3.7 RP11-265F19.1 RP11-270G15.2
 RP11-274H2.2 RP11-274H2.3 RP11-291C6.1 RP11-305I9.1 RP11-316C10.1
 RP11-340E6.1 RP11-383G6.3 RP11-383G6.4 RP11-38P22.2 RP11-39E3.3 RP11-39E3.4
 RP11-39E3.5 RP11-39E3.6 RP11-402E20.1 RP11-420J11.2 RP11-427D1.1
 RP11-438D8.2 RP11-438D8.3 RP11-438D8.4 RP11-439C8.1 RP11-439C8.2
 RP11-451G4.1 RP11-451G4.2 RP11-451G4.3 RP11-454C18.2 RP11-483E7.1
 RP11-484M3.4 RP11-484M3.5 RP11-496B10.1 RP11-496B10.3 RP11-496B10.5
 RP11-517B11.2 RP11-517B11.4 RP11-517B11.6 RP11-548O1.1 RP11-622L21.1
 RP11-639F1.1 RP11-639F1.2 RP11-639F1.3 RP11-63E16.1 RP11-63L4.1 RP11-649A16.1
 RP11-64D22.1 RP11-64D22.2 RP11-64D22.5 RP11-651P23.2 RP11-651P23.3 RP11-651P23.4
 RP11-651P23.5 RP11-651P23.6 RP11-656A15.1 RP11-758I14.2 RP11-758I14.3 RP11-785G3.1
 RP11-788A4.1 RP11-788A4.2 RP11-789L4.1 RP11-88H10.1 RP11-88H10.2 RP11-88H10.3
 RP11-933H2.4 RP1-317E23.3 RP3-422F24.2 RP4-635B5.1 RUNDC2B SCARNA17 SCARNA18
 SEPN1 SLC30A2 SNORA58 snoU13 SPN STMN1 SUCNR1 SULT1A4 TM4SF4 TRIM63
 TRPC1 TTC14 U1 U3 U4 U6 U7 U8 UPK1B WWTR1
 XRN1 Y_RNA ZBTB38 
PANTHER analysis: 62 mapped ids are found, 141 mapped ids are not found. 
The comparison of losses represents losses in TN DCIS and TN invasive breast 
disease  
1. p-values < 0.05; 
2. A gene list is mapped from 98 genomic regions found on chromosomes 1, 4, 
10, 12, 15, 18, 19, X; 
3. These regions encompass 317 genes altered in TN DCIS and TN invasive 
breast disease; 
Genes:  
5S_rRNA AC005184.1 AC008245.1 AC009731.1 AC012379.1 AC012379.2 AC013452.1 AC013452.2 AC013558.1 AC018413.1
 AC018797.3 AC022046.2 AC025263.1 AC034110.1 AC034110.2 AC036176.2 AC064801.1 AC068473.1 AC083805.1
 AC083805.2 AC090360.1 AC090393.1 AC090669.1 AC091551.1 AC091643.1 AC091646.1 AC093827.1 AC100783.1
 AC100843.1 AC104059.1 AC114688.1 AC134978.1 AC139100.1 AC139100.2 ACE2 ADNP2 AF196969.5 
AF196972.1 AF196972.10 AF196972.2 AF196972.3 AF196972.4 AF196972.9 AF213884.1 AF224669.3 AF241726.2
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 AF241726.4 AF241726.6 AFF1 AL031311.1 AL136137.1 AL353691.1 AL356741.1 AL591378.1 AL591394.1
 AL592043.1 AL627402.1 ALPK2 ANXA3 APOF ARAF ARD1B ARHGAP24 ARHGEF16 ATP9B
 AVIL BCL2 BEST3 BMX C18orf22 C4orf36 CA5B CA5BP CASK CBLN2
 CDH19 CDH7 CDK4 CEP152 CHST7 CHTF8P COPS2 CTD-2522E6.4 CTDP1
 CTDSP2 CXorf24 CXorf36 CXorf58 CYP27B1 CYP2A6 DNAJC12 DUSP21 EBP
 EIF2S3 ELAC1 FAM47A FGF5 FIGF FRAS1 FTLP16 FTSJ1 GALK2
 GALR1 GPR34 GPR82 GRPR GS1-541M1.1 GS1-541M1.2 GS1-594A7.3
 GS1-594A7.5 HERC4 HMGA1L1 hsa-mir-221 hsa-mir-222 hsa-mir-26a-2 hsa-mir-551a
 HSBP1L1 IL1RAPL1 INE1 KAL1 KCNG2 KDM6A KDSR KIAA1468 KLHL15 KLHL8
 KRT8P14 L1CAM MALT1 MANBA MAOA MAOB MAPK10 March9 MBP ME2
 MEGF6 MEX3C NDP NDUFB11 NFATC1 NFKB1 NTS NUAK1 NUS1P1 OTC
 PARD6G PCTK1 PIGN PIR PORCN PPP1R2P9 PQLC1 PRDM8 PTCHD2
 PTPN13 RAB3IP RASGEF1B RASSF9 RBM10 RBM19 RBM3 RNF152 RP11-10L12.1
 RP11-10L12.2 RP11-10L12.4 RP11-10L12.5 RP11-10L12.6 RP11-1148L6.5 
RP11-1148L6.6 RP11-126O1.1 RP11-149B9.2 RP11-162A12.1 RP11-162K6.1 RP11-204C16.4
 RP11-245M24.1 RP11-281B1.2 RP11-305F18.1 RP11-342D14.1 RP11-344N17.11
 RP11-344N17.12 RP11-344N17.13 RP11-344N17.2 RP11-344N17.3 RP11-344N17.6
 RP11-344N17.7 RP11-344N17.8 RP11-344N17.9 RP11-377B2.2 RP11-377G16.2
 RP11-38O23.3 RP11-38O23.4 RP11-38O23.5 RP11-38O23.7 RP11-397E7.1
 RP11-397E7.2 RP11-397E7.3 RP11-397E7.4 RP11-438E5.1 RP11-474D14.2
 RP11-476C8.2 RP11-479I1.4 RP11-524P6.1 RP11-540L11.2 RP11-545D19.1
 RP1-154K9.2 RP11-552E4.2 RP11-552E4.3 RP11-552E4.4 RP11-552E4.5
 RP11-571E6.1 RP11-571E6.3 RP11-571E6.4 RP11-57G10.6 RP11-617O8.1
 RP11-640A1.1 RP11-644A7.1 RP11-652N17.1 RP11-689K5.3 RP11-692P14.1
 RP11-702C7.1 RP11-702C7.2 RP11-75A9.2 RP11-75A9.3 RP11-778J15.1
 RP11-792D21.1 RP11-792D21.2 RP11-9H16.1 RP1-22N22.1 RP1-290C9.2
 RP13-202B6.2 RP13-479F17.2 RP13-928P6.3 RP1-50A13.1 RP1-50A13.2
 RP1-54B20.7 RP1-69M21.2 RP1-71L16.1 RP1-71L16.2 RP1-71L16.6 RP3-326I13.1 RP3-
393P12.2 RP3-393P12.3 RP4-733D15.1 RP5-1174J21.1 RP5-1174J21.2 RP5-972B16.2 RP6-105D16.1
 RP6-218J18.3 RP6-99M1.1 RPGR RPL12P8 RTTN SALL3 SERPINB5 SHC4 SIRT1
 SLC10A6 SLC38A5 SLC9A7 SMAD4 SNORA11 SNORA25 SNORA31 SNORA68 SNORD56
 snoU13 SOCS6 SPACA5 SPACA5B SSX1 SSX3 SSX4 SSX4B SSX5 SSX6
 SSX9 STAT2 SYN1 TBC1D25 TIMP1 TMEM27 TNFRSF11A TSHZ1 TSPAN7
 TXNL1 TXNL4A U1 U2 U52112.12 U6 U7 U8 UBA1
 UBE2D3 USP11 VCX3B VENTXP1 WAS WDR13 WDR7 Y_RNA Z98304.1 ZADH2 ZCCHC2
 ZFX ZNF157 ZNF182 ZNF236 ZNF407 ZNF41 ZNF516 ZNF532 ZNF630
 ZNF673 ZNF674 ZNF81 
PANTHER analysis: 138 mapped ids are found, 179 mapped ids are not found. 
5.8.10.6 Total Loss of Triple Negative DCIS Compared to Total Loss in Triple 
Negative Invasive Breast Disease 
There were total losses present in TN DCIS (n=13/19) that are not observed from TN 
invasive breast disease (n=0/7). 
1. p-values < 0.05; 
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2. A gene list is mapped from 150 genomic regions found on chromosomes 3, 4, 
5, 6, 8, 9, 13, 14, 15, 17, 18, 22 & X;  
3. These regions encompass 419 genes altered in TN DCIS; 
Genes: 
 5S_rRNA 7SK AARSD1 AB019438.55 AB019438.63 AB019438.66 AB019439.3 ABCD4
 AC002117.1 AC003043.1 AC003043.2 AC003102.3 AC003963.2 AC004222.1 AC004596.1 AC004968.1 AC004968.2 AC005399.1
 AC006059.1 AC006349.1 AC006445.1 AC006445.6 AC006445.7 AC006445.8 AC007126.1 AC007722.1 AC008105.1 AC011193.1
 AC012409.1 AC015936.1 AC015936.3 AC016251.1 AC019131.2 AC020704.1 AC021205.1 AC025287.1 AC025287.2 AC025287.3 
AC025287.4 AC026202.1 AC026202.5 AC027139.2 AC027139.3 AC027139.4 AC027708.1 AC027807.1 AC027807.2 AC036222.1
 AC044797.1 AC044797.2 AC044797.3 AC055813.1 AC055873.1 AC068400.1 AC079915.1 AC084809.2 AC084809.3 AC084882.1 
AC087650.1 AC087742.1 AC092047.1 AC092048.1 AC092421.1 AC098830.1 AC100793.2 AC102948.1 AC102948.2 AC103702.1 
AC103965.1 AC104260.1 AC105750.1 AC107982.4 AC109357.1 AC112693.1 AC113171.1 AC114477.1 AC121253.1 AC124789.1
 AC134669.1 AC138150.3 AC138150.4 AC183087.1 AC183087.2 ACBD4 ACTR10  ADAM11 ADAM3A ADAM5P ADAMTSL3
 ADH4 ADH5 AGBL1 AKAP6 AL008582.1 AL035659.2 AL035659.4 AL035659.6 AL079307.3 AL079307.4 
AL079307.5 AL132989.2 AL135978.1 AL136359.1 AL139021.2 AL139089.1 AL162377.1 AL162377.2 AOC2 AOC3 AP000351.4
 ARAP2 ARHGAP23 ARID4A ARL4D ARRDC4 ASB16 ASPN ATXN7L3 AY269186.1 AY269186.2 AZI2 
BBS12 BOD1L BRCA1 BTF3 C14orf149 C14orf166 C14orf38 C14orf54 C17orf102 C17orf104
 C17orf105 C17orf46 C17orf53 C17orf65 C1QL1 C4orf37 CA10 CARTPT CCDC103 CCDC43 CD300LG CDC6 
CECR2 CECR9 CENPP CETN4P CHADL CMC1 CSMD1 CTD-2015H6.1 CTD-2015H6.2 CTD-2015H6.3CTNS CWC25
 DBF4B DCAKD DDT DDX52 DHRS11 DHX8 DTHD1 DUSP3 ECM2 EDEM1 EFTUD2 EIF4BP4
 EIF4E EP300 ETV4 EVI2A EVI2B FAM149B2 FAM151B FAM169B FAM171A2 FAM177A2
 FAM187A FAM18B FAM19A1 FBXL2 FBXO33 FBXW10 FGF2 FLT3 FMNL1 FOXD1 FRMD6 
FZD2 G6PC G6PC3 GFAP GJC1 GNG2 GOLGA8B GPATCH8 GPC5 GPHN GPR179 GRN
 GSTT2 HDAC5 HEXIM1 HEXIM2 HIGD1B HMGB1L14 HOXB7 HOXB9 hsa-mir-1233 hsa-mir-1281 hsa-mir-1469 hsa-
mir-196a-1 hsa-mir-2117 hsa-mir-759 HSP90AB2P IFI35 IGHV1-45 IGHV1-46 IGHV3-33-2 IGHV3-35 IGHV3-36
 IGHV3-37 IGHV3-38 IGHV3-41 IGHV3-42 IGHV3-43 IGHV3-47 IGHV4-34 IGHV4-39 IGHV7-34-1 IGHV7-40 IGHVII-
33-1 IGHVII-40-1 IGHVII-43-1 IGHVII-44-2 IGHVII-46-1 IGHVIII-38-1 IGHVIII-44 IGHVIV-44-1 IKZF3 IPO11 ITGA2B ITGAE
 JKAMP KCNH5 KIAA0586 KIF18B KIF2A KLHL5 L3MBTL2 LECT1 LIN52 LPAR4 LRRC70
 LSM12 LYZL4 MAP3K14 MCTP2 MEOX1 METAP1 MITF MPP2 MPP3 MPP5 MRM1
 MRPL45 MYO1D NAGS NF1 NID2 NKTR NKX3-2 NMT1 NR2F2 NUDT6 OCLN_2 OLFM4 OMD
 OMG P2RX5 PARK2 PCDH8 PDCD6IP PDS5B PIP5K2B PLCD3 PPY PRPSAP2 PSMA3 PSMB3 PSME3
 PYY RAB28 RAD51L1 RANGAP1 RGS6 RHCG RNF180 RP11-1072C15.1 RP11-1280N14.3 RP11-1280N14.4
 RP11-1299A16.1 RP11-1299A16.2 RP11-12M9.4 RP11-159J2.1 RP11-159J2.2 RP11-170N16.1
 RP11-170N16.2 RP11-187O7.1 RP11-209K10.1 RP11-219I21.1 RP11-223D18.1
 RP11-241P3.2 RP11-248N6.1 RP11-248N6.2 RP11-24H2.1 RP11-24H2.2 RP11-301J16.5
 RP11-30C8.1 RP11-30C8.2 RP11-327P2.5 RP11-341G5.1 RP11-357H14.4 RP11-360F5.1
 RP11-360F5.2 RP11-360F5.3 RP11-369I16.1 RP11-380B4.2 RP11-428B4.2 RP11-431M7.2
 RP11-431M7.3 RP11-431O22.2 RP11-442J17.4 RP11-474L7.4 RP11-475D8.1 RP11-48B14.1
 RP11-520F24.1 RP11-520F24.2 RP11-520F24.3 RP11-522B15.1 RP11-522B15.2 RP11-571L19.2
 RP11-571L19.4 RP11-696N14.1 RP11-799A12.1 RP11-799A12.2 RP11-79P5.2 RP11-79P5.3 RP11-79P5.5
 RP11-79P5.6 RP11-79P5.7 RP11-79P5.8 RP11-81N13.1 RP11-85I21.1 RP11-880O3.1
 RP11-95I19.1 RP11-95I19.2 RP1-85F18.4 RP1-85F18.5 RP1-85F18.6 RP4-613B23.1 RP4-756G23.5 RPL27 RTN1
 RUNDC1 RUNDC3A SEC22C SHISA6 SHPK SIPA1L1 SLC25A21 SLC25A39 SLC4A1 SMN1 SMOC1
 SNORA18 SNORA40 SNORD56 SNORD74 snoU13 snoZ178 SOCS7 SOST SPATA5 SPATA8 SPRED1 SRCIN1
 SS18L2 SUCLG2 SYNRG SYT16 TAX1BP3 TBC1D3 TEF TIMM9 TMEM101 TMEM132E TMEM93
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 TMEM98 TMUB2 TOMM20L TRPV1 TRPV3 TSPAN5 U3 U6 U7 UBP1 UBTF VAT1 VSX2
 WIPF2 WSCD1 Y_RNA ZBTB47 ZC3H7B ZCCHC5 ZCWPW2 ZFYVE16 
PANTHER analysis: 194 mapped ids are found, 225 mapped ids are not found.  
There were total losses present in TN invasive breast (n=7/7) disease that are not 
observed in TN DCIS (n=0/19). 
1. p-values < 0.05; 
2. A gene list is mapped from 98 genomic regions found on chromosomes 3, 4, 
5, 9, 10, 12, 13, 14, 15, 17;  
3. These regions encompass 479 genes altered in TN invasive breast disease; 
Genes:  
5S_rRNA 7SK AATF AB019437.56 ABHD12B ABLIM2 ABR AC003664.1 AC005277.1 AC005304.1
 AC005304.2 AC005304.3 AC005324.1 AC005324.2 AC005324.4 AC005324.6 AC005324.7 AC005358.1 AC005358.3 AC005517.1 
AC005517.2 AC005517.3 AC005703.2 AC005703.3 AC005772.2 AC005773.1 AC005838.2 AC005863.1 AC005863.2 AC007686.1
 AC013248.1 AC013248.2 AC015842.1 AC015922.1 AC015922.2 AC015922.7 AC024610.1 AC027045.1 AC073940.1 AC087742.1
 AC087742.2 AC090283.1 AC090283.3 AC090516.1 AC090516.2 AC090519.1 AC090519.10 AC090519.11
 AC090519.2 AC090519.3 AC090519.4 AC090519.5 AC090519.6 AC090519.7 AC090519.8 AC090519.9 AC091487.1 AC093819.1
 AC093824.1 AC098487.1 AC103560.1 AC104650.2 AC108477.2 AC123769.1 ACCN1 ADCK1 AE000658.6 AE000659.1 
AE000659.10 AE000659.12 AE000659.13 AE000659.14 AE000659.15 AE000659.16 
AE000659.17 AE000659.18 AE000659.19 AE000659.23 AE000659.6 AE000659.8 AE000659.9
 AF111168.1 AF111168.3 AGPAT9 AHSA1 AL049775.1 AL121768.1 AL133223.1 AL133413.1 AL136160.1 AL137024.1
 AL139041.1 AL157702.1 AL158058.1 AL162727.1 AL353141.1 AL353782.1 AL353805.1 AL354751.2 AL354751.3 AL354896.1
 AL356214.2 AL357172.1 AL358334.1 AL358334.2 AL359180.1 AL359392.1 AL360004.1 AL365364.1 AL732479.1 ALDOB
 ALKBH1 AMBP ANKFY1 ANKRD40 ANKS6 ARD1B ASTN2 ATAD1 ATP5C1P1 BAAT
 C10orf4 C13orf23 C13orf36 C14orf148 C14orf156 C14orf174 C14orf178 C14orf184 C14orf23 C4orf41 C9orf107 
C9orf109 C9orf110 C9orf125 C9orf147 C9orf170 C9orf30 C9orf44 C9orf80 CACNA1G CASC4 CATSPERB
 CDC20P CDKN2AIP CDRT1 CDRT4 CDRT7 CEP55 CNOT6L COL27A1 CTC-448D22.1
 CTC-507E12.1 CTD-2158P22.1 CTD-2158P22.2 CTD-2158P22.4 CTD-2175M1.1
 CTDSPL2 CYB5D2 CYP26A1 CYP26C1 DAB2IP DBC1 DDIT4L DHRS7C DKK2 DLEU1
 DLEU2 DTWD2 DYNLL1P1 ELAC2 EML5 EXOC6 FAM154A FAM170A FAM175A FAM18B2
 FAM190 FAM190A FAM33B FKBP15 FLRT2 FOXG1 FRMD5 FYTTD1P1 GABBR2 GALNT12
 GALNTL6 GAPDHP34 GAS1 GAS7 GK2 GLP2R GMPSP GNG5P5 GPM6A GPR107 GPR120 GRID1
 GRIN3A GSTZ1 HELT HS3ST3A1 hsa-mir-1260 hsa-mir-15a hsa-mir-16-1 hsa-mir-346 hsa-mir-455 hsa-mir-548h-3
 hsa-mir-95 HSD17B4 HSDL2 HTRA3 IGHV1-67 IGHV1-68 IGHV1-69 IGHV2-70 IGHV3-62 IGHV3-63 IGHV3-64
 IGHV3-65 IGHV3-66 IGHV3-71 IGHV3-72 IGHV3-73 IGHV4-61 IGHVII-60-1 IGHVII-62-1 IGHVII-65-1 IGHVII-67-1
 IGHVIII-67-2 IGHVIII-67-3 IGHVIII-67-4 IL6STP1 ING2 ISM2 KIAA1737 KIAA1958 KIF12 KRT222 KRT24
 KRT25 KTN1 LGI1 LHFP LHX6 LMO7 MEIS3P1 MITF MMRN1 MORN5
 MRPL50 MRRF MURC MYOCD MYOF NDUFA8 NGB NHLRC3 NRXN3 NTN1 NXN
 OR1B1 OR1H1P OR1J2 OR1J4 OR1L1 OR1L3 OR1L4 OR1L6 OR1L8 OR1N1
 OR1N2 OR1Q1 OR7E94P PAPPA PAPSS1 PAPSS2 PDE6C PDZRN3 PMP22 POMT2 PPP3R2 PYGL
 RASGEF1B RBM18 RBP4 RCVRN RFXAP RGS3 RNF20 ROR2 RP11-100G15.10 RP11-100G15.2
 RP11-100G15.3 RP11-100G15.4 RP11-100G15.5 RP11-100G15.6 RP11-100G15.7
 RP11-115D19.1 RP11-115G5.1 RP11-118F2.2 RP11-118F2.3 RP11-122F14.4 RP11-
1258F18.1 RP11-127L21.1 RP11-127L21.2 RP11-15B17.1 RP11-162D16.4 RP11-168K11.2
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 RP11-168K11.3 RP11-16L6.3 RP11-181F12.1 RP11-18B16.1 RP11-18B16.2 RP11-197L7.2
 RP11-20O12.1 RP11-226P1.1 RP11-234K19.1 RP11-234K19.2 RP11-24E1.1
 RP11-264C15.2 RP11-276E15.4 RP11-276H19.1 RP11-276H19.2 RP11-276H19.4 RP11-280G19.1
 RP11-280G19.2 RP11-296L20.1 RP11-299L17.1 RP11-32M23.4 RP11-332E3.2
 RP11-348J12.2 RP11-349E4.1 RP11-34F20.4 RP11-34F20.5 RP11-352E6.1
 RP11-352E6.2 RP11-35N6.1 RP11-35N6.3 RP11-35N6.4 RP11-35N6.6 RP11-367N14.1
 RP11-367N14.2 RP11-385D13.1 RP11-386B13.1 RP11-386B13.3 RP11-386B13.4 RP11-388N2.1
 RP11-394D2.1 RP11-395D3.1 RP11-397J18.1 RP11-408O19.3 RP11-421P11.5
 RP11-438E5.1 RP11-44F21.4 RP11-452B18.1 RP11-452B18.2 RP11-45A16.3 RP11-45A16.4
 RP11-45I20.1 RP11-462C21.1 RP11-477L16.2 RP11-478K15.1 RP11-478K15.2
 RP11-478K15.3 RP11-478K15.4 RP11-478K15.5 RP11-480P3.1 RP11-490D19.6
 RP11-490D19.8 RP11-499E18.1 RP11-51N22.1 RP11-51N22.2 RP11-521H3.1
 RP11-524G24.2 RP11-527F15.1 RP11-534I8.1 RP11-542G1.1 RP11-542G1.2
 RP11-542G1.3 RP11-545P6.1 RP11-545P6.2 RP11-54K22.1 RP11-565F19.1
 RP11-567N4.2 RP11-567N4.3 RP11-576C12.1 RP11-588P8.1 RP11-58C3.2
 RP11-598G2.1 RP11-610O8.1 RP11-616K22.1 RP11-61P7.3 RP11-624A4.1 RP11-624L12.1
 RP11-626E13.1 RP11-64P14.7 RP11-67K19.3 RP11-67M1.1 RP11-689K5.3 RP11-692E14.1
 RP11-701P16.3 RP11-701P16.4 RP11-713M6.1 RP11-713M6.2 RP11-722P15.1 RP11-765K14.1
 RP11-806K15.1 RP11-84H6.1 RP11-88G17.2 RP11-92C4.3 RP11-94C24.10 RP11-94C24.11
 RPL10P3 RPS3AP5 RWDD4A SEPT7P7 SH3TC1 SLC31A2 SLC39A8 SLC46A2 SLC4A4 SMAD9 SMARCE1
 SNCA SNORA26 SNORA31 SNORA32 SNORA46 SNORA70 SNORA74 SNORD112 SNORD65 snoU13
 snoU83B SNW1 SNX30 SORBS2 SPRY2 SPTLC1 SPTLC2 STOML3 STON2 STOX2 STX8
 TBC1D26 TEKT3 TIMM22 TLK1P1 TMED8 TMEFF1 TMEM20 TMEM63C TRIM16 TRIM32
 TTC8 TTLL11 U1 U3 U4 U6 U7 UBE2G1 USP43 VEGFC VIPAR
 WDR16 WDR20 Y_RNA ZDHHC22 ZFP37 ZNF189 ZNF286 ZNF29P ZNF618 ZNF883 
ZYG11AP1 ZZEF1 
PANTHER analysis: 160 mapped ids are found, 319 mapped ids are not found. 
5.8.10.7 CdLOH of Triple Negative DCIS Compared to CdLOH in Triple 
Negative Invasive Breast Disease.   
There is considerable overlap between CdLOH in TN DCIS (n=1/19) and CdLOH in 
TN invasive breast disease (n=3/7). 
1. p-values < 0.05; 
2. A gene list is mapped from 55 genomic regions found on chromosomes 1, 10, 
11, 12, 18, 19, X;   
3. These regions encompass 133 genes altered in TN DCIS and TN invasive 
breast disease; 
Genes:  
Mar09  AC005184.1 AC009731.1 AC011260.2 AC022046.2 AC025263.1 AC036176.2 AC064801.1 AC083805.1 AC083805.2
 AC090666.1 AC090669.1 AC100783.1 AC100843.1 AC139100.1 AC139100.2 AL031311.1 AL136137.1 AL353691.1 
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AL356741.1 AL627402.1 ALPK2 ARHGEF16 AVIL BCL2 BEST3 C10orf100 CASK CBLN2 CD226
 CDK4 CHEK1 CHTF8P CTDSP2 CXorf36 CXorf58 CYP27B1 CYP2A6 DNAJC12 DOK6
 DUSP21 EIF2S3 ELAC1 GPR34 GPR82 GRPR GS1-541M1.1 GS1-541M1.2
 HERC4 HMGA1L1 hsa-mir-26a-2 hsa-mir-551a IL1RAPL1 KAL1 KDM6A KDSR KIAA1468 
KLHL15 L1CAM MALT1 MAOA MAOB MBD2 ME2 MEGF6 NDP NEDD4L
 NRG3 NTS NUAK1 OS9 PARD6G PHLPP1 PIGN PPP1R2P9 RAB3IP RASSF9 RBM19
 RNF152 RP11-126O1.1 RP11-149B9.2 RP11-202D18.2 RP11-204C16.4 RP11-20E23.1
 RP11-342D14.1 RP11-377B2.2 RP11-472N6.1 RP11-474D14.2 RP11-479I1.4
 RP11-514F8.2 RP11-524P6.1 RP11-540L11.2 RP1-154K9.2 RP11-57G10.6 RP11-617O8.1 RP11-640A1.1
 RP11-652N17.1 RP11-702C7.1 RP11-702C7.2 RP11-9H16.1 RP1-22N22.1 RP1-
290C9.2 RP1-50A13.1 RP1-50A13.2 RP3-326I13.1 RP5-1174J21.1 RP5-1174J21.2 RP6-
105D16.1 RP6-218J18.3 RPL12P8 RTTN SCN8A SERPINB5 SH2D4B SIRT1 SNORA68 snoU13 
TNFRSF11A TXNL1 U1 U2 U52112.12 U6 U8 VCX3B VENTXP1 VPS4B WDR7 Y_RNA
 ZCCHC2 ZFX ZNF407 ZNF532 
PANTHER analysis: 65 mapped ids are found, 68 mapped ids are not found. 
 
There are some similarities between CdLOH in TN invasive breast disease (n=4/7) 
and CdLOH in TN DCIS (n=1/19). 
1 p-values < 0.05; 
2 A gene list is mapped from 71 genomic regions found on chromosomes 1, 10, 
11, 12, 18, 19, X; 
3 These regions encompass 167 genes altered in TN DCIS and TN invasive 
breast disease; 
Genes:  
Mar09 5S_rRNA AC005184.1 AC008245.1 AC009731.1 AC011260.2 AC022046.2 AC025263.1 AC036176.2 AC064801.1 AC083805.1
 AC083805.2 AC090360.1 AC090393.1 AC090666.1 AC090669.1 AC091551.1 AC091643.1 AC100783.1 AC100843.1 AC114688.1
 AC139100.1 AC139100.2 ADNP2 AF196972.3 AF196972.4 AL031311.1 AL136137.1 AL353691.1 AL356741.1 AL627402.1 
ALPK2 ARHGEF16 ATP9B AVIL BCL2 BEST3 C10orf100 C18orf22 CASK CBLN2
 CD226 CDH19 CDH7 CDK4 CHEK1 CHTF8P CTDSP2 CXorf36 CXorf58 CYP27B1
 CYP2A6 DNAJC12 DOK6 DUSP21 EIF2S3 ELAC1 FTSJ1 GPR34 GPR82 GRPR GS1-541M1.1
 GS1-541M1.2 HERC4 HMGA1L1 hsa-mir-26a-2 hsa-mir-551a HSBP1L1 IL1RAPL1 KAL1 KDM6A KDSR
 KIAA1468 KLHL15 L1CAM MALT1 MAOA MAOB MBD2 MBP ME2 MEGF6 MEX3C NDP
 NEDD4L NFATC1 NRG3 NTS NUAK1 OS9 PARD6G PHLPP1 PIGN PPP1R2P9 PQLC1
 RAB3IP RASSF9 RBM19 RNF152 RP11-126O1.1 RP11-149B9.2 RP11-162A12.1 RP11-202D18.2 RP11-
204C16.4 RP11-20E23.1 RP11-342D14.1 RP11-377B2.2 RP11-38O23.5 RP11-38O23.7 RP11-472N6.1
 RP11-474D14.2 RP11-479I1.4 RP11-514F8.2 RP11-524P6.1 RP11-540L11.2 RP1-154K9.2
 RP11-552E4.2 RP11-552E4.3 RP11-57G10.6 RP11-617O8.1 RP11-640A1.1 RP11-652N17.1 RP11-702C7.1
 RP11-702C7.2 RP11-9H16.1 RP1-22N22.1 RP1-290C9.2 RP1-50A13.1 RP1-
50A13.2 RP3-326I13.1 RP5-1174J21.1 RP5-1174J21.2 RP6-105D16.1 RP6-218J18.3
 RPL12P8 RTTN SALL3 SCN8A SERPINB5 SH2D4B SIRT1 SLC38A5 SNORA68 snoU13
283 
 
 SOCS6 SSX5 TNFRSF11A TSHZ1 TXNL1 TXNL4A U1 U2 U52112.12 U6 U7 
U8 VCX3B VENTXP1 VPS4B WDR7 Y_RNA ZADH2 ZCCHC2 ZFX ZNF236 ZNF407 ZNF532 
PANTHER analysis: 83 mapped ids are found, 84 mapped ids are not found.  
 
5.8.10.8 CnLOH of Triple Negative DCIS Compared to CnLOH in Triple 
Negative Invasive Breast Disease  
There is CnLOH present in TN DCIS (n=18/19) that are not observed in TN invasive 
breast disease (n=0/7). This represents CnLOH for TN DCIS. 
1. P-values <0.0001; 
2. A gene list is mapped from 78 genomic regions found on chromosomes 1, 2, 
3, 6, 7, 10, 20, 21; 
3. These regions encompass 529 genes altered in TN DCIS; 
Genes:  
sept7 5S_rRNA 7SK ABHD11 AC004455.1 AC004691.5 AC005154.5 AC005189.6 AC005537.2 AC005582.1
 AC006022.4 AC006466.5 AC006478.1 AC006960.7 AC006978.1 AC007392.3 AC007403.1 AC007403.2 AC009474.1 
AC009474.2 AC010132.10 AC010132.11 AC010132.9 AC011738.4 AC018685.2 AC027269.2 AC063927.2
 AC063927.3 AC063927.4 AC063927.5 AC063927.6 AC063927.7 AC063927.8 AC063927.9 AC073464.11
 AC073464.9 AC073846.1 AC073846.2 AC073846.3 AC078784.1 AC078811.1 AC087069.2 AC092265.1 AC092898.1
 AC093168.1 AC107027.2 AC108729.1 AC117477.1 AC121332.1 ADCYAP1R1 ADPRHL2 AF064859.2 AF127577.10
 AF127577.11 AF127577.12 AF127577.8 AF127936.3 AF127936.5 AF127936.6 AF127936.7 AF127936.8 
AF130358.5 AF165138.6 AF165138.7 AIF1 AIM1L AJ006998.2 AJ009632.3 AL022170.1 AL023807.1 AL031655.1
 AL031655.2 AL034372.1 AL034449.2 AL035670.1 AL049570.1 AL050322.1 AL121988.1 AL133268.1 AL136230.1 
AL138724.3 AL138889.1 AL139044.1 AL139044.2 AL139286.1 AL160037.2 AL160400.1 AL160400.2 AL162579.1 AL355877.1
 AL589723.1 AL590062.1 AL591845.1 AL645811.1 ANKRD20B ANLN AOAH AP000304.12
 AP000313.1 AP000313.2 AP000318.2 AP000569.2 AP000569.8 AP001347.1 AP001347.5 AP001347.6 AP001466.1
 AP001466.7 AP001634.5 APOM AQP1 ARHGAP31 ASS1P1 ASTE1 ATP2C1 ATP5LP2
 ATP5O ATP6V1G2 B4GALT4 BAK1 BAT1 BAT2 BAT3 BAT4 BAT5
 BCL7B BIN1 BLVRA BPESC1 BRWD1 BZW1L1 C1orf113 C1orf212 C1orf216
 C20orf187 C21orf81 C3orf16 C3orf30 C3orf72 C6orf125 C6orf15 C6orf227 C6orf25 C6orf26 C6orf27
 C6orf47 C7orf25 C7orf44 CAMK1D CAP2 CATSPER4 CCDC21 CCHCR1 CD52
 CDSN CEP70 CHCHD6 CLDN3 CLDN4 CLIC1 CLSPN CMAH CNKSR1
 COL21A1 COL6A6 COL8A2 COMMD2 CPNE4 CRHR2 CSF3R CSNK2B CST2
 CST5 CSTP1 CTD-2021J15.1 CTD-2021J15.2 CYCSP42 CYP39A1 DDAH2 DHFRP2
 DLGAP3 DNAJC30 EEF1A1P25 EIF2C1 EIF2C3 EIF2C4 ENTPD6 EPDR1 ERLEC1P1 ESYT3
 EXTL1 FABP7 FAIM FAM176B FAM188B FAM65B FAM8A1 FAT1P1 FGFR3P
 FOXL2 FTLP18 GAPDHP39 GARS GGNBP1 GGTLA4 GHRHR GJA4 GJB3
 GJB4 GJB5 GLI3 GMNN GPR116 GRRP1 GS1-179L18.1 GS1-278J22.1
 GS1-278J22.2 GSTO3P HCG27 HCP5 HECW1 HIST1H1A HIST1H1PS2 HLA-B HLA-
C HLA-DQA1 HLA-DQB1 HLA-S HMGCS2 hsa-mir-548a-1 HSF2BP IGSF11 INMT IP6K3
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 ITPR3 ITSN1 KDM1B KIAA0319L KIF13A LEMD2 LIPI LRRC16A LSAMP LSM10
 LST1 LTA LTB LY6G5B LY6G5C LY6G6C LY6G6D LY6G6E LY6G6F
 MAP7D1 MCCD1 MEP1A MICA MICB MLN MLXIPL MME MRAS MRPL3
 MRPL32 MRPS15 MRPS22 MRPS24 MRPS6 MSH5 MT-ATP6 MT-CO1 MT-CO3 
MTCO3P1 MT-ND1 MT-ND2 MT-ND3 MT-ND4 MT-ND4L  MT-ND5 MT-ND6 NCDN NCR3
 NCRNA00240 NEK11 NF1L1 NFKBIL1 NHLRC1 NRIP1 NUDT16 NUDT16P NUP153
 OR2AD1P OR2W1 OSCP1 PA2G4P2 PABPC1P10 PAFAH2 PCBP2P1 PCCB PDIK1L
 PFN2 PHGDH PIK3CB PIK3R4 PKIB PLA2G7 PLCB1 PLCH1 PLXNA1 
POLR2CP POLR2LP POM121L3P POU5F1 PPIAP9 PRIM2 PRR23A PRR23B PRR23C PSMA2
 PSMB2 PSMG1 PSORS1C1 PSORS1C2 PSORS1C3 RAD23BLP RBM11 RBM24 RBPMSLP 
RCAN2 RHOT1P2 RNF13 RNF144B RP11-102J14.1 RP11-115O13.1 RP11-117F22.1 RP11-117L15.1
 RP11-14H3.3 RP11-153N17.1 RP11-167H9.3 RP11-167H9.4 RP11-191A15.1
 RP11-191A15.2 RP11-191A15.3 RP11-191A15.4 RP11-201E8.1 RP11-221J22.1
 RP11-221J22.2 RP11-231P20.2 RP11-231P20.3 RP11-232M24.1 RP11-238O13.1
 RP11-255N4.2 RP11-255N4.3 RP11-263A24.1 RP11-265F19.1 RP11-268F1.2
 RP11-268F1.3 RP11-280F2.1 RP11-280F2.2 RP11-280H21.1 RP11-305I9.1
 RP11-306L14.1 RP11-324H4.1 RP11-367G6.1 RP11-384F7.1 RP11-384F7.2
 RP11-394D14.1 RP11-39E3.3 RP11-39E3.4 RP11-39E3.5 RP11-39E3.6
 RP11-40M23.1 RP11-435D7.3 RP11-446F17.3 RP11-446H18.3 RP11-451G4.2
 RP11-451G4.3 RP11-463H24.1 RP11-484M3.4 RP11-484M3.5 RP11-517B11.2
 RP11-517B11.4 RP11-517B11.6 RP11-548O1.1 RP11-548O1.3 RP11-561O4.1
 RP11-569G9.7 RP11-605F14.3 RP11-622P13.2 RP11-631B21.1 RP11-631B21.2
 RP11-639F1.1 RP11-639F1.2 RP11-639F1.3 RP11-63E16.1 RP11-649A16.1
 RP11-651P23.2 RP11-651P23.3 RP11-651P23.4 RP11-651P23.5 RP11-651P23.6
 RP11-768G7.1 RP11-768G7.2 RP11-768G7.3 RP11-779P15.1 RP11-779P15.2
 RP11-795J1.1 RP11-795J1.2 RP11-810H18.1 RP11-933H2.4 RP11-93B21.1
 RP11-96L14.7 RP1-245M18.2 RP1-273P12.1 RP1-273P12.3 RP1-278O22.2
 RP1-71H19.2 RP3-347E1.2 RP3-425P12.1 RP3-425P12.2 RP3-425P12.4 
RP3-425P12.5 RP3-437I16.1 RP3-468B3.2 RP3-501N12.3 RP3-522P13.1 RP3-522P13.2
 RP3-522P13.3 RP3-525L6.2 RP4-564O4.1 RP4-635B5.1 RP4-665N4.4 RP4-665N4.5
 RP4-697P8.2 RP4-697P8.3 RP4-718N17.1 RP4-718N17.2 RP4-728D4.2
 RP4-728D4.3 RP4-738P15.1 RP4-738P15.4 RP4-765A10.1 RP4-765A10.2 RP4-
796I8.1 RP5-1100I6.1 RP5-1100I6.2 RP5-877J2.1 RP5-983H21.3 RP5-997D16.2
 RPL15P4 RPL3P2 RRP1B SAMSN1 SCARNA17 SCARNA18 SCGN SEPT7P3 SFRP4 SH3BGRL3 
SLC25A27 SLC30A2 SLC5A3 SMPDL3A SNORA38 SNORA58 SNORA63 SNORA73 SNORD45 SNORD83
 snoU13 STAG1 STK40 STX1A TBL2 TCF19 TDRD6 TEKT2 TFAP2E THRAP3
 TMEM45A TNF TPMT TRAPPC3 TRIM38 TRIM63 TXNDC3 U1 U3 U4 U5 
U6 U7 UBXN11 UPK1B UQCRHP1 URGCP USP25 USP8P VARS VN1R11P
 VN1R13P VPS37D WASF5P WBSCR22 WBSCR26 WBSCR27 WBSCR28 WWTR1 XXbac-
BPG181B23.4 XXbac-BPG181B23.6 XXbac-BPG248L24.10 XXbac-BPG248L24.11 XXbac-BPG248L24.12 XXbac-
BPG254F23.5 XXbac-BPG254F23.6 XXbac-BPG254F23.7 XXbac-BPG296P20.14 XXbac-BPG296P20.15
 XXbac-BPG299F13.14 XXbac-BPG32J3.18 XXbac-BPG3 J3.19 XXyac-YX60D10.1 Y_RNA
 Z93017.1 ZDHHC20P2 ZMYM4 ZNF593 ZNF683 ZPLD1 




There is CnLOH present in TN invasive breast disease (n=6/7) that are not observed 
in TN DCIS (n=0/19). 
1. p-values < 0.05; 
2. A gene list is mapped from 40 genomic regions found on chromosomes 1, 2, 
3, 10, 11, 12, 19, 20; 
3. These regions encompass 291 genes altered in TN invasive breast disease; 
Genes: 
ZSWIM4 5S _rRNA 7SK ABRA AC004016.1 AC004016.2 AC005082.1 AC005082.12 AC005082.2 AC006039.1 AC006039.4 AC006039.5
 AC008686.2 AC009908.1 AC011118.2 AC011626.1 AC016405.1 AC017084.1 AC017084.6 AC021876.3 AC021876.4 AC022021.2
 AC022201.4 AC023590.1 AC023632.1 AC025370.1 AC025370.2 AC025647.3 AC027238.1 AC027419.1 AC048346.1 AC064807.1 
AC068228.4 AC068228.5 AC084083.1 AC084083.2 AC084114.1 AC090192.1 AC090192.2 AC090193.2 AC090802.1 AC090811.1 AC090921. 
AC090922.1 AC099680.1 AC103816.1 AC104212.2 AC120053.1 ADD2 AL049651.1 AL136985.2 AL160287.2 AL161932.2 AL451107.1
 AL512654.1 ANGPT1 ANKRD46 ANXA13 AP000428.1 AP002852.1 AP002907.1 AP003550.10 APBB1IP ARHGAP12 ATAD2 
ATP6V1G1P4 BAALC BRD7P6 C10orf50 C7orf30 C7orf31 C8orf37 C8orf39 C8orf54 C8orf56 C8orf76
 C8orf85 CACHD1 CCND1 CCNY CDH17 CLSTN2 COLEC10 CREM CSDA CSGALNACT2
 CSTF2T CTC-788C1.1 CTHRC1 CUL2 CYB5P4 CYCS DCAF13 DEPDC1 DERL1 DFNA5 EXT1
 EYA1 FABP5 FAM159A FAM83A FAM91A1 FAM92A1 FBXO32 FBXO43 FER1L6 FGF19
 FXYD4 FZD6 GAPDP2 GEM GLUDP5 GPNMB GPX7 HAS2 HAS2AS HNRNPF hsa-mir-1273hsa-
mir-23a hsa-mir-24-2 hsa-mir-27a hsa-mir-548d-1 IAPP IGF2BP3 KB-1137H10.1 KB-1247B1.1 KB-1554H10.1
 KB-1615E4.1 KB-1980E6.1 KIAA0196 KIF5B KLF10 KLHL38 KLHL7 KRT18P3 MACROD1 MAL2 MED30
 MPP7 MTSS1 MYSM1 NCALD NDUFB9 NIPAL2 NOV NRP1 NSMCE2 NUPL2 ODF1
 ORAOV1 OSBPL3 OVCH1 OXR1 PABPC1 PCDH15 PCMTD1 PDP1 PDSS1 PDZK1IP1 PIK3C2G
 POP1 PRB3 PRH1 PRH2 PRKG1 PRR4 RAD54B RASGEF1A RAVER2  RBM12B RET RGS22
 RNF139 RNF19A RP11-1082L8.1 RP11-1110J8.1RP11-128B16.3 RP11-13L2.1 RP11-13L2.2 RP11-14C22.3
 RP11-14C22.4 RP11-14C22.6 RP11-152P17.1 RP11-167O6.2 RP11-168L22.2 RP11-168O22.1 RP11-
189G24.2 RP11-200A13.1 RP11-200A13.2RP11-241I20.1 RP11-241I20.3 RP11-241I20.4 RP11-241I20.5
 RP11-273P3.1 RP11-297A16.2 RP11-30P9.1 RP11-318G8.1 RP11-324I22.2 RP11-342D11.2 
RP11-351M16.1 RP11-351M16.2 RP11-351M16.3 RP11-359G22.2 RP11-414D17.1 RP11-472N13.3 RP11-484J3.1 RP11-51B10.3 RP11-
51B10.4 RP11-539E17.1 RP11-668N23.1 RP11-68L1.1 RP11-68L1.2 RP11-778D12.1 RP1-18D14.2 RP1-18D14.3 RP1-
18D14.4 RP11-941H19.1 RP11-941H19.2 RP11-959I15.1 RP13-16H11.1 RP13-16H11.2 RP13-16H11.5
 RP13-16H11.6 RP13-16H11.7 RP3-388N13.1 RP4-694A7.2 RP4-694A7.3 RP4-694A7.4
 RP4-753D10.3 RP4-753D10.5 RP4-794H19.2 RP5-1033K19.2 RPE65 RRM2B RSPO2
 SAMD12 SLC25A32 SLC30A8 SLCO1A2 SLCO1B1 SNORA20 SNORA31 SNORA32 SNORD77 snoU13 SNX31
 SPAG1 SQLE SSTR4 STYK1 TAS2R10 TAS2R13 TAS2R14 TAS2R19 TAS2R20 TAS2R31 
TAS2R42 TAS2R50 TAS2R7 TAS2R8 TAS2R9 TASP1 TATDN1 TCEB1P18 TGFA THBD TMEM65
 TMEM67 TMEM74 TMTC1 TNFRSF11B TPD52 TRHR TRIB1 TRIM42 TRMT12 TRPS1 U3 U4
 U6 U6atac U7 UBR5 WAC WDR67 WDYHV1 Y_RNA ZFPM2 ZHX1 ZHX2 ZNF572 
 
PANTHER analysis: 140 mapped ids are found, 151 mapped ids are not found.  
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5.8.11 Copy Number Aberrations for HER2 Positive DCIS Compared to Oestrogen 
Receptor Positive DCIS and Triple Negative DCIS. 
These series examines the difference between Her2 positive pure DCIS and 
oestrogen receptor positive DCIS and triple negative positive DCIS 
Frequency plots showing copy number aberrations between HER2 positive DCIS 
compared to oestrogen receptor positive DCIS and triple negative DCIS were 
provided by Breakthrough Breast Cancer/Research Oncology, King’s College London 
Bioinformatics Department (Figure 44).  
 
Figure 44: Frequency plots showing copy number aberrations between HER2 positive 
pure DCIS compared to oestrogen positive dcis and triple negative DCIS 
(amplifications, duplications, gains, Sc gains, losses, total losses CdLOH and 
















5.8.11.1 Amplification in HER2 Positive DCIS Compared to ER Positive DCIS 
and Triple Negative DCIS. 
There are overlaps between the amplifications found in HER2 positive pure DCIS 
(n=6/7) and all other pure DCIS (TN and ER n=4/17). 
1. p-values < 0.05;  
2. A gene list is mapped from 7 regions on chromosome 17; 
3. These regions encompass 45 genes altered in HER2 positive DCIS; 
Genes: 
 AC002094.1 AC002094.2 AC002094.3 AC002094.4 AC002094.5 AC015917.1 AC015917.2 AC015917.3 AC061975.1 AC061975.2
 AC061975.3 AC061975.4 AC061975.5 AC061975.6 AC079199.1 AC079199.2 AC087491.2 C17orf37 CRKRS EFCAB5
 ERBB2 GRB7 IFT20 IKZF3 NEUROD2 PGAP3 PNMT POLDIP2 PPP1R1B PPY2 PYY2
 RP11-338L22.1 SARM1 SLC13A2 SLC46A1 snoU13 SSH2 STARD3 TCAP TMEM199
 TMEM97 TNFAIP1 U6 VTN ZPBP2 




5.8.11.2 Duplication of HER2 Positive DCIS Compared to Oestrogen Positive 
DCIS and Triple Negative DCIS. 
There were duplications present in HER2 positive DCIS (n=3/7) not observed in ER 
and TN pure DCIS (n=0/17). 
1. p-values < 0.05; 
2. A gene list is mapped from 14 regions found on chromosomes 1, 3, 8, 17;  
3. These regions encompass 91 genes altered in HER2 positive DCIS; 
Genes: 
 5S_rRNA AC005746.1 AC005901.1 AC011118.2 AC083928.1 AC092811.1 AC104958.1 AC120042.2 AC120053.1 AP003357.3
 ARFGEF1 ARL14 BCAS3 C17orf82 C1orf46 C1orf68 C8orf39 C8orf44 C8orf46 COL14A1 COPS5
 CSMD3 CSPP1 CTC-820M8.1 DEPDC6  DNAH14 ENAH FAM92A1 GGH IVL KB-1589B1.1 KB-
1683C8.1 KPRP LAPTM4B LBR LCE1A LCE1B LCE1C LCE1D LCE1E LCE1F LCE2A
 LCE2B LCE2C LCE2D LCE3A LCE3B LCE3C LCE3D LCE3E LCE4A LCE6A
 LRRC67 MATN2 MRPL13 MTBP MTDH MYBL1 PDP1 RBM12B RP11-145A3.1
 RP11-145A3.2 RP11-145A3.4 RP1-13P20.6 RP11-453N18.1 RP11-496N12.6 RP1-20N18.4
 RP1-43O17.1 RP1-43O17.2 RP1-52J10.9 RP3-388N13.1 SMCP SNORA31 SNTB1
 SPRR1A SPRR1B SPRR2A SPRR2B SPRR2D SPRR2E SPRR3 SPRR4 SRP9 TBX2
 TBX4 TMEM67 TTPA U6 U7 VCPIP1 Y_R  
PANTHER analysis:  58 mapped ids are found, 33 mapped ids are not found.  
5.8.11.3 Genomic Gains in HER2 Positive DCIS Compared to Oestrogen 
Positive DCIS and Triple Negative DCIS. 
There are genomic gains in HER2 positive pure DCIS (n=4/7) not present in ER and 
TN pure DCIS (n=0/17). 
1. p-values < 0.05; 
2. A gene list is mapped from 10 genomic regions found on chromosomes 1, 5, 
6, 20;  
3. These regions encompass 92 genes altered in HER2 positive pure DCIS; 
Genes: 
 AACSL AC022096.2 AC027317.2 AC027317.2 AC091934.1 AC104115.1 AC104117.1 AC104117.2 AC136940.3 AC145098.1
 AC145098.2 AC145098.3 AC146507.1 ADAMTS2 AGXT2L2 AL050329.1 AL589736.1 CNOT6 COL23A1 CTB-129O4.1
 CTC-573N18.1 CTD-2301A4.1 CTD-2301A4.3 DBN1 DDX41 DMRTA2 DOK3
 EIF4E1B EYS F12 FAF1 FAM193B FGFR4 FGFR4 FKBP1C FLT4 GCNT1P4
 GFPT2 GRK6 GRM6 HNRNPAB LGSN LMAN2 MACROD2 MAPK9 MXD3 NSD1
293 
 
 OR2AI1P OR2Y1 PDLIM7 PFN3 PHF3 PRELID1 PRR7 PTP4A1 RAB24 RASGEF1C
 RGS14 RP11-1334A24.4 RP11-1334A24.5 RP11-1334A24.6 RP11-164N20.1 RP11-183G22.1
 RP11-183G22.2 RP11-183G22.3 RP11-184C23.1 RP11-184C23.3 RP11-184C23.4
 RP11-252I14.1 RP11-349P19.1 RP11-442B12.1 RP11-448N11.2 RP11-451H23.1
 RP11-451H23.2 RP11-451H23.3 RP11-59D5__B.2 RP11-59D5__B.3 RP3-407E4.2 RP3-
407E4.3 RP3-407E4.4 RP5-1148A21.1 SCGB3A1 SLC34A1 SNCB TSPAN17 U1 U1
 U6 ZFP2 ZNF346 ZNF346 ZNF354A ZNF354B ZNF354C ZNF454 ZNF879 
PANTHER analysis: 47 mapped ids are found, 45 mapped ids are not found.  
 
There are genomic gains in TN and ER pure DCIS (n=5/17) with associated genomic 
gains in HER2 positive pure DCIS (n=6/7). 
1. p-values < 0.05; 
2. A gene list is mapped from 14 genomic regions found on chromosomes 
1,8,17.  
3. These regions encompass 129 genes altered in TN v DCIS, ER pure DCIS 
and HER2 positive pure DCIS.  
Genes:  
5S_rRNA AC012533.1 AC016057.1 AC016240.1 AC022598.1 AC022861.1 AC022861.2 AC022861.3 AC022861.4 AC022861.5
 AC022861.6 AC022861.7 AC023644.1 AC024367.1 AC027006.1 AC037450.1 AC083928.1 AC087491.2 AC091175.1 AC099805.1
 AC103816.1 AC104012.1 AC104212.2 AC110998.1 AC132219.1 AC132219.2 AF121898.1 AL592492.2 ARFGEF1 C8orf44
 C8orf45 C8orf46 CHMP4C CNBD1 COPS5 CPA6 CSPP1 DCAF4L2 E2F5 ERBB2
 EYA1 FABP12 FABP4 FABP5 FABP9 FAM164A HEY1 IKZF3 IL7 IMPA1
 JPH1 LRRC67 LRRCC1 LY96 MMP16 MRPS28 MSC MYBL1 NBPF10 NBPF14
 NBPF15 NBPF16 NEUROD2 PAG1 PGAP3 PKIA PMP2 PNMT PPIAL4A PPP1R1B
 PTTG3P RALYL RP11-289I10.1 RP11-289I10.2 RP11-34M16.1 RP11-34M16.2
 RP11-367C12.1 RP11-367E12.1 RP11-453N18.1 RP11-48B3.1 RP11-495P10.1
 RP11-495P10.2 RP11-508K19.1 RP11-656G20.1 RP11-666A1.1 RP11-666A1.2
 RP11-666A1.3 RP11-666A1.4 RP11-666A1.5 RP11-69I13.1 RP11-6I2.1 RP11-763B22.2
 RP11-763B22.3 RP11-763B22.4 RP11-7F18.1 RP11-89F3.2 RP11-89F3.3 RP11-91G11.1 RP11-941H19.1
 RP11-941H19.2 RP11-98H4.1 RP6-74O6.1 SGK3 SLC10A5 SNHG6 SNORA20 SNORD87
 snoU13 SNX16 STARD3 STMN2 TCAP TCEB1 TMEM70 TPD52 TRPA1 U1 U11
 U2 U6 U7 U8 VCPIP1 WWP1 Y_RNA ZBTB10 ZFAND1 ZFHX4
 ZNF704 
PANTHER analysis: 56 mapped ids are found, 73 mapped ids are not found. 
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5.8.11.4 Genomic Sc Gains in HER2 Positive DCIS Compared to Oestrogen 
Positive DCIS and Triple Negative DCIS. 
There were Sc gains present in HER2 positive pure DCIS (n=6/7) and ER and TN 
pure DCIS (n=4/17).  
1. p-values < 0.05; 
2. A gene list is mapped from 10 regions found on chromosomes 1, 3, 5, 8, 20;  
3. These regions encompass 188 genes altered in HER2 positive pure DCIS and 
ER and TN pure DCIS; 
Genes: 
 5S_rRNA 7SK A4GNT AACSL AADAC AADACL2 AC022096.2 AC026320.2 AC027317.2 AC087667.1
 AC091934.1 AC092965.1 AC104117.1 AC104117.2 AC104629.1 AC104629.2 AC104629.3 AC104629.4 ADAMTS2 ARMC8
 C3orf36 C3orf55 C3orf72 CCDC50 CCRL1 CDV3 CEP63 CEP70 CLDN18 DBR1 DEFB121
 DEFB122 DEFB123 DEFB124 DHX36 DMRTA2 DNAJC13 DZIP1L EEF1A1P25 EIF4E1B EPHB1
 ESYT3 FAF1 FAIM FGF12 FGFR4 FOXL2 GAPDHP39 GFM1 GPR149 GPR79 GRM6
 HM13 IL20RB IQCJ KY LXN MFSD1 MLF1 MRAS MSL2 NCK1
 NCRNA00028 NPHP3 OSTN OTTHUMG00000159780 PCCB PDCD10 PHC3 PIK3CB PPP2R3A
 PRKCI PYDC2 RAB6B RARRES1 REM1 RP11-102M11.1 RP11-113A11.1 RP11-117F22.1
 RP11-12N13.1 RP11-12N13.2 RP11-12N13.3 RP11-12N13.4 RP11-12N13.5 RP11-12N13.6
 RP11-167H9.1 RP11-183G22.1 RP11-183G22.2 RP11-183G22.3 RP11-192K2.3
 RP11-197K6.1 RP11-202A13.1 RP11-202A13.2 RP11-206M11.4 RP11-206M11.7 RP11-
217E22.1 RP11-217E22.2 RP11-217E22.5 RP11-237P21.1 RP11-23D24.1 RP11-23D24.2
 RP11-278L15.1 RP11-278L15.2 RP11-290K4.1 RP11-290K4.2 RP11-293N1.1
 RP11-2A4.1 RP11-2A4.3 RP11-2G17.1 RP11-305O4.1 RP11-305O4.2 RP11-333H9.6 RP11-379F4.1
 RP11-379F4.4 RP11-404G16.1 RP11-404G16.2 RP11-413G22.2 RP11-440K22.1
 RP11-450H5.1 RP11-452B4.1 RP11-454C18.1 RP11-454C18.2 RP11-463H24.1 RP11-463H24.4
 RP11-468F18.2 RP11-538P18.1 RP11-538P18.2 RP11-548O1.1 RP11-548O1.3
 RP11-575C1.1 RP11-576M8.2 RP11-598P12.1 RP11-642L11.1 RP11-64D22.1
 RP11-64D22.2 RP11-64D22.5 RP11-655G22.1 RP11-655G22.2 RP11-656G9.3 RP11-657O9.1
 RP11-65E22.3 RP11-731C17.1 RP11-785G3.1 RP11-79L9.2 RP11-79M21.2 RP11-79M21.3
 RP11-85F14.1 RP11-85F14.5 RP11-85F14.6 RP11-91K8.2 RP13-81O8.1 RP3-
324O17.4 RSRC1 RYK SERPINI1 SERPINI2 SHOX2 SLCO2A1 SNCB SNORA33 snoU13 SOX14
 SRPRB STAG1 SUCNR1 TF TM4SF1 TM4SF18 TMEM22 TOPBP1 TSPAN17 TXNDC6 U1
 U6 U7 U8 UBA5 UTS2D VEPH1 WDR49 Y_RNA ZBBX ZFP2 ZNF346 
ZNF354B ZNF354C ZNF454 ZNF879 
PANTHER analysis: 82 mapped ids are found, 106 mapped ids are not found.  
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5.8.11.5 Losses in HER2 Positive DCIS Compared to Oestrogen Positive DCIS 
and Triple Negative DCIS. 
There were losses present in HER2 positive pure DCIS (n=3/7) not observed in ER 
and TN positive pure DCIS (n=0/17). 
1. p-values < 0.05;  
2. A gene list is mapped from 9 regions found on chromosomes 1, 8, 15, 16, X;  
3. These regions encompass 87 genes altered in HER2 positive pure DCIS; 
Genes: 
 AC009113.1 AC009113.2 AC009113.3 AC010531.1 AC010531.2 AC027702.2 AC092139.1 AC092139.2 AC092384.1 AC092384.2
 AC099524.1 AC116552.1 AC136285.1 AC138028.1 AC138028.2 AC138028.3 ACSF3 AGPAT6 AHDC1 AL049610.1
 ANK1 AP3M2 APRT C16orf81 C16orf85 CBFA2T3 CD164L2 CDH15 CDT1 CTU2
 CYBA FAM38A FBXO31 FCN3 GALNS GAN GINS4GLRA4 GOLGA7 GPR3 hsa-mir-486
 IKBKB IL17C LL0XNC01-250H12.2 LL0XNC01-250H12.3 MAP1LC3B MAP3K6 MORF4L2 MVD MYST3
 NGFRAP1 NKX6-3 PABPN1L PLAT PLCG2 PLP1 RAB40A RAB9B RNF166 RP11-173M1.1
 RP11-178L8.1 RP1-144C9.2 RP11-589C21.1 RP1-159A19.4 RP4-752I6.1 RP5-1055C14.4
 RP5 1055C14.6 RP5-1055C14.7 RP5-1142A6.2 SLC20A2 SNAI3 SNORD112 snoU13
 snoU13 SYTL1 TCEAL1 TCEAL3 TCEAL4 TMEM31 TRAPPC2L WASF2 Y_RNA Z73964.1
 ZC3H18 ZCCHC14 ZFPM1 ZNF469 ZNF778 
PANTHER analysis: 50 mapped ids are found, 37 mapped ids are not found.  
 
There were losses present in ER and TN pure DCIS (n=10/17) not observed in any 
HER2 positive pure DCIS (n=0/24).   
1. P-values < 0.05; 
2. A gene list is mapped from 3 genomic regions from chromosome 19;   
3. These regions encompass  3  genes altered in non HER2 DCIS; 
Genes: 
 MUC16   AC008734.1 AC008734.2 




5.8.11.6 Total Loss in HER2 Positive DCIS Compared to Oestrogen Positive 
DCIS and Triple Negative DCIS. 
There were total losses present in HER2 positive pure DCIS (n= 7/7) also present in 
some ER and TN pure DCIS (n=4 /17). 
1. p-values < 0.05; 
2. A gene list is mapped from 28 regions found on chromosomes 3, 6, 16, 17;  
3. These regions encompass 293 genes altered in HER2 positive pure DCIS and 
ER and TN pure; 
Genes:  
5S_rRNA 7SK AARS AC000003.1 AC003664.1 AC003958.1 AC003958.2 AC003958.5 AC003958.6 AC004223.2
 AC004675.1 AC005224.2 AC005277.1 AC005304.1 AC005304.2 AC005304.3 AC005358.1 AC005358.3 AC005410.2 AC006070.11
 AC006070.12 AC006070.13 AC006070.7 AC009060.1 AC009060.2 AC009060.3 AC011193.1 AC012184.1
 AC015842.1 AC015849.1 AC015849.4 AC019349.4 AC024610.1 AC025335.1 AC025518.1 AC026468.1 AC026954.6 AC027045.1
 AC069363.1 AC087742.1 AC091178.1 AC100793.1 AC100808.10 AC100808.7 AC104581.1 AC107993.1 AC113189.5
 AC123769.1 AC126327.1 AC126327.4 AC129492.6 AC131056.1 AC135178.7 ACADVL ACAP1 ACCN1 ALOX12B
 ALOX15B ALOXE3 AMAC1L3 ANKFY1 ARHGEF15 ARL5C ATP6V0A1 AURKB BECN1 C17orf102
 C17orf44 C17orf59 C17orf61 C17orf68 C17orf74 C17orf81 C17orf96 C17orf98 CACNB1 CCDC56
 CCL1 CCL11 CCL13 CCL14 CCL15 CCL16 CCL18 CCL2 CCL23 CCL3
 CCL3L1 CCL4 CCL4L1 CCL4L2 CCL7 CCL8 CCR10 CCT6B CD68 CDRT15
 CDRT15P CHD3 CHRNB1 CISD3 CLDN7 CLEC18A CLEC18C CNTD1 CNTNAP1 CNTROB
 COASY COG4 COX10 CTB-75G16.1 CTD-2303K11.1 CTD-3193K9.1 CWC25
 CYB5D1 CYB5D2 DDX19A DDX19B DHRS11 DHRS7C DLG4 DNAH2 DNAH9 DULLARD
 DUSP7 DVL2 EFNB3 EIF4A1 EIF5A ELAC2 EXOSC6 EZH1 FAM134C FBXO47
 FGF11 FNDC8 FUK FXR2 GABARAP GAS7 GGNBP2 GPS2 GUCY2D HES7
 HS3ST3A1 hsa-mir-140 hsa-mir-1972 hsa-mir-324 hsa-mir-548h-3 hsa-mir-744 HSD17B1 HSD17B1P1 KCNAB3
 KCTD11 KDM6B KRBA2 KRT31 KRT33A KRT33B KRT34 KRT37 KRT38 KRTAP16-1
 KRTAP17-1 KRTAP2-1 KRTAP2-4 KRTAP29-1 KRTAP4-1 KRTAP4-12 KRTAP4-14 KRTAP4-2 KRTAP4-3 KRTAP4-4
 KRTAP4-5 KRTAP4-6 KRTAP4-7 KRTAP4-8 KRTAP4-9 KRTAP9-1 KRTAP9-2 KRTAP9-3 KRTAP9-4 KRTAP9-6
 KRTAP9-7 KRTAP9-8 KRTAP9-9 LASP1 LIG3 LSMD1 LYZL6 MAP2K4 MLLT6 MLX
 MPDU1 MRM1 MYH10 MYO19 MYOCD NAGLU NDEL1 NEURL4 NLE1 NLGN2
 ODF4 PCGF2 PDXDC2 PER1 PFAS PHF23 PIGW PIP5K2B PLEKHH3 PLSCR3
 PLXDC1 POLR2A PSMB3 PSMC3IP PSME3 PTRF RAD51L3 RAMP2 RANGRF RDM1
 RFFL RNF222 RP11-106J23.1 RP11-1096G20.1 RP11-462C21.1 RP11-554D15.1
 RP11-554D15.3 RP11-554D15.4 RP11-565F19.1 RP11-713H12.1 RP5-837J1.1 RPL19
 RPL23 RPL26 RPS27P26 SCARNA21 SENP3 SLC25A35 SLC2A4 SNORA21 SNORA48 SNORA67
 SNORA69 SNORA74 snoU13 snoU6-77 SOX15 SPEM1 ST3GAL2 STAC2 STAT3 STX8
 TBC1D3B TBC1D3C TBC1D3G TBC1D3H TMEM102 TMEM107 TMEM132E TMEM88 TMEM95 TNFSF12
 TNFSF12-TNFSF13 TNFSF13 TNK1 TP53 TRAPPC1 TUBG1 TUBG2 U11 U6 U7
 U8 UBE2G1 USP43 VAMP2 Vault VPS25 WDR16 WDR51A WNK4 WRAP53
 WWP2 Y_RNA YBX2 ZBTB4 ZNF18 ZNF830 ZNHIT3 ZZEF1 
PANTHER analysis: 192 mapped ids are found, 101 mapped ids are not found.  
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There were total losses present in more than half of the ER pure DCIS and TN pure 
DCIS (n=11/17) not present in any of the HER2 positive pure DCIS cases (n=0/7) 
1. p-values < 0.05; 
2. A gene list is mapped from 42 genomic regions found on chromosomes 
6,11,13,17, 19.  
3. These regions encompass 67 genes altered in ER pure DCIS and TN pure 
DCIS. 
Genes: 
 5S_rRNA AC008734.1 AC008734.2 AC087498.1 AC090282.1 AC097370.1 ACRV1 ACTL9 ADAMTS10 AL136359.1
 AL137001.1 AP001482.1 AP003027.2 ASPA C11orf87 CEP164 CHEK1 CTD-2557P19.1 DDX25
 GRAMD1B GRM5 hsa-mir-1253  HYLS1 MUC16 OLFM4 OR10D1P OR10D3P OR1A1 OR1A2
 OR1D2 OR1D5 OR1E1 OR1E2 OR1G1 OR2Z1 OR3A1 OR3A2 OR3A3 OR3A4 OR6X1
 OR8D1 OR8D2 OR8F1P OR8G2P OR8G5 PARK2 PATE1 PATE2 PATE3 PATE4 PUS3
 RAP1GAP2 RP11-24H2.1 RP11-24H2.2 RP11-301J16.2 RP11-301J16.3 RP11-301J16.5 
RP11-301J16.7 RP11-442J17.4 SCN3B SPATA22 TRPV3 U1 U6 VWA5A WSCD1
 ZNF202 
Genes PANTHER analysis: 39 mapped ids are found, 28 mapped ids are not found.  
5.8.11.7 CdLOH in HER2 Positive DCIS Compared to Oestrogen Positive DCIS 
and Triple Negative DCIS. 
There is CdLOH present in HER2 positive pure DCIS (n= 4/7) not observed in any of 
the ER and TN pure DCIS (n= 0/17). 
1. p-values < 0.05; 
2. A gene list is mapped from 13 regions found on chromosomes 1, 5, 8, 10, 16, 
17, X;  
3. These regions encompass 83 genes altered in HER2 positive pure DCIS; 
Genes:  
AC009113.1 AC009113.2 AC009113.3 AC010531.1 AC010531.2 AC092139.1 AC092139.2 AC092384.1 AC092384.2 AC099524.1
 AC116552.1 AC136285.1 AC138028.1 AC138028.2 AC138028.3 ACSF3 AGPAT6 AHDC1 AL049610.1 ANK1
 APRT ATAD1 C16orf81 C16orf85 CBFA2T3 CD164L2 CDH15 CDT1 CFLP1 CTU2
 CYBA FAM38A FBXO31 FCN3 GALNS GAN GINS4 GLRA4 GOLGA7 GPR3 hsa-mir-486
 IKBKB IL17C LL0XNC01-250H12.2 LL0XNC01-250H12.3 MAP1LC3B MAP3K6 MORF4L2 MVD NGFRAP1
 NKX6-3 PABPN1L PAPSS2 PLAT PLCG2 PLP1 RAB40A RAB9B RNF166 RP11-173M1.1
 RP11-178L8.1 RP1-144C9.2 RP1-159A19.4 RP4-752I6.1 RP5-1055C14.4 RP5-1055C14.6
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 RP5-1055C14.7 RP5-1142A6.2 SLC20A2 SNAI3 snoU13 SYTL1 TCEAL1 TCEAL3
 TCEAL4 TMEM31 TRAPPC2L WASF2 Z73964.1 ZC3H18 ZCCHC14 ZFPM1 ZNF469 
PANTHER analysis: 50 mapped ids are found, 33 mapped ids are not found.  
 
There is CdLOH present in ER pure DCIS (n= 9/17) not observed in HER2 Positive 
pure DCIS (n=0/7) 
1. p-values < 0.05; 
2. A gene list is mapped from 1 genomic regions found on chromosomes 19; 
3. These regions encompass 1 gene altered in ER pure DCIS; 
Gene: Muc16 
PANTHER analysis: 1 mapped id is found. 
5.8.11.8 CnLOH in HER2 Positive DCIS Compared to Oestrogen Positive DCIS 
and Triple Negative DCIS. 
There is CnLOH present in HER2 positive pure DCIS (n=7/7) not observed in ER and 
TN pure DCIS (n=0/17) 
1. p-values < 0.05;  
2. A gene list is mapped from 14 regions found on chromosomes 1, 2, 12, X;  
3. These regions encompass 104 genes altered in HER2 positive pure DCIS; 
4. Genes: AC117494.1 5S_rRNA AC004074.1 AC004074.3 AC004074.4 AC004673.1 AC092198.1 AC117517.1 AF241726.2
 AF241726.4 AF241726.6 AL031115.1 AL121578.2 AL161779.1 AL591845.1 AL627402.1 ATP6AP2 BCOR
 C1orf113 C2orf55 CASK CTD-2324A24.1 CXorf38 CYBB DDX3X DDX53 DYNLT3
 FAM176B FAM3C2 FTLP16 GS1-433O24.1 GS1-590J15.1 hsa-let-7f-2 hsa-mir-492 hsa-mir-98
 HSD17B10 HUWE1 IQSEC2 LSM10 MED14 MID1IP1 MKRNP5 NAP1L2 NAV3 NYX
 OSCP1 OTC PTCHD1 PTCHD1 RIBC1 RP11-126D17.1 RP11-126D17.4
 RP11-157D23.1 RP11-157D23.2 RP11-169L17.2 RP11-169L17.3 RP11-169L17.5
 RP11-185O17.3 RP11-204C16.4 RP11-265P11.1 RP11-265P11.2 RP11-272G22.1
 RP11-272G22.2 RP11-272G22.3 RP11-320G24.1 RP11-40F8.2 RP11-469E19.1
 RP11-478I12.1 RP11-494I9.1 RP11-494I9.2 RP11-540L11.2 RP11-654E17.2
 RP1-169I5.4 RP11-77G22.2 RP11-77G22.3 RP13-126P21.1 RP13-13A3.1
 RP13-444K19.1 RP3-339A18.3 RP3-339A18.6 RP4-646N3.1 RP4-646N3.3 RP5-
1172N10.2 RP5-972B16.2 RP5-972B16.2 RP6-186E3.1 RP6-29D12.2 RP6-29D12.3 RP6-
29D12.4 RPGR SLC6A15 SMC1A SNORA31 SNORA63 snoU13 snoU13 STK40 SYT1
 THRAP3 TSPAN7 U4 U6 U6 U6 U7 USP9X Vault Y_RNA
 Y_RNA ZXDB 
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PANTHER analysis: 30 mapped ids are found, 74 mapped ids are not found.  
 
There is CnLOH present in ER and TN pure DCIS (n=017/17) not observed in HER2 
positive pure DCIS (n=0/7).  
1. p-values < 0.05; 
2. A gene list is mapped from 84 genomic regions found on chromosomes 1, 2, 
3, 4, 6, 7, 9, 10, 11, 12, 18, 20, 21;   
3. These regions encompass 630 genes altered in ER pure DCIS and TN pure 
DCIS; 
Genes:  
7SK AACS ABCB11 ABHD11 ABTB2 AC007556.3 AC009336.1 AC009336.21 AC009336.23
 AC009336.24 AC009475.2 AC010145.2 AC010145.3 AC010148.1 AC011998.2 AC011998.4 AC011998.5 AC016739.1
 AC016739.2 AC016757.1 AC017048.1 AC017048.2 AC017048.3 AC017048.4 AC026366.1 AC026366.2 AC055713.1 AC064874.1
 AC068706.1 AC068799.1 AC069209.1 AC069214.1 AC069234.1 AC073069.2 AC073846.1 AC073846.2 AC073846.3 AC078875.1
 AC090670.1 AC091609.1 AC091611.1 AC092162.1 AC092576.1 AC095030.1 AC096536.1 AC097713.2 AC097713.3 AC097713.4
 AC099680.1 AC104169.1 AC104387.1 AC104837.1 AC114486.1 AC114814.2 AC114814.3 AC114814.4 AC117503.2 AC122688.1
 AC125603.1 AC126309.2 AC127164.1 AC131263.2 AC132216.1 ACADS ACOT11 ACTL8 ADAMTSL2 ADH5P2
 AFG3L2 AGAP1 AK3L1 AK5 AL031427.1 AL033381.1 AL033381.2 AL034344.1 AL035400.1 AL035706.1
 AL049710.1 AL049710.2 AL049710.4 AL049745.2 AL109843.1 AL136324.1 AL137855.1 AL138781.1 AL139244.1 AL157773.1
 AL158068.1 AL158167.1 AL160060.2 AL161452.1 AL161740.1 AL161915.1 AL162579.1 AL353771.1 AL353898.1 AL353898.2
 AL353898.3 AL353898.4 AL354946.1 AL355574.1 AL357054.1 AL358512.1 AL390994.1 AL391728.1 AL512329.1 AL512329.2
 AL512329.3 ALDH4A1 ANAPC5 ANKRD13C ANXA10 AP000302.58 AP005264.2 ARHGEF10L ARHGEF19
 ARL4C ATP5GP1 ATP6V0A2 BAG2 BBS5 BCAS2 BEND6 BMP6 BRDT BRI3BP
 BSND BTBD8 C11orf74 C12orf43 C12orf49 C1orf134 C1orf141 C1orf168 C1orf175 C1orf177
 C1orf191 C1orf224 C1orf64 C1orf83 C1orf89 C2orf19 C6orf142 C6orf195 C8A C8B
 C9orf116 C9orf62 C9orf69 CABP1 CAGE1 CAMKK2 CAMSAP1 CAPN10 CAPRIN1 CCDC73
 CCDC92 CDC7 CDCP2 CIDEA CLCNKA CLCNKB CLDN3 CLDN4 COL5A1 COX6B1P7
 CR392000.1 CR392000.2 CRISP1 CRYZ CST1 CST2 CST4 CST5 CSTP1 CSTP2 CTH
 CYB5RL DAB1 DBH DCLRE1B DDI2 DDX55 DDX60 DEFB110 DEFB112 DEFB113
 DEFB114 DEFB133 DENND2C DEPDC1 DEPDC7 DHCR24 DHRS9 DHX37 DIO1 DIRAS3
 DNAH10 DNAJC30 DOK7 DSP DST EEF1E1 EIF2B1 EIF2S2P5 EIF3M ELTD1
 ENTPD8 EPHX4 ESPNL EVX2 EXD3 EXOC2 FAM101A FAM131C FAM132B FAM151A
 FAM163B FAM83B FASTKD1 FBLIM1 FBXO21 FBXO3 FBXO42 FBXW8 FCN1 FCN2
 FOXC1 FOXF2 FOXQ1 FTLP17 G6PC2 GDI2P2 GFRAL GLIS1 GLT6D1 GMDS
 GOT2L1 GPR177 GPR35 GREB1L GTF2H3 HCRTR2 HECW2 HHLA3 HIPK1 HNF1A
 HOXD1 HOXD10 HOXD11 HOXD12 HOXD13 HOXD3 HOXD4 HOXD8 HOXD9 HRK hsa-
mir-10b hsa-mir-1262 hsa-mir-1290 hsa-mir-604 hsa-mir-938 HSP90B3P HSPB11 HSPB7 HUS1B IFFO2 IFI44
 IFI44L IFNGR2 IGSF21 IL12RB2 IL17A IL23R ILKAP IRF4 KBTBD10 KCNT1
 KDM2B KIAA0649 KIAA1586 KLHL30 KLHL31 KSR2 LASS6 LCN1 LCN9 LDLRAD1
 LHX3 LIN28AP3 LMO2 LPAR3 LPCAT2BP LPHN2 LRP2 LRPAP1 LRRC1 LRRC40
 LRRC42 LRRC7 LYZL1 MACROD2 MAP1LC3B2 MCOLN2 MCOLN3 MIER1 MLEC MRPL37
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 MRPS11P1 MRPS2 MTL1 MTX2 MUTED MYCN MYCNOS MYLK4 NACC2 NAT10
 NCOR2 NCRNA00118 NCRNA00159 NCRNA00173 NEGR1 NELF NOS1
 NOSTRIN NOXA1 NRARP OASL OBP2A OFCC1 OLFM1 OMA1 ORAI1 OSBPL6
 P2RX4 P2RX7 PADI2 PAEP PARS2 PAX7 PCSK9 PDE11A PEBP1 PGAM3P
 PGK2 PIGK PIN1L PIP5K1P1 PKHD1 PLEKHM2 PNPLA7 PPAP2B PRIM2 PRKAA2
 PRPF31 PRRG4 PTGFR QSER1 QSOX2 RAB23 RAMP1 RAPGEF4 RBM45 RFC5
 RILPL1 RIOK1 RNF34 RNFT2 RP11-101C11.1 RP11-109I2.3 RP11-124G5.1
 RP11-124I4.2 RP11-129K24.3 RP11-129K24.4 RP11-12C17.2 RP11-139O18.1
 RP11-145H9.3 RP11-157J24.1 RP11-159J16.1 RP11-169K16.4 RP11-169K16.6
 RP11-169K16.7 RP11-169K16.8 RP11-169K16.9 RP11-175G14.1 RP11-17E13.3
 RP11-180O5.2 RP11-181B18.1 RP11-192N10.2 RP11-203B9.4 RP11-203H2.1
 RP11-203H2.2 RP11-213P13.1 RP11-218C14.5 RP11-240D10.2 RP11-240D10.4
 RP11-240G22.1 RP11-243M12.1 RP11-263F14.3 RP11-288G3.2 RP11-288G3.3
 RP11-288G3.4 RP11-288I21.1 RP11-292O17.1 RP11-2B19.1 RP11-310I9.1
 RP11-320E2.1 RP11-324K6.1 RP11-335E14.1 RP11-338K17.1 RP11-339A11.1
 RP11-343L14.2 RP11-363H12.1 RP11-375A5.1 RP11-377K22.2 RP11-377K22.3
 RP11-378I13.1 RP11-380J14.1 RP11-380L11.1 RP11-393N21.1 RP11-397G17.1
 RP11-399H11.2 RP11-399H11.3 RP11-407P2.1 RP11-411K7.1 RP11-411K7.2
 RP11-411K7.4 RP11-411K7.5 RP11-426A6.5 RP11-426A6.7 RP11-426A6.8
 RP11-426A6.9 RP11-42O15.2 RP11-432J22.2 RP11-447M12.2 RP11-473A10.2
 RP11-475O6.1 RP11-478C1.6 RP11-478C1.7 RP11-478C1.8 RP11-47K11.2
 RP11-47K11.3 RP11-518D3.1 RP11-518D3.3 RP11-518D3.4 RP11-524H19.1
 RP11-524H19.2 RP11-524K22.1 RP11-529E10.8 RP11-532F6.2 RP11-534G20.3
 RP11-548C21.1 RP11-549I9.1 RP11-550H2.1 RP11-550H2.2 RP11-555H7.2
 RP11-5P18.1 RP11-5P18.10 RP11-5P18.2 RP11-5P18.3 RP11-5P18.5
 RP11-614L17.1 RP11-622P13.2 RP1-167A19.5 RP11-67L3.2 RP11-67L3.4 RP11-67L3.5 RP11-67L3.6
 RP11-69L16.4 RP11-69L16.5 RP11-69L16.6 RP11-719J20.1 RP11-724O16.1
 RP11-779P15.1 RP11-779P15.2 RP11-79N23.1 RP1-181J22.1 RP11-82L20.1
 RP11-91I11.1 RP11-98L5.2 RP11-98L5.4 RP11-98L5.5 RP1-20B11.2 RP1-28O17.1 RP1-303A1.1
 RP13-476E20.1 RP1-71H19.2 RP3-334F4.1 RP3-334F4.2 RP3-335N17.2 RP3-336K20__B.2 RP3-
368B9.1 RP3-380B4.1 RP3-417L20.3 RP3-417L20.4 RP3-445O10.1 RP3-510B21.1
 RP4-552O12.2 RP4-591B8.2 RP4-609E1.2 RP4-609E1.3 RP4-621B10.3 RP4-
633H17.2 RP4-641G12.3 RP4-641G12.4 RP4-654H19.2 RP4-660H19.1 RP4-677H15.2
 RP4-677H15.4 RP4-694A7.2 RP4-694A7.3 RP4-694A7.4 RP4-705F19.1 RP4-
705F19.2 RP4-706A16.2 RP4-706A16.3 RP4-710M16.2 RP4-726F1.1 RP4-733M16.2 RP4-
734C18.1 RP4-753D5.3 RP4-753D5.4 RP4-758J24.4 RP4-763G1.1 RP4-763G1.2
 RP5-1033K19.2 RP5-1073O3.7 RP5-1077H22.1 RP5-1103B4.3 RP5-1177M21.1 RP5-
827O9.1 RP5-831K15.1 RP5-836J3.1 RP5-837I24.1 RP5-837I24.2 RP5-837I24.3 RP5-
837I24.4 RP5-837I24.5 RP5-837I24.6 RP5-866L20.1 RP5-866L20.2 RP5-866L20.3
 RP5-997D24.3 RP5-997D24.5 RP6-102O10.1 RP6-239D12.1 RPE65 RPS11P1
 RPS17P5 RPS5L RSC1A1 SARDH SCARB1 SCLY SERBP1 SFRS11 SH3BP4 SLC25A34
 SLC35D1 SNORA31 SNORA58 SNORA70 SNORA9 SNORD112 SNORD115 snoU13 SNRNP48 SOHLH1
 SORBS2 SPC25 SPEN SSBP3 SSR1 SSX2IP ST6GALNAC3 ST6GALNAC5
 STX1A SUDS3 SVIL TAOK3 TAS1R2 TCEB1P18 TCP11L1 TCTN2 TESC TFAP2B
 TFAP2D TGFBR3 TINAG TMED2 TMEM48 TMEM50B TMEM59 TMEM61 TMEM82 TRIM33
 TTC22 TTC4 TTLL7 TUBB6 TXNDC5 TYW3 U4atac U5 U6 U6atac U7
 UBAC1 UBC UBE2F UNC119B USP24 VPS37D VSIG10 WBSCR22 WBSCR26 WDR63
 WDR78 WSB2 XXyac-YX60D10.1 Y_RNA YIPF1 ZBTB17 ZFYVE28 ZNF326 ZNF385B
 ZNF451 ZNF664 
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PANTHER analysis: 292 mapped ids are found, 338 mapped ids are not found;  
 
5.9 Summary and Discussion of Genomic Differences between Pure DCIS and DCIS 
Associated with Invasive Breast Disease 
This section addresses point 2 of the study aims (page 67): “To undertake an analysis 
of archival DCIS samples to identify genomic variation, abnormalities and changes 
between different pure DCIS lesions and DCIS lesions associated with invasion” and 
refers to pure ER positive DCIS compared to ER positive DCIS associated with 
invasive tumour (5.8.4) and pure TN DCIS compared to TN DCIS associated with 
invasive tumour (5.8.8) 
 
Comparisons of copy number aberrations were used to produce charts highlighting 
molecular functions, biological processes and protein classes were generated. 
Examples are given within this chapter; however the majority of charts are saved to 
the accompanying disc.   
 
In this initial analysis of the genomic data, only regions showing complete differences 
are examined. Caution should be taken in this series when looking at CnLOH in the 
samples analysed here due to the lack on corresponding normal tissues. Samples 
were normalised against a standard via Affymetrix, but not against associated normal 
tissues from the same sample.  
5.9.1 Genomic Differences found in Oestrogen Receptor Positive Pure DCIS 
Versus Oestrogen Receptor Positive DCIS Associated with Invasive Breast 
Disease 
 (See section 5.8.4)  
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The frequency plots for ER pure DCIS and ER positive DCIS associated with invasion 
show a high degree of heterogeneity with ER pure DICS having some homologous 
regions but mainly distinct and separate CNAs compared to ER positive DCIS 
associated with invasive breast disease. There are no amplifications present in ER 
positive pure DCIS whereas ER positive DCIS associated with invasive breast 
disease shows amplification found on chromosomes 6 and 8. CdLOH are varied, with 
ER pure DCIS showing loss of heterozygosity found on chromosomes 3, 5, 7, 9, 10, 
11, 12, 11, 16, 17 and X. CdLOH is present on chromosome 5, 7, 10, 11, 12, 16, 17, 
19, X in ER positive DCIS associated with tumour. ER positive pure DCIS shows 
duplication on chromosome 8 although this is not seen in the ER positive DCIS 
associated with invasive breast disease.  
There are a large number of gains seen in ER positive DCIS associated with invasive 
breast disease across all chromosomes (except 13, X) whilst ER positive pure DCIS 
show gains less frequently on all, except certain regions found on chromosomes 1, 
2, 4, 5, 6, 9, 11, 12, 16, 17, 18, 19 and 20.  There are no gains on 12, 14 or 20. 
 
As with pure TN DCIS versus TN DCIS associated with invasive breast disease, it 
may be that for ER positive lesions further genomic changes maybe either required 
or assist in the pathway to invasive disease.  
 
There are amplifications identified in ER positive DCIS associated with invasive 
breast disease which we did not observe in ER positive pure DCIS. PANTHER 
analysis reveals 29 mapped genes. Of these, 13 are histones with epigenetic post 
translational modifications of histones being described as hallmarks of cancer (226). 
Elsheikh et al have correlated global histone modifications with breast tumour 
phenotypes, prognostic factors and patient outcome in invasive breast cancer. 
Utilising IHC on TMAs they identified; “Variations in bulk histone modifications in 
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different grades, morphologic types, and phenotype classes of invasive breast 
tumors. Furthermore, we have identified hypomodified and hypermodified tumor 
clusters, which correlate with known prognostic factors and clinical outcome” (227). 
 
In this series there are duplications in the ER positive pure DCIS but not in ER positive 
DCIS associated with invasive breast disease. PANTHER analysis reveals a single 
gene, ASPH, which has been shown to be amplified in breast tumours in one previous 
study (228). Kadota et al (228) describe ASPH as one of four potentially novel 
oncogenes although they did not investigate ASPH further.  
 
For gains in ER positive pure DCIS and ER positive DCIS associated with invasive 
breast disease there is considerable overlap in the gene patterns with no specific 
gains identified, and therefore these have not been further examined in this initial 
analysis.  
 
Sc gains were found in ER positive pure DCIS not present in ER positive DCIS 
associated with invasive breast disease. PANTHER analysis reveals 8 mapped 
genes. Of these 2 are tyrosine kinases, one of these, tyrosine kinases (PTK2), has 
been previously shown to be up-regulated in DCIS (229). Also known as FAC 
Lightfoot et al (234) describe this kinase as a mediator of several functions including 
proliferation adhesion and survival. They found overexpression in DCIS in 66% of 
cases (n=34/51) and 33% of invasive lesion (n=6/18) but no expression in fibrocystic 
disease. They suggest that FAK has an active role in DCIS and survival in 
tumourigeneis.  Other Sc gains were found in ER positive DCIS associated with 
invasive breast disease not observed in ER positive pure DCIS. PANTHER analysis 
reveals 62 know genes with a variety of molecular, biological and protein classes (see 
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PANTHER analysis) is used to create pie charts and radar map for molecular 






Figure 45: Molecular functions associated with Sc gains in ER positive DCIS 
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Figure 46: Biological processes associated with Sc gains in ER positive DCIS 
associated with invasive breast disease and ER positive pure DCIS 
 
Figure 47: Protein classes associated with ER positive DCIS associated with invasive 
breast disease and ER positive pure DCIS. 
 
Oh the 62 genes, TNFRSF4 (a tumour necrosis factor) has been previously described 
in both invasive disease and DCIS (230). Also known by the alias OX40, this 
membrane-bound member of the tumour-necrosis-factor-receptor (TNFR) 
superfamily, plays an important role in proliferation, survival and infiltration of 
activated T cells via binding to OX40L (230). Xie et al  suggest that high OX40 
expression may be associated with malignant transformation, progression, invasion 
and metastasis in breast cancer biology (230). 
 
There are losses in ER positive DCIS associated with invasive breast disease not 
observed in ER positive pure DCIS. PANTHER analysis reveals 42 mapped genes, 
of which 6 are zinc finger proteins. Losses include NRG3 which encodes for the EGF 
containing  ligands that mediate binding to ERBB receptor tyrosine kinases (231). 




































Total losses in pure ER positive DCIS include RB1 (retinoblastoma gene) that has 
tumour suppressor function. It has been shown to be frequently altered in breast 
carcinomas leading to loss of expression (233). Total Losses seen in DCIS associated 
with invasive breast disease but not in pure DCIS are far more common (Figures 49-
51). PANTHER analysis reveals 219 mapped genes. There is a wide variation in the 
genes and the molecular functions with total loss. Of these MAP2K4 (mitogen 
activated protein kinase) whose deletion has been suggested as one of a set of 
putative cancer genes (234). 
 
 
Figure 48: Molecular functions associated with total loss in ER positive DCIS 
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Figure 49: Biological processes associated with total loss in ER positive DCIS 
associated with invasive breast disease 
 
Figure 50: Protein classes associated with ER positive DCIS associated with invasive 
breast disease. 
 
There is CdLOH present in ER positive pure DCIS not observed in ER positive DCIS 
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genes with a variety of molecular functions and protein classes. A number matrix 
metalloproteases or MMPs (MMP1, MMP3, MMP 7, MMP8, MMP10, MMP13, 
MMP20, MMP27, PTGFD) have CdLOH ER positive pure DCIS.  Loss of Matrix 
metalloproteases (MMPs) activity may result in a wide range of diseases including 
cancer (235). 
 
CdLOH present in ER positive DCIS associated with invasive breast disease has 
similarities to the ER pure DCIS with no speicifc changes identified and is not 
examined further in this initial analysis. 
 
There is CnLOH present in ER positive pure DCIS not observed in ER positive DCIS 
associated with invasive breast disease. PANTHER analysis reveals 248 mapped 
genes 
representing a wide variety of molecular functions (Figures 51-53). ERBB 2, MDM2 
(a regulator of p53) and Notch2 have CnLOH. MDM2 (236) and Notch2 (237) have 
been suggested as candidate genes in breast cancer progression.  
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Figure 52: Biological processes associated with CnLOH in ER positive pure DCIS 
 
Figure 53: Protein classes associated with CnLOH in ER positive pure DCIS 
 
There is CnLOH in ER positive DCIS associated with invasive breast disease which 
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genes. In this series the gene S100z shows CnLOH whereas in one previous study it 
was reported to be up-regulated (238).  
 
5.9.2 Genomic Differences found in Triple Negative Pure DCIS Versus Triple 
Negative DCIS Associated with Invasive Breast Disease 
The frequency plots for CNAs show that samples of triple negative DCIS associated 
with invasion in this series exhibit many more genomic aberrations at the 
chromosomal level than pure triple negative DCIS.  CdLOH, gains, losses and Sc 
gains all show a higher frequency of aberrations for the DCIS associated with invasive 
breast disease than pure DCIS which has not progressed. There are some homology 
present with CnLOH (see below) and total losses in TN pure DCIS and TN DCIS 
associated with breast disease. CdLOH are also located on distinctly separate 
chromosomal and loci for pure TN DCIS (chromosome 7, 16) compared to CdLOH 
on chromosome 3, 4, 5, 8, 9, 13, 14, 15, X for TN DCIS associated with invasive 
disease. Aberrations in both are located on chromosome 17 but in different regions. 
Gains are present found on chromosomes 1 and 8 for both types of lesion, but at a 
lower frequency for TN pure DCIS. Gains are found only on chromosome 3, 6, 11, 
13, 18, 21 for TN DCIS associated with invasive breast disease. Losses show a 
similar pattern, with pure TN DCIS having distinct losses on chromosome 7, 16, and 
19 compared to distinct losses on 4, 5, 8, 9, 14, X in TN DCIS associated with invasive 
breast disease. Sc gains on chromosome 1, 2, 5, 6, 8, 9 are more abundant in TN 
DCIS associated with invasive breast disease with pure DCIS only showing Sc gains 
on chromosome 1.  
These differences in TN pure DCIS and TN DCIS associated with invasive breast 
disease may indicate that although a cancerous phenotype exists within pure TN 
DCIS several further copy number aberrations may be necessary to switch to an 
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invasive TN phenotype. Both gains and losses are present in TN DCIS associated 
with invasion which are not seen in pure TN DCIS in this series. There is a degree of 
homology in some chromosomal changes such as gains on chromosome 1 and 
losses on chromosome 4 in both pure TN DCIS and TN DCIS associated with invasive 
breast disease. However, there are few gains and losses present found in pure DCIS 
alone.  
 
Comparison of TN pure DCIS and TN DCIS associated with invasive breast disease 
shows no amplifications or duplications found in either process.  
 
Comparing the chromosomal gains in TN pure DCIS and in TN DCIS associated with 
invasion there is some homology present, with pure TN DCIS cases having gains 
comparable to those seen in the TN DCIS associated with invasion in 5/9 cases. 
However, the TN DCIS associated with invasion shows additional gains not present 
in the TN pure DCIS. PANTHER analysis of the genes identifies 16 known genes with 
a range of biological functions associated with several protein classes (Figure 54-56). 
Of these, one - NFIB has been previously identified as associated with ER negative 
invasive breast cancer (239) and proposed as a genomically distinct TN subgroup 












Figure 54: Molecular functions associated with the genomic gains identified in TN 





Figure 55: Biological processes associated with the gains identified in TN DCIS 
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Figure 56: Protein classes associated with the genomic gains identified in TN DCIS 
associated with invasive breast cancer. 
 
Sc gains were present in TN DCIS associated with invasive breast disease but not in 
TN pure DCIS. PANTHER analysis maps 86 of the 350 genes giving a range of 
molecular and biological functions associated with several protein classes (Figure 57-
59) 
 
 Figure 57: Molecular functions associated with Sc gains for TN DCIS associated with 
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Figure 58: Biological processes associated with Sc gains for TN DCIS associated with 
invasive breast disease. 
 
Figure 59: Protein classes associated with Sc gains in TN DCIS associated with 
invasive breast disease. 
 
The genes showing Sc gains in TN DCIS associated with invasive breast disease but 
not observed in TN pure DCIS include PTP1B (Protein tyrosine phosphatase 1B) 
which has been reported to have both tumour suppressor and tumour promoting roles 
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tumour-suppressive effects has Sc gains in this series (242). PLK3 also shows Sc 
gain; this is a member of the pololike kinases and whilst is involved in cell cycle 
regulation its expression remains steady throughout the cell cycle. It has been shown 
to be widely expressed in cancer cell lines (243). Some cadherin’s (CDNH) 6 (K-
cadherin), 9 (T1 cadherin) 12 (n-cadherin), 18 (ungrouped) show Sc gains in this 
series.  
 
As opposed to the Sc gains seen in the TN DCIS associated with invasive compared 
to the pure form of TN DCIS, losses in TN pure DCIS not observed in TN DCIS 
associated with invasive disease are noted, with six genes mapped by PANTHER 
analysis. Three of these are in the type 1 keratins (14, 16, 17) which are structural 
components of the cytoskeleton. 
Conversely, 7 gene losses are mapped by PANTHER analysis in TN DCIS associated 
with invasive breast disease showing a variety of molecular functions.  
 
Total losses for pure DCIS not observed in TN DCIS associated with invasive disease 
reveal 40 genes mapped by PANTHER analysis. These include BRCA1, zinc finger 
like proteins (333 and 558) and olfactory receptor (OR) gene. Previous studies have 
shown up-regulation of ten OR genes in breast cancer cell lines clustered in 11q12.1 
(244).  
 
Total losses for TN DCIS associated with invasive breast but not observed in TN 
pure DCIS associated with invasive disease reveal 46 genes mapped by PANTHER 
analysis. These include metalloproteases, protease zinc finger protein, and extra 
cellular matrix protein.  In this series there is total loss of the apoptotic marker 
PDCD6IP (3p23) in some cases of TN DCIS. Previously copy number analysis has 
reported that amplification of this gene is associated with an increased risk of 
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recurrence in invasive breast disease when considered as part of a trio of markers 
(CYP24/PDCD6IP/BIRC) for ER/PR-positive cancers. Individually PDCD6IP is 
reported to have no significant correlation in invasive breast cancer prognosis but 
does when associated with CYP24 and BIRC (245) highlighting the complex 
interactions of different genomic markers.  
CdLOH for TN DCIS associated with invasive disease not observed in TN pure DCIS 
revealed 12 genes mapped by PANTHER analysis. These include a kinase 
suppressor of Ras1 (KSR1) which has been identified as a potential tumour 
suppressor in BRCA1 tumours (246). CnLOH for TN DCIS associated with invasive 
disease show similarities in 5/9 cases with the CnLOH in pure DCIS. However, there 
are 10/10 cases showing CdLOH observed in TN pure DCIS not observed in TN DCIS 
associated with invasive disease. PANTHER analysis reveals genes mapped by 
PANTHER analysis. Conversely, CdLOH for TN pure DCIS not observed in TN DCIS 
associated with invasive disease revealed 4 altered genes mapped by PANTHER 
analysis of which 3 are keratins -14, 16,17.  
5.7.3 Observations on Genomic Analysis of Pure DCIS Compared to DCIS 
Associated with Invasive Breast Disease. 
In this series the following observations can be made regarding analyses: 
Amplifications and duplications between pure DCIS and DCIS associated with 
invasive disease show no similarity regardless of subtype.  
Gains and losses show similarity for all types of DCIS with regard to chromosomal 
region, however the number of genomic gains or losses in DCIS associated with 
tumours is greater than those found in pure DCIS. In addition there are gains present 
in tumour associated DCIS not seen in pure DCIS lesions. This would fit with a 
hypothesis that further downstream genetic mutations occur post DCIS and lead 
certain credence to the possibility that not all pure DCIS is not wholly committed to an 
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invasive phenotype. Downstream events post establishment of pure DCIS may be 
required to for the initiation of invasive potential. SC gains show no overall pattern 
between these two cohorts.  
Total losses between pure DCIS and DCIS associated with tumour show few 
matching genetic aberrations. As with amplifications and duplications and Sc gains 
these differences may indicate drivers in pure DCIS that inhibit the progression to 
invasive disease or in DCIS associated with invasion they may indicate invasive 
promoting genes.  An alternative approach is that these differences could indicate 
increased heterogeneity giving rise to unidentified subtypes. 
Copy neutral and copy deletion loss of hetereozygosity is marked in both sets of data 
regardless of tumour subtype.   The use of MIP arrays used control tissue of normal 
human breast as a reference point to give a baseline for the samples analysed. Ideally 
the control reference would have been taken from normal tissue from the same 
patient. The lack of normal tissue availability prevented this approach so it is 
acknowledged that there may be a certain amount of background “noise” which gives 
a higher number of comparative genomic differences than expected as there would 
be a disparity between the normal tissue of different individuals.  
  
5.10 Summary of Genomic Differences between DCIS and Invasive Breast 
Disease 
This section addresses point 4 in the study aims: “To identify any protein and/or 
genomic changes in all DCIS (pure and that associated with invasion) compared to 
invasive breast disease to determine potential biomarkers responsible for progression 




In this series only those copy number aberrations seen in one series and absent in 
the second set, i.e. present in pure DCIS but not in invasive carcinoma, and vice 
versa, are addressed in this initial analysis.  
 
5.10.1 Genomic Difference between ER Positive DCIS and ER Positive Invasive 
Breast Disease. (See section 5.8.4).  
The frequency plots for CNAs in all ER positive DCIS compared to ER positive 
invasive disease show a mixed pattern, with some homology and a degree of 
heterogeneity. CdLOH shows similar aberrations on regions of chromosomes 8, 10, 
11, 13, 15, 19, 20 X for both sample sets although ER positive DCIS has a lower 
frequencies. However, there are exclusive CnLOH regions found on chromosomes 1, 
3, 4, 7, 10, 14, 15, 18, X in ER positive invasive breast cancer not seen in ER positive 
DCIS. There are duplications seen only in ER positive invasive disease, found on 
chromosomes 1, 8, 9, 10, 17, 21 not present in ER positive DCIS. The gains found 
show homology on chromosome 6 and 16 with a lower frequency in DCIS. There are 
losses on chromosomes 1, 2, 5, 7, 8, 11, 13, 15, 16, 19, 21 X found in both sample 
sets with a lower frequency found in ER positive DCIS. The exception is chromosome 
11 where ER positive DCIS samples have greater losses than ER positive tumours. 
Sc gains are seen at similar frequencies but, as with other CNAs, the frequency in 
DCIS is lower. For total loss there are many more aberrations in ER positive invasive 
breast disease than ER positive DCIS. Again, there are some homologous regions 
(chromosomes 2, 6, 8, 8, 10, 13, 14, 16, 17, x) and regions of exclusive total loss for 
ER breast disease (chromosomes 2, 3, 4, 5, 7, 8, 9, 10, 12, 13, 14, 15, 16, 19, 20, 
21, X). These data all indicate that further genomic differences are present in invasive 




There are no amplifications in the comparison of ER positive DCIS versus ER positive 
invasive breast disease.  
 
Duplications found in ER DCIS are also present in ER positive invasive breast disease 
and are not addressed in this initial analysis. Conversely, there are duplications in ER 
positive invasive disease not present in ER positive DCIS. PANTHER analysis 
reveals 137 mapped genes. In this series the gene loss or CnLOH of PTPRD is found 
in both pure ER positive DCIS and ER DCIS associated with invasion. In this series 
Muc1 is also duplicated;  this has previously been shown to be elevated in ER positive 
invasive breast disease (247) but having less frequent expression (i.e. fewer cases) 
in ER positive DCIS (248).  Notch2 also show duplications (236). 
 
There are genomic similarities in the pattern of gains, Sc gains and losses in ER 
positive DCIS and ER positive invasive breast disease which have not been analysed 
in this preliminary study.  
 
There are total losses of genes present in ER positive DCIS that are not present in 
ER positive invasive breast disease. PANTHER analysis reveals 40 genes showing 
total loss. Total loss in this series includes BRCA1 and several olfactory receptor 
genes. 
 
CdLOH found in ER DCIS are also present in duplications for ER positive invasive 
breast disease and are not examined in this thesis.  
 
There is CnLOH present in ER positive DCIS not observed in ER positive invasive 
breast disease. PANTHER analysis reveals 42 mapped genes. Of these genes 
MACROD2 has been suggested as a possible cause of Tamoxifen resistance when 
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overexpressed in metastatic tumours (249). PANTHER analysis of the converse, 
CnLOH present in ER positive invasive breast disease not observed in ER positive 
DCIS, reveals 37 mapped genes. Of these genes TIMELESS, one of the core 
circadian genes, has been proposed as an epigenetic risk factor by possibly 
regulating hormone functions. Its overexpression is reported to influence breast 
carcinogenesis (250) and warrants 
 
5.10.2 Genomic Difference between Triple Negative DCIS and Triple Negative 
Invasive Breast Disease.  
The frequency plots for CNAs show that there is a high degree of homology between 
TN DCIS and TN invasive tumours. DCIS lesions show similar but less complex copy 
number aberrations to the invasive disease. This concurs with the findings by 
Johnson et al who performed a similar MIP analysis on 21 cases of invasive ductal 
carcinoma with synchronous DCIS  although with no phenotypic subgrouping (251). 
In the present series, a high degree of total loss is apparent found on chromosomes 
3, 13, 14, 15 and 17. Gains found on chromosomes 3 and 6 are also identified in both 
TN DCIS and in TN invasive carcinoma, whilst gains in TN invasive breast cancer are 
seen in chromosome 11 although this is not apparent in TN DCIS. CdLOH is seen in 
both TN DCIS and TN invasive breast disease found on chromosomes 4, 12, 18 and 
X. However, for CnLOH TN DCIS shows a higher degree of complexity than TN 
invasive disease. CnLOH for TN DCIS are present more frequently found on 
chromosomes 1, 2, 3, 6, 7, 8, 9, 10,11, 12, 19 20, and X. CNLOH is present in TN 
DCIS found on chromosomes 5, 13, 16 and 21, where no CnLOH is found in TN 




Gains and (and Sc gains) show very similar patterns between DCIS and invasive 
breast disease with regard to chromosome number. The level of complexity is raised 
in the invasive samples. 
 
There are no amplifications in the comparison of TN DCIS versus TN invasive breast 
disease.  
 
There are duplications found in TN invasive breast cancer not present in TN DCIS. 
PANTHER analysis reveals 62 mapped genes. Of these, protein tyrosine kinases 
PTPRK and PTK7 show duplications. PTPRK has been reported as a potential 
tumour suppressor (252) whilst positive immunohistochemical expression of 
antibodies raised against PTK7 has been shown in anthracycline-resistant invasive 
breast disease (253). 
 
Gains, Sc gains and losses in TN DCIS and TN invasive disease show overlap of 
genes and are not examined in this initial analysis. 
 
There are total gene losses found in some cases of TN DCIS not observed in some 
cases of TN invasive disease. PANTHER analysis reveals 205 mapped genes with a 
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Figure 62: Protein classes associated with total loss in TN DCIS 
 
In this series, FOXD1 shows total genomic loss in some cases of TN DCIS whilst it 
has been suggested as an upregulated oncogene in breast cancer (254).  
 
There are total losses found in some cases of TN invasive breast disease not seen in 
some cases of TN pure DCIS. PANTHER analysis reveals 160 mapped genes. 
Olfactory receptor genes are predominant with 11 showing total loss (OR1B1, OR1J2, 
OR1J4, OR1L1, OR1L3, OR1L4, OR1L6, OR1L8, OR1N1, OR1N2, OR1Q1). 
Fonseca-Sanchez et al identify 55 olfactory receptor genes up-regulated in breast 
cancer cell lines (244). However, the olfactory receptor gene family is the largest in 
the genome. 
 
There is CnLOH present in TN DCIS that are not observed in TN invasive breast 
disease. PANTHER analysis reveals 205 mapped genes. Genes showing high levels 
of CNLOH in invasive breast cancer include, CSNK2B and HLA-DQA1. CSNK2B is a 
casein kinase a ubiquitous protein kinase which regulates metabolic pathways, signal 



























down-regulation of casein 2 induces loss of breast cancer cell viability and may be a 
potential target for triple negative breast cancer therapy. HLA-DQA1 (major 
histocompatibility complex, class II, DQ alpha 1) is one of the HLA (human leucocyte 
antigen complex). It encodes for a protein of the major histocompatibility complex 
(MHC II) which is involved in antigen presentation within the immune system. A 
variant of HLA-DQA1 has been implicated in increased risk of breast cancer (256).  
 
There is CnLOH present in TN invasive breast disease not observed in TN DCIS.  
PANTHER analysis reveals 140 mapped genes. Of these, there is CnLOH of a 
number of taste receptor genes (TAS2R10, TAS2R13, TAS2R14, TAS2R19, 
TAS2R20, TAS2R31, TAS2R42, TAS2R50, TAS2R7, TAS2R8, TAS2R9). There is 
no current literature on the significance of these in breast cancer.  
 
5.10.3 Observations on Genomic Analysis of DCIS Compared to DCIS Invasive 
Breast Disease. 
In this series the following observations can be made which are true for all DCIS 
compared to invasive tumour regardless of subtype (see 5.8.6. and 5.6.10) No 
amplifications are present for DCIS compared to invasive breast disease. 
Duplications are more prevalent in invasive breast disease indicating more genomic 
instability. Invasive breast disease exhibits a greater number of gains and SC gains 
compared to DCIS further illustrating more complex genetic aberrations. There are 
also greater losses in invasive breast disease. There is a similar pattern observed in 
the chromosomal regions of duplications, gains, losses which could in turn be 
explained as a sampling bias. DCIS and invasive samples from the same patient were 
included in this cohort and not matched against each other in this analysis. This would 
result in similar chromosomal regions of instability if the DCIS had similar genetic 
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aberrations to the associated invasive tumour analysed. The discrepancy in lower 
signal could be due in part to the pure DCIS samples not showing the same genomic 
changes as DCIS associated with invasive breast disease. Interestingly cnLOH 
(unlike cdLOH) shows greater genomic variation in DCIS than invasive breast 
disease. It may be that these multiple minor variations reduce as clonal expansion 
takes place of tumour cells with a proliferative advantage. Further research on this 
dataset is required to illicit the key drivers of these results.   
5.11 Summary of Genomic Differences between Pure DCIS versus Invasive Breast 
Disease  
5.11.1 Pure ER Positive DCIS compared to ER Positive Invasive Breast Disease  
The frequency plots for CNAs between ER positive pure DCIS and ER positive 
invasive breast disease exhibit some homologous regions for both gains and losses 
when compared to invasive breast disease, albeit with much higher frequencies seen 
in ER positive invasive breast cancers. Gains on chromosome 6, 8 16, 20 and 21 are 
mirrored between both sets. Similarly losses on regions of chromosomes 8, 9, 11 12, 
15, 16, 19, X are also present in both types of sample in this series. There are a 
greater number of losses on several regions of chromosome 11 in ER positive pure 
DCIS. Sc gains in this series show little homology, with Sc gains found on 
chromosomes 1 and 8 in ER pure DCIS and Sc gains found on chromosomes 6 and 
20 in ER positive invasive breast disease. There are Sc gains on chromosome 8 for 
ER pure DCIS also seen in ER positive invasive breast disease. There are many more 
CNAs showing total loss in ER positive invasive breast disease than ER positive pure 
DCIS.  
These finding somewhat contradict the findings seen in the comparison of ER positive 
pure DCIS and ER positive DCIS associated with invasive breast cancer. ER positive 
invasive breast cancer samples compared to ER positive pure DCIS seem to have 
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more in common than pure DCIS and DCIS associated with invasive breast disease. 
It must be acknowledged that this is a small cohort (ER positive pure DCIS n=8, ER 
positive invasive breast disease n=9) and this may contribute. However, it may be 
that combinations of genomic changes are required in the progression from DCIS to 
an invasive phenotype. There may be genomic changes already present in pure DCIS 
that are required for tumour survival that are uninvolved in progression to an invasive 
state. These may be conserved in an invasive tumour but play no role in invasion. 
Conversely these genomic changes may be required to trigger downstream mutations 
in order for invasion to occur and be conserved as either drivers of invasion or 
redundant post DCIS mutations.  
 
There are no amplifications in ER positive pure DCIS in this series. There are 
amplifications in ER positive invasive breast disease. PANTHER analysis reveals 1 
gene (EIF3H) which has previously been significantly associated with risk of low-
grade breast cancer (257). Located on chromosome 8q23 the exact role of E1F3H in 
cell cycle regulation is unknown(258). The EIF3H gene encodes the eukaryotic 
translation initiation factor 3 (EIF-3) complex, associated in several steps in protein 
synthesis initiation and mRNA recruitment. Translational control is a crucial 
component of cancer development and progression (259), and EIF3H in particular is 
frequently amplified in breast and prostate cancers (260). 
 
No duplications are found in either ER positive pure DCIS or ER positive invasive 
breast disease. 
There were gains present in both ER positive pure DCIS and ER positive invasive 
breast cancer and, without significant differences, these are not addressed in this 
thesis. However, there were gains found in ER positive invasive breast disease not 
found in ER positive pure DCIS. PANTHER analysis reveals 26 mapped genes. Of 
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these 26 genes, SPIRE1 has been proposed as a possible driver of invasion as 
under- or over-expression can result in increased or decreased extra cellular matrix 
degradation (261). 
There were Sc gains present in both ER positive pure DCIS and ER positive invasive 
breast disease which are not analysed in this preliminary assessment.  
There are losses present in ER positive pure DCIS and ER positive invasive breast 
disease not addressed in this initial analysis. 
There are total losses of genes which are present in ER positive pure DCIS but not 
seen in ER positive invasive breast disease. PANTHER analysis reveals 13 mapped 
genes. Of these, NOX4 is proposed as a contributory gene in the epithelial to 
mesenchymal transition (EMT) process involved in cancer invasion (262). 
There are genes showing total loss in ER positive invasive breast disease not found 
in ER positive pure DCIS. PANTHER analysis reveals 172 mapped genes. GBJ2 is a 
gene responsible for cellular adhesion and has also been shown to be present in 
invasive disease and proposed as a possible cause for invasion, although this is 
contradicted by the present findings (263).  
 
There is CdLOH present in both ER positive pure DCIS and ER positive invasive 
breast disease not analysed in this thesis.  Similarly there are CnLOH present in both 
ER positive pure DCIS and ER positive invasive breast disease which are omitted 
from this preliminary work.  
5.11.2 Pure Triple Negative DCIS versus Triple Negative Invasive Breast Disease 
(See section 5.8.9).  
The frequency plots for pure TN DCIS compared to TN invasive breast disease exhibit 
many more CNAs in the invasive breast disease compared to DCIS although some 
homology is present the majority of changes exist in TN invasive breast disease 
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alone. The genomic frequencies also show a higher complexity of genomic 
aberrations across multiple chromosome regions compared to corresponding ER 
positive DCIS and invasive breast disease. This reveals a much more complex 
phenotype, which may possibly contain sub-groups within this series. CdLOH is found 
exclusively on regions of chromosomes 4, 5, 8, 9, 10, 12, 13, 14, 15, 16, 18, X for TN 
invasive breast cancer. Shared regions, although at much lower frequency, are found 
on chromosomes 4, 5, 14 and 15. Exclusive regions of gain are seen on 
chromosomes 1, 3, 6, 8, 9, 10, 13 and 20. Sc gains are seen exclusively in TN 
invasive breast carcinomas in this series found on chromosomes 1, 3 and 8.  
 
These findings are similar to those seen in TN pure DCIS versus TN DCIS associated 
with invasive breast disease indicating that genomic changes found in invasive breast 
disease are much more complex than those seen in DCIS.  
There are no amplifications in TN pure DCIS or TN invasive breast cancer in this 
series. 
There are similarities in duplication of gene which are seen in both TN pure DCIS and 
TN invasive breast disease and these are not further addressed in this initial analysis. 
 
There are similarities in gains found in both TN pure DCIS and TN invasive breast 
disease so these are not specifically addressed in this initial analysis. However, there 
are genomic gains present in some samples of TN invasive breast disease not 
observed in TN pure DCIS. PANTHER analysis reveals 5 mapped genes. None of 
these genes have been linked in previous studies to tumourigenesis or breast cancer. 
  
There are no Sc gains in TN pure DCIS in this series. Sc gains are, however, present 
in TN invasive breast disease. PANTHER analysis reveals 51 mapped genes. This 
includes the gene ALDH1L1, loss of function or expression of this gene is associated 
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with decreased apoptosis, increased cell motility, and cancer progression. ALDH1L1 
may contribute to ALDH1 activity in breast cancer as high expression of ALDH1A1 
mRNA was found to be significantly correlated with poor overall survival in some 
breast cancer patients (264). 
 
There are similarities found in genomic losses found in TN pure DCIS also present in 
TN invasive breast disease, these are not examined in this thesis. However, there are 
genomic losses found in TN invasive breast disease not observed in TN pure DCIS. 
PANTHER analysis reveals 13 mapped genes. Of these SMAD4 has been suggested 
as a mediator in the TGF beta pathway acting as a tumour suppressor gene 
supressing carcinogenesis (265).  
 
There are total genomic losses present in TN pure DCIS not observed in TN invasive 
breast disease. PANTHER analysis reveals 41 mapped genes. In this group are 13 
olfactory related genes (OLFM4, OR2Z1, OR2Z1, OR4C3, OR4C5, OR4S1, OR4X1, 
OR4X2, OR7A10, OR7A17, OR7A5, OR7C1, OR7C2). The total loss of OLFM4 in 
this series is contradictory to previous studies where OLFM4 gene product 
(Olfactomedin-4) is cited as a candidate biomarker for detection or progression for a 
variety of solid tumours including breast cancer (266, 267).  
 
There are total genomic losses present in TN invasive breast disease not observed 
in TN pure DCIS. PANTHER analysis reveals 39 mapped genes. These include the 
loss of 3 genes encoding for keratins (KRT222, KRT24, KRT25). Loss of keratins has 
been suggested as one of the possible key components in invasion, although it is 
acknowledged that loss alone of keratins is not sufficient to cause invasion and/or 




CdLOH found in TN pure DCIS are also present in TN invasive breast disease and 
have not been analysed in this thesis. There is CdLOH present in TN invasive breast 
cancer not observed in TN pure DCIS. PANTHER analysis reveals 165 mapped 
genes. Genes include BCL2, SMAD4, MLH3, alcohol dehydrogenases (ADH1A, 
ADH1B, ADH4, ADH5, ADH7, ADNP2) and NFKB1. NFKB1 is one of the down 
regulated genes proposed as part of a seven-gene signature a panel for predicting 
distant recurrence in patients with triple-negative breast cancers receiving adjuvant 
chemotherapy following surgery (269).  
 
PANTHER analysis of the CnLOH seen in TN pure DCIS not observed in TN invasive 
breast disease reveals 335 mapped genes. These include NEDD9 (270) NRD1(271) 
TGFBR3(272) which have all been associated with invasion in breast cancer. There 
is CnLOH present in TN invasive breast disease not observed in TN pure DCIS. 
PANTHER analysis reveals 152 mapped genes. These include BUB3 (273) MCM7 
(274) SPIRE1 (261) TGFBR3 (272) which have all been associated with invasion in 
breast cancer.  
 
5.11.3 Observations of Genomic Analysis of Pure DCIS Compared to Invasive Breast 
Disease. 
See sections 5.8.5 and 5.8.9. As with other series the genomic aberrations for 
amplifications, duplications, gains, losses, Sc gains and total loss for invasive ER 
positive breast disease are more pronounced than compared to pure ER positive 
DCIS. For TN pure DCIS and TN invasive breast disease this is similar without any 
amplifications or duplications. However, there is greater variation in the chromosomal 
regions affected for all the pure DCIS compared to the invasive breast disease. This 
is partially accounted for by the unmatched samples being excluded in this part of the 
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analysis. However there may be potential genomic regions of interest that identify 
markers only found in pure DCIS i.e. lesions that are unlikely to progress. Further 
work is required to elucidate these potential markers. 
 
5.12 Summary of HER2 positive DCIS versus ER positive DCIS and triple negative 
DCIS 
(See section 5.8.11)  
Frequency plots for HER2 positive pure DCIS compared to ER positive pure DCIS 
and TN positive pure DCIS show a surprising similarity. As expected, amplification on 
chromosome 17 has a much higher frequency than in TN or ER positive pure DCIS 
as this is the locus of the ERBB2 gene which encodes for the HER2 protein and thus 
the definition of HER2 positivity in the series. However, CdLOH found on 
chromosomes 8 and 17, duplication on 8, gains on 3, 8, 17, 20, 21, losses on 6, 8, 17 
Sc gains on 3, 8 and total losses on 13, 17 all have similarities between the two 
groups, albeit at different frequencies.  
 
These findings may indicate that, whilst there are specific genomic changes that are 
present in immunohistochemical phenotypes that may be suitable targets for 
therapeutic decisions, these may be independent of genes that are responsible for 
either the tumourigenesis of DCIS or its progression to an invasive phenotype.  
 
There are differences, as expected, between the two sets particularly with total losses 
in HER2 positive DCIS found on chromosomes 1, 3, 5, 6, 8, 9, 10, 13, 18, 19, 21 and 




There are similarities between amplifications found in HER2 positive DCIS, ER 
positive DCIS and TN DCIS. These are not addressed in this initial analysis.  
 
There were duplications present in HER2 positive DCIS not observed in ER and TN 
DCIS. PANTHER analysis reveals 58 mapped genes. Of these 17 are genes related 
to the LCE (late cornified envelope) gene cluster within the epidermal differentiation 
complex on chromosome 1. These have previously been reported in a mouse model 
of triple negative breast cancer as potential novel driver mutations (275). They have 
not been previously linked to HER2 positive DCIS. 
There are genomic gains in HER2 positive pure DCIS not observed in ER positive 
and TN pure DCIS. PANTHER analysis reveals 47 mapped genes. Of these genes 
MACROD2 is has been suggested as a possible cause of Tamoxifen resistance when 
overexpressed in metastatic tumours (249) but has not been described in association 
with DCIS. 
 
Genomic gains and Sc gains found in ER positive DCIS, TN DCIS associated with 
genomic gains in HER2 Pure DCIS demonstrate similar genetic profiles and are not 
discussed in this work.  
 
There are losses of genes present in HER2 positive DCIS which were not observed 
in ER and TN positive DCIS. PANTHER analysis reveals 48 mapped genes. One of 
these CDT1 is an integral part of the pre-replication complex associated with geminin 
and minichromosome maintenance proteins involved in cellular proliferation (276). 
Loss of CDT1 expression would be expected to inhibit cellular proliferation and thus 
may be of importance in preventing further progression of DCIS. 
 
Conversely, there were losses present in ER and TN pure DCIS not observed in 
HER2 positive pure DCIS. PANTHER analysis identifies 1 gene (MUC16). Increased 
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serum levels of Ca125 (Muc16) have been shown to correlate with increased 
pathological grade of breast carcinoma (277).  
 
Total losses in HER2 positive pure DCIS observed in ER and TN pure DCIS show 
similarity and are not examined in this preliminary research. 
 
There were total losses present in ER pure DCIS and TN pure DCIS not observed in 
HER2 positive pure DCIS. PANTHER analysis identifies 39 mapped genes. As 
previously noted (section 5.4.3.2) there are several olfactory genes (OLFM4, OR1A1, 
OR1A2, OR1D2, OR1E1, OR1E2, OR1G1, OR2Z1, OR2Z1, OR3A1, OR3A2, 
OR3A3, OR6X1, OR8D1, OR8D2) showing total loss within TN DCIS.  
 
There is CdLOH present in HER2 positive pure DCIS not observed in ER and TN 
pure DCIS. PANTHER analysis reveals 50 mapped genes. Of these one, IKBKB, was 
used in a panel of 21 breast cancer related genes compared in DCIS and associated 
invasive breast disease. The authors state there “were no significant differences in 
copy number DCIS and adjacent IDC, indicating that DCIS is genetically as advanced 
as its invasive counterpart” (278). 
In the CdLOH analysis comparing ER positive and TN pure DCIS with HER2 positive 
pure DCIS, one gene (Muc6) is been identified (see total loss in this paragraph).  
. 
There is CnLOH present in HER2 DCIS not observed in ER positive and TN DCIS. 
PANTHER analysis identifies 30 mapped genes. DDX3 is an RNA helicase that has 
antiapoptotic properties, and promotes proliferation and transformation (279). It has 
been suggested that the protein product could be a potential therapeutic target as 




There is CnLOH present in ER and TN pure DCIS not observed in HER2 positive 
pure DCIS. PANTHER analysis identifies 292 mapped genes. There are several 
interleukin genes identified (IL12RB2, IL17A, IL23R, ILKAP). Interleukins are key 
regulators of immune response which may influence increased risk of developing 
breast cancer (280).  
5.12.1 Observations of Genomic Analysis of Pure Her2 DCIS compared to Pure ER 
positive DCIS and Pure TN DCIS 
The frequency plots for pure Her2 DCIS show, unsurprisingly, amplification on 
chromosome 17 not present in ER positive or TN pure DCIS. However, with the 
exception of cnLOH the severity of genomic changes (amplification, duplication, 
gains, Sc gains, losses, total losses and cdLOH) is more marked in HER2 pure DCIS 
than in either pure ER positive or pure TN DCIS. There is a significant degree of 
homology in chromosomal regions. This homology could indicate that regardless of 
subtype that all pure DCIS has common genomic aberrations that either initiate and/or 
maintain the formation of DCIS. Common gains and losses on the same area e.g. 
chromosomes 3 and 8 would therefore be candidates for further study. One area of 
large variation within this series is the number of total losses found in pure Her2 DCIS 
when compared to other types of pure DCIS. The reason for this comparatively high 





Chapter 6. Conclusions 
6.1 Tissue Microarrays 
Tissue microarrays have become an established method for analysing tissue samples 
from archival formalin fixed paraffin wax embedded samples. In this series using 
traditional tinctorial staining, immunohistochemistry and in situ hybridisation we have 
shown the versatility of such a technique. TMAs have increased the number of 
samples that can be analysed using a variety of biomarkers with a relatively little cost. 
We have demonstrated that some morphology can be retained with larger cores. 
However, it is also shown that care and planning is required in using TMAs analysis. 
Design and planning of TMAs should reflect the scientific question being asked but 
also enable subsequent further studies on the precious tissue resource. Problems 
associated with scoring methods for immunohistochemistry and the need for 
standardisation of TMA research have been highlighted in a publication related to this 
theses (281). In this series of DCIS samples we have analysed a selection of 
biomarkers with varying success. This DCIS cohort remains as a TMA resource for 
further studies. 
 
5.13 6.2 Immunohistochemical Studies of DCIS 
The first aim of this thesis was “To determine the expression of a range of 
immunohistochemical markers in DCIS lesions and determine if these markers can 





These immunohistochemical studies of DCIS have demonstrated that DCIS can be 
classified into different phenotypic subgroups which are essentially similar to those 
found in invasive breast cancer. The frequencies within the groups differ slightly from 
those seen in the literature regarding invasive breast cancer. This could be due to 
several factors: the cohort used in this study was obtained from a central London 
hospital. Compared to other regions in the United Kingdom, at least, there may be 
differences in the patient demographic as London is a particularly ethnically diverse 
population. The choice of antibodies to define the phenotypic subgroups and the 
methods used to score markers also varies from some of those used in other studies 
of invasive breast cancer. The need to standardise immunohistochemical reporting 
and staining methods needs further work. 
 
In this study we found that although immunohistochemical assessment may be used 
to define subgroups this was not related to the propensity for a DCIS lesion to 
progress to an invasive phenotype or to remain in a pure DCIS form in this series, i.e. 
in terms of recurrence of the disease. This does not necessarily exclude the possibility 
that panels of IHC biomarkers could be used to determine either invasive potential or 
risk of recurrence of DCIS. The choice of IHC markers in this study was based upon 
those already established in invasive breast cancer and either used to predict 
treatment options in some instances (ER and HER2) or with some evidence of 
prognostic significance in the literature. It is possible that there is an 
immunohistochemical marker, or panel of markers, yet to be discovered that could 
identify the potential to switch from DCIS to an invasive phenotype. It is also possible 
that there may not be such a marker or panel and the heterogeneity of DCIS prevents 
such prediction with this ‘routine’ technique.  
6.3 Genomic Studies of DCIS 
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The second aim of this study was to create a database of significant size providing 
information on DCIS samples with genomic, immunohistochemical and demographic 
data. In this respect the aim has been fulfilled. Chapter 5 contains only a small fraction 
of the data that is available to be analysed and even in this small subset of the 
available data there is scope for greater analysis. The entire database has great 
potential for a number of research questions. Should a researcher wish to examine 
the role of a single gene of interest and its expression in pure DCIS, DCIS associated 
with invasion or even its absence then a search of the files can be carried out. 
Alternatively comparison of groups either currently acknowledged such as the basal-
like group or groups not yet identified could be elucidated from this data. This study 
has produced one of the largest genomic data sets on DCIS created to date. It is 
hoped that this valuable resource will help define the molecular diversity found in both 
precursor and invasive breast disease to enable improved treatment options for 
patients.  
One advantage of this dataset is the nature of the information provided. This data is 
not simply a list of genes that may or may not have potential as biomarkers for 
therapeutic intervention but also contains demographic data on patients, protein 
expression, immunohistochemical profiles and a number of genomic identifiers. This 
includes information on copy neutral loss of heterozygosity which is not produced 
through previous genomic studies. However, the advent of whole genome profiling at 
reduced costs does indicate that such data sets for comparison will be available in 
the future building upon the work produced here. The data is currently being analysed 
by the King’s College bioinformatics team and further insights of how this information 
can be used are expected.  
 
The third aim of this thesis was to undertake an analysis of archival DCIS samples to 
identify genomic variation, abnormalities and changes between different pure DCIS 
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lesions and DCIS lesions associated with invasion. This aim has only been partially 
fulfilled.   
Given the vast amount of data available it is not possible within the realm of this thesis 
to address each of the possible genes that may, or may not, be involved in 
progression to an invasive state. The copy number aberrations discussed here are a 
small subset of all the potential markers identified in this heterogeneous disease. The 
author also acknowledges that the selection of candidate genes here is based upon 
a combination of selection based upon literature review of breast cancer pathways 
and personal choice (see 6.4 Limitations of the Study). 
There are few studies have examined the genomic diversity of DCIS in a large number 
of samples. This is one of the largest to date utilising the relatively new molecular 
inversion probe array platform. Given the known heterogeneity of DCIS, we focussed 
upon comparing smaller defined sub-groups of DCIS identified using a surrogate 
immunopanel for the molecular phenotypes as described in invasive cancer by Perou 
et al (76).  Pure DCIS, DCIS associated with invasive disease and invasive disease 
have all been compared. Whilst chromosomal changes have been shown across all 
types of DCIS there with similar frequencies, differences have been identified 
between DCIS subtypes (triple negative, HER2 positive and oestrogen positive). 
Some of these are expected (i.e. HER2 gene amplification on chromosome 17) but 
many others have yet to be fully analysed. Additionally there are also similarities 
between pure DCIS, DCIS associated with invasion and invasive breast disease. The 
overall similarity of copy number aberrations in both DCIS and invasive breast cancer 
indicates that DCIS already has a significant genetic heterogeneity compared to 
normal mammary epithelium. It may be that the transition from normal tissue to DCIS 
is where key drivers of tumourigenesis are found. However, further analysis of DCIS 
at the genomic level has may be required to identify if all key drivers of the invasive 
phenotype are in place are at the DCIS stage or if further CNVs are required. 
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Differences in different types of DCIS and their associated invasive tumours have 
demonstrated a vast array of copy number changes and identified a host of genes 
some of which may be involved in the transition to an invasive state.  
 
The use of this MIP arrays to analyse over 80 DCIS and associated invasive breast 
disease samples has resulted in a vast amount of genomic data. It has to be 
acknowledged that this thesis cannot hope to give a robust and systematic analysis 
of all of this data. This work has outlined a few of the genes that may be of significance 
in the transition state from DCIS to invasion. Whilst there are possible flaws in the 
selection criteria for the genes highlighted (see limitations of the study), this work has 
provided a significant amount of genomic data previously unavailable in such a large 
series which will prove invaluable for further studies on DCIS. In addition to the large 
amount of information available this series of samples can be analysed further within 
distinctive subgroups; analysis of high grade versus low grade DCIS, pure DCIS 
versus DCIS associated with invasion and invasive breast disease are available for 
further study. Unlike many previous studies, the DCIS samples studied here are fully 
classified in terms of histopathological features, immunoprofiling and a large amount 
of detailed genomic data and therefore can be segregated into a variety of subgroups 
to help elucidate the changes that give rise to such heterogeneity in DCIS. It is hoped 
that further work upon this series of genomic data will continue to help further our 
understanding of DCIS and its subsequent progression to invasive disease thus 
facilitating the development of better clinical treatments and decisions.  
 
The final aim of this study was to identify any protein and/or genomic changes in all 
DCIS (pure and that associated with invasion) compared to invasive breast disease 
to determine potential biomarkers responsible for progression to an invasive state. In 
this respect the study has fallen short of the stated aim. Identification of specific 
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proteins and genes still remains elusive. However, this body of work has produced a 
dataset that could potentially be used in conjunction with other research to help 
determine such candidates in the future. The author acknowledges that this is a 
challenging proposition given the diversity shown at the molecular level of both 
precursor lesions and invasive forms of breast neoplasms.  
 
6.4 Limitations of the Study 
In this study, samples of DCIS and associated invasive tissues were examined. Due 
to the natural progression of breast cancers, the timeframe for collection of these 
samples had to, by necessity, particularly for the DCIS cases, be over a significant 
period. The analysis of a large cohort of samples over an extended time period is 
fraught with certain problems. These include, but may not be exclusive of, the 
following: 
6.4.1 Availability of clinical data 
Clinical data over a time period may be lost due to changes in saving such data and 
changes in the fine details and definitions of the dataset collated. The time period for 
the samples in this study encompassed the switch from a paper-based system and 
through different computer-based systems and data from one system may have been 
incompatible with newer or alternative systems. The King’s College Breast Cancer 
Tissue and Data Bank provided a most thorough examination and upgrade of the 
clinical data available. However, it has to be acknowledged that the data provided to 
the bank did have omissions. These gaps could be for a variety of reasons; patients 
moving to different localities, poor data storage, and lack of details in original patient 
files. The latter is the most likely cause of missing data; as our understanding of the 
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complexities of breast cancer have improved the information required and 
subsequent data collection have become increasingly complicated.  
 
As our understanding of breast cancer has improved, so have treatment options. The 
introduction of new drugs (new chemotherapy agents such as the taxanes and 
anthracyclines, trastuzumab, tamoxifen and the aromatase inhibitors) and 
radiotherapy options have varied over time. Additionally, surgical considerations such 
as the historical use of mastectomy over wide local excision have reduced the number 
of cases with follow-up samples.  
6.4.2 Technical Considerations 
Alongside therapeutic and surgical advances, there have been significant changes in 
the technical and laboratory treatment of samples. Improved fixation, reduced cold 
ischaemic times, slicing of large samples, better processing and advances in 
microscopy have all improved the quality of tissue being analysed. This has led to 
more accurate and better reporting of disease states. 
Immunohistochemistry is widely used as a diagnostic tool in histology. Improvements 
in antibody clones, immunohistochemical detection methods, antigen retrieval and 
automation have improved the somewhat capricious nature of this science. 
Accordingly the introduction of external quality assurance schemes to ensure 
reproducibly and correct laboratory procedures are followed has improved 
standardisation of this technique. This does however introduce disparities to samples 
taken over a long time period. Original reporting and scoring of markers, for example, 
oestrogen receptor have changed as clones have improved and clinical cut-offs have 
changed. Historically negative ER cases may now be considered ER positive due to 
enhanced detection. Re-evaluation may not be entirely accurate as changes in the 
use of fixatives and processing may produce false negative or even false positive 
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results. Assessment of historical tissue samples should therefore be judged with 
caution with known positives and negatives from the same time period assessed in 
the modern setting.  
6.4.3 Genomics 
The science of genomics has moved at an astonishing pace since the release of the 
first human genome in 2000 AD. Whole genome analysis is now both available within 
a relatively short timeframe at much reduced costs. This has huge benefits for 
research. However this has raised issues regarding the interpretation of such vast 
amounts of data. This study has undertaken one of the larger genomic studies of 
DCIS to date using MIP array analysis of over eighty samples. This created a vast 
amount of bioinformatics data giving almost whole genome wide information on all of 
these samples. It is beyond the scope of a single PhD thesis to analyse such data, 
so a compromise on the best approach had to be taken. In this study comparison of 
different types of DCIS was first undertaken. This created gene lists of often of 
thousands of possible genes to analyse for each particular genomic aberration 
(amplification, duplication, CdLOH, CnLOH, gains, losses, total losses, Sc gains). It 
was after discussion with the bioinformatics team decided appropriate to concentrate 
on those samples that showed the greatest variation between each other i.e. where 
copy number differences occurred in one set of samples (e.g. ER positive pure DCIS) 
but not another (e.g. TN pure DCIS). This gave a slightly more manageable subset 
ranging from an estimated 1% to 10% of data to be analysed, dependent upon the 
particular CNA comparison. Even with this reduction, there were still hundreds of 
possible genes to analyse. Those suggested here have no basis in selection other 
than they have been cited previously in the literature. This does raise the possibility 
of exclusion based upon literary bias. In defence of the selection criteria is the 
understanding at the outset that that this work was never destined to be a stand-alone 
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study and that further analysis would be essential. This thesis may therefore be 
regarded as an initial analysis. 
6.5 Further Work 
As mentioned to in the previous sections, there is a significant amount of further work 
that may be undertaken beyond this study. For the immunohistochemical analysis 
there are many antibody markers that could be assessed in the remaining TMA 
series. In the selection for this study, certain markers of interest in apoptosis (BCL2, 
TUNEL, survivin), stem cell markers (ALDH1, CD44, CD24), proliferation markers 
(geminin) were all omitted based solely on considerations of time and cost. These are 
just a few of the hundreds of markers already available, not including those in 
development. One of the advantages of the TMA construction in this series is that 
there is a reserve of tissue that has already has pathological and genomic analysis 
performed. This will hopefully help define the suitability of this cohort for use with a 
particular marker of interest.  
The genomic component of this thesis has yielded a comprehensive resource for over 
eighty samples of DCIS lesions. The analysis of these data sets has only just begun. 
In the present study only a fraction of the data has been examined with a limited 
number of genes identified.  The data mining methods here will be evaluated for their 
suitability in determining progression from pure DCIS to an invasive phenotype as 
well as differences between various forms of DCIS lesion. Different methods of 
analysis can be explored and further extraction of DNA from samples will provide an 
additional resource for future studies. As molecular techniques become further 
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location ER Average PR HER2 EGFR CK5/6 CK14 KI67 MCM2 
DCIS 15A A1 0 0 0 0 0 1 1 0 
DCIS 15A A2 0 0 0 0 0 0 x 0 
DCIS 15A A4 2 0 0 0 x 10 1 0 
DCIS 15A A5 0 0 1 3 0 5 40 10 
DCIS 15A B1 x x x 0 x x x x 
DCIS 15A B3 0 0 0 3 0 0 10 40 
DCIS 15A B4 0 0 0 0 0 0 30 x 
DCIS 15A B5 2 0 0 1 0 0 15 30 
DCIS 15A C2 5 0 0 0 0 0 5 5 
DCIS 15A C3 1 0 1 2 0 0 5 5 
DCIS 15A C4 5 7 2 0 0 0 1 1 
DCIS 15A C5 8 8 0 0 0 0 0 2 
DCIS 15A D1 x x x x x x x x 
DCIS 15A D2 x x x x x x x x 
DCIS 15A D3 0 x x x x x x x 
DCIS 15A D4 x x x x x x x x 
DCIS 15A E1 2 x x x x x x x 
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DCIS 15A E2 0 0 0 0 0 x 0 5 
DCIS 15A E3 5 x x x x x x x 
DCIS 15A E4 8 x 0 0 0 0 1 1 









(HER2) CK5/6 (%) CK14 (%) KI67 (%) MCM 
DCIS 16A A2 8 5 x 0 0 0 1 3 
DCIS 16A A4 7 0 3 0 0 0 1 5 
DCIS 16A A5 2 4 2 0 0 0 0 0 
DCIS 16A B1 3 x x x x x x x 
DCIS 16A B3 5 8 2 0 0 0 2 5 
DCIS 16A B4 1 x x x 0 0 x x 
DCIS 16A B5 4 0 0 x 0 0 20 45 
DCIS 16A C2 5 8 2 x 0 0 10 25 
DCIS 16A C3 4 0 1 3 0 0 25 30 
DCIS 16A C4 2 0 0 1 0 0 10 25 
DCIS 16A C5 4 0 3 1 0 0 5 35 
DCIS 16A D1 0 0 0 0 0 0 15 40 
DCIS 16A D2 3 x x x x x x x 
DCIS 16A D3 5 x x x x x x x 
DCIS 16A D4 5 8 0 0 0 0 x x 
DCIS 16A E1 5 0 x x 0 0 10 10 
DCIS 16A E2 1 x 3 0 0 0 x x 
363 
 
DCIS 16A E3 4 0 3 0 0 0 10 30 
DCIS 16A E4 2 0 2 1 1 0 2 10 
DCIS 16A E5 x 0 x 2 0 0 3 35 
INV T 15 A1 0 0 0 3 15 0 8 8 
INV T 15 A2 0 0 0 3 0 0 5 2 
INV T 15 A4 0 0 0 3 60 95 4 53 









(HER2) CK5/6 (%) CK14 (%) KI67 (%) MCM 
INV T 15 A6 0 0 2 3 0 20 30 17 
INV T 15 A7 0 0 0 3 0 100 10 37 
INV T 15 B1 0 0 0 0 0 0 50 17 
INV T 15 B3 4 0 x 2 0 25 20 15 
INV T 15 B4 6 0 1 2 0 0 20 7 
INV T 15 B5 8 6 0 0 0 0 3 1 
INV T 15 B6 8 7 2 0 0 0 15 5 
INV T 15 B7 8 8 0 0 0 0 0 0 
INV T 15 C2 8 7 1 0 0 0 15 5 
INV T 15 C3 8 8 1 0 0 0 4 1 
INV T 15 C4 3 0 0 1 0 0 x x 
INV T 15 C5 8 0 3 1 0 0 5 2 
INV T 15 C6 4 0 0 3 0 0 20 7 
INV T 15 C7 6 0 0 3 0 0 5 2 
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INV T 15 D1 8 8 3 0 0 0 8 3 
INV T 15 D2 8 7 0 0 0 0 5 2 
INV T 15 D3 7 8 2 1 0 0 4 1 
INV T 15 D4 8 6 0 1 0 0 3 1 
INV T 15 D6 8 6 1 1 0 0 4 1 
INV T 15 D7 8 0 3 0 0 0 4 1 
INV T 15 E1 8 7 0 0 0 0 0 0 
INV T 15 E2 8 8 0 0 0 0 4 1 
INV T 15 E3 7 0 3 0 0 0 5 x 









(HER2) CK5/6 (%) CK14 (%) KI67 (%) MCM 
INV T 15 E5 8 8 0 1 0 0 5 2 
INV T 15 E6 4 0 0 2 0 0 35 12 
INV T 15 E7 0 0 0 2 0 0 20 7 
INV T 15 F1 3 0 3 0 0 0 x x 
INV T 15 F2 0 3 0 2 5 4 20 10 
INV T 15 F3 8 8 3 0 0 0 8 3 
INV T 15 F4 8 8 0 0 0 0 5 2 
INV T 15 F5 8 4 0 1 0 0 4 1 
INV T 15 F7 8 0 0 0 0 0 5 2 
INV T 15 G1 4 0 3 1 0 0 15 5 
INV T 15 G2 8 0 3 0 0 0 x x 
365 
 
 INV T 15 G3 3 0 0 2 20 0 25 15 
INV T 15 G4 0 0 0 2 10 0 40 17 
INV T 15 G6 8 0 2 0 0 0 5 2 
INV T 15 G7 4 0 0 3 0 0 12 4 
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Size recoded at 





Radical mastectomy  Left 5 7.0 
Not 





Radical mastectomy  Left 5 16.0 
Not 





Simple mastectomy  Right 0 13.0 
Not 





Simple mastectomy  Right 7 5.0 
Not 
available High grade Cribriform None None Y DCIS Less than 15mm 
100491 
Micdo Right 
Simple mastectomy  Right 14 16.0 
Not 





Radical mastectomy  Right 7 29.0 
Not 










Wide local excision Right 62 21.0 
Not 
available High grade Cribriform Marked None Y DCIS 15mm or more 
100528 
Micdo Left 
Simple mastectomy  Left 24 2.0 
Not 





Simple mastectomy  Left 0 15.0 
Not 
available High grade Solid Marked Marked Y DCIS 15mm or more 
100538 
Biopsy Left 














Simple mastectomy  Right 19 25.0 0.0 High grade Solid Marked Marked Y DCIS 15mm or more 

































specimens Size Margins Grade 
Main 
architecture Necrosis Ci 
Recurren





Wide local excision Left 12 12.0 0.0 
Intermediate 

































grade Cribriform Mild None Y DCIS 15mm or more 
100591 
Biopsy Left 
Radical mastectomy  Left 19 25.0 0.0 
Intermediate 































Wide local excision Left 34 18.0 0.0 
Intermediate 
grade Cribriform Mild Moderate Y DCIS 15mm or more 
100613 Referral Right Excision biopsy Right 0 11.0 0.0 High grade Solid Moderate Mild N N Less than 15mm 
100615 Biopsy Left Excision biopsy Left 33 16.0 0.0 High grade Cribriform Moderate Mild N N 15mm or more 
100617 
Referral Left 
Simple mastectomy Left 22 21.0 0.0 
Intermediate 





Wide local excision Right 30 17.0 0.0 
Intermediate 
grade Cribriform Moderate Mild Y DCIS 15mm or more 
100619 
Referral Left 
Simple mastectomy Left 33 21.0 
Not 









grade Cribriform None Mild Y DCIS Less than 15mm 





































Size recoded at 
median of 15mm 
100631 
Referral   
Simple mastectomy Left 769 15.0 
Not 





Wide local excision Right 36 6.0 0.0 
Intermediate 





Wide local excision Right 27 15.0 0.0 High grade Solid Marked Marked 
No 
research 
id number DCIS 15mm or more 
369 
 
NOTE: All patient identifiers and dates have been removed.  
Table 32: Patient Demographics: RID= Research Number  
  
100643 
Referral   
Excision biopsy Left 226 20.0 0.0 
Intermediate 





Wide local excision Right 43 10.0 0.0 High grade Cribriform Mild Moderate Y DCIS Less than 15mm 
100645 
Micdo Right 
Simple mastectomy Right 29 15.0 0.0 High grade Micropapillary Mild Moderate 
No 
research 
id number   15mm or more 
100646 Referral Left Excision biopsy Left 108             Y DCIS   
100649 
Referral Right 




grade Cribriform Mild Mild N N Less than 15mm 





Wide local excision Left 126 16.0 0.0 High grade Solid Marked Marked 
No 
research 





Wide local excision, 
simple mastectomy Left 63 17.0 
Not 





Simple mastectomy Right 54 14.0 0.0 High grade Cribriform Marked Marked Y DCIS Less than 15mm 
100663 
Referral Right 
Simple mastectomy Right 80 7.0 
Not 
available Low grade Cribriform None None N N Less than 15mm 





Wide local excision, 
simple mastectomy Left 34 14.0 0.0 
Intermediate 





Wide local excision, 
simple mastectomy 
Right 






























Size recoded at 





Wide local excision. 
Simple mastectomy Right 36 15.0 
Not 





Simple mastectomy Right 43 27.0 0.0 High grade Micropapillary Marked Marked Y DCIS 15mm or more 
100696 
Micdo Left 
Simple mastectomy Left 55 8.0 
Not 












left 34 1.0 
Not 





Simple mastectomy Right 28 20.0 
Not 
available High grade Cribriform Mild Mild 
No 
research 
id number   15mm or more 
             N  
117057 Micdo Right Simple mastectomy Right 27 19.0 0.0 High grade Solid None Mild Y DCIS 15mm or more 
117066 
    
Wide local excision Right 27 22.0 0.0 
Intermediate 
































grade Papillary None Mild N N 15mm or more 
117098 
Micdo Left 
Wide local excision & 




grade Papillary None None Y DCIS   
117105 
Referral Right 









Wide local excision Right 21 12.0 0.0 
Intermediate 
grade Micropapillary None None Y DCIS Less than 15mm 
117122 
Referral Right 
Simple mastectomy Right ? Na 
Not 
available Low grade Cribriform None None N N   
117124 
Referral Left 
Simple mastectomy Left 14 29.0 
Not 
available High grade Cribriform Mod Mild N N 15mm or more 





























Size recoded at 





Wide local excision Right 58 13.0 0.0 
Intermediate 
grade Cribriform None Moderate 
No id 
number DCIS Less than 15mm 
117130 
Referral   
Excision biopsy& 
wide local excision Left ? 6.0 3.0 High grade Solid Marked Marked N N Less than 15mm 
117145 
Referral Right 
Simple mastectomy Right ? 16.0 
Not 
available High grade Cribriform Marked Moderate N N 15mm or more 
117147 
Wle Right 
Simple mastectomy Right 62 19.0 
Not 









grade Papillary None Mild Y DCIS Less than 15mm 
117152 
Referral Left 
Simple mastectomy Left ? 24.0 
Not 





Wide local excision Right 20 13.0 0.0 
Intermediate 
grade Solid Mild None Y DCIS Less than 15mm 
117159 
Wle Right 
Radical mastectomy Right 26 17.0 
Not 





Simple mastectomy Right 28 16.0 0.0 
Intermediate 
grade Cribriform Mod None Y DCIS 15mm or more 
117174 
Sm Left 
Referral Left 0 21.0 
Not 
available High grade Solid Mod Marked Y DCIS 15mm or more 
117176 
Referral Left 














Referral & simple 
mastectomy Left 14 20.0 0.0 High grade Solid Mod Moderate Y DCIS 15mm or more 
117183 
Referral Left 
Excision biopsy Left ? 8.0 
Not 





Ref & wide local 
excision Right 43 Na 
Not 
available High grade Cribriform None Moderate Y DCIS   
117185 
Referral Left 
Excision biopsy & 
simple mastectomy Left ? 27.0 0.0 
Intermediate 










Wide local excision Right 23 8.0 1.0 Low grade Cribriform None None 
No 
research 





Wide local excision Right 23 27.0 0.0 
Intermediate 

































































0 1 0 0 0 0 0.5 0 1.0 1 1.0 1 7 1 33 1 
100453 
0 0 5 1 1 0 0.0 0 5.0 1 0.5 0 13 1 40 1 
100465 
1 1 1 0 0 0 0.5 0 1.0 1 0.5 0 13 1 28 1 
100466 
                                
100491 
1 0 0 0 0 0 0.0 0 0.0 0 0.0 0 17 1 40 1 
100494 
1 0 1 0 0 0 1.0 0 5.0 1 5.0 1 45 1 91 1 
100508 
0 0     2 0     1.0 1 5.0 1 40 1 35 1 
100523 
0 0 7 1 2 0 0.0 0 0.0 0 0.0 0 10 1 5 0 
100528 
                                
100534 
1 0 0 0 0 0 0.5 0 2.0 1 20.0 1 13 1 88 1 
100538 
0 0 4 1 0 0 0.0 0 0.0 0 0.5 0 8 1 30 1 
100541 
1 0 3 0 0 0 2.0 1 0.0 0 5.0 1 28 1 85 1 
100543 
1 0 1 0 0 0 0.5 0 1.0 1 2.0 1 18 1 72 1 
100546 
0 0 8 1 6 1 0.0 0 0.0 0 1.0 1 0 0 4 0 
100547 
0 0 8 1 6 1 0.0 0 1.0 1 0.0 0 1 0 25 0 
100548 
1 0 8 1 0 0 0.5 0 0.0 0 0.5 0 2 0 13 0 
100550 
0 0 6 1 2 0 0.0 0 1.0 1 10.0 1 6 1 48 1 
100555 
0 0 8 1 7 1 0.5 0 0.0 0 1.0 1 5 1 25 0 
100561 
1 1 0 0 0 0 0.5 0 0.0 0 0.0 0 7 1 78 1 
100562 




1 0 8 1 0 0 0.5 0 1.0 1 1.0 1 30 1 50 1 
 





























































0 0 7 1 7 1 0.0 0 0.0 0 0.0 0 5 1 15 0 
100590 
0 0 7 1 2 0 0.0 0 0.0 0 0.0 0 6 1 0 0 
100597 
0 0 8 1 6 1 0.0 0 0.0 0 0.0 0 5 1 13 0 
100601 
1       0 0 0.0 0     0.0 0     0 0 
100602 
0 0 8 1 4 1 0.0 0 0.0 0 0.0 0 10 1 70 1 
100606 
0 0 6 1 6 1 1.0 0 0.5 0 0.5 0 5 1 23 0 
100607 
1 0 0 0 0 0 1.0 0 10.0 1 5.0 1 40 1 30 1 
100609 
0 1 0 0 0 0 60.0 1 50.0 1 0.0 0 15 1 18 0 
100611 
1 0 3 1 0 0 1.0 0 0.0 0 0.0 0 0 0 30   
100613 
1 0 5 1 0 0 0.0 0     0.0 0 1 0 35 1 
100615 
0 0 4 1 0 0 0.0 0 0.0 0 0.0 0 1 0 9 0 
100617 
0 0 8 1 2 0 0.0 0 0.0 0 0.0 0 0 0 16 0 
100618 
0 0 8 1 8 1 0.0 0 1.0 1 0.0 0 2 0 15 0 
100619 
1 0 0 0 0 0 1.0 0 1.0 1 1.0 1 25 1 80 1 
100621 
0 0 7 1 8 1 1.0 0 0.0 0 0.0 0 7 1 20 0 
100630 
0 0 7 1 3 1 0.0 0 0.0 0 0.0 0 0 0 5 0 
100631 
0 1 5 1 1 0 5.0 1 0.0 0 0.0 0 0 0 63 1 
100633 
0 0 8 1 4 1 0.0 0 0.0 0 0.0 0 0 0 8 0 
100637 
0 0 6 1 0 0 0.0 0 2.0 1 0.0 0 4 0 53 1 
100639 




0 0 8 1 7 1 0.0 0 0.0 0 0.0 0 0 0 43 1 
100644 
0 0 8 1 7 1 1.0 0 0.0 0 0.0 0 3 0 30 1 
100645 
1 0 0 0 0 0 0.0 0 0.0 0 0.0 0 5 1 27 0 
100646 
































































0 0 8 1 8 1 0.0 0 0.0 0 0.0 0 5 1 65 1 
100650 
1 0 0 0 0 0 0.0 0 0.0 0 0.0 0 10 1 70 1 
100651 
1 0 0 0 0 0 10.0 1 15.0 1 5.0 1 10 1 50 1 
 
                
100662 
1 0 0 0 0 0 0.0 0 1.0 1 0.0 0 7 1 47 1 
100663 
0 0 8 1 6 1 0.0 0 5.0 1 0.0 0 0 0 7 0 
100667 
0 0 6 1 6 1 0.0 0 0.0 0 0.0 0 18 1 32 1 
100671 
1 0 8 1 7 1 2.0 1 1.0 1 0.0 0 10 1 32 1 
100674 
0 0 6 1 3 1 2.0 1 10.0 1 5.0 1 8 1 23 0 
100676 
0 0 0 0 0 0 1.0 0 0.0 0 0.0 0 6 1 23 0 
100679 
1 0 8 1 1 0 1.0 0 1.0 1 0.0 0 5 1 42 1 
100696 
0 0     7 1 0.0 0 0.0 0 0.0 0 3 0 13 0 
100699 
                                
100701 
                                
100703 
0 0 8 1 7 1 0.0 0 0.0 0 0.0 0 3 0 29 1 
117044 
1 0 0 0 0 0 1.0 0 1.0 1 1.0 1 10 1 13 0 
117057 
0 0 8 1 8 1 5.0 1 2.0 1 2.0 1 0 0 20 0 
117061 
0 0 8 1 5 1 0.0 0 0.0 0 0.0 0 0 0 10 0 
117066 
0 0 6 1 0 0 0.0 0 0.0 0 0.0 0 8 1 10 0 
117079 
0 0 0 0 2 0 5.0 1 1.0 1 0.0 0 10 1 0 0 
117081 
0 0 7 1 0 0 0.0 0 1.0 1 0.0 0 5 1 27 0 
117088 




0 0 8 1 7 1 1.0 0 0.5 0 0.5 0 3 0 11 0 
117098 
































































0 0 8 1 4 1 0.0 0 0.0 0 0.0 0 0 0 10 0 
117119 
0 0     0 0 0.0 0     0.0 0 1 0 1 0 
117122 
0       8 1             0 0 1 0 
117124 
0 0 8 1 4 1 1.0 0 0.0 0 0.0 0 2 0 40 1 
117125 
0 0 8 1   1 2.0 1 0.0 0 0.0 0 0 0 10 0 
117145 
0 0 8 1 6 1 0.0 0 0.0 0 0.0 0 2 0 28 1 
117147 
1 1 1 0 0 0 0.0 0 0.0 0 0.0 0 12 1 82 1 
117148 
0 0 8 1 8 1 0.0 0 0.0 0 0.0 0         
117152 
0 0 8 1 4 1 0.0 0 0.0 0 0.0 0 2 0 10 0 
117155 
0 0     5 1     1.0 1 0.0 0 2 0 25 0 
117159 
0 0 0 0 0 0 0.0 0 0.0 0 0.0 0 3 0 35 1 
117163 
0 0 8 1 6 1 0.0 0 0.0 0 0.0 0 5 1 57 1 
117164 
0 0 8 1 1 0 5.0 1 5.0 1 5.0 1 20 1 87 1 
117174 
1 0 0 0 0 0 1.0 0 1.0 1 0.0 0 27 1 75 1 
117176 
0   8 1 8 1 0.0 0 0.0 0 0.0 0         
117178 
0 0 8 1 8 1 0.0 0 1.0 1 0.0 0 5 1 43 1 
117181 
0 0 8 1 4 1 5.0 1 3.0 1 5.0 1 7 1 23 0 
117183 
0 0 5 1 5 1 0.0 0 0.0 0 0.0 0     40 1 
117184 
0 0 6 1 1 0 0.0 0 0.0 0 0.0 0 0 0 10 0 
117185 
0 0     6 1             0 0 10 0 
117195 
0 0 8 1 5 1 0.0 0 0.0 0 0.0 0 8 1 35 1 
117204 








5.18 Appendix 4: Immunohistochemistry Protocols 
i) Dewax slides in dewax solution followed by alcohol. 
ii) Epitope retrieval solution according to antibody. 
iii) Peroxidase block, 5 mins. 
iv) Primary antibody incubation, 15 mins. 
v) Post-primary, 8 mins. 
vi) Polymer, 8 mins. 
vii) DAB, 10 mins. 
viii) DAB Enhancer, 10 mins. 
ix) Haematoxylin counterstain, 5 mins. 
x) Rinse in water, dehydrate, clear and mount manually. 
 
Bond wash buffer rinses were carried out by the machine between each of these 
steps.   
Antibodies were diluted using Bond Antibody Diluent. Bond epitope retrieval solutions 
1, & 2 were used where stated at a temperature of 95ºC 
 





ER 6F11  1/100 ER1 30 
PR 1/400 ER1 30 
CK5/6 1/100 ER1 30 
CK5 1/100 ER1 30 
CK14 1/100 ER1 30 
EGFR 1/50 ER1 20 
 
 













                                                                                            
                                                                                                
382 
 




















Cty. Cor. Chi Square
Cty. Cor. P-Value
Fis her's Exact P-Value
Summary Table for FINAL KI67 (AT MEDIAN, 5%), FINAL HER2 STATUS








Observed Frequencies for FINAL KI67 (AT MEDIAN, 5%), FINAL HER2 STATUS




















Cty. Cor. Chi Square
Cty. Cor. P-Value
Fis her's Exact P-Value
Summary Table for FINAL EGFR STATUS, FINAL KI67 (AT MEDIAN, 5%)








Observed Frequencies for FINAL EGFR STATUS, FINAL KI67 (AT MEDIAN, 5%)























Cty. Cor. Chi Square
Cty. Cor. P-Value
Fis her's Exact P-Value
Summary Table for FINAL ER STATUS, FINAL KI67 (AT MEDIAN, 5%)








Observed Frequencies for FINAL ER STATUS, FINAL KI67 (AT MEDIAN, 5%)




















Cty. Cor. Chi Square
Cty. Cor. P-Value
Fis her's Exact P-Value
Summary Table for FINAL PR STATUS, FINAL KI67 (AT MEDIAN, 5%)








Observed Frequencies for FINAL PR STATUS, FINAL KI67 (AT MEDIAN, 5%)




















Cty. Cor. Chi Square
Cty. Cor. P-Value
Fis her's Exact P-Value
Summary Table for FINAL CK5 (AT 1%), FINAL KI67 (AT MEDIAN, 5%)








Observed Frequencies for FINAL CK5 (AT 1%), FINAL KI67 (AT MEDIAN, 5%)
 Row exclusion: DCIS STATVIEW DATASET
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Cty. Cor. Chi Square
Cty. Cor. P-Value
Fis her's Exact P-Value
Summary Table for FINAL CK5/6 (AT 1%), FINAL KI67 (AT MEDIAN, 5%)








Observed Frequencies for FINAL CK5/6 (AT 1%), FINAL KI67 (AT MEDIAN, 5%)




















Cty. Cor. Chi Square
Cty. Cor. P-Value
Fis her's Exact P-Value
Summary Table for FINAL CK14 (AT 1%), FINAL KI67 (AT MEDIAN, 5%)








Observed Frequencies for FINAL CK14 (AT 1%), FINAL KI67 (AT MEDIAN, 5%)




















Cty. Cor. Chi Square
Cty. Cor. P-Value
Fis her's Exact P-Value
Summary Table for FINAL MCM2 (AT MEDIAN, 27.5%), FINAL KI67 (AT MEDIAN, 5%)








Observed Frequencies for FINAL MCM2 (AT MEDIAN, 27.5%), FINAL KI67 (AT MEDIAN, 5%)
























Summary Table for GRADE, FINAL KI67 (AT MEDIAN, 5%)










Observed Frequencies for GRADE, FINAL KI67 (AT MEDIAN, 5%)

















Summary Table for ARCH, FINAL KI67 (AT MEDIAN, 5%)












Observed Frequencies for ARCH, FINAL KI67 (AT MEDIAN, 5%)

















Summary Table for NECROSIS, FINAL KI67 (AT MEDIAN, 5%)












Observed Frequencies for NECROSIS, FINAL KI67 (AT MEDIAN, 5%)

















Summary Table for CI, FINAL KI67 (AT MEDIAN, 5%)












Observed Frequencies for CI, FINAL KI67 (AT MEDIAN, 5%)




















Cty. Cor. Chi Square
Cty. Cor. P-Value
Fis her's Exact P-Value
Summary Table for FINAL MCM2 (AT MEDIAN, 27.5%), FINAL HER2 STATUS








Observed Frequencies for FINAL MCM2 (AT MEDIAN, 27.5%), FINAL HER2 STATUS




















Cty. Cor. Chi Square
Cty. Cor. P-Value
Fis her's Exact P-Value
Summary Table for FINAL EGFR STATUS, FINAL MCM2 (AT MEDIAN, 27.5%)








Observed Frequencies for FINAL EGFR STATUS, FINAL MCM2 (AT MEDIAN, 27.5%)
 Row exclusion: DCIS STATVIEW DATASET
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Cty. Cor. Chi Square
Cty. Cor. P-Value
Fis her's Exact P-Value
Summary Table for FINAL ER STATUS, FINAL MCM2 (AT MEDIAN, 27.5%)








Observed Frequencies for FINAL ER STATUS, FINAL MCM2 (AT MEDIAN, 27.5%)




















Cty. Cor. Chi Square
Cty. Cor. P-Value
Fis her's Exact P-Value
Summary Table for FINAL PR STATUS, FINAL MCM2 (AT MEDIAN, 27.5%)








Observed Frequencies for FINAL PR STATUS, FINAL MCM2 (AT MEDIAN, 27.5%)




















Cty. Cor. Chi Square
Cty. Cor. P-Value
Fis her's Exact P-Value
Summary Table for FINAL CK5 (AT 1%), FINAL MCM2 (AT MEDIAN, 27.5%)








Observed Frequencies for FINAL CK5 (AT 1%), FINAL MCM2 (AT MEDIAN, 27.5%)




















Cty. Cor. Chi Square
Cty. Cor. P-Value
Fis her's Exact P-Value
Summary Table for FINAL CK5/6 (AT 1%), FINAL MCM2 (AT MEDIAN, 27.5%)








Observed Frequencies for FINAL CK5/6 (AT 1%), FINAL MCM2 (AT MEDIAN, 27.5%)
 Row exclusion: DCIS STATVIEW DATASET
387 
 




















Cty. Cor. Chi Square
Cty. Cor. P-Value
Fis her's Exact P-Value
Summary Table for FINAL CK14 (AT 1%), FINAL MCM2 (AT MEDIAN, 27.5%)








Observed Frequencies for FINAL CK14 (AT 1%), FINAL MCM2 (AT MEDIAN, 27.5%)
 Row exclusion: DCIS STATVIEW DATASET
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Cty. Cor. Chi Square
Cty. Cor. P-Value
Fis her's Exact P-Value
Summary Table for FINAL KI67 (AT MEDIAN, 5%), FINAL MCM2 (AT MEDIAN, 27.5%)








Observed Frequencies for FINAL KI67 (AT MEDIAN, 5%), FINAL MCM2 (AT MEDIAN, 27.5%)

















Summary Table for GRADE, FINAL MCM2 (AT MEDIAN, 27.5%)










Observed Frequencies for GRADE, FINAL MCM2 (AT MEDIAN, 27.5%)

















Summary Table for ARCH, FINAL MCM2 (AT MEDIAN, 27.5%)












Observed Frequencies for ARCH, FINAL MCM2 (AT MEDIAN, 27.5%)

















Summary Table for NECROSIS, FINAL MCM2 (AT MEDIAN, 27.5%)












Observed Frequencies for NECROSIS, FINAL MCM2 (AT MEDIAN, 27.5%)

















Summary Table for CI, FINAL MCM2 (AT MEDIAN, 27.5%)












Observed Frequencies for CI, FINAL MCM2 (AT MEDIAN, 27.5%)
 Row exclusion: DCIS STATVIEW DATASET
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Section 2: Non Parametric Tests- Univariate Paired analysis: 
Oestrogen receptor in DCIS, frequencies and paired univariate analysis. 
 
 ER and HER2 IHC  
 Fishers exact test p value < 0.0001 
 
 ER -ve ER +ve Total 
HER2 -ve 23 145 168 
HER2 +ve 36 19 55 
Total 59 164 223 
 
ER and EGFR IHC 
Fishers exact test p value < 0.0001. 
 
 ER -ve ER +ve Total 
EGFR -ve 45 159 204 
EGFR +ve 10 1 11 
Total 55 160 215 
 
 
ER and PR IHC 
Fishers exact test p value <0.0001. 
 
 ER -ve ER +ve Total 
PR -ve 56 55 111 
PR +ve 0 102 102 
Total 56 157 213 
 
ER and CK5 IHC 
Fishers exact test p value = 0.0033. 
 
 ER -ve ER +ve Total 
CK5 -ve 41 147 188 
CK5 +ve 15 16 31 
Total 56 163 219 
 
ER and CK5/6 IHC 
Fishers exact test p value = 0.298 
 
 ER -ve ER +ve Total 
CK5/6 -ve 33 114 147 
CK5/6 +ve 25 41 66 




ER and CK14 IHC 
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ER and Ki67 (>5%) IHC  







ER and MCM2 (>5%) IHC 







ER and Histological Grade 








ER and Histological Architecture 
















 ER and Chronic Inflammation 
 ER -ve ER +ve Total 
CK14 -ve 40 142 182 
CK14 +ve 18 19 37 
Total 58 161 219 
 ER -ve ER +ve Total 
Ki67 -ve 8 78 86 
Ki67+ve 51 79 130 
Total 59 157 216 
 ER -ve ER +ve Total 
MCM2 -ve 15 77 92 
MCM2+ve 44 83 127 
Total 59 160 219 
 ER -ve ER +ve Total 
HG 35 55 90 
IG 4 46 50 
LG 0 9 9 
Total 39 110 149 
 ER -ve ER +ve Total 
Crib 5 55 60 
Micropap 7 6 13 
Pap 1 11 12 
Solid 26 38 64 
Total 39 110 149 
 ER -ve ER +ve Total 
Marked 23 18 41 
Mild 6 37 43 
Moderate 8 28 36 
None 2 27 29 










Progesterone Receptor in DCIS, frequencies and paired univariate analysis. 
PR and HER2 
Fishers exact test p value <0.0001 
 
 HER2 -ve HER2 +ve Total 
PR -ve 70 50 120 
PR +ve 104 6 110 
Total 174 56 230 
 
PR and EGFR IHC 




 PR -ve PR +ve Total 
EGFR -ve 102 105 207 
EGFR +ve 11 0 11 
Total 113 105 218 
 
PR and CK5/6 IHC 






 PR and CK5 IHC 
Fishers exact test p value = 0.2385 
 
 PR -ve PR +ve Total 
CK5 -ve 94 92 186 
CK5 +ve 19 11 30 








PR and CK14 IHC 
 ER -ve ER +ve Total 
Marked 25 10 35 
Mild 3 49 52 
Moderate 9 25 34 
None 1 25 26 
Total 38 109 147 
 PR -ve PR +ve Total 
CK5/6 -ve 69 76 145 
CK5/6 +ve 42 25 67 
Total 111 101 212 
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PR and Ki67 (>5%) IHC 






PR and MCM2 (<5%) IHC 






PR and Histological Grade 








PR and Histological Architecture 









PR and Necrosis 







PR and Chronic Inflammation 
Chi squared p value <0.0001 
 PR -ve PR +ve Total 
CK14 -ve 94 90 184 
CK14 +ve 23 14 37 
Total 117 104 221 
 PR -ve PR +ve Total 
Ki67 -ve 36 60 96 
Ki67+ve 82 46 128 
Total 118 106 224 
 PR -ve PR +ve Total 
MCM2 -ve 42 60 102 
MCM2+ve 77 49 126 
Total 119 109 228 
 PR -ve PR +ve Total 
HG 54 37 91 
IG 23 33 56 
LG 0 10 10 
Total 77 80 157 
 PR -ve PR +ve Total 
Crib 22 43 65 
Micropap 12 3 15 
Pap 4 8 12 
Solid 39 26 65 
Total 77 80 157 
 PR -ve PR +ve Total 
Marked 28 13 41 
Mild 20 24 44 
Moderate 21 17 38 
None 8 26 34 













5.20 Appendix 6: DNA Extraction and Purification Protocols 
PROTOCOL TO EXTRACT DNA FROM PARAFFIN EMBEDDED TISSUE 
 
DAY 1 - SLIDE PREPARATION 
8m sections (number depending on size of specimen,) cut and mounted on slides. 
 Air dry overnight 
DAY 2 -PARAFFIN REMOVAL & STAINING 
Xylene 1 for 5’ 
Xylene 2 for 5’ 
100% ETOH 1 for 30’’ 
100% ETOH 2 for 30’’ 
70% ETOH for 30’’ 
Wash in autoclaved water for 2’ 
Repeat wash with fresh autoclaved water  
Stain with nuclear fast red (NFR) 1% - 4’ 
Wash with autoclaved water for 2’ 
Repeat wash with fresh autoclaved water 
DAY 2 -MICRODISSECTION 
 PR -ve PR +ve Total 
Marked 30 6 36 
Mild 17 38 55 
Moderate 17 17 34 
None 12 18 30 
Total 76 79 155 
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Use H&E sections previously prepared and marked by Consultant Pathologists as a 
guide 
Examine NFR stained sections under light microscope and using 12G sterile 
needle/scalpel scrape away unwanted areas and blow off with air spray 
Incubate slides in 1M Na Thiocyanate at 37°C overnight. 
 
DAY 3 – COMPLETE MICRODISSECTION AND TISSUE LYSIS 
Wash in PBS-A, 10min on shaker, replace PBS then another 10mins on shaker.  
 Air dry. 
  Label appropriately (top and side) as many 1.5 ml eppendorf tubes as the samples 
you have (N) and add 180 l of DNeasy Buffer ATL to each tube 
  Pipette 2-5 l of ATL buffer at the edge of each section to moisten the tissue and lift 
using pipette tip or needle 
  Transfer the tissue in the appropriately labelled tube containing the ATL buffer.  
  Repeat steps 3-5 for all sections 
Once microdissection is completed, add 20 l Proteinase K, vortex for 15 seconds 
and spin.  
Seal tubes with parafilm and incubate @56-58°C in a rotisserie/or on shaker in oven 
overnight.  
 
Day 4 - DNA EXTRACTION 
Reagents from Qiagen DNeasy Blood and Tissue Kit  
Protocol: Purification of Total DNA from Animal Tissues (Spin-Column Protocol) 
At 12 hours check that tissue fully lysed. If so, vortex well for 15 seconds and continue 
with DNeasy protocol by adding 200ul Buffer AL etc. 
 If tissue not fully lysed, add extra 20ul of DNeasy Proteinase K, vortex for 15 seconds 
and return to oven for 1-4hours, until tissue fully lysed 
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Once fully lysed continue with DNeasy protocol. 
 
NB – Once lysed, samples can remain in buffer at -20 C until extraction proceeds 
      -  Store at -20C after extraction 
 
DCIS DNA Extraction using Qiagen FFPE Kit. 
 
This protocol is adapted from the “QIAamp DNA FFPE Tissue handbook” October 
2007. The original protocol is “Isolation of Genomic DNA from FFPE tissue sections” 
on page 15. This protocol is required AFTER manual microdissection of tissue 
sections on uncoated slides and follows incubation in 1M sodium thiocyanate prior to 
proteinase k treatment. It starts at point 14 of the original protocol. The reagents are 
all (except ETOH) part of the FFPE DNA extraction kit. 
 
 
Between six and twelve samples should be prepared prior to extracting and be placed 
in 1.5ml eppendorfs tubes. Place frozen tube on wet ice and proceed with protocol. 
In an eppendorf holder set out one row of samples followed by 1 set of labelled eluting 
columns on collecting tubes. Next 2 sets of collecting tubes followed by 2 sets of 
eppendorfs with labels corresponding to the sample numbers. The final set should be 
identified in some way as a spare.  
Vortex all samples for approx. 15seconds 
Add 200l of buffer AL to each sample, if sample had extra proteinase k then add an 
additional 10-20 l. The solution is viscous so pipette slowly. Re-vortex samples. 
Add 200l of 100% alcohol (ETOH) to each sample vortexing each sample 
immediately. The solution may start to precipitate, if this occurs keep vortexing until 
an almost clear homogenate is seen. 
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NB AL and ETOH can be premixed for all samples before adding.  
Transfer the entire sample into a corresponding eluting column. 
Centrifuge at 8000rpm (6000g) for one minute. 
Place each eluting column into a new collection tube and discard the old one and 
contents.  
Add 500l of AW1 (check solution is correctly made up and ensure there is no 
precipitate present) to each sample. Spin at 8000rpm (6000g) for one minute. Put 
eluting column into new collection tube and discard old collecting tube and contents.  
Add 500l of AW2 and spin for 3.5 minutes at 13,500 rpm. Remove eluting and 
collection tubes ensuring that no liquid touches eluting tube membrane. If this occurs 
then re-spin.   
Place eluting column into first labelled eppendorfs (not spare) and discard collecting 
tube and contents ensuring eluting tube membranes stay dry. 
Add 20l of ATE to eluting column making sure it is placed directly onto the 
membrane. Do this for all samples and then spin at 8000rpm for 1 minute. 
Repeat step twelve spinning into same eppendorf to give total volume of ATE/DNA to 
35-40l. 
Place eluting column into second eppendorf (spare) making sure lid is closed on first 
samples. Add 50l of AE and spin at 8000rpm for one minute. Remove from 
centrifuge and discard eluting column and close sample lids. 
Test for DNA quality using nanodrop and MultiplexPCR. If yield sufficient proceed to 
pico green testing and then store samples at -20C. NB Nandrop deemed to be poor 
for quality analysis proceed straight to PicoGreen if desired. 
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Total DNA per 
original sample (ng 
per 40μl) 
DCISJPB1OK 001 A1 Triple Negative Pure DCIS 40 0.456 91.2 3648 
DCISJPB1OK 002 A2 Triple Negative Pure DCIS 40 1.030 206.0 8240 
DCISJPB1OK 003 A3 Triple Negative Pure DCIS 40 0.102 20.4 816 
DCISJPB1OK 004 A4 
Triple negative DCIS 
associated with tumour 40 0.0479 9.58 383.2 
DCISJPB1OK 005 A5 
Triple negative Tumour 
associated with DCIS 40 1.15 230 9200 
DCISJPB1OK 006 A6 Triple Negative Pure DCIS 40 0.188 37.6 1504 
DCISJPB1OK 007 A7 HER2 Positive 40 0.91 18.2 728 
DCISJPB1OK 008 A8 HER2 Positive 40 1.39 27.8 1112 
DCISJPB1OK 009 A9 Pure DCIS ER positive  40 1.600 320 12800 
DCISJPB1OK 010 A10 
Triple negative DCIS 
associated with tumour 40 0.668 134 5360 
DCISJPB1OK 011 A11 
Triple negative Tumour 
associated with DCIS 40 0.917 183 7320 
DCISJPB1OK 012 B1 
Matched Normal from Triple 
negative DCIS and Tumour 40 0.818 16.36 654.4 
DCISJPB1OK 013 B2 
Triple negative DCIS 
associated with tumour 40 0.858 172 6880 
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DCISJPB1OK 014 B3 
Triple negative Tumour 
associated with DCIS 40 1.13 226 9040 
 









Total DNA per 
original sample (ng 
per 40μl) 
DCISJPB1OK 015 B4 
Matched Normal from Triple 
negative DCIS and Tumour 40 1.69 33.8 1352 
DCISJPB1OK 016 B5 
HER2 Positive 40 0.778 15.56 622.4 
DCISJPB1OK 017 B6 
Pure DCIS ER positive  40 0.643 128.6 5144 
DCISJPB1OK 018 B7 
Triple negative DCIS 
associated with tumour 40 1.24 248 9920 
DCISJPB1OK 019 B8 
Triple negative Tumour 
associated with DCIS 40 0.831 166 6640 
DCISJPB1OK 020 B9 
Triple Negative Pure DCIS 40 0.222 44.4 1776 
DCISJPB1OK 021 B10 
Pure DCIS ER positive  40 2.510 502 20080 
DCISJPB1OK 022 B11 
Triple Negative Pure DCIS 40 0.078 15.7 627.2 
DCISJPB1OK 023 B12 
HER2 Positive 40 1.06 21.2 848 
DCISJPB1OK 024 C1 
Pure DCIS ER positive  40 1.670 334 13360 
DCISJPB1OK 025 C2 
HER2 Positive 40 1.46 29.2 1168 
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DCISJPB1OK 026 C3 
Triple negative DCIS 
associated with tumour 40 0.782 156 6240 
DCISJPB1OK 027 C4 
Triple negative Tumour 
associated with DCIS 40 0.936 187 7480 
DCISJPB1OK 028 C5 
Matched Normal from Triple 














Total DNA per 
original sample 
(ng per 40μl) 
DCISJPB1OK 029 C6 
Triple negative DCIS 
associated with tumour 40 1.59 318 12720 
DCISJPB1OK 030 C7 
Triple negative Tumour 
associated with DCIS 40 1.37 274 10960 
DCISJPB1OK 031 C8 
Matched Normal from Triple 
negative DCIS and Tumour 40 0.297 5.94 237.6 
DCISJPB1OK 032 C9 Triple Negative Pure DCIS 40 0.153 30.6 1224 
DCISJPB1OK 033 C10 
Triple negative DCIS 
associated with tumour 40 1.68 336 13440 
DCISJPB1OK 034 C11 
Triple negative Tumour 
associated with DCIS 40 2.68 536 21440 
DCISJPB1OK 035 D1 
Matched Normal from Triple 
negative DCIS and Tumour 40 1.84 36.8 1472 
DCISJPB1OK 036 D2 HER2 Positive 40 0.951 19.02 760.8 
DCISJPB1OK 037 D3 HER2 Positive 40 1.75 35 1400 
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DCISJPB1OK 038 D4 Triple Negative Pure DCIS 40 0.049 9.7 389.6 
DCISJPB1OK 039 D5 
Matched Normal from Triple 
negative DCIS and Tumour 40 1.28 25.6 1024 
DCISJPB1OK 040 D6 Pure DCIS ER positive  40 0.447 89.4 3576 
DCISJPB1OK 041 D7 
Triple negative DCIS 
associated with tumour 40 0.265 53 2120 
DCISJPB1OK 042 D8 
Triple negative Tumour 
associated with DCIS 40 1.86 372 14880 
 









Total DNA per 
original sample (ng 
per 40μl) 
DCISJPB1OK 043 D9 
Triple negative DCIS 
associated with tumour 40 0.647 129 5160 
DCISJPB1OK 044 D10 
Triple negative Tumour 
associated with DCIS 40 1.23 246 9840 
DCISJPB1OK 045 D11 
Matched Normal from Triple 
negative DCIS and Tumour 40 1.86 372 14880 
DCISJPB1OK 046 D12 
Triple negative DCIS 
associated with tumour 40 1.13 226 9040 
DCISJPB1OK 047 E1 
Triple negative Tumour 
associated with DCIS 40 2.12 434 17360 
DCISJPB1OK 048 E2 
Matched Normal from Triple 
negative DCIS and Tumour 40 0.558 11.16 446.4 
DCISJPB1OK 049 E3 
Pure DCIS ER positive  40 2.330 466 18640 
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DCISJPB1OK 050 E4 
Pure DCIS ER positive  40 1.150 230 9200 
DCISJPB1OK 051 E5 
DCIS ER positive associated 
with tumour 40 0.702 140.4 5616 
DCISJPB1OK 052 E6 
Tumour ER positive associated 
with DCIS 40 0.780 156 6240 
DCISJPB1OK 053 E7 
Matched Normal from ER 
positive DCIS and Tumour 40 0.582 11.64 465.6 
DCISJPB1OK 054 E8 
DCIS ER positive associated 
with tumour 40 0.105 21 840 
DCISJPB1OK 055 E9 
Tumour ER positive associated 
with DCIS 40 1.190 238 9520 
 
 









Total DNA per 
original sample (ng 
per 40μl) 
DCISJPB1OK 056 E10 
Matched Normal from ER 
positive DCIS and Tumour 40 2.06 41.2 1648 
DCISJPB1OK 057 E11 
DCIS ER positive associated 
with tumour 40 0.611 122.2 4888 
DCISJPB1OK 058 F1 
Tumour ER positive associated 
with DCIS 40 0.788 157.6 6304 
DCISJPB1OK 059 F2 
Matched Normal from ER 
positive DCIS and Tumour 40 0.0883 1.766 70.64 
DCISJPB1OK 060 F3 
DCIS ER positive associated 
with tumour 40 0.367 73.4 2936 
402 
 
DCISJPB1OK 061 F4 
Tumour ER positive associated 
with DCIS 40 1.760 352 14080 
DCISJPB1OK 062 F5 
Matched Normal from ER 
positive DCIS and Tumour 40 1.46 29.2 1168 
DCISJPB1OK 063 F6 
DCIS ER positive associated 
with tumour 40 1.150 230 9200 
DCISJPB1OK 064 F7 
Tumour ER positive associated 
with DCIS 40 1.350 270 10800 
DCISJPB1OK 065 F8 Pure DCIS ER positive  40 0.277 55.4 2216 
DCISJPB1OK 066 F9 Pure DCIS ER positive  40 1.560 312 12480 
DCISJPB1OK 067 F10 
DCIS ER positive associated 
with tumour 40 0.568 113.6 4544 
DCISJPB1OK 068 F11 
Tumour ER positive associated 
with DCIS 40 0.794 158.8 6352 
DCISJPB1OK 070 G1 
Matched Normal from ER 
positive DCIS and Tumour 40 1.29 25.8 1032 
 









Total DNA per 
original sample (ng 
per 40μl) 
DCISJPB1OK 069 F12 
HER2 Positive 40 2.19 43.8 1752 
DCISJPB1OK 071 G2 
Pure DCIS ER positive  40 0.571 114.2 4568 
DCISJPB1OK 072 G3 
Triple Negative Pure DCIS 40 0.062 12.4 494.4 
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DCISJPB1OK 073 G4 
Triple Negative Pure DCIS 40 0.400 80.0 3200 
DCISJPB1OK 074 G5 
Triple Negative Pure DCIS 40 0.835 167.0 6680 
DCISJPB1OK 075 G6 
Triple Negative Pure DCIS 40 0.085 17.0 680 
DCISJPB1OK 076 G7 
DCIS ER positive associated 
with tumour 40 0.628 125.6 5024 
DCISJPB1OK 077 G8 
Tumour ER positive associated 
with DCIS 40 0.234 46.8 1872 
DCISJPB1OK 078 G9 
DCIS ER positive associated 
with tumour 40 0.095 19.08 763.2 
DCISJPB1OK 079 G10 
Tumour ER positive associated 
with DCIS 40 0.189 37.8 1512 
DCISJPB1OK 080 G11 
Matched Normal from ER 
positive DCIS and Tumour 40 1.03 20.6 824 
DCISJPB1OK 081 H1 
DCIS ER positive associated 
with tumour 40 0.932 186.4 7456 
DCISJPB1OK 082 H2 
Tumour ER positive associated 
with DCIS 40 0.875 175 7000 
DCISJPB1OK 083 H3 
Matched Normal from ER 





5.22 Appendix 8. MIP Array Analysis- DNA Samples sent to Affymetrix 
List of specimens 
UNIQUE IDENTIFER 
PLATE 
REFERENCE Specimen type 
DCISJPB1OK 001 A1 
Triple Negative Pure 
DCIS 
DCISJPB1OK 002 A2 
Triple Negative Pure 
DCIS 
DCISJPB1OK 003 A3 
Triple Negative Pure 
DCIS 
DCISJPB1OK 004 A4 Triple negative DCIS 
DCISJPB1OK 005 A5 
Triple negative 
Tumour 
DCISJPB1OK 006 A6 
Triple Negative Pure 
DCIS 
DCISJPB1OK 007 A7 
HER2 Positive 
 
DCISJPB1OK 008 A8 HER2 Positive 
DCISJPB1OK 009 A9 Pure DCIS ER positive  
DCISJPB1OK 010 A10 Triple negative DCIS 
DCISJPB1OK 011 A11 
Triple negative 
Tumour 
DCISJPB1OK 012 B1 
Matched Normal from 
Triple negative DCIS 
and Tumour 
DCISJPB1OK 013 B2 Triple negative DCIS 
DCISJPB1OK 014 B3 
Triple negative 
Tumour 
DCISJPB1OK 015 B4 
Matched Normal from 
Triple negative DCIS 
and Tumour 
DCISJPB1OK 016 B5 HER2 Positive 
DCISJPB1OK 017 B6 Pure DCIS ER positive  
DCISJPB1OK 018 B7 Triple negative DCIS 
DCISJPB1OK 019 B8 
Triple negative 
Tumour 
DCISJPB1OK 020 B9 
Triple Negative Pure 
DCIS 
DCISJPB1OK 021 B10 Pure DCIS ER positive  
DCISJPB1OK 022 B11 
Triple Negative Pure 
DCIS 
DCISJPB1OK 023 B12 HER2 Positive 
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DCISJPB1OK 024 C1 Pure DCIS ER positive  
DCISJPB1OK 025 C2 HER2 Positive 
DCISJPB1OK 026 C3 Triple negative DCIS 
DCISJPB1OK 027 C4 
Triple negative 
Tumour 
DCISJPB1OK 028 C5 
Matched Normal from 
Triple negative DCIS 
and Tumour 
DCISJPB1OK 029 C6 Triple negative DCIS 
DCISJPB1OK 030 C7 
Triple negative 
Tumour 
DCISJPB1OK 031 C8 
Matched Normal from 
Triple negative DCIS 
and Tumour 
DCISJPB1OK 032 C9 
Triple Negative Pure 
DCIS 
DCISJPB1OK 033 C10 Triple negative DCIS 
DCISJPB1OK 034 C11 
Triple negative 
Tumour 
DCISJPB1OK 035 D1 
Matched Normal from 
Triple negative DCIS 
and Tumour 
DCISJPB1OK 036 D2 HER2 Positive 
DCISJPB1OK 037 D3 HER2 Positive 
DCISJPB1OK 038 D4 
Triple Negative Pure 
DCIS 
DCISJPB1OK 039 D5 
Matched Normal from 
Triple negative DCIS 
and Tumour 
DCISJPB1OK 040 D6 Pure DCIS ER positive  
DCISJPB1OK 041 D7 Triple negative DCIS 
DCISJPB1OK 042 D8 
Triple negative 
Tumour 
DCISJPB1OK 043 D9 Triple negative DCIS 
DCISJPB1OK 044 D10 
Triple negative 
Tumour 
DCISJPB1OK 045 D11 
Matched Normal from 
Triple negative DCIS 
and Tumour 
DCISJPB1OK 046 D12 Triple negative DCIS 
DCISJPB1OK 047 E1 
Triple negative 
Tumour 
DCISJPB1OK 048 E2 
Matched Normal from 




DCISJPB1OK 049 E3 Pure DCIS ER positive  
DCISJPB1OK 050 E4 Pure DCIS ER positive  
DCISJPB1OK 051 E5 
Tumour ER positive 
(basal negative) 
DCISJPB1OK 052 E6 
DCIS ER positive (basal 
negative) 
DCISJPB1OK 053 E7 
Matched Normal from 
ER positive DCIS and 
Tumour 
DCISJPB1OK 054 E8 
Tumour ER positive 
(basal negative) 
DCISJPB1OK 055 E9 
DCIS ER positive (basal 
negative) 
DCISJPB1OK 056 E10 
Matched Normal from 
ER positive DCIS and 
Tumour 
DCISJPB1OK 057 E11 
Tumour ER positive 
(basal negative) 
DCISJPB1OK 058 F1 
DCIS ER positive (basal 
negative) 
DCISJPB1OK 059 F2 
Matched Normal from 
ER positive DCIS and 
Tumour 
DCISJPB1OK 060 F3 
Tumour ER positive 
(basal negative) 
DCISJPB1OK 061 F4 
DCIS ER positive (basal 
negative) 
DCISJPB1OK 062 F5 
Matched Normal from 
ER positive DCIS and 
Tumour 
DCISJPB1OK 063 F6 
Tumour ER positive 
(basal negative) 
DCISJPB1OK 064 F7 
DCIS ER positive (basal 
negative) 
DCISJPB1OK 065 F8 Pure DCIS ER positive  
DCISJPB1OK 066 F9 Pure DCIS ER positive  
DCISJPB1OK 067 F10 
Tumour ER positive 
(basal negative) 
DCISJPB1OK 068 F11 
DCIS ER positive (basal 
negative) 
DCISJPB1OK 069 F12 
Matched Normal from 
ER positive DCIS and 
Tumour 
DCISJPB1OK 070 G1 HER2 Positive 
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DCISJPB1OK 071 G2 
Triple Negative Pure 
DCIS 
DCISJPB1OK 072 G3 
Triple Negative Pure 
DCIS 
DCISJPB1OK 073 G4 
Triple Negative Pure 
DCIS 
DCISJPB1OK 074 G5 
Triple Negative Pure 
DCIS 
DCISJPB1OK 075 G6 Pure DCIS ER positive  
DCISJPB1OK 076 G7 
Tumour ER positive 
(basal negative) 
DCISJPB1OK 077 G8 
DCIS ER positive (basal 
negative) 
DCISJPB1OK 078 G9 
Tumour ER positive 
(basal negative) 
DCISJPB1OK 079 G10 
DCIS ER positive (basal 
negative) 
DCISJPB1OK 080 G11 
Matched Normal from 
ER positive DCIS and 
Tumour 
DCISJPB1OK 081 H1 
Tumour ER positive 
(basal negative) 
DCISJPB1OK 082 H2 
DCIS ER positive (basal 
negative) 
DCISJPB1OK 083 H3 
Matched Normal from 









P238/1989 A09  
DCISJPB10K 




P300/1991 B10  
DCISJPB10K 
P598/1992 C01  
DCISJPB10K 




P413/1997 E03  
DCISJPB10K 
P754/1997 E04  
P198/1999 F08 na 
DCISJPB10K 
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P914/1988 A07  
DCISJPB10K 




P539/1989 B05  
DCISJPB10K 
P558/1991 B12  
DCISJPB10K 




P461/1994 D02  
P970/1995 D03 Na 
DCISJPB10K 
070 
 P346/2000 G01  
TN 
DCISJPB10K 




P997/1982 A02  
DCISJPB10K 







P267/1991 B09  
DCISJPB10K 
P313/1991 B11  
DCISJPB10K 











P701/2001 G05  
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 case no normal DCIS invasive breast disease 
ER 
P123/1998 E07 
 
E06 
 
E05 
 
P1310/2004 H03 
 
H02 
 
H01 
 
P168/1999  
 
F07 
 
F06 
 
P258/2004  
 
G08 
 
G07 
 
P339/2000  
 
F11 
 
F10 
 
P367/2004 G11 
 
G10 
 
G09 
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P46/1999 F05 
 
F04 
 
F03 
 
P585/1998 E10 
 
E09 
 
E08 
 
P769/1998 F02 
 
F01 
 
E11 
 
Triple 
Negati
ve 
P110/1987  
 
A04 
 
A05 
 
P126/1997 D11 
 
D09 
 
D10 
 
P137/1997 E02 
 
D12 
 
E01 
 
P220/1990  
 
B07 
 
B08 
 
421 
 
P456/1989 B01 
 
A10 
 
A11 
 
P497/1989  
 
B02 
 
B03 
 
P9/1994 D01 
 
C10 
 
C11 
 
P540/1993 C08 
 
C06 
 
 
 
P730/1992 C05 
 
C03 
 
 
 
P1012/1995 D05 
 
 
 
 
 
P400/2000 F12 
 
 
 
 
 
422 
 
P536/1989 B04 
 
 
 
 
 
P1202/1995  
 
D07 
 
 
 
423 
 
 
